Data	O
from	O
experimental	O
studies	O
suggest	O
that	O
octreotide,	B-Claim
the	I-Claim
long	I-Claim
acting	I-Claim
somatostatin	I-Claim
analogue,	I-Claim
improves	I-Claim
survival	I-Claim
of	I-Claim
animals	I-Claim
with	I-Claim
pancreatic	I-Claim
cancer.	I-Claim

To	O
assess	O
the	O
antitumour	O
effect	O
of	O
octreotide,	O
a	O
randomized	O
trial	O
was	O
performed	O
comparing	O
octreotide	O
with	O
supportive	O
care	O
in	O
advanced	O
pancreatic	O
cancer	O
patients.	O

All	O
patients,	O
aged	O
59-75	O
years,	O
were	O
not	O
liable	O
to	O
radical	O
surgical	O
treatment	O
and	O
were	O
not	O
submitted	O
to	O
other	O
treatments	O
(chemo	O
and/or	O
radiotherapy).	O

Six	O
patients	O
were	O
enrolled,	O
4	O
of	O
these	O
treated	O
with	O
octreotide	O
(500	O
micrograms	O
two	O
times	O
a	O
day	O
subcutaneous	O
for	O
six	O
months)	O
and	O
the	O
other	O
2	O
were	O
inserted	O
a	O
control	O
group.	O

The	B-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
octreotide	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
advantage	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(restored	I-Premise
appetite,	I-Premise
improvement	I-Premise
of	I-Premise
digestion	I-Premise
and	I-Premise
intestine	I-Premise
function,	I-Premise
remission	I-Premise
of	I-Premise
abdominal	I-Premise
pain	I-Premise
and	I-Premise
preservation	I-Premise
of	I-Premise
baseline	I-Premise
body	I-Premise
weight)	I-Premise
with	I-Premise
a	I-Premise
mean	I-Premise
>	I-Premise
80	I-Premise
of	I-Premise
karnofsky	I-Premise
performance	I-Premise
score.	I-Premise

Monitoring	B-Premise
of	I-Premise
tumour	I-Premise
size	I-Premise
changes	I-Premise
(US-TC)	I-Premise
over	I-Premise
the	I-Premise
6	I-Premise
months	I-Premise
study	I-Premise
period,	I-Premise
showed	I-Premise
slackened	I-Premise
neoplastic	I-Premise
growth	I-Premise
in	I-Premise
all	I-Premise
treated	I-Premise
patients,	I-Premise
whereas	B-Premise
neoplasm	I-Premise
grew	I-Premise
according	I-Premise
to	I-Premise
an	I-Premise
almost	I-Premise
exponential	I-Premise
trend	I-Premise
in	I-Premise
untreated	I-Premise
patients.	I-Premise

Also	O
survival	B-Premise
was	I-Premise
better	I-Premise
in	I-Premise
treated	I-Premise
patients:	I-Premise
in	O
particular,	O
2	O
patients	O
out	O
of	O
4	O
who	O
completed	O
the	O
study	O
underwent	O
follow-up	O
until	O
they	O
died	O
12	O
and	O
16	O
months	O
after	O
beginning	O
of	O
treatment,	O
respectively.	O

Karnofsky	B-Premise
performance	I-Premise
score	I-Premise
was	I-Premise
particularly	I-Premise
high	I-Premise
in	I-Premise
both	I-Premise
patients.	I-Premise

This	O
supports	O
the	O
view	O
that	O
octreotide	B-Claim
is	I-Claim
endowed	I-Claim
with	I-Claim
antiproliferative	I-Claim
activity.	I-Claim

In	O
conclusion	O
octreotide	B-Claim
therapy	I-Claim
seems	I-Claim
to	I-Claim
confer	I-Claim
a	I-Claim
survival	I-Claim
benefit	I-Claim
and	I-Claim
a	I-Claim
better	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
advanced	I-Claim
pancreatic	I-Claim
tumour.	I-Claim

Additional	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
and	O
to	O
clarify	O
other	O
questions	O
about	O
dose	O
and	O
somatostatin	O
receptors	O
in	O
this	O
kind	O
of	O
tumour.	O

In	O
a	O
prospective	O
randomized	O
study,	O
287	O
patients	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
stage	O
IIIb	O
or	O
IV	O
with	O
ECOG	O
performance	O
status	O
(PS)	O
0-1	O
or	O
2	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
best	O
supportive	O
care	O
(BSC)	O
or	O
supportive	O
care	O
plus	O
combination	O
chemotherapy	O
(IEP	O
regimen:	O
ifosfamide	O
3	O
gm/m2	O
IV	O
with	O
mesna	O
uroprotection,	O
epirubicin	O
60	O
mg/m2	O
IV	O
on	O
day	O
1	O
and	O
cisplatin	O
60	O
mg/m2	O
IV	O
on	O
day	O
2;	O
or	O
MVP	O
regimen:	O
mitomycin-C	O
8	O
mg/m2,	O
cisplatin	O
100	O
mg/m2	O
IV	O
on	O
day	O
1,	O
vinblastine	O
4	O
mg/m2	O
IV	O
on	O
days	O
1	O
and	O
15).	O

Serial	O
assessment	O
of	O
Karnofsky	O
performance	O
status	O
(KPS),	O
modified	O
Functional	O
Living	O
Index-Cancer	O
(T-FLIC)	O
and	O
modified	O
Quality	O
of	O
Life-Index	O
(T-QLI)	O
were	O
used	O
to	O
estimate	O
the	O
quality	O
of	O
life.	O

Interviews	O
were	O
done	O
at	O
entry,	O
at	O
the	O
third	O
month	O
and	O
at	O
2	O
months	O
post	O
complete	O
treatment.	O

At	O
least	O
two	O
courses	O
of	O
chemotherapy	O
were	O
considered	O
to	O
be	O
adequate	O
for	O
response	O
evaluation.	O

Patients	O
were	O
treated	O
for	O
a	O
total	O
of	O
four	O
to	O
six	O
courses	O
or	O
until	O
progression	O
of	O
disease.	O

Partial	B-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
40	I-Premise
and	I-Premise
41.7%	I-Premise
in	I-Premise
IEP	I-Premise
and	I-Premise
MVP	I-Premise
arms.	I-Premise

Median	B-Premise
survival	I-Premise
durations	I-Premise
were	I-Premise
5.9	I-Premise
and	I-Premise
8.1	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
IEP	I-Premise
and	I-Premise
MVP	I-Premise
chemotherapy	I-Premise
arms,	I-Premise
and	I-Premise
4.1	I-Premise
months	I-Premise
for	I-Premise
BSC	I-Premise
(log-rank	I-Premise
test:	I-Premise
P	I-Premise
=	I-Premise
0.0003).	I-Premise

One	B-Premise
year	I-Premise
survival	I-Premise
was	I-Premise
13,	I-Premise
29.8	I-Premise
and	I-Premise
39.3%	I-Premise
for	I-Premise
the	I-Premise
BSC,	I-Premise
IEP	I-Premise
and	I-Premise
MVP	I-Premise
regimens,	I-Premise
respectively.	I-Premise

Two	B-Premise
years	I-Premise
survival	I-Premise
was	I-Premise
7.8,	I-Premise
6.4	I-Premise
and	I-Premise
13.1%	I-Premise
for	I-Premise
the	I-Premise
BSC,	I-Premise
IEP	I-Premise
and	I-Premise
MVP	I-Premise
regimens,	I-Premise
respectively.	I-Premise

Improvement	B-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(QOL)	I-Premise
scores	I-Premise
at	I-Premise
the	I-Premise
first,	I-Premise
second	I-Premise
and	I-Premise
third	I-Premise
interview	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
chemotherapy	I-Premise
arms	I-Premise
only,	I-Premise
not	I-Premise
in	I-Premise
the	I-Premise
BSC	I-Premise
arm.	I-Premise

We	O
conclude	O
that	O
combination	B-Claim
chemotherapy	I-Claim
improves	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
prolonging	I-Claim
the	I-Claim
survival	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
slow-release	O
formulation	O
of	O
cytarabine	O
(DepoCyt;	O
Chiron	O
Corp,	O
Emeryville,	O
CA,	O
and	O
Skye	O
Pharma,	O
Inc,	O
San	O
Diego,	O
CA)	O
that	O
maintains	O
cytotoxic	O
concentrations	O
of	O
cytarabine	O
(ara-C)	O
in	O
the	O
CSF	O
of	O
most	O
patients	O
for	O
more	O
than	O
14	O
days.	O

Twenty-eight	O
patients	O
with	O
lymphoma	O
and	O
a	O
positive	O
CSF	O
cytology	O
were	O
randomized	O
to	O
receive	O
DepoCyt	O
50	O
mg	O
once	O
every	O
2	O
weeks	O
or	O
free	O
ara-C	O
50	O
mg	O
twice	O
a	O
week	O
for	O
1	O
month.	O

Patients	O
whose	O
CSF	O
cytology	O
converted	O
to	O
negative	O
and	O
who	O
did	O
not	O
have	O
neurologic	O
progression	O
received	O
an	O
additional	O
3	O
months	O
of	O
consolidation	O
therapy	O
and	O
then	O
4	O
months	O
of	O
maintenance	O
therapy.	O

All	O
patients	O
received	O
dexamethasone	O
4	O
mg	O
orally	O
bid	O
on	O
days	O
1	O
through	O
5	O
of	O
each	O
2-week	O
cycle.	O

The	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
71%	I-Premise
for	I-Premise
DepoCyt	I-Premise
and	I-Premise
15%	I-Premise
for	I-Premise
ara-C	I-Premise
on	I-Premise
an	I-Premise
intent-to-treat	I-Premise
basis	I-Premise
(P	I-Premise
=.006).	I-Premise

All	B-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
on	I-Premise
the	I-Premise
DepoCyt	I-Premise
arm	I-Premise
but	I-Premise
only	I-Premise
53%	I-Premise
of	I-Premise
those	I-Premise
on	I-Premise
the	I-Premise
ara-C	I-Premise
arm	I-Premise
were	I-Premise
able	I-Premise
to	I-Premise
complete	I-Premise
the	I-Premise
planned	I-Premise
1-month	I-Premise
induction	I-Premise
therapy	I-Premise
regimen.	I-Premise

Time	B-Premise
to	I-Premise
neurologic	I-Premise
progression	I-Premise
and	I-Premise
survival	I-Premise
trend	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
DepoCyt	I-Premise
(median,	I-Premise
78.5	I-Premise
v	I-Premise
42	I-Premise
days	I-Premise
and	I-Premise
99.5	I-Premise
v	I-Premise
63	I-Premise
days,	I-Premise
respectively;	I-Premise
P	I-Premise
>.05).	I-Premise

DepoCyt	B-Premise
treatment	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
an	I-Premise
improved	I-Premise
mean	I-Premise
change	I-Premise
in	I-Premise
Karnofsky	I-Premise
performance	I-Premise
score	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
induction	I-Premise
(P	I-Premise
=.041).	I-Premise

The	B-Premise
major	I-Premise
adverse	I-Premise
events	I-Premise
on	I-Premise
both	I-Premise
arms	I-Premise
were	I-Premise
headache	I-Premise
and	I-Premise
arachnoiditis,	I-Premise
which	I-Premise
were	I-Premise
often	I-Premise
caused	I-Premise
by	I-Premise
the	I-Premise
underlying	I-Premise
disease.	I-Premise

DepoCyt	B-Claim
injected	I-Claim
once	I-Claim
every	I-Claim
2	I-Claim
weeks	I-Claim
produced	I-Claim
a	I-Claim
high	I-Claim
response	I-Claim
rate	I-Claim
and	I-Claim
a	I-Claim
better	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
as	I-Claim
measured	I-Claim
by	I-Claim
Karnofsky	I-Claim
score	I-Claim
relative	I-Claim
to	I-Claim
that	I-Claim
produced	I-Claim
by	I-Claim
free	I-Claim
ara-C	I-Claim
injected	I-Claim
twice	I-Claim
a	I-Claim
week.	I-Claim

For	B-Claim
several	I-Claim
decades,	I-Claim
both	I-Claim
preoperative	I-Claim
intra-arterial	I-Claim
chemotherapy	I-Claim
and	I-Claim
preoperative	I-Claim
irradiation	I-Claim
have	I-Claim
been	I-Claim
accepted	I-Claim
treatments	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
tumors	I-Claim
of	I-Claim
the	I-Claim
head	I-Claim
and	I-Claim
neck.	I-Claim

Unfortunately,	O
arguments	O
have	O
often	O
been	O
put	O
forward	O
in	O
favor	O
of	O
one	O
or	O
other	O
of	O
the	O
two	O
methods,	O
but	O
without	O
the	O
performance	O
of	O
an	O
objective,	O
randomized	O
investigation.	O

To	O
resolve	O
this	O
situation,	O
the	O
authors	O
have	O
carried	O
out	O
a	O
multicenter,	O
randomized	O
prospective	O
study	O
of	O
selected	O
patients	O
with	O
a	O
view	O
to	O
deciding	O
which	O
method	O
affords	O
better	O
results	O
in	O
complex	O
tumor	O
therapy	O
from	O
the	O
aspects	O
of	O
survival	O
and	O
postoperative	O
quality	O
of	O
life.	O

One	O
hundred	O
thirty-one	O
patients	O
with	O
operable	O
sublingual	O
or	O
lingual	O
squamous	O
cell	O
carcinoma	O
in	O
stages	O
T2NXM0	O
to	O
T4MXM0	O
were	O
randomized	O
into	O
2	O
groups:	O
1	O
group	O
participated	O
in	O
preoperative	O
chemotherapy	O
with	O
cisplatin	O
and	O
epirubicin	O
(total	O
doses:	O
200	O
mg	O
cisplatin,	O
120	O
mg	O
epirubicin)	O
via	O
the	O
external	O
carotid	O
artery,	O
whereas	O
the	O
other	O
group	O
received	O
preoperative	O
radiation	O
therapy	O
(46	O
grays).	O

Following	O
subsequent	O
radical	O
surgery,	O
the	O
patients	O
received	O
regular	O
follow-up	O
for	O
5	O
years.	O

By	O
the	O
end	O
of	O
the	O
5	O
years,	O
95	O
of	O
the	O
131	O
patients	O
had	O
conformed	O
to	O
the	O
protocol.	O

Of	O
those	O
95,	O
47	O
had	O
received	O
preoperative	O
chemotherapy	O
and	O
48	O
preoperative	O
irradiation.	O

After	B-Premise
5	I-Premise
years,	I-Premise
18	I-Premise
of	I-Premise
the	I-Premise
47	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
chemotherapy	I-Premise
and	I-Premise
15	I-Premise
of	I-Premise
the	I-Premise
48	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
irradiation	I-Premise
were	I-Premise
still	I-Premise
alive	I-Premise
and	I-Premise
tumor	I-Premise
free.	I-Premise

A	B-Premise
few	I-Premise
more	I-Premise
patients	I-Premise
had	I-Premise
died	I-Premise
of	I-Premise
recurrence	I-Premise
or	I-Premise
regional	I-Premise
metastasis	I-Premise
in	I-Premise
the	I-Premise
chemotherapy	I-Premise
group	I-Premise
(23	I-Premise
patients)	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
irradiation	I-Premise
group	I-Premise
(20	I-Premise
patients).	I-Premise

Occurrence	B-Premise
of	I-Premise
a	I-Premise
second	I-Premise
carcinoma	I-Premise
was	I-Premise
3	I-Premise
times	I-Premise
as	I-Premise
frequent	I-Premise
in	I-Premise
the	I-Premise
irradiation	I-Premise
group	I-Premise
(9	I-Premise
patients)	I-Premise
as	I-Premise
in	I-Premise
the	I-Premise
chemotherapy	I-Premise
group	I-Premise
(3	I-Premise
patients).	I-Premise

Overall,	O
the	B-Claim
survival	I-Claim
rates	I-Claim
were	I-Claim
by-and-large	I-Claim
the	I-Claim
same	I-Claim
for	I-Claim
the	I-Claim
two	I-Claim
groups.	I-Claim

Regarding	B-Claim
postoperative	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
the	I-Claim
chemotherapy	I-Claim
group	I-Claim
presented	I-Claim
a	I-Claim
more	I-Claim
favorable	I-Claim
picture.	I-Claim

The	B-Claim
long	I-Claim
term	I-Claim
survival	I-Claim
results	I-Claim
subsequent	I-Claim
to	I-Claim
preoperative	I-Claim
intra-arterial	I-Claim
chemotherapy	I-Claim
or	I-Claim
preoperative	I-Claim
radiotherapy	I-Claim
were	I-Claim
practically	I-Claim
the	I-Claim
same.	I-Claim

Regarding	B-Claim
postoperative	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
patients	I-Claim
who	I-Claim
underwent	I-Claim
intra-arterial	I-Claim
chemotherapy	I-Claim
appeared	I-Claim
to	I-Claim
be	I-Claim
in	I-Claim
a	I-Claim
slightly	I-Claim
more	I-Claim
favorable	I-Claim
situation.	I-Claim

The	O
authors	O
consider	O
it	O
important	O
to	O
stress	O
these	O
findings,	O
as	O
they	O
are	O
not	O
aware	O
of	O
a	O
similar	O
randomized	O
study	O
of	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity.	O

To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
oral	O
bexarotene	O
(Targretin	O
capsules;	O
Ligand	O
Pharmaceuticals	O
Incorporated,	O
San	O
Diego,	O
Calif).	O

The	O
effects	O
of	O
2	O
randomized	O
doses	O
of	O
6.5	O
mg/m(2)	O
per	O
day	O
(with	O
crossover	O
for	O
progression)	O
vs	O
650	O
mg/m(2)	O
per	O
day	O
(later	O
modified	O
to	O
300	O
mg/m(2)	O
per	O
day)	O
were	O
evaluated	O
in	O
an	O
open-label,	O
multicenter,	O
phase	O
2	O
and	O
3	O
study	O
conducted	O
between	O
February	O
1997	O
and	O
November	O
1998.	O

Eighteen	O
international	O
cutaneous	O
T-cell	O
lymphoma	O
clinics	O
at	O
academic	O
referral	O
centers.	O

Fifty-eight	O
patients	O
with	O
biopsy-proven	O
stage	O
IA	O
through	O
IIA	O
cutaneous	O
T-cell	O
lymphoma	O
that	O
was	O
refractory	O
to	O
(or	O
patients	O
were	O
intolerant	O
of)	O
treatment	O
or	O
had	O
reached	O
at	O
least	O
a	O
6-month	O
response	O
plateau	O
under	O
at	O
least	O
2	O
forms	O
of	O
prior	O
therapy	O
(median	O
of	O
3.5	O
prior	O
therapies).	O

Bexarotene	O
(Targretin	O
capsules)	O
administered	O
once	O
daily	O
with	O
meal	O
for	O
16	O
weeks	O
or	O
longer.	O

Primary	O
end	O
point	O
classification	O
of	O
overall	O
response	O
rate	O
of	O
complete	O
and	O
partial	O
remissions	O
determined	O
by	O
either	O
the	O
Physician's	O
Global	O
Assessment	O
of	O
Clinical	O
Condition	O
or	O
the	O
objective	O
Composite	O
Assessment	O
of	O
Index	O
Lesion	O
Severity.	O

Body	O
surface	O
area,	O
time	O
to	O
response,	O
duration	O
of	O
disease	O
control,	O
time	O
to	O
disease	O
progression,	O
individual	O
index	O
lesion	O
signs	O
and	O
symptoms,	O
and	O
quality	O
of	O
life	O
parameters	O
were	O
secondary	O
outcomes.	O

Responses	B-Premise
(>	I-Premise
or	I-Premise
=	I-Premise
50%	I-Premise
improvement)	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
3	I-Premise
(20%)	I-Premise
of	I-Premise
15	I-Premise
patients	I-Premise
with	I-Premise
an	I-Premise
initial	I-Premise
dose	I-Premise
at	I-Premise
6.5	I-Premise
mg/m(2)	I-Premise
per	I-Premise
day	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
0%-40%),	I-Premise
15	I-Premise
(54%)	I-Premise
of	I-Premise
28	I-Premise
patients	I-Premise
at	I-Premise
300	I-Premise
mg/m(2)	I-Premise
per	I-Premise
day	I-Premise
(95%	I-Premise
CI,	I-Premise
35%-72%),	I-Premise
and	I-Premise
10	I-Premise
(67%)	I-Premise
of	I-Premise
15	I-Premise
patients	I-Premise
at	I-Premise
above	I-Premise
300	I-Premise
mg/m(2)	I-Premise
per	I-Premise
day	I-Premise
(95%	I-Premise
CI,	I-Premise
43%-91%).	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
progressive	I-Premise
disease	I-Premise
was	I-Premise
47%,	I-Premise
21%,	I-Premise
and	I-Premise
13%	I-Premise
at	I-Premise
the	I-Premise
same	I-Premise
dose	I-Premise
levels,	I-Premise
respectively.	I-Premise

Eight	B-Premise
(73%)	I-Premise
of	I-Premise
11	I-Premise
patients	I-Premise
crossing	I-Premise
over	I-Premise
from	I-Premise
6.5	I-Premise
mg/m(2)	I-Premise
per	I-Premise
day	I-Premise
to	I-Premise
higher	I-Premise
doses	I-Premise
subsequently	I-Premise
responded.	I-Premise

The	B-Premise
median	I-Premise
duration	I-Premise
of	I-Premise
response	I-Premise
from	I-Premise
start	I-Premise
of	I-Premise
therapy	I-Premise
could	I-Premise
not	I-Premise
be	I-Premise
estimated	I-Premise
for	I-Premise
the	I-Premise
15	I-Premise
patients	I-Premise
at	I-Premise
300	I-Premise
mg/m(2)	I-Premise
per	I-Premise
day	I-Premise
owing	I-Premise
to	I-Premise
low	I-Premise
relapse	I-Premise
rates	I-Premise
in	I-Premise
2	I-Premise
patients	I-Premise
(13%);	I-Premise
at	I-Premise
higher	I-Premise
doses	I-Premise
it	I-Premise
was	I-Premise
516	I-Premise
days.	I-Premise

The	B-Premise
following	I-Premise
drug-related	I-Premise
adverse	I-Premise
effects	I-Premise
were	I-Premise
reversible	I-Premise
and	I-Premise
treatable:	I-Premise
hypertriglyceridemia	I-Premise
(46	I-Premise
patients	I-Premise
[79%]),	I-Premise
hypercholesterolemia	I-Premise
(28	I-Premise
patients	I-Premise
[48%]),	I-Premise
headache	I-Premise
(27	I-Premise
patients	I-Premise
[47%]),	I-Premise
central	I-Premise
hypothyroidism	I-Premise
(23	I-Premise
patients	I-Premise
[40%]),	I-Premise
asthenia	I-Premise
(21	I-Premise
patients	I-Premise
[36%]),	I-Premise
and	I-Premise
leukopenia	I-Premise
(16	I-Premise
patients	I-Premise
[28%]).	I-Premise

No	B-Premise
cases	I-Premise
of	I-Premise
drug-related	I-Premise
neutropenic	I-Premise
fever,	I-Premise
sepsis,	I-Premise
or	I-Premise
death	I-Premise
occurred.	I-Premise

Pancreatitis	B-Premise
occurred	I-Premise
in	I-Premise
3	I-Premise
patients	I-Premise
with	I-Premise
triglyceride	I-Premise
levels	I-Premise
higher	I-Premise
than	I-Premise
14.69	I-Premise
mmol/L	I-Premise
(1300	I-Premise
mg/dL),	I-Premise
all	I-Premise
of	I-Premise
whom	I-Premise
were	I-Premise
taking	I-Premise
300	I-Premise
mg/m(2)	I-Premise
or	I-Premise
more	I-Premise
of	I-Premise
oral	I-Premise
bexarotene	I-Premise
per	I-Premise
day.	I-Premise

Bexarotene	B-Claim
(Targretin	I-Claim
capsules)	I-Claim
(the	I-Claim
first	I-Claim
retinoid	I-Claim
X	I-Claim
receptor-selective	I-Claim
rexinoid)	I-Claim
was	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
effective	I-Claim
as	I-Claim
an	I-Claim
oral	I-Claim
treatment	I-Claim
for	I-Claim
15	I-Claim
(54%)	I-Claim
of	I-Claim
28	I-Claim
patients	I-Claim
with	I-Claim
refractory	I-Claim
or	I-Claim
persistent	I-Claim
early-stage	I-Claim
cutaneous	I-Claim
T-cell	I-Claim
lymphoma	I-Claim
at	I-Claim
doses	I-Claim
of	I-Claim
300	I-Claim
mg/m(2)	I-Claim
per	I-Claim
day.	I-Claim

Hypertriglyceridemia	B-Claim
and	I-Claim
hypothyroidism	I-Claim
require	I-Claim
monitoring	I-Claim
but	I-Claim
are	I-Claim
reversible	I-Claim
and	I-Claim
manageable	I-Claim
with	I-Claim
concomitant	I-Claim
medication.	I-Claim

The	O
standard	O
treatment	O
for	O
patients	O
with	O
clinically	O
resectable	O
rectal	O
cancer	O
is	O
surgery.	O

Postoperative	B-Claim
radiochemotherapy	I-Claim
is	I-Claim
recommended	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
disease	I-Claim
(pT3/4	I-Claim
or	I-Claim
pN+).	I-Claim

In	B-Claim
recent	I-Claim
years,	I-Claim
encouraging	I-Claim
results	I-Claim
of	I-Claim
preoperative	I-Claim
radiotherapy	I-Claim
have	I-Claim
been	I-Claim
reported.	I-Claim

This	O
prospective	O
randomized	O
phase-III	O
trial	O
(CAO/ARO/AIO-94)	O
compares	O
the	O
efficacy	O
of	O
neoadjuvant	O
radiochemotherapy	O
to	O
standard	O
postoperative	O
radiochemotherapy.	O

We	O
report	O
on	O
the	O
design	O
of	O
the	O
study	O
and	O
first	O
results	O
with	O
regard	O
to	O
toxicity	O
of	O
radiochemotherapy	O
and	O
postoperative	O
morbidity.	O

Patients	O
with	O
locally	O
advanced	O
operable	O
rectal	O
cancer	O
(uT3/4	O
or	O
uN+,	O
Mason	O
CS	O
III/IV)	O
were	O
randomly	O
assigned	O
to	O
pre-	O
or	O
postoperative	O
radiochemotherapy:	O
A	O
total	O
dose	O
of	O
50.4	O
Gy	O
(single	O
dose	O
1.8	O
Gy)	O
was	O
applied	O
to	O
the	O
tumor	O
and	O
the	O
pelvic	O
lymph	O
nodes.	O

5-FU	O
(1,000	O
mg/m2/d)	O
was	O
administered	O
concomitantly	O
in	O
the	O
first	O
and	O
fifth	O
week	O
of	O
radiation	O
as	O
120-h	O
continuous	O
infusion.	O

Four	O
additional	O
cycles	O
of	O
5-FU	O
chemotherapy	O
(500	O
mg/m2/d,	O
i.v.	O
bolus)	O
were	O
applied.	O

Radiochemotherapy	O
was	O
identical	O
in	O
both	O
arms	O
except	O
for	O
a	O
small-volume	O
boost	O
of	O
5.4	O
Gy	O
in	O
the	O
postoperative	O
setting.	O

Time	O
interval	O
between	O
radiochemotherapy	O
and	O
surgery	O
was	O
4-6	O
weeks	O
in	O
both	O
arms.	O

Techniques	O
of	O
surgery	O
were	O
standardized	O
and	O
included	O
total	O
mesorectal	O
excision.	O

In	O
addition,	O
stratification	O
according	O
to	O
surgeons	O
involved	O
has	O
been	O
provided	O
for.	O

Primary	O
endpoints	O
of	O
the	O
study	O
are	O
5-year	O
overall-survival,	O
local	O
and	O
distant	O
control,	O
secondary	O
endpoints	O
include	O
rate	O
of	O
curative	O
(R0)	O
resections	O
and	O
sphincter	O
saving	O
procedures,	O
toxicity	O
of	O
radiochemotherapy,	O
surgical	O
complications	O
and	O
quality	O
of	O
life.	O

As	O
of	O
15th	O
November	O
2000,	O
628	O
patients	O
were	O
randomized	O
from	O
26	O
participating	O
institutions:	O
310	O
patients	O
were	O
randomized	O
to	O
postoperative	O
radiochemotherapy,	O
318	O
patients	O
to	O
preoperative	O
radiochemotherapy.	O

Acute	B-Premise
toxicity	I-Premise
(WHO)	I-Premise
of	I-Premise
radiochemotherapy	I-Premise
was	I-Premise
low,	I-Premise
with	I-Premise
less	I-Premise
than	I-Premise
15%	I-Premise
of	I-Premise
patients	I-Premise
experiencing	I-Premise
Grade	I-Premise
3	I-Premise
or	I-Premise
higher	I-Premise
toxicity:	I-Premise
The	B-Premise
principal	I-Premise
toxicity	I-Premise
was	I-Premise
diarrhea,	I-Premise
with	I-Premise
12%	I-Premise
in	I-Premise
the	I-Premise
postoperative	I-Premise
radiochemotherapy	I-Premise
arm	I-Premise
and	I-Premise
10%	I-Premise
in	I-Premise
the	I-Premise
preoperative	I-Premise
radiochemotherapy	I-Premise
arm	I-Premise
having	I-Premise
Grade-3,	I-Premise
and	I-Premise
1%	I-Premise
in	I-Premise
either	I-Premise
arm	I-Premise
having	I-Premise
Grade-4	I-Premise
diarrhea.	I-Premise

Erythema,	B-Premise
nausea	I-Premise
and	I-Premise
leukopenia	I-Premise
were	I-Premise
the	I-Premise
next	I-Premise
common	I-Premise
toxicities,	I-Premise
with	I-Premise
less	I-Premise
than	I-Premise
3%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
either	I-Premise
arm	I-Premise
suffering	I-Premise
Grade	I-Premise
3	I-Premise
or	I-Premise
greater	I-Premise
leukopenia	I-Premise
or	I-Premise
nausea.	I-Premise

Postoperative	B-Premise
complication	I-Premise
rates	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms,	I-Premise
with	I-Premise
12%	I-Premise
(postoperative	I-Premise
radiochemotherapy)	I-Premise
and	I-Premise
13%	I-Premise
(preoperative	I-Premise
radiochemotherapy)	I-Premise
of	I-Premise
patients,	I-Premise
respectively,	I-Premise
suffering	I-Premise
from	I-Premise
anastomotic	I-Premise
leakage,	I-Premise
4%	I-Premise
(postoperative	I-Premise
radiochemotherapy)	I-Premise
and	I-Premise
3%	I-Premise
(preoperative	I-Premise
radiochemotherapy)	I-Premise
from	I-Premise
postoperative	I-Premise
bleeding,	I-Premise
and	I-Premise
6%	I-Premise
(postoperative	I-Premise
radiochemotherapy)	I-Premise
and	I-Premise
5%	I-Premise
(preoperative	I-Premise
radiochemotherapy)	I-Premise
from	I-Premise
delayed	I-Premise
wound	I-Premise
healing.	I-Premise

The	B-Claim
patient	I-Claim
accrual	I-Claim
of	I-Claim
our	I-Claim
trial	I-Claim
is	I-Claim
satisfactory,	I-Claim
neoadjuvant	B-Claim
radiochemotherapy	I-Claim
is	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
bears	I-Claim
no	I-Claim
higher	I-Claim
risk	I-Claim
for	I-Claim
postoperative	I-Claim
morbidity.	I-Claim

This	O
randomized,	O
double-blind,	O
placebo-controlled	O
clinical	O
trial	O
assessed	O
the	O
effects	O
of	O
epoetin	O
alfa	O
on	O
transfusion	O
requirements,	O
hematopoietic	O
parameters,	O
quality	O
of	O
life	O
(QOL),	O
and	O
safety	O
in	O
anemic	O
cancer	O
patients	O
receiving	O
nonplatinum	O
chemotherapy.	O

The	O
study	O
also	O
explored	O
a	O
possible	O
relationship	O
between	O
increased	O
hemoglobin	O
and	O
survival.	O

Three	O
hundred	O
seventy-five	O
patients	O
with	O
solid	O
or	O
nonmyeloid	O
hematologic	O
malignancies	O
and	O
hemoglobin	O
levels	O
<	O
or	O
=	O
10.5	O
g/dL,	O
or	O
greater	O
than	O
10.5	O
g/dL	O
but	O
<	O
or	O
=	O
12.0	O
g/dL	O
after	O
a	O
hemoglobin	O
decrease	O
of	O
>	O
or	O
=	O
1.5	O
g/dL	O
per	O
cycle	O
since	O
starting	O
chemotherapy,	O
were	O
randomized	O
2:1	O
to	O
epoetin	O
alfa	O
150	O
to	O
300	O
IU/kg	O
(n	O
=	O
251)	O
or	O
placebo	O
(n	O
=	O
124)	O
three	O
times	O
per	O
week	O
subcutaneously	O
for	O
12	O
to	O
24	O
weeks.	O

The	O
primary	O
end	O
point	O
was	O
proportion	O
of	O
patients	O
transfused;	O
secondary	O
end	O
points	O
were	O
change	O
in	O
hemoglobin	O
and	O
QOL.	O

The	O
protocol	O
was	O
amended	O
before	O
unblinding	O
to	O
prospectively	O
collect	O
and	O
assess	O
survival	O
data	O
12	O
months	O
after	O
the	O
last	O
patient	O
completed	O
the	O
study.	O

Epoetin	B-Premise
alfa,	I-Premise
compared	I-Premise
with	I-Premise
placebo,	I-Premise
significantly	I-Premise
decreased	I-Premise
transfusion	I-Premise
requirements	I-Premise
(P	I-Premise
=.0057)	I-Premise
and	I-Premise
increased	I-Premise
hemoglobin	I-Premise
(P	I-Premise
<.001).	I-Premise

Improvement	B-Premise
of	I-Premise
all	I-Premise
primary	I-Premise
cancer-	I-Premise
and	I-Premise
anemia-specific	I-Premise
QOL	I-Premise
domains,	I-Premise
including	I-Premise
energy	I-Premise
level,	I-Premise
ability	I-Premise
to	I-Premise
do	I-Premise
daily	I-Premise
activities,	I-Premise
and	I-Premise
fatigue,	I-Premise
was	I-Premise
significantly	I-Premise
(P	I-Premise
<.01)	I-Premise
greater	I-Premise
for	I-Premise
epoetin	I-Premise
alfa	I-Premise
versus	I-Premise
placebo	I-Premise
patients.	I-Premise

Although	O
the	O
study	O
was	O
not	O
powered	O
for	O
survival	O
as	O
an	O
end	O
point,	O
Kaplan-Meier	B-Premise
estimates	I-Premise
showed	I-Premise
a	I-Premise
trend	I-Premise
in	I-Premise
overall	I-Premise
survival	I-Premise
favoring	I-Premise
epoetin	I-Premise
alfa	I-Premise
(P	I-Premise
=.13,	I-Premise
log-rank	I-Premise
test),	I-Premise
and	O
Cox	B-Premise
regression	I-Premise
analysis	I-Premise
showed	I-Premise
an	I-Premise
estimated	I-Premise
hazards	I-Premise
ratio	I-Premise
of	I-Premise
1.309	I-Premise
(P	I-Premise
=.052)	I-Premise
favoring	I-Premise
epoetin	I-Premise
alfa.	I-Premise

Adverse	B-Premise
events	I-Premise
were	I-Premise
comparable	I-Premise
between	I-Premise
groups.	I-Premise

Epoetin	B-Claim
alfa	I-Claim
safely	I-Claim
and	I-Claim
effectively	I-Claim
ameliorates	I-Claim
anemia	I-Claim
and	I-Claim
significantly	I-Claim
improves	I-Claim
QOL	I-Claim
in	I-Claim
cancer	I-Claim
patients	I-Claim
receiving	I-Claim
nonplatinum	I-Claim
chemotherapy.	I-Claim

Encouraging	B-Claim
results	I-Claim
regarding	I-Claim
increased	I-Claim
survival	I-Claim
warrant	I-Claim
another	I-Claim
trial	I-Claim
designed	I-Claim
to	I-Claim
confirm	I-Claim
these	I-Claim
findings.	I-Claim

To	O
assess	O
comparatively,	O
in	O
terms	O
of	O
quality-adjusted	O
survival,	O
three	O
front-line	O
treatments	O
in	O
patients	O
with	O
stage	O
B-	O
or	O
C-chronic	O
lymphocytic	O
leukemia	O
(CLL).	O

To	O
describe	O
better	O
and	O
compare	O
the	O
survival	O
after	O
randomization	O
of	O
patients	O
from	O
the	O
CLL90	O
trial	O
that	O
randomly	O
compared	O
ChOP	O
(cyclophosphamide,	O
doxorubicin,	O
oncovin,	O
prednisone),	O
CAP	O
(cyclophosphamide,	O
doxorubicin,	O
prednisone)	O
and	O
fludarabine	O
in	O
advanced	O
CLL,	O
we	O
performed	O
a	O
quality-adjusted	O
survival	O
analysis.	O

This	O
consisted	O
of	O
defining	O
four	O
clinical	O
states	O
(toxicity,	O
treatment	O
free	O
of	O
toxicity,	O
no	O
treatment	O
nor	O
symptoms,	O
relapse),	O
then	O
summing	O
up	O
the	O
average	O
times	O
spent	O
in	O
each	O
state	O
weighted	O
by	O
utility	O
coefficients	O
that	O
reflect	O
relative	O
value	O
according	O
to	O
quality	O
of	O
life.	O

The	O
resulting	O
quality-adjusted	O
time	O
without	O
symptoms	O
or	O
toxicity	O
(Q-TWIST)	O
was	O
compared	O
between	O
randomized	O
groups,	O
and	O
sensitivity	O
(threshold)	O
analyses	O
to	O
the	O
choice	O
of	O
utility	O
coefficients	O
was	O
performed.	O

Over	B-Premise
73	I-Premise
months	I-Premise
after	I-Premise
randomization,	I-Premise
the	I-Premise
fludarabine	I-Premise
group	I-Premise
gained	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
45	I-Premise
days	I-Premise
of	I-Premise
toxicity-free	I-Premise
survival	I-Premise
at	I-Premise
CAP,	I-Premise
and	I-Premise
61	I-Premise
days	I-Premise
over	I-Premise
ChOP.	I-Premise

The	B-Premise
mean	I-Premise
TWIST	I-Premise
was	I-Premise
27.05	I-Premise
months	I-Premise
with	I-Premise
CAP,	I-Premise
31.5	I-Premise
months	I-Premise
with	I-Premise
ChOP	I-Premise
and	I-Premise
32.95	I-Premise
months	I-Premise
with	I-Premise
fludarabine.	I-Premise

The	B-Premise
threshold	I-Premise
analyses	I-Premise
showed	I-Premise
that,	I-Premise
whatever	I-Premise
the	I-Premise
utility	I-Premise
weights,	I-Premise
the	I-Premise
mean	I-Premise
Q-TWIST	I-Premise
was	I-Premise
always	I-Premise
greater	I-Premise
with	I-Premise
ChOP	I-Premise
or	I-Premise
fludarabine	I-Premise
as	I-Premise
compared	I-Premise
to	I-Premise
CAP.	I-Premise

Fludarabine	B-Claim
was	I-Claim
consistently	I-Claim
a	I-Claim
better	I-Claim
treatment	I-Claim
than	I-Claim
ChOP,	I-Claim
except	B-Premise
in	I-Premise
the	I-Premise
unlikely	I-Premise
case	I-Premise
of	I-Premise
high	I-Premise
utility	I-Premise
weights	I-Premise
attributed	I-Premise
to	I-Premise
toxicity	I-Premise
and	I-Premise
low	I-Premise
utility	I-Premise
weights	I-Premise
attributed	I-Premise
to	I-Premise
treatment.	I-Premise

Nevertheless,	O
from	B-Premise
a	I-Premise
clinical	I-Premise
point	I-Premise
of	I-Premise
view,	I-Premise
differences	I-Premise
between	I-Premise
ChOP	I-Premise
and	I-Premise
fludarabine	I-Premise
were	I-Premise
moderate	I-Premise
or	I-Premise
event	I-Premise
slight	I-Premise
(mean	I-Premise
difference	I-Premise
in	I-Premise
TWIST	I-Premise
of	I-Premise
1.45	I-Premise
months).	I-Premise

We	O
conclude	O
that	O
patients	B-Claim
with	I-Claim
advanced	I-Claim
CLL	I-Claim
have	I-Claim
a	I-Claim
moderate	I-Claim
benefit	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
Q-TWIST	I-Claim
when	I-Claim
treated	I-Claim
with	I-Claim
fludarabine	I-Claim
over	I-Claim
ChOP.	I-Claim

These	B-Claim
two	I-Claim
treatments	I-Claim
are	I-Claim
always	I-Claim
superior	I-Claim
to	I-Claim
CAP.	I-Claim

Cutaneous	B-Claim
T-cell	I-Claim
lymphoma	I-Claim
(CTCL)	I-Claim
can	I-Claim
be	I-Claim
associated	I-Claim
with	I-Claim
painful,	I-Claim
pruritic,	I-Claim
disfiguring	I-Claim
lesions.	I-Claim

As	O
part	O
of	O
a	O
multicenter,	O
randomized	O
phase	O
III	O
trial	O
in	O
patients	O
with	O
heavily	O
pretreated	O
advanced	O
and/or	O
recurrent	O
CTCL,	O
the	O
effects	O
of	O
an	O
interleukin-2	O
receptor-targeted	O
fusion	O
protein,	O
denileukin	O
diftitox	O
(DAB389IL-2,	O
ONTAK),	O
on	O
patient-rated	O
overall	O
quality	O
of	O
life	O
(QOL),	O
skin	O
appearance,	O
and	O
pruritus	O
severity	O
were	O
evaluated.	O

A	O
total	O
of	O
71	O
patients	O
with	O
stage	O
IB-IVA	O
CTCL	O
received	O
intravenous	O
denileukin	O
diftitox	O
9	O
microg/kg/day	O
or	O
18	O
microg/kg/day	O
over	O
15-60	O
minutes	O
for	O
5	O
consecutive	O
days	O
on	O
an	O
outpatient	O
basis;	O
cycles	O
were	O
planned	O
for	O
every	O
21	O
days	O
for	O
a	O
total	O
of	O
8	O
cycles	O
over	O
6	O
months.	O

Prior	O
to	O
each	O
treatment	O
cycle,	O
patients	O
were	O
evaluated	O
for	O
disease	O
response	O
and	O
were	O
asked	O
to	O
self-rate	O
their	O
overall	O
QOL	O
via	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-General	O
(FACT-G)	O
questionnaire,	O
skin	O
appearance	O
(7-point	O
scale),	O
and	O
pruritus	O
severity	O
(10-cm	O
visual	O
analogue	O
scale).	O

Composite	B-Premise
FACT-G	I-Premise
and	I-Premise
most	I-Premise
individual	I-Premise
subscale	I-Premise
scores	I-Premise
(physical,	I-Premise
social/family,	I-Premise
emotional,	I-Premise
and	I-Premise
functional	I-Premise
well	I-Premise
being)	I-Premise
in	I-Premise
documented	I-Premise
responders	I-Premise
(n	I-Premise
=	I-Premise
21)	I-Premise
gradually	I-Premise
increased	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
period,	I-Premise
generally	I-Premise
reaching	I-Premise
statistical	I-Premise
significance	I-Premise
(P	I-Premise
<	I-Premise
0.05)	I-Premise
by	I-Premise
cycle	I-Premise
3,	I-Premise
and	I-Premise
were	I-Premise
significantly	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.041)	I-Premise
higher	I-Premise
than	I-Premise
the	I-Premise
scores	I-Premise
of	I-Premise
nonresponders	I-Premise
at	I-Premise
endpoint.	I-Premise

Additionally	B-Premise
for	I-Premise
responders,	I-Premise
assessments	I-Premise
of	I-Premise
skin	I-Premise
severity	I-Premise
and	I-Premise
pruritus	I-Premise
severity	I-Premise
showed	I-Premise
significant	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.05)	I-Premise
improvements	I-Premise
at	I-Premise
study	I-Premise
endpoint	I-Premise
compared	I-Premise
with	I-Premise
baseline.	I-Premise

Adverse	B-Premise
transfusion-related	I-Premise
events	I-Premise
(eg,	I-Premise
hypersensitivity	I-Premise
reactions,	I-Premise
flu-like	I-Premise
syndrome)	I-Premise
were	I-Premise
common	I-Premise
during	I-Premise
cycles	I-Premise
1	I-Premise
and	I-Premise
2,	I-Premise
and	I-Premise
vascular-leak	I-Premise
syndrome	I-Premise
occurred	I-Premise
in	I-Premise
25%	I-Premise
of	I-Premise
patients.	I-Premise

Denileukin	B-Claim
diftitox	I-Claim
was	I-Claim
not	I-Claim
associated	I-Claim
with	I-Claim
any	I-Claim
clinically	I-Claim
significant	I-Claim
myelosuppression.	I-Claim

Heavily	B-Claim
pretreated	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
and/or	I-Claim
recurrent	I-Claim
CTCL	I-Claim
who	I-Claim
responded	I-Claim
to	I-Claim
denileukin	I-Claim
diftitox	I-Claim
therapy	I-Claim
showed	I-Claim
significant	I-Claim
improvements	I-Claim
in	I-Claim
self-rated	I-Claim
overall	I-Claim
QOL,	I-Claim
skin	I-Claim
appearance,	I-Claim
and	I-Claim
pruritus	I-Claim
severity.	I-Claim

Low	B-Claim
anterior	I-Claim
resection	I-Claim
with	I-Claim
coloanal	I-Claim
anastomosis	I-Claim
prevents	I-Claim
a	I-Claim
definitive	I-Claim
stoma	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
distal	I-Claim
rectal	I-Claim
cancer.	I-Claim

However,	B-Premise
imperative	I-Premise
stool	I-Premise
urge,	I-Premise
stool	I-Premise
fragmentation,	I-Premise
prolonged	I-Premise
stooling	I-Premise
sessions,	I-Premise
and	I-Premise
minor	I-Premise
problems	I-Premise
of	I-Premise
incontinence	I-Premise
are	I-Premise
frequently	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
postoperative	I-Premise
situation	I-Premise
and	I-Premise
negatively	I-Premise
affect	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

Therefore,	O
the	O
colonic	O
J-pouch	O
was	O
originally	O
constructed	O
to	O
create	O
a	O
stool	O
reservoir.	O

In	O
a	O
randomized,	O
prospective	O
study,	O
the	O
short	O
(5	O
cm)	O
colonic	O
J-pouch	O
was	O
tested	O
for	O
function	O
and	O
continence	O
vs.	O
straight	O
coloanal	O
anastomosis.	O

Over	O
a	O
period	O
of	O
30	O
months,	O
74	O
consecutive	O
patients	O
(55	O
males)	O
with	O
rectal	O
cancer	O
in	O
the	O
lower	O
and	O
middle	O
third	O
of	O
the	O
rectum	O
were	O
included	O
and	O
randomized	O
into	O
two	O
groups.	O

Anastomosis	O
was	O
performed	O
either	O
as	O
a	O
coloanal	O
or	O
a	O
colon-pouch-anal	O
anastomosis.	O

The	O
standardized	O
surgical	O
procedure	O
included	O
mobilization	O
of	O
the	O
left	O
hemicolon,	O
central	O
ligation	O
of	O
the	O
inferior	O
mesenteric	O
artery	O
and	O
vein,	O
preaortal	O
lymph	O
node	O
dissection,	O
autonomic	O
nerve	O
preservation,	O
and	O
total	O
mesorectal	O
excision.	O

The	O
anastomosis	O
was	O
performed	O
at	O
the	O
upper	O
anal	O
canal	O
or	O
at	O
the	O
intersphincteric	O
level.	O

All	O
patients	O
were	O
evaluated	O
preoperatively	O
and	O
six	O
months	O
postoperatively	O
for	O
fecal	O
continence,	O
including	O
sphincter	O
manometry	O
and	O
defecation	O
habits.	O

In	O
addition,	O
quality	O
of	O
life	O
was	O
determined	O
by	O
use	O
of	O
a	O
standardized	O
questionnaire	O
(European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer,	O
EORTC-QLQ-C30).	O

Thirty-seven	O
patients	O
were	O
randomized	O
into	O
each	O
group.	O

In	O
general,	O
problems	B-Premise
with	I-Premise
continence	I-Premise
for	I-Premise
liquids	I-Premise
or	I-Premise
gas	I-Premise
occurred	I-Premise
less	I-Premise
frequently	I-Premise
in	I-Premise
the	I-Premise
colonic	I-Premise
J-pouch	I-Premise
group	I-Premise
6	I-Premise
months	I-Premise
after	I-Premise
surgery.	I-Premise

The	B-Premise
frequency	I-Premise
of	I-Premise
bowel	I-Premise
movements	I-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
J-pouch	I-Premise
group	I-Premise
(2.5	I-Premise
per	I-Premise
day)	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
coloanal	I-Premise
group	I-Premise
(4.7	I-Premise
per	I-Premise
day).	I-Premise

Importantly,	O
in	B-Premise
a	I-Premise
manometric	I-Premise
study	I-Premise
at	I-Premise
the	I-Premise
same	I-Premise
postoperative	I-Premise
point,	I-Premise
neorectal	I-Premise
capacity	I-Premise
was	I-Premise
decreased	I-Premise
to	I-Premise
a	I-Premise
similar	I-Premise
degree	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
preoperative	I-Premise
rectal	I-Premise
volume.	I-Premise

Thus,	O
the	B-Premise
expected	I-Premise
and	I-Premise
postulated	I-Premise
reservoir	I-Premise
effect	I-Premise
could	I-Premise
not	I-Premise
be	I-Premise
achieved	I-Premise
by	I-Premise
forming	I-Premise
a	I-Premise
5-cm	I-Premise
colonic	I-Premise
J-pouch.	I-Premise

The	B-Claim
colonic	I-Claim
J-pouch	I-Claim
was	I-Claim
superior	I-Claim
with	I-Claim
regard	I-Claim
to	I-Claim
continence	I-Claim
for	I-Claim
gas	I-Claim
and	I-Claim
liquids	I-Claim
compared	I-Claim
with	I-Claim
a	I-Claim
straight	I-Claim
coloanal	I-Claim
anastomosis.	I-Claim

Furthermore,	O
stool	B-Claim
frequency	I-Claim
was	I-Claim
significantly	I-Claim
lower	I-Claim
in	I-Claim
the	I-Claim
J-pouch	I-Claim
group	I-Claim
than	I-Claim
in	I-Claim
the	I-Claim
coloanal	I-Claim
reconstruction	I-Claim
group.	I-Claim

However,	O
because	B-Premise
neorectal	I-Premise
capacity	I-Premise
decreased	I-Premise
equally	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
we	B-Claim
speculate	I-Claim
that	I-Claim
the	I-Claim
advantage	I-Claim
of	I-Claim
the	I-Claim
colonic	I-Claim
J-pouch	I-Claim
is	I-Claim
not	I-Claim
in	I-Claim
the	I-Claim
creation	I-Claim
of	I-Claim
a	I-Claim
larger	I-Claim
neorectal	I-Claim
reservoir	I-Claim
but	I-Claim
rather	I-Claim
may	I-Claim
be	I-Claim
related	I-Claim
to	I-Claim
decreased	I-Claim
motility.	I-Claim

To	O
investigate	O
the	O
effect	O
of	O
recombinant	O
human	O
erythropoietin	O
(epoetin	O
beta)	O
on	O
anemia,	O
transfusion	O
need,	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
severely	O
anemic	O
patients	O
with	O
low-grade	O
non-Hodgkin's	O
lymphoma	O
(NHL),	O
chronic	O
lymphocytic	O
leukemia	O
(CLL),	O
or	O
multiple	O
myeloma	O
(MM).	O

Transfusion-dependent	O
patients	O
with	O
NHL	O
(n	O
=	O
106),	O
CLL	O
(n	O
=	O
126),	O
or	O
MM	O
(n	O
=	O
117)	O
and	O
a	O
low	O
serum	O
erythropoietin	O
concentration	O
were	O
randomized	O
to	O
receive	O
epoetin	O
beta	O
150	O
IU/kg	O
or	O
placebo	O
subcutaneously	O
three	O
times	O
a	O
week	O
for	O
16	O
weeks.	O

Primary	O
efficacy	O
criteria	O
were	O
transfusion-free	O
and	O
transfusion-	O
and	O
severe	O
anemia-free	O
survival	O
(hemoglobin	O
[Hb]	O
>	O
8.5	O
g/dL)	O
between	O
weeks	O
5	O
to	O
16.	O

Response	O
was	O
defined	O
as	O
an	O
increase	O
in	O
Hb	O
>	O
or	O
=	O
2	O
g/dL	O
with	O
elimination	O
of	O
transfusion	O
need.	O

QOL	O
was	O
assessed	O
by	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
scale.	O

Transfusion-free	B-Premise
(P	I-Premise
=.0012)	I-Premise
survival	I-Premise
and	I-Premise
transfusion-	I-Premise
and	I-Premise
severe	I-Premise
anemia-free	I-Premise
survival	I-Premise
(P	I-Premise
=.0001)	I-Premise
were	I-Premise
significantly	I-Premise
greater	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
beta	I-Premise
group	I-Premise
versus	I-Premise
placebo	I-Premise
(Wald	I-Premise
chi(2)	I-Premise
test),	I-Premise
giving	I-Premise
a	I-Premise
relative	I-Premise
risk	I-Premise
reduction	I-Premise
of	I-Premise
43%	I-Premise
and	I-Premise
51%,	I-Premise
respectively.	I-Premise

The	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
67%	I-Premise
and	I-Premise
27%	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
beta	I-Premise
versus	I-Premise
the	I-Premise
placebo	I-Premise
group,	I-Premise
respectively	I-Premise
(P	I-Premise
<.0001).	I-Premise

After	B-Premise
12	I-Premise
and	I-Premise
16	I-Premise
weeks	I-Premise
of	I-Premise
treatment,	I-Premise
QOL	I-Premise
significantly	I-Premise
improved	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
beta	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(P	I-Premise
<.05);	I-Premise
this	B-Premise
improvement	I-Premise
correlated	I-Premise
with	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
Hb	I-Premise
concentration	I-Premise
(>	I-Premise
or	I-Premise
=	I-Premise
2	I-Premise
g/dL).	I-Premise

A	O
target	O
Hb	O
that	O
could	O
be	O
generally	O
recommended	O
could	O
not	O
be	O
identified.	O

Many	B-Claim
severely	I-Claim
anemic	I-Claim
and	I-Claim
transfusion-dependent	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
MM,	I-Claim
NHL,	I-Claim
and	I-Claim
CLL	I-Claim
and	I-Claim
a	I-Claim
low	I-Claim
performance	I-Claim
status	I-Claim
benefited	I-Claim
from	I-Claim
epoetin	I-Claim
therapy,	I-Claim
with	I-Claim
elimination	I-Claim
of	I-Claim
severe	I-Claim
anemia	I-Claim
and	I-Claim
transfusion	I-Claim
need,	I-Claim
and	I-Claim
improvement	I-Claim
in	I-Claim
QOL.	I-Claim

This	O
randomised	O
trial	O
compared	O
three	O
chemotherapy	O
regimens	O
in	O
the	O
first-line	O
treatment	O
of	O
advanced	O
colorectal	O
cancer,	O
in	O
terms	O
of	O
their	O
effect	O
on	O
overall	O
and	O
progression-free	O
survival;	O
other	O
endpoints	O
included	O
toxicity,	O
symptom	O
palliation,	O
and	O
quality	O
of	O
life.	O

905	O
patients	O
were	O
randomly	O
assigned	O
the	O
de	O
Gramont	O
regimen	O
(n=303;	O
folinic	O
acid	O
200	O
mg/m(2),	O
fluorouracil	O
bolus	O
400	O
mg/m(2),	O
and	O
infusion	O
600	O
mg/m(2)	O
on	O
days	O
1	O
and	O
2,	O
repeated	O
every	O
14	O
days),	O
the	O
Lokich	O
regimen	O
(n=301;	O
protracted	O
venous	O
infusion	O
of	O
fluorouracil	O
300	O
mg/m(2)	O
daily),	O
or	O
raltitrexed	O
(n=301;	O
3	O
mg/m(2)	O
intravenously	O
every	O
21	O
days).	O

Analyses	O
were	O
by	O
intention	O
to	O
treat.	O

Median	O
follow-up	O
of	O
survivors	O
was	O
67	O
weeks.	O

For	B-Premise
the	I-Premise
de	I-Premise
Gramont,	I-Premise
Lokich,	I-Premise
and	I-Premise
raltitrexed	I-Premise
groups,	I-Premise
respectively,	I-Premise
median	I-Premise
survival	I-Premise
was	I-Premise
294,	I-Premise
302,	I-Premise
and	I-Premise
266	I-Premise
days.	I-Premise

The	B-Premise
hazard	I-Premise
ratios	I-Premise
for	I-Premise
overall	I-Premise
survival	I-Premise
were	I-Premise
0.88	I-Premise
(95%	I-Premise
CI	I-Premise
0.70-1.12,	I-Premise
p=0.17)	I-Premise
for	I-Premise
de	I-Premise
Gramont	I-Premise
versus	I-Premise
Lokich,	I-Premise
and	I-Premise
0.99	I-Premise
(0.79-1.25,	I-Premise
p=0.94)	I-Premise
for	I-Premise
de	I-Premise
Gramont	I-Premise
versus	I-Premise
raltitrexed.	I-Premise

An	B-Premise
increase	I-Premise
in	I-Premise
treatment-related	I-Premise
deaths	I-Premise
was	I-Premise
seen	I-Premise
on	I-Premise
raltitrexed	I-Premise
(de	I-Premise
Gramont	I-Premise
one,	I-Premise
Lokich	I-Premise
two,	I-Premise
raltitrexed	I-Premise
18)	I-Premise
due	I-Premise
to	I-Premise
combined	I-Premise
gastrointestinal	I-Premise
and	I-Premise
haematological	I-Premise
toxicity.	I-Premise

Patients'	B-Premise
assessment	I-Premise
of	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
showed	I-Premise
that	I-Premise
raltitrexed	I-Premise
was	I-Premise
inferior	I-Premise
to	I-Premise
the	I-Premise
fluorouracil-based	I-Premise
regimens,	I-Premise
especially	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
palliation	I-Premise
and	I-Premise
functioning.	I-Premise

The	B-Claim
deGramont	I-Claim
and	I-Claim
Lokich	I-Claim
regimens	I-Claim
were	I-Claim
similar	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
survival,	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
and	I-Claim
response	I-Claim
rates.	I-Claim

The	B-Claim
Lokich	I-Claim
regimen	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
more	I-Claim
central	I-Claim
line	I-Claim
complications	I-Claim
and	I-Claim
hand-foot	I-Claim
syndrome.	I-Claim

Raltitrexed	B-Claim
showed	I-Claim
similar	I-Claim
response	I-Claim
rates	I-Claim
and	I-Claim
overall	I-Claim
survival	I-Claim
to	I-Claim
the	I-Claim
de	I-Claim
Gramont	I-Claim
regimen	I-Claim
and	I-Claim
was	I-Claim
easier	I-Claim
to	I-Claim
administer,	I-Claim
but	B-Claim
resulted	I-Claim
in	I-Claim
greater	I-Claim
toxicity	I-Claim
and	I-Claim
inferior	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

The	O
study	O
was	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
treatment	O
with	O
a	O
combination	O
of	O
trastuzumab	O
(Herceptin;	O
Genentech,	O
Inc,	O
South	O
San	O
Francisco,	O
CA)	O
and	O
chemotherapy	O
versus	O
chemotherapy	O
alone	O
on	O
health-related	O
quality	O
of	O
life	O
(HRQL)	O
in	O
patients	O
with	O
HER-2/neu	O
overexpressing,	O
metastatic	O
breast	O
cancer.	O

A	O
sample	O
of	O
400	O
patients,	O
not	O
previously	O
treated	O
for	O
metastatic	O
disease	O
and	O
randomized	O
to	O
receive	O
either	O
trastuzumab	O
plus	O
chemotherapy	O
(208	O
patients)	O
or	O
chemotherapy	O
alone	O
(192	O
patients),	O
completed	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
Care	O
Quality	O
of	O
Life	O
Questionnaire	O
at	O
baseline	O
and	O
on	O
at	O
least	O
one	O
subsequent	O
occasion	O
at	O
8,	O
20,	O
32,	O
44,	O
and	O
56	O
weeks.	O

HRQL	O
improvement	O
or	O
worsening	O
was	O
defined	O
as	O
a	O
>or=	O
10-point	O
change	O
(range,	O
0	O
to	O
100	O
points)	O
in	O
the	O
scores	O
of	O
six	O
preselected	O
domains	O
(global	O
quality	O
of	O
life	O
[QOL],	O
physical,	O
role,	O
social,	O
and	O
emotional	O
functioning,	O
and	O
fatigue).	O

Stable	O
HRQL	O
was	O
defined	O
as	O
a	O
change	O
of	O
less	O
than	O
10.	O

A	O
Bonferroni	O
correction	O
was	O
applied	O
for	O
multiple	O
testing.	O

After	B-Premise
completion	I-Premise
of	I-Premise
chemotherapy,	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
trastuzumab	I-Premise
and	I-Premise
chemotherapy	I-Premise
reported	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
fatigue	I-Premise
(P	I-Premise
<.05)	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
their	I-Premise
baseline	I-Premise
scores.	I-Premise

Higher	B-Premise
proportions	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
the	I-Premise
combined	I-Premise
therapy	I-Premise
achieved	I-Premise
improvement	I-Premise
in	I-Premise
global	I-Premise
QOL	I-Premise
(P	I-Premise
<.05)	I-Premise
than	I-Premise
did	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
chemotherapy	I-Premise
alone.	I-Premise

Higher	B-Premise
proportions	I-Premise
of	I-Premise
the	I-Premise
combined	I-Premise
therapy	I-Premise
group	I-Premise
also	I-Premise
achieved	I-Premise
improvement	I-Premise
in	I-Premise
physical	I-Premise
and	I-Premise
role	I-Premise
functioning	I-Premise
and	I-Premise
in	I-Premise
fatigue	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
chemotherapy	I-Premise
group,	I-Premise
but	B-Premise
the	I-Premise
differences	I-Premise
were	I-Premise
not	I-Premise
statistically	I-Premise
significant.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
proportions	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
that	I-Premise
reported	I-Premise
worsening.	I-Premise

Statistically	B-Claim
significantly	I-Claim
higher	I-Claim
proportions	I-Claim
of	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
a	I-Claim
combination	I-Claim
of	I-Claim
trastuzumab	I-Claim
and	I-Claim
chemotherapy	I-Claim
reported	I-Claim
improved	I-Claim
global	I-Claim
QOL	I-Claim
than	I-Claim
did	I-Claim
patients	I-Claim
treated	I-Claim
by	I-Claim
chemotherapy	I-Claim
alone.	I-Claim

To	O
compare	O
protracted	O
venous	O
infusion	O
(PVI)	O
fluorouracil	O
(5-FU)	O
with	O
PVI	O
5-FU	O
plus	O
mitomycin	O
(MMC)	O
in	O
patients	O
with	O
advanced	O
pancreatic	O
cancer	O
in	O
a	O
multicenter,	O
prospectively	O
randomized	O
study.	O

Two	O
hundred	O
eight	O
patients	O
were	O
randomized	O
to	O
PVI	O
5-FU	O
(300	O
mg/m(2)/d	O
for	O
a	O
maximum	O
of	O
24	O
weeks)	O
or	O
PVI	O
5-FU	O
plus	O
MMC	O
(7	O
mg/m(2)	O
every	O
6	O
weeks	O
for	O
four	O
courses).	O

The	O
major	O
end	O
points	O
were	O
tumor	O
response,	O
survival,	O
toxicity,	O
and	O
quality	O
of	O
life	O
(QOL).	O

The	O
two	O
treatment	O
groups	O
were	O
balanced	O
for	O
baseline	O
demographic	O
factors,	O
and	O
62%	O
had	O
metastatic	O
disease.	O

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
8.4%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI])	I-Premise
3.2%	I-Premise
to	I-Premise
13.7%	I-Premise
for	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
PVI	I-Premise
5-FU	I-Premise
alone	I-Premise
compared	I-Premise
with	I-Premise
17.6%;	I-Premise
95%	I-Premise
CI	I-Premise
10.3%	I-Premise
to	I-Premise
25.1%	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
plus	I-Premise
MMC	I-Premise
(P	I-Premise
=.04).	I-Premise

Median	B-Premise
failure-free	I-Premise
survival	I-Premise
was	I-Premise
2.8	I-Premise
months	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
and	I-Premise
3.8	I-Premise
months	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
plus	I-Premise
MMC	I-Premise
(P	I-Premise
=.14).	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
5.1	I-Premise
months	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
and	I-Premise
6.5	I-Premise
months	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
plus	I-Premise
MMC	I-Premise
(P	I-Premise
=.34).	I-Premise

Toxicities	B-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
were	I-Premise
mild.	I-Premise

There	B-Premise
was	I-Premise
an	I-Premise
increased	I-Premise
incidence	I-Premise
of	I-Premise
neutropenia	I-Premise
in	I-Premise
the	I-Premise
5-FU	I-Premise
plus	I-Premise
MMC	I-Premise
arm	I-Premise
(P	I-Premise
<.01),	I-Premise
although	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
infection	I-Premise
were	I-Premise
seen.	I-Premise

No	B-Premise
patients	I-Premise
developed	I-Premise
hemolytic	I-Premise
uremic	I-Premise
syndrome.	I-Premise

Global	B-Claim
QOL	I-Claim
improved	I-Claim
significantly	I-Claim
after	I-Claim
24	I-Claim
weeks	I-Claim
of	I-Claim
treatment	I-Claim
compared	I-Claim
with	I-Claim
baseline	I-Claim
for	I-Claim
patients	I-Claim
receiving	I-Claim
5-FU	I-Claim
plus	I-Claim
MMC,	I-Claim
although	B-Premise
there	I-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
QOL	I-Premise
between	I-Premise
arms.	I-Premise

PVI	B-Claim
5-FU	I-Claim
plus	I-Claim
MMC	I-Claim
resulted	I-Claim
in	I-Claim
a	I-Claim
superior	I-Claim
response	I-Claim
rate	I-Claim
in	I-Claim
comparison	I-Claim
with	I-Claim
PVI	I-Claim
5-FU	I-Claim
alone	I-Claim
in	I-Claim
advanced	I-Claim
pancreatic	I-Claim
cancer,	I-Claim
but	B-Claim
this	I-Claim
did	I-Claim
not	I-Claim
translate	I-Claim
into	I-Claim
a	I-Claim
survival	I-Claim
advantage.	I-Claim

These	B-Claim
results	I-Claim
emphasize	I-Claim
the	I-Claim
importance	I-Claim
of	I-Claim
chemotherapy	I-Claim
in	I-Claim
this	I-Claim
setting	I-Claim
and	I-Claim
the	I-Claim
continuing	I-Claim
value	I-Claim
of	I-Claim
the	I-Claim
fluoropyrimidines	I-Claim
in	I-Claim
pancreatic	I-Claim
cancer.	I-Claim

We	O
compared	O
the	O
clinical	O
effects	O
and	O
impact	O
on	O
quality	O
of	O
life	O
(QOL)	O
of	O
patients	O
who	O
received	O
a	O
3-month	O
course	O
of	O
flutamide	O
monotherapy	O
before	O
radical	O
prostatectomy	O
with	O
those	O
who	O
received	O
a	O
3-month	O
course	O
of	O
luteinizing	O
hormone-releasing	O
hormone	O
(LHRH)	O
agonist	O
monotherapy.	O

Thirty-seven	O
patients	O
with	O
non-metastatic	O
prostate	O
cancer	O
were	O
enrolled	O
in	O
this	O
study	O
(19,	O
flutamide;	O
18,	O
LHRH	O
agonist).	O

The	O
rates	O
of	O
change	O
of	O
serum	O
prostate-specific	O
antigen	O
(PSA)	O
and	O
testosterone	O
levels,	O
downsizing	O
of	O
prostate	O
volume,	O
the	O
rate	O
of	O
organ	O
confined	O
disease,	O
adverse	O
effects	O
and	O
perioperative	O
scores	O
measured	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Prostate	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
(EORTC-P)	O
and	O
the	O
Sapporo	O
Medical	O
University	O
Sexual	O
Function	O
Questionnaire	O
(SMUF)	O
were	O
analyzed.	O

At	B-Premise
radical	I-Premise
prostatectomy,	I-Premise
pathological	I-Premise
variables	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

Serum	B-Premise
testosterone	I-Premise
level	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
(mean	I-Premise
359.2	I-Premise
compared	I-Premise
to	I-Premise
10.5,	I-Premise
P	I-Premise
<	I-Premise
0.001),	I-Premise
complete	B-Premise
response	I-Premise
rate	I-Premise
of	I-Premise
PSA	I-Premise
(13%	I-Premise
compared	I-Premise
to	I-Premise
57%,	I-Premise
P	I-Premise
=	I-Premise
0.028)	I-Premise
and	I-Premise
rate	I-Premise
of	I-Premise
downsizing	I-Premise
of	I-Premise
prostate	I-Premise
volume	I-Premise
(mean,	I-Premise
-17.7%	I-Premise
compared	I-Premise
to	I-Premise
-35.4%,	I-Premise
P	I-Premise
=	I-Premise
0.038)	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
flutamide	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
LHRH	I-Premise
group.	I-Premise

After	B-Premise
neoadjuvant	I-Premise
hormone	I-Premise
therapy,	I-Premise
the	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
sexual	I-Premise
problem	I-Premise
domain	I-Premise
of	I-Premise
EORTC-P	I-Premise
(P	I-Premise
=	I-Premise
0.033)	I-Premise
and	I-Premise
sexual	I-Premise
desire	I-Premise
score	I-Premise
of	I-Premise
SMUF	I-Premise
(P	I-Premise
=	I-Premise
0.021)	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
flutamide	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
LHRH	I-Premise
group.	I-Premise

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
34	I-Premise
months	I-Premise
after	I-Premise
prostatectomy,	I-Premise
biochemical	I-Premise
failure-free	I-Premise
survival	I-Premise
rate	I-Premise
in	I-Premise
the	I-Premise
flutamide	I-Premise
group	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
from	I-Premise
that	I-Premise
in	I-Premise
the	I-Premise
LHRH	I-Premise
group.	I-Premise

This	B-Claim
study	I-Claim
suggests	I-Claim
that	I-Claim
flutamide	I-Claim
monotherapy	I-Claim
can	I-Claim
be	I-Claim
an	I-Claim
acceptable	I-Claim
modality	I-Claim
as	I-Claim
an	I-Claim
option	I-Claim
for	I-Claim
neoadjuvant	I-Claim
hormone	I-Claim
therapy.	I-Claim

We	O
previously	O
reported	O
that	O
treatment	O
of	O
patients	O
with	O
symptomatic	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
with	O
single	O
agent	O
Gemcitabine	O
(GEM)	O
resulted	O
in	O
a	O
superior	O
clinical-benefit	O
response	O
rate	O
(RR)	O
compared	O
to	O
cisplatin-based	O
combination	O
chemotherapy.	O

We	O
now	O
report	O
the	O
detailed	O
individual	O
symptom	O
control	O
analysis,	O
and	O
the	O
influence	O
of	O
cisplatin-use,	O
age,	O
performance	O
status	O
(PS)	O
and	O
duration	O
of	O
treatment.	O

Patients	O
received	O
either	O
GEM	O
(1000	O
mg/m(2),	O
days	O
1,	O
8	O
and	O
15)	O
or	O
cisplatin	O
(100	O
mg/m(2),	O
day	O
1)	O
plus	O
Vindesine	O
(3	O
mg/m(2),	O
days	O
1	O
and	O
15)	O
(PV),	O
both	O
every	O
4	O
weeks.	O

Scores	O
of	O
9	O
symptoms	O
were	O
listed	O
weekly	O
by	O
the	O
patient	O
on	O
visual	O
analogue	O
scales.	O

Improvement	O
of	O
a	O
symptom	O
was	O
defined	O
as	O
2	O
consecutive	O
cycles	O
of	O
improvement	O
over	O
baseline.	O

Baseline	O
symptoms	O
in	O
the	O
169	O
patients	O
were	O
well	O
balanced	O
between	O
the	O
2	O
arms	O
(84	O
GEM,	O
85	O
PV).	O

Both	B-Premise
patients	I-Premise
with	I-Premise
objective	I-Premise
response	I-Premise
and	I-Premise
disease	I-Premise
stabilisation	I-Premise
had	I-Premise
clearly	I-Premise
better	I-Premise
symptom	I-Premise
control	I-Premise
than	I-Premise
those	I-Premise
with	I-Premise
disease	I-Premise
progression.	I-Premise

Symptom	B-Premise
control	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
'disease-specific'	I-Premise
symptoms	I-Premise
such	I-Premise
as	I-Premise
cough,	I-Premise
dyspnea,	I-Premise
pain	I-Premise
or	I-Premise
haemoptysis.	I-Premise

Compared	B-Premise
to	I-Premise
PV,	I-Premise
a	I-Premise
significantly	I-Premise
larger	I-Premise
number	I-Premise
of	I-Premise
GEM-patients	I-Premise
had	I-Premise
better	I-Premise
scores	I-Premise
for	I-Premise
'constitutional'	I-Premise
items	I-Premise
such	I-Premise
as	I-Premise
anorexia	I-Premise
(P=0.007),	I-Premise
ability	I-Premise
to	I-Premise
carry	I-Premise
on	I-Premise
with	I-Premise
daily	I-Premise
activities	I-Premise
(P=0.04)	I-Premise
and	I-Premise
overall	I-Premise
impression	I-Premise
of	I-Premise
quality-of-life	I-Premise
(P=0.008).	I-Premise

Symptom	B-Premise
control	I-Premise
was	I-Premise
very	I-Premise
similar	I-Premise
in	I-Premise
younger	I-Premise
(<65	I-Premise
years)	I-Premise
versus	I-Premise
older	I-Premise
(>/=65	I-Premise
years)	I-Premise
patients,	I-Premise
and	I-Premise
only	I-Premise
slightly	I-Premise
better	I-Premise
in	I-Premise
those	I-Premise
with	I-Premise
a	I-Premise
Karnofsky	I-Premise
PS	I-Premise
>/=80%	I-Premise
compared	I-Premise
to	I-Premise
those	I-Premise
<80%.	I-Premise

Most	B-Premise
of	I-Premise
the	I-Premise
symptom	I-Premise
improvement	I-Premise
occurred	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
3	I-Premise
cycles,	I-Premise
with	I-Premise
some	I-Premise
further	I-Premise
symptom	I-Premise
improvement	I-Premise
in	I-Premise
the	I-Premise
following	I-Premise
cycles	I-Premise
in	I-Premise
the	I-Premise
GEM-arm	I-Premise
only.	I-Premise

Both	B-Claim
GEM	I-Claim
and	I-Claim
PV	I-Claim
yield	I-Claim
a	I-Claim
symptom	I-Claim
control	I-Claim
rate	I-Claim
much	I-Claim
higher	I-Claim
than	I-Claim
expected	I-Claim
by	I-Claim
the	I-Claim
objective	I-Claim
tumour	I-Claim
RR.	I-Claim

GEM	B-Claim
is	I-Claim
equally	I-Claim
effective	I-Claim
in	I-Claim
controlling	I-Claim
'disease-specific'	I-Claim
symptoms,	I-Claim
but	I-Claim
superior	I-Claim
in	I-Claim
controlling	I-Claim
'constitutional'	I-Claim
symptoms.	I-Claim

Most	B-Premise
of	I-Premise
the	I-Premise
symptom	I-Premise
control	I-Premise
was	I-Premise
achieved	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
3	I-Premise
cycles	I-Premise
of	I-Premise
treatment,	I-Premise
with	I-Premise
some	I-Premise
further	I-Premise
improvement	I-Premise
thereafter	I-Premise
in	I-Premise
the	I-Premise
GEM-arm	I-Premise
only.	I-Premise

Androgen	B-Claim
deprivation	I-Claim
therapy	I-Claim
is	I-Claim
a	I-Claim
common	I-Claim
treatment	I-Claim
in	I-Claim
men	I-Claim
with	I-Claim
prostate	I-Claim
cancer	I-Claim
that	I-Claim
may	I-Claim
cause	I-Claim
fatigue,	I-Claim
functional	I-Claim
decline,	I-Claim
increased	I-Claim
body	I-Claim
fatness,	I-Claim
and	I-Claim
loss	I-Claim
of	I-Claim
lean	I-Claim
body	I-Claim
tissue.	I-Claim

These	B-Claim
physical	I-Claim
changes	I-Claim
can	I-Claim
negatively	I-Claim
affect	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Resistance	B-Claim
exercise	I-Claim
may	I-Claim
help	I-Claim
to	I-Claim
counter	I-Claim
some	I-Claim
of	I-Claim
these	I-Claim
side	I-Claim
effects	I-Claim
by	I-Claim
reducing	I-Claim
fatigue,	I-Claim
elevating	I-Claim
mood,	I-Claim
building	I-Claim
muscle	I-Claim
mass,	I-Claim
and	I-Claim
reducing	I-Claim
body	I-Claim
fat.	I-Claim

In	O
a	O
two-site	O
study,	O
155	O
men	O
with	O
prostate	O
cancer	O
who	O
were	O
scheduled	O
to	O
receive	O
androgen	O
deprivation	O
therapy	O
for	O
at	O
least	O
3	O
months	O
after	O
recruitment	O
were	O
randomly	O
assigned	O
to	O
an	O
intervention	O
group	O
that	O
participated	O
in	O
a	O
resistance	O
exercise	O
program	O
three	O
times	O
per	O
week	O
for	O
12	O
weeks	O
(82	O
men)	O
or	O
to	O
a	O
waiting	O
list	O
control	O
group	O
(73	O
men).	O

The	O
primary	O
outcomes	O
were	O
fatigue	O
and	O
disease-specific	O
quality	O
of	O
life	O
as	O
assessed	O
by	O
self-reported	O
questionnaires	O
after	O
12	O
weeks.	O

Secondary	O
outcomes	O
were	O
muscular	O
fitness	O
and	O
body	O
composition.	O

Men	B-Premise
assigned	I-Premise
to	I-Premise
resistance	I-Premise
exercise	I-Premise
had	I-Premise
less	I-Premise
interference	I-Premise
from	I-Premise
fatigue	I-Premise
on	I-Premise
activities	I-Premise
of	I-Premise
daily	I-Premise
living	I-Premise
(P	I-Premise
=.002)	I-Premise
and	I-Premise
higher	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=.001)	I-Premise
than	I-Premise
men	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Men	B-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
demonstrated	I-Premise
higher	I-Premise
levels	I-Premise
of	I-Premise
upper	I-Premise
body	I-Premise
(P	I-Premise
=.009)	I-Premise
and	I-Premise
lower	I-Premise
body	I-Premise
(P	I-Premise
<.001)	I-Premise
muscular	I-Premise
fitness	I-Premise
than	I-Premise
men	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

The	B-Premise
12-week	I-Premise
resistance	I-Premise
exercise	I-Premise
intervention	I-Premise
did	I-Premise
not	I-Premise
improve	I-Premise
body	I-Premise
composition	I-Premise
as	I-Premise
measured	I-Premise
by	I-Premise
changes	I-Premise
in	I-Premise
body	I-Premise
weight,	I-Premise
body	I-Premise
mass	I-Premise
index,	I-Premise
waist	I-Premise
circumference,	I-Premise
or	I-Premise
subcutaneous	I-Premise
skinfolds.	I-Premise

Resistance	B-Claim
exercise	I-Claim
reduces	I-Claim
fatigue	I-Claim
and	I-Claim
improves	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
muscular	I-Claim
fitness	I-Claim
in	I-Claim
men	I-Claim
with	I-Claim
prostate	I-Claim
cancer	I-Claim
receiving	I-Claim
androgen	I-Claim
deprivation	I-Claim
therapy.	I-Claim

This	B-Claim
form	I-Claim
of	I-Claim
exercise	I-Claim
can	I-Claim
be	I-Claim
an	I-Claim
important	I-Claim
component	I-Claim
of	I-Claim
supportive	I-Claim
care	I-Claim
for	I-Claim
these	I-Claim
patients.	I-Claim

To	O
determine	O
the	O
effects	O
of	O
exercise	O
training	O
on	O
cardiopulmonary	O
function	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
postmenopausal	O
breast	O
cancer	O
survivors	O
who	O
had	O
completed	O
surgery,	O
radiotherapy,	O
and/or	O
chemotherapy	O
with	O
or	O
without	O
current	O
hormone	O
therapy	O
use.	O

Fifty-three	O
postmenopausal	O
breast	O
cancer	O
survivors	O
were	O
randomly	O
assigned	O
to	O
an	O
exercise	O
(n	O
=	O
25)	O
or	O
control	O
(n	O
=	O
28)	O
group.	O

The	O
exercise	O
group	O
trained	O
on	O
cycle	O
ergometers	O
three	O
times	O
per	O
week	O
for	O
15	O
weeks	O
at	O
a	O
power	O
output	O
that	O
elicited	O
the	O
ventilatory	O
equivalent	O
for	O
carbon	O
dioxide.	O

The	O
control	O
group	O
did	O
not	O
train.	O

The	O
primary	O
outcomes	O
were	O
changes	O
in	O
peak	O
oxygen	O
consumption	O
and	O
overall	O
QOL	O
from	O
baseline	O
to	O
postintervention.	O

Peak	O
oxygen	O
consumption	O
was	O
assessed	O
by	O
a	O
graded	O
exercise	O
test	O
using	O
gas	O
exchange	O
analysis.	O

Overall	O
QOL	O
was	O
assessed	O
by	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Breast	O
scale.	O

Fifty-two	O
participants	O
completed	O
the	O
trial.	O

The	O
exercise	O
group	O
completed	O
98.4%	O
of	O
the	O
exercise	O
sessions.	O

Baseline	O
values	O
for	O
peak	O
oxygen	O
consumption	O
(P	O
=.254)	O
and	O
overall	O
QOL	O
(P	O
=.286)	O
did	O
not	O
differ	O
between	O
groups.	O

Peak	B-Premise
oxygen	I-Premise
consumption	I-Premise
increased	I-Premise
by	I-Premise
0.24	I-Premise
L/min	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group,	I-Premise
whereas	B-Premise
it	I-Premise
decreased	I-Premise
by	I-Premise
0.05	I-Premise
L/min	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(mean	I-Premise
difference,	I-Premise
0.29	I-Premise
L/min;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
0.18	I-Premise
to	I-Premise
0.40;	I-Premise
P	I-Premise
<.001).	I-Premise

Overall	B-Premise
QOL	I-Premise
increased	I-Premise
by	I-Premise
9.1	I-Premise
points	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
0.3	I-Premise
points	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(mean	I-Premise
difference,	I-Premise
8.8	I-Premise
points;	I-Premise
95%	I-Premise
CI,	I-Premise
3.6	I-Premise
to	I-Premise
14.0;	I-Premise
P	I-Premise
=.001).	I-Premise

Pearson	B-Premise
correlations	I-Premise
indicated	I-Premise
that	I-Premise
change	I-Premise
in	I-Premise
peak	I-Premise
oxygen	I-Premise
consumption	I-Premise
correlated	I-Premise
with	I-Premise
change	I-Premise
in	I-Premise
overall	I-Premise
QOL	I-Premise
(r	I-Premise
=	I-Premise
0.45;	I-Premise
P	I-Premise
<.01).	I-Premise

Exercise	B-Claim
training	I-Claim
had	I-Claim
beneficial	I-Claim
effects	I-Claim
on	I-Claim
cardiopulmonary	I-Claim
function	I-Claim
and	I-Claim
QOL	I-Claim
in	I-Claim
postmenopausal	I-Claim
breast	I-Claim
cancer	I-Claim
survivors.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
two	O
doses	O
of	O
gefitinib	O
(Iressa	O
[ZD1839];	O
AstraZeneca,	O
Wilmington,	O
DE),	O
a	O
novel	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor,	O
in	O
patients	O
with	O
pretreated	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

This	O
was	O
a	O
randomized,	O
double-blind,	O
parallel-group,	O
multicenter	O
phase	O
II	O
trial.	O

Two	O
hundred	O
ten	O
patients	O
with	O
advanced	O
NSCLC	O
who	O
were	O
previously	O
treated	O
with	O
one	O
or	O
two	O
chemotherapy	O
regimens	O
(at	O
least	O
one	O
containing	O
platinum)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
250-mg	O
or	O
500-mg	O
oral	O
doses	O
of	O
gefitinib	O
once	O
daily.	O

Efficacy	B-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
the	I-Premise
250-	I-Premise
and	I-Premise
500-mg/d	I-Premise
groups.	I-Premise

Objective	B-Premise
tumor	I-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
18.4%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
11.5	I-Premise
to	I-Premise
27.3)	I-Premise
and	I-Premise
19.0%	I-Premise
(95%	I-Premise
CI,	I-Premise
12.1	I-Premise
to	I-Premise
27.9);	I-Premise
among	I-Premise
evaluable	I-Premise
patients,	I-Premise
symptom	I-Premise
improvement	I-Premise
rates	I-Premise
were	I-Premise
40.3%	I-Premise
(95%	I-Premise
CI,	I-Premise
28.5	I-Premise
to	I-Premise
53.0)	I-Premise
and	I-Premise
37.0%	I-Premise
(95%	I-Premise
CI,	I-Premise
26.0	I-Premise
to	I-Premise
49.1);	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
times	I-Premise
were	I-Premise
2.7	I-Premise
and	I-Premise
2.8	I-Premise
months;	I-Premise
and	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
times	I-Premise
were	I-Premise
7.6	I-Premise
and	I-Premise
8.0	I-Premise
months,	I-Premise
respectively.	I-Premise

Symptom	B-Premise
improvements	I-Premise
were	I-Premise
recorded	I-Premise
for	I-Premise
69.2%	I-Premise
(250	I-Premise
mg/d)	I-Premise
and	I-Premise
85.7%	I-Premise
(500	I-Premise
mg/d)	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
a	I-Premise
tumor	I-Premise
response.	I-Premise

Adverse	B-Premise
events	I-Premise
(AEs)	I-Premise
at	I-Premise
both	I-Premise
dose	I-Premise
levels	I-Premise
were	I-Premise
generally	I-Premise
mild	I-Premise
(grade	I-Premise
1	I-Premise
or	I-Premise
2)	I-Premise
and	I-Premise
consisted	I-Premise
mainly	I-Premise
of	I-Premise
skin	I-Premise
reactions	I-Premise
and	I-Premise
diarrhea.	I-Premise

Drug-related	B-Premise
toxicities	I-Premise
were	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
the	I-Premise
higher-dose	I-Premise
group.	I-Premise

Withdrawal	B-Premise
due	I-Premise
to	I-Premise
drug-related	I-Premise
AEs	I-Premise
was	I-Premise
1.9%	I-Premise
and	I-Premise
9.4%	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
gefitinib	I-Premise
250	I-Premise
and	I-Premise
500	I-Premise
mg/d,	I-Premise
respectively.	I-Premise

Gefitinib	B-Claim
showed	I-Claim
clinically	I-Claim
meaningful	I-Claim
antitumor	I-Claim
activity	I-Claim
and	I-Claim
provided	I-Claim
symptom	I-Claim
relief	I-Claim
as	I-Claim
second-	I-Claim
and	I-Claim
third-line	I-Claim
treatment	I-Claim
in	I-Claim
these	I-Claim
patients.	I-Claim

At	B-Claim
250	I-Claim
mg/d,	I-Claim
gefitinib	I-Claim
had	I-Claim
a	I-Claim
favorable	I-Claim
AE	I-Claim
profile.	I-Claim

Gefitinib	B-Claim
250	I-Claim
mg/d	I-Claim
is	I-Claim
an	I-Claim
important,	I-Claim
novel	I-Claim
treatment	I-Claim
option	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
pretreated	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

Imatinib	B-Claim
(Gleevec),	I-Claim
a	I-Claim
highly	I-Claim
effective	I-Claim
specific	I-Claim
tyrosine	I-Claim
kinase	I-Claim
inhibitor,	I-Claim
demonstrates	I-Claim
a	I-Claim
better	I-Claim
side	I-Claim
effect	I-Claim
profile	I-Claim
than	I-Claim
interferon-alpha	I-Claim
(IFN),	I-Claim
which	I-Claim
impairs	I-Claim
patients'	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QoL).	I-Claim

This	O
phase	O
III	O
international	O
study	O
evaluated	O
QoL	O
outcomes	O
in	O
1,106	O
newly	O
diagnosed	O
patients	O
with	O
chronic-phase	O
chronic	O
myeloid	O
leukemia	O
(CML)	O
who	O
were	O
randomized	O
to	O
receive	O
either	O
imatinib	O
400	O
mg	O
daily	O
or	O
IFN	O
up	O
to	O
5	O
MU/m(2)/d	O
with	O
cytarabine	O
(Ara-C)	O
20	O
mg/m(2)/d	O
added	O
for	O
10	O
days	O
every	O
month	O
(IFN	O
+	O
LDAC).	O

Crossover	O
to	O
the	O
other	O
treatment	O
arm	O
was	O
permitted	O
due	O
to	O
a	O
lack	O
of	O
efficacy	O
or	O
treatment	O
intolerance.	O

QoL	O
was	O
assessed	O
with	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Biologic	O
Response	O
Modifiers	O
(FACT-BRM)	O
at	O
baseline,	O
monthly	O
for	O
6	O
months	O
and	O
then	O
at	O
months	O
9,	O
12,	O
and	O
18.	O

The	O
Trial	O
Outcome	O
Index	O
(TOI;	O
a	O
composite	O
endpoint	O
of	O
physical/functional/treatment-specific	O
subscales)	O
was	O
the	O
primary	O
endpoint.	O

Secondary	O
endpoints	O
measured	O
were	O
social/family	O
well-being	O
(SFWB)	O
and	O
emotional	O
well-being	O
(EWB).	O

QoL	O
was	O
analyzed	O
for	O
the	O
first	O
18	O
months	O
of	O
treatment	O
using	O
mixed	O
effects	O
growth	O
curve	O
models.	O

The	O
primary	O
analyses	O
were	O
intention-to-treat	O
(ITT);	O
secondary	O
analyses	O
incorporated	O
crossover	O
as	O
a	O
time-dependent	O
covariate.	O

A	O
total	O
of	O
1,049	O
patients	O
completed	O
at	O
least	O
one	O
QoL	O
assessment.	O

Two	B-Premise
hundred	I-Premise
sixty-one	I-Premise
patients	I-Premise
(50%)	I-Premise
crossed	I-Premise
over	I-Premise
from	I-Premise
IFN	I-Premise
to	I-Premise
imatinib	I-Premise
and	I-Premise
11	I-Premise
(2%)	I-Premise
crossed	I-Premise
over	I-Premise
from	I-Premise
imatinib	I-Premise
to	I-Premise
IFN.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
decline	I-Premise
in	I-Premise
TOI	I-Premise
scores	I-Premise
for	I-Premise
the	I-Premise
IFN	I-Premise
treatment	I-Premise
arm	I-Premise
compared	I-Premise
with	I-Premise
preservation	I-Premise
of	I-Premise
baseline	I-Premise
TOI	I-Premise
scores	I-Premise
in	I-Premise
the	I-Premise
imatinib	I-Premise
arm	I-Premise
(P	I-Premise
<.001,	I-Premise
ITT).	I-Premise

Mean	B-Premise
social/family	I-Premise
and	I-Premise
EWB	I-Premise
scores	I-Premise
were	I-Premise
22.8	I-Premise
and	I-Premise
19.5,	I-Premise
respectively,	I-Premise
for	I-Premise
imatinib	I-Premise
and	I-Premise
21.6	I-Premise
and	I-Premise
17.6,	I-Premise
respectively,	I-Premise
for	I-Premise
IFN	I-Premise
(P	I-Premise
<.001,	I-Premise
ITT).	I-Premise

After	B-Premise
crossing	I-Premise
over	I-Premise
from	I-Premise
IFN	I-Premise
to	I-Premise
imatinib,	I-Premise
patients	I-Premise
experienced	I-Premise
a	I-Premise
significant	I-Premise
(P	I-Premise
<.001)	I-Premise
increase	I-Premise
in	I-Premise
TOI	I-Premise
scores.	I-Premise

Imatinib	B-Claim
offers	I-Claim
clear	I-Claim
QoL	I-Claim
advantages	I-Claim
over	I-Claim
IFN	I-Claim
as	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
chronic-phase	I-Claim
CML.	I-Claim

In	O
addition,	O
patients	B-Claim
who	I-Claim
crossed	I-Claim
over	I-Claim
to	I-Claim
imatinib	I-Claim
reported	I-Claim
higher	I-Claim
QoL	I-Claim
than	I-Claim
those	I-Claim
who	I-Claim
remained	I-Claim
on	I-Claim
IFN.	I-Claim

To	O
investigate	O
whether	O
docetaxel	O
plus	O
platinum	O
regimens	O
improve	O
survival	O
and	O
affect	O
quality	O
of	O
life	O
(QoL)	O
in	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
compared	O
with	O
vinorelbine	O
plus	O
cisplatin	O
as	O
first-line	O
chemotherapy.	O

Patients	O
(n	O
=	O
1,218)	O
with	O
stage	O
IIIB	O
to	O
IV	O
NSCLC	O
were	O
randomly	O
assigned	O
to	O
receive	O
docetaxel	O
75	O
mg/m2	O
and	O
cisplatin	O
75	O
mg/m2	O
every	O
3	O
weeks	O
(DC);	O
docetaxel	O
75	O
mg/m2	O
and	O
carboplatin	O
area	O
under	O
the	O
curve	O
of	O
6	O
mg/mL	O
*	O
min	O
every	O
3	O
weeks	O
(DCb);	O
or	O
vinorelbine	O
25	O
mg/m2/wk	O
and	O
cisplatin	O
100	O
mg/m2	O
every	O
4	O
weeks	O
(VC).	O

Patients	B-Premise
treated	I-Premise
with	I-Premise
DC	I-Premise
had	I-Premise
a	I-Premise
median	I-Premise
survival	I-Premise
of	I-Premise
11.3	I-Premise
v	I-Premise
10.1	I-Premise
months	I-Premise
for	I-Premise
VC-treated	I-Premise
patients	I-Premise
(P	I-Premise
=.044;	I-Premise
hazard	I-Premise
ratio,	I-Premise
1.183	I-Premise
[97.2%	I-Premise
confidence	I-Premise
interval,	I-Premise
0.989	I-Premise
to	I-Premise
1.416]).	I-Premise

The	B-Premise
2-year	I-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
21%	I-Premise
for	I-Premise
DC-treated	I-Premise
patients	I-Premise
and	I-Premise
14%	I-Premise
for	I-Premise
VC-treated	I-Premise
patients.	I-Premise

Overall	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
31.6%	I-Premise
for	I-Premise
DC-treated	I-Premise
patients	I-Premise
v	I-Premise
24.5%	I-Premise
for	I-Premise
VC-treated	I-Premise
patients	I-Premise
(P	I-Premise
=.029).	I-Premise

Median	B-Premise
survival	I-Premise
(9.4	I-Premise
v	I-Premise
9.9	I-Premise
months	I-Premise
[for	I-Premise
VC];	I-Premise
P	I-Premise
=.657;	I-Premise
hazard	I-Premise
ratio,	I-Premise
1.048	I-Premise
[97.2	I-Premise
confidence	I-Premise
interval,	I-Premise
0.877	I-Premise
to	I-Premise
1.253])	I-Premise
and	I-Premise
response	I-Premise
(23.9%)	I-Premise
with	I-Premise
DCb	I-Premise
were	I-Premise
similar	I-Premise
to	I-Premise
those	I-Premise
results	I-Premise
for	I-Premise
VC.	I-Premise

Neutropenia,	B-Premise
thrombocytopenia,	I-Premise
infection,	I-Premise
and	I-Premise
febrile	I-Premise
neutropenia	I-Premise
were	I-Premise
similar	I-Premise
with	I-Premise
all	I-Premise
three	I-Premise
regimens.	I-Premise

Grade	B-Premise
3	I-Premise
to	I-Premise
4	I-Premise
anemia,	I-Premise
nausea,	I-Premise
and	I-Premise
vomiting	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
(P	I-Premise
<.01)	I-Premise
with	I-Premise
VC	I-Premise
than	I-Premise
with	I-Premise
DC	I-Premise
or	I-Premise
DCb.	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
either	I-Premise
docetaxel	I-Premise
regimen	I-Premise
had	I-Premise
consistently	I-Premise
improved	I-Premise
QoL	I-Premise
compared	I-Premise
with	I-Premise
VC-treated	I-Premise
patients,	I-Premise
who	I-Premise
experienced	I-Premise
deterioration	I-Premise
in	I-Premise
QoL.	I-Premise

DC	B-Claim
resulted	I-Claim
in	I-Claim
a	I-Claim
more	I-Claim
favorable	I-Claim
overall	I-Claim
response	I-Claim
and	I-Claim
survival	I-Claim
rate	I-Claim
than	I-Claim
VC.	I-Claim

Both	B-Claim
DC	I-Claim
and	I-Claim
DCb	I-Claim
were	I-Claim
better	I-Claim
tolerated	I-Claim
and	I-Claim
provided	I-Claim
patients	I-Claim
with	I-Claim
consistently	I-Claim
improved	I-Claim
QoL	I-Claim
compared	I-Claim
with	I-Claim
VC.	I-Claim

These	B-Claim
findings	I-Claim
demonstrate	I-Claim
that	I-Claim
a	I-Claim
docetaxel	I-Claim
plus	I-Claim
platinum	I-Claim
combination	I-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
treatment	I-Claim
option	I-Claim
with	I-Claim
a	I-Claim
favorable	I-Claim
therapeutic	I-Claim
index	I-Claim
for	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
or	I-Claim
metastatic	I-Claim
NSCLC.	I-Claim

To	O
investigate	O
whether	O
the	O
relative	O
dose-intensity	O
of	O
cyclophosphamide,	O
doxorubicin,	O
vincristine,	O
and	O
prednisone	O
(CHOP)	O
chemotherapy	O
could	O
be	O
improved	O
by	O
prophylactic	O
administration	O
of	O
granulocyte	O
colony-stimulating	O
factor	O
(G-CSF)	O
in	O
elderly	O
patients	O
with	O
aggressive	O
non-Hodgkin's	O
lymphoma	O
(NHL).	O

Patients	O
aged	O
65	O
to	O
90	O
years	O
(median,	O
72	O
years)	O
with	O
stage	O
II	O
to	O
IV	O
aggressive	O
NHL	O
were	O
randomly	O
assigned	O
to	O
receive	O
standard	O
CHOP	O
every	O
3	O
weeks	O
or	O
CHOP	O
plus	O
G-CSF	O
every	O
3	O
weeks	O
on	O
days	O
2	O
to	O
11	O
of	O
each	O
cycle.	O

In	B-Premise
389	I-Premise
eligible	I-Premise
patients,	I-Premise
the	I-Premise
relative	I-Premise
dose	I-Premise
intensities	I-Premise
(RDIs)	I-Premise
of	I-Premise
cyclophosphamide	I-Premise
(median,	I-Premise
96.3%	I-Premise
v	I-Premise
93.9%;	I-Premise
P	I-Premise
=.01)	I-Premise
and	I-Premise
doxorubicin	I-Premise
(median,	I-Premise
95.4%	I-Premise
v	I-Premise
93.3%;	I-Premise
P	I-Premise
=.04)	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
CHOP	I-Premise
plus	I-Premise
G-CSF.	I-Premise

The	B-Premise
complete	I-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
55%	I-Premise
and	I-Premise
52%	I-Premise
for	I-Premise
CHOP	I-Premise
and	I-Premise
CHOP	I-Premise
plus	I-Premise
G-CSF,	I-Premise
respectively	I-Premise
(P	I-Premise
=.63).	I-Premise

The	B-Premise
actuarial	I-Premise
overall	I-Premise
survival	I-Premise
at	I-Premise
5	I-Premise
years	I-Premise
was	I-Premise
22%	I-Premise
with	I-Premise
CHOP	I-Premise
alone,	I-Premise
compared	I-Premise
with	I-Premise
24%	I-Premise
with	I-Premise
CHOP	I-Premise
plus	I-Premise
G-CSF	I-Premise
(P	I-Premise
=.76),	I-Premise
with	I-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
33	I-Premise
months.	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
CHOP	I-Premise
plus	I-Premise
G-CSF	I-Premise
had	I-Premise
an	I-Premise
identical	I-Premise
incidence	I-Premise
of	I-Premise
infections,	I-Premise
with	I-Premise
World	I-Premise
Health	I-Premise
Organization	I-Premise
grade	I-Premise
3	I-Premise
to	I-Premise
4	I-Premise
(34	I-Premise
of	I-Premise
1,191	I-Premise
cycles	I-Premise
v	I-Premise
36	I-Premise
of	I-Premise
1,195	I-Premise
cycles).	I-Premise

Only	B-Premise
the	I-Premise
cumulative	I-Premise
days	I-Premise
with	I-Premise
antibiotics	I-Premise
were	I-Premise
fewer	I-Premise
with	I-Premise
CHOP	I-Premise
plus	I-Premise
G-CSF	I-Premise
(median,	I-Premise
0	I-Premise
v	I-Premise
6	I-Premise
days;	I-Premise
P	I-Premise
=.006)	I-Premise
than	I-Premise
with	I-Premise
CHOP	I-Premise
alone.	I-Premise

The	B-Premise
number	I-Premise
of	I-Premise
hospital	I-Premise
admissions	I-Premise
and	I-Premise
the	I-Premise
number	I-Premise
of	I-Premise
days	I-Premise
in	I-Premise
hospital	I-Premise
were	I-Premise
not	I-Premise
different.	I-Premise

In	B-Claim
elderly	I-Claim
patients,	I-Claim
G-CSF	I-Claim
improved	I-Claim
the	I-Claim
RDI	I-Claim
of	I-Claim
CHOP,	I-Claim
but	B-Premise
this	I-Premise
did	I-Premise
not	I-Premise
lead	I-Premise
to	I-Premise
a	I-Premise
higher	I-Premise
complete	I-Premise
response	I-Premise
rate	I-Premise
or	I-Premise
better	I-Premise
overall	I-Premise
survival.	I-Premise

G-CSF	B-Claim
did	I-Claim
not	I-Claim
prevent	I-Claim
serious	I-Claim
infections.	I-Claim

The	O
standard	O
treatment	O
for	O
patients	O
with	O
clinically	O
resectable	O
rectal	O
cancer	O
is	O
surgery.	O

Postoperative	B-Claim
radiochemotherapy	I-Claim
(RCT)	I-Claim
is	I-Claim
recommended	I-Claim
for	I-Claim
advanced	I-Claim
disease	I-Claim
(pT3/4	I-Claim
or	I-Claim
pN+).	I-Claim

In	O
recent	O
years,	O
encouraging	O
results	O
of	O
pre-operative	O
radiotherapy	O
have	O
been	O
reported.	O

This	O
prospective	O
randomized	O
phase-III-trial	O
(CAO/ARO/AIO-94)	O
compares	O
the	O
efficacy	O
of	O
neoadjuvant	O
RCT	O
to	O
standard	O
postoperative	O
RCT.	O

We	O
report	O
on	O
the	O
design	O
of	O
the	O
study	O
and	O
first	O
results	O
with	O
regard	O
to	O
toxicity	O
of	O
RCT	O
and	O
postoperative	O
morbidity.	O

Patients	O
with	O
locally	O
advanced	O
operable	O
rectal	O
cancer	O
(uT3/4	O
or	O
uN+,	O
Mason	O
CS	O
III/IV)	O
were	O
randomly	O
assigned	O
to	O
pre	O
or	O
postoperative	O
RCT:	O
A	O
total	O
dose	O
of	O
50.4	O
Gy	O
(single	O
dose	O
1.8	O
Gy)	O
was	O
applied	O
to	O
the	O
tumour	O
and	O
the	O
pelvic	O
lymph	O
nodes.	O

5-FU	O
(1000	O
mg/m2/d)	O
was	O
administered	O
concomitantly	O
in	O
the	O
1th	O
and	O
5th	O
week	O
of	O
radiation	O
as	O
120	O
h-continuous	O
infusion.	O

Four	O
additional	O
cycles	O
of	O
5-FU-chemotherapy	O
(500	O
mg/m2/d,	O
i.v.- O

bolus)	O
were	O
applied.	O

RCT	O
was	O
identical	O
in	O
both	O
arms	O
except	O
for	O
a	O
small-volume	O
boost	O
of	O
5.4	O
Gy	O
postoperatively.	O

The	O
time	O
interval	O
between	O
RCT	O
and	O
surgery	O
was	O
4-6	O
weeks	O
in	O
both	O
arms.	O

Techniques	O
of	O
surgery	O
were	O
standardized	O
and	O
included	O
total	O
mesorectal	O
excision.	O

Primary	O
endpoints	O
of	O
the	O
study	O
are	O
5-year	O
survival	O
and	O
local	O
and	O
distant	O
control.	O

Secondary	O
endpoints	O
include	O
the	O
rate	O
of	O
curative	O
(R0)	O
resection	O
and	O
sphincter	O
saving	O
procedures,	O
toxicity	O
of	O
RCT,	O
surgical	O
complications	O
and	O
quality	O
of	O
life.	O

As	O
of	O
July	O
2002,	O
805	O
patients	O
were	O
randomized	O
from	O
26	O
participating	O
institutions.	O

Acute	B-Premise
toxicity	I-Premise
(WHO)	I-Premise
of	I-Premise
RCT	I-Premise
was	I-Premise
low,	I-Premise
with	I-Premise
less	I-Premise
than	I-Premise
15%	I-Premise
of	I-Premise
patients	I-Premise
experiencing	I-Premise
grade	I-Premise
3	I-Premise
or	I-Premise
higher	I-Premise
toxicity:	I-Premise
The	B-Premise
principal	I-Premise
toxicity	I-Premise
was	I-Premise
diarrhea,	I-Premise
with	I-Premise
12%	I-Premise
in	I-Premise
the	I-Premise
postoperative	I-Premise
RCT-arm	I-Premise
and	I-Premise
11%	I-Premise
in	I-Premise
the	I-Premise
pre-operative	I-Premise
RCT-arm	I-Premise
having	I-Premise
grade	I-Premise
3-,	I-Premise
and	I-Premise
1%	I-Premise
in	I-Premise
either	I-Premise
arm	I-Premise
having	I-Premise
grade	I-Premise
4-diarrhea.	I-Premise

Erythema,	B-Premise
nausea	I-Premise
and	I-Premise
leukopenia	I-Premise
were	I-Premise
the	I-Premise
next	I-Premise
common	I-Premise
toxicities,	I-Premise
with	I-Premise
less	I-Premise
than	I-Premise
3%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
either	I-Premise
arm	I-Premise
suffering	I-Premise
grade	I-Premise
3	I-Premise
or	I-Premise
greater	I-Premise
leukopenia	I-Premise
or	I-Premise
nausea.	I-Premise

Postoperative	B-Premise
complication	I-Premise
rates	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms,	I-Premise
with	I-Premise
12%	I-Premise
(postop.	I-Premise
RCT)	I-Premise
and	I-Premise
12%	I-Premise
(pre-op.	I-Premise
RCT)	I-Premise
of	I-Premise
patients,	I-Premise
respectively,	I-Premise
suffering	I-Premise
from	I-Premise
anastomotic	I-Premise
leakage,	I-Premise
3%	I-Premise
(postop.	I-Premise
RCT)	I-Premise
and	I-Premise
3%	I-Premise
(pre-op.	I-Premise
RCT)	I-Premise
from	I-Premise
postoperative	I-Premise
bleeding,	I-Premise
and	I-Premise
6%	I-Premise
(postop.	I-Premise
RCT)	I-Premise
and	I-Premise
4%	I-Premise
(pre-op.	I-Premise
RCT)	I-Premise
from	I-Premise
delayed	I-Premise
wound	I-Premise
healing.	I-Premise

The	B-Claim
patient	I-Claim
accrual	I-Claim
to	I-Claim
the	I-Claim
trial	I-Claim
is	I-Claim
satisfactory.	I-Claim

Neoadjuvant	B-Claim
RCT	I-Claim
is	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
bears	I-Claim
no	I-Claim
higher	I-Claim
risk	I-Claim
for	I-Claim
postoperative	I-Claim
morbidity.	I-Claim

Research	B-Claim
suggests	I-Claim
that	I-Claim
stress-reduction	I-Claim
programs	I-Claim
tailored	I-Claim
to	I-Claim
the	I-Claim
cancer	I-Claim
setting	I-Claim
help	I-Claim
patients	I-Claim
cope	I-Claim
with	I-Claim
the	I-Claim
effects	I-Claim
of	I-Claim
treatment	I-Claim
and	I-Claim
improve	I-Claim
their	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Yoga,	O
an	O
ancient	O
Eastern	O
science,	O
incorporates	O
stress-reduction	O
techniques	O
that	O
include	O
regulated	O
breathing,	O
visual	O
imagery,	O
and	O
meditation	O
as	O
well	O
as	O
various	O
postures.	O

The	O
authors	O
examined	O
the	O
effects	O
of	O
the	O
Tibetan	O
yoga	O
(TY)	O
practices	O
of	O
Tsa	O
lung	O
and	O
Trul	O
khor,	O
which	O
incorporate	O
controlled	O
breathing	O
and	O
visualization,	O
mindfulness	O
techniques,	O
and	O
low-impact	O
postures	O
in	O
patients	O
with	O
lymphoma.	O

Thirty-nine	O
patients	O
with	O
lymphoma	O
who	O
were	O
undergoing	O
treatment	O
or	O
who	O
had	O
concluded	O
treatment	O
within	O
the	O
past	O
12	O
months	O
were	O
assigned	O
to	O
a	O
TY	O
group	O
or	O
to	O
a	O
wait-list	O
control	O
group.	O

Patients	O
in	O
the	O
TY	O
group	O
participated	O
in	O
7	O
weekly	O
yoga	O
sessions,	O
and	O
patients	O
in	O
the	O
wait-list	O
control	O
group	O
were	O
free	O
to	O
participate	O
in	O
the	O
TY	O
program	O
after	O
the	O
3-month	O
follow-up	O
assessment.	O

Eighty	O
nine	O
percent	O
of	O
TY	O
participants	O
completed	O
at	O
least	O
2-3	O
three	O
yoga	O
sessions,	O
and	O
58%	O
completed	O
at	O
least	O
5	O
sessions.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
TY	I-Premise
group	I-Premise
reported	I-Premise
significantly	I-Premise
lower	I-Premise
sleep	I-Premise
disturbance	I-Premise
scores	I-Premise
during	I-Premise
follow-up	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
wait-list	I-Premise
control	I-Premise
group	I-Premise
(5.8	I-Premise
vs.	I-Premise
8.1;	I-Premise
P	I-Premise
<	I-Premise
0.004).	I-Premise

This	B-Premise
included	I-Premise
better	I-Premise
subjective	I-Premise
sleep	I-Premise
quality	I-Premise
(P	I-Premise
<	I-Premise
0.02),	I-Premise
faster	I-Premise
sleep	I-Premise
latency	I-Premise
(P	I-Premise
<	I-Premise
0.01),	I-Premise
longer	I-Premise
sleep	I-Premise
duration	I-Premise
(P	I-Premise
<	I-Premise
0.03),	I-Premise
and	I-Premise
less	I-Premise
use	I-Premise
of	I-Premise
sleep	I-Premise
medications	I-Premise
(P	I-Premise
<	I-Premise
0.02).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
intrusion	I-Premise
or	I-Premise
avoidance,	I-Premise
state	I-Premise
anxiety,	I-Premise
depression,	I-Premise
or	I-Premise
fatigue.	I-Premise

The	B-Claim
participation	I-Claim
rates	I-Claim
suggested	I-Claim
that	I-Claim
a	I-Claim
TY	I-Claim
program	I-Claim
is	I-Claim
feasible	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
cancer	I-Claim
and	I-Claim
that	I-Claim
such	I-Claim
a	I-Claim
program	I-Claim
significantly	I-Claim
improves	I-Claim
sleep-related	I-Claim
outcomes.	I-Claim

However,	B-Premise
there	I-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
for	I-Premise
the	I-Premise
other	I-Premise
outcomes.	I-Premise

Recombinant	B-Claim
human	I-Claim
erythropoietin	I-Claim
(r-HuEPO)	I-Claim
corrects	I-Claim
cancer-related	I-Claim
anemia	I-Claim
and,	I-Claim
thereby,	I-Claim
improves	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
measure	O
the	O
impact	O
of	O
erythropoietin	O
on	O
hemoglobin	O
and	O
mood	O
state	O
in	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
and	O
mild	O
anemia	O
(Hgb	O
<	O
12.0	O
g/dL).	O

Women	O
were	O
randomized	O
to	O
receive	O
usual	O
care	O
(G1)	O
or	O
usual	O
care	O
plus	O
r-HuEPO	O
(G2).	O

Usual	O
care	O
included	O
transfusions	O
as	O
necessary	O
and	O
fatigue	O
education.	O

R-HuEPO	O
was	O
begun	O
at	O
40,000U	O
subcutaneously	O
per	O
week.	O

At	O
4	O
weeks,	O
the	O
dose	O
was	O
increased	O
to	O
60,000U	O
if	O
Hgb	O
had	O
not	O
increased	O
>	O
or	O
=	O
1.0	O
g/dL.	O

The	O
drug	O
was	O
discontinued	O
at	O
8	O
weeks	O
if	O
hemoglobin	O
improvement	O
was	O
<	O
1.0	O
g/dL.	O

The	O
study	O
was	O
terminated	O
early	O
(n	O
=	O
27,	O
G1	O
=	O
13,	O
G2	O
=	O
14)	O
when	O
4/14	O
(28.5%)	O
subjects	O
in	O
G2	O
developed	O
thrombotic	O
events	O
(deep	O
vein	O
thrombosis	O
[DVT]	O
in	O
1;	O
DVT	O
plus	O
pulmonary	O
embolism	O
[PE]	O
in	O
1;	O
DVT	O
plus	O
PE	O
1	O
month	O
after	O
drug	O
discontinuation	O
in	O
1;	O
and	O
brachial	O
vein	O
thrombosis	O
with	O
infected	O
Mediport	O
in	O
1).	O

In	B-Premise
all	I-Premise
four	I-Premise
patients,	I-Premise
Hgb	I-Premise
levels	I-Premise
were	I-Premise
normal	I-Premise
at	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
the	I-Premise
event.	I-Premise

No	B-Premise
patient	I-Premise
in	I-Premise
G1	I-Premise
developed	I-Premise
a	I-Premise
thrombotic	I-Premise
event.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
demographic	I-Premise
characteristics	I-Premise
or	I-Premise
current	I-Premise
chemotherapy	I-Premise
regimen	I-Premise
in	I-Premise
G1	I-Premise
vs.	I-Premise
G2.	I-Premise

The	O
decision	O
to	O
terminate	O
the	O
trial	O
was	O
made	O
after	O
considerable	O
deliberation.	O

The	B-Premise
increased	I-Premise
incidence	I-Premise
of	I-Premise
thrombotic	I-Premise
events	I-Premise
in	I-Premise
the	I-Premise
r-HuEPO	I-Premise
(G2)	I-Premise
arm	I-Premise
of	I-Premise
this	I-Premise
study	I-Premise
exceeds	I-Premise
that	I-Premise
in	I-Premise
prior	I-Premise
studies	I-Premise
in	I-Premise
this	I-Premise
population	I-Premise
and	I-Premise
prior	I-Premise
r-HuEPO	I-Premise
trials.	I-Premise

This	B-Claim
may	I-Claim
relate	I-Claim
to	I-Claim
the	I-Claim
administration	I-Claim
of	I-Claim
r-HuEPO	I-Claim
in	I-Claim
this	I-Claim
high-risk	I-Claim
population,	I-Claim
but	B-Claim
the	I-Claim
small	I-Claim
sample	I-Claim
size	I-Claim
and	I-Claim
possible	I-Claim
predisposing	I-Claim
risk	I-Claim
factors	I-Claim
preclude	I-Claim
definitive	I-Claim
conclusions.	I-Claim

To	O
compare	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
in	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
receiving	O
the	O
combination	O
of	O
doxorubicin	O
and	O
paclitaxel	O
(AT)	O
or	O
doxorubicin	O
and	O
cyclophosphamide	O
(AC)	O
as	O
first-line	O
chemotherapy	O
treatment.	O

Eligible	O
patients	O
(n	O
=	O
275)	O
with	O
anthracycline-naive	O
measurable	O
metastatic	O
breast	O
cancer	O
were	O
randomly	O
assigned	O
to	O
AT	O
(doxorubicin	O
60	O
mg/m(2)	O
as	O
an	O
intravenous	O
bolus	O
plus	O
paclitaxel	O
175	O
mg/m(2)	O
as	O
a	O
3-hour	O
infusion)	O
or	O
AC	O
(doxorubicin	O
60	O
mg/m(2)	O
plus	O
cyclophosphamide	O
600	O
mg/m(2))	O
every	O
3	O
weeks	O
for	O
a	O
maximum	O
of	O
six	O
cycles.	O

Dose	O
escalation	O
of	O
paclitaxel	O
(200	O
mg/m(2))	O
and	O
cyclophosphamide	O
(750	O
mg/m(2))	O
was	O
planned	O
at	O
cycle	O
2	O
to	O
reach	O
equivalent	O
myelosuppression	O
in	O
the	O
two	O
groups.	O

HRQOL	O
was	O
assessed	O
with	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
and	O
the	O
EORTC	O
Breast	O
Module	O
at	O
baseline	O
and	O
the	O
start	O
of	O
cycles	O
2,	O
4,	O
and	O
6,	O
and	O
3	O
months	O
after	O
the	O
last	O
cycle.	O

Seventy-nine	O
percent	O
of	O
the	O
patients	O
(n	O
=	O
219)	O
completed	O
a	O
baseline	O
measure.	O

However,	O
there	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
HRQOL	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
groups.	I-Premise

In	B-Premise
both	I-Premise
groups,	I-Premise
selected	I-Premise
aspects	I-Premise
of	I-Premise
HRQOL	I-Premise
were	I-Premise
impaired	I-Premise
over	I-Premise
time,	I-Premise
with	I-Premise
increased	I-Premise
fatigue,	I-Premise
although	B-Premise
some	I-Premise
clinically	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
emotional	I-Premise
functioning	I-Premise
were	I-Premise
seen,	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
a	I-Premise
reduction	I-Premise
in	I-Premise
pain	I-Premise
over	I-Premise
time.	I-Premise

Overall,	B-Claim
global	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
was	I-Claim
maintained	I-Claim
in	I-Claim
both	I-Claim
treatment	I-Claim
groups.	I-Claim

This	B-Claim
information	I-Claim
is	I-Claim
important	I-Claim
when	I-Claim
advising	I-Claim
women	I-Claim
patients	I-Claim
of	I-Claim
the	I-Claim
expected	I-Claim
HRQOL	I-Claim
consequences	I-Claim
of	I-Claim
treatment	I-Claim
regimens	I-Claim
and	I-Claim
should	I-Claim
help	I-Claim
clinicians	I-Claim
and	I-Claim
their	I-Claim
patients	I-Claim
make	I-Claim
informed	I-Claim
treatment	I-Claim
decisions.	I-Claim

Malnutrition	B-Claim
occurs	I-Claim
frequently	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
cancer	I-Claim
of	I-Claim
the	I-Claim
gastrointestinal	I-Claim
(GI)	I-Claim
or	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
area	I-Claim
and	I-Claim
can	I-Claim
lead	I-Claim
to	I-Claim
negative	I-Claim
outcomes.	I-Claim

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
impact	O
of	O
early	O
and	O
intensive	O
nutrition	O
intervention	O
(NI)	O
on	O
body	O
weight,	O
body	O
composition,	O
nutritional	O
status,	O
global	O
quality	O
of	O
life	O
(QoL)	O
and	O
physical	O
function	O
compared	O
to	O
usual	O
practice	O
in	O
oncology	O
outpatients	O
receiving	O
radiotherapy	O
to	O
the	O
GI	O
or	O
head	O
and	O
neck	O
area.	O

Outpatients	O
commencing	O
at	O
least	O
20	O
fractions	O
of	O
radiotherapy	O
to	O
the	O
GI	O
or	O
head	O
and	O
neck	O
area	O
were	O
randomised	O
to	O
receive	O
intensive,	O
individualised	O
nutrition	O
counselling	O
by	O
a	O
dietitian	O
using	O
a	O
standard	O
protocol	O
and	O
oral	O
supplements	O
if	O
required,	O
or	O
the	O
usual	O
practice	O
of	O
the	O
centre	O
(general	O
advice	O
and	O
nutrition	O
booklet).	O

Outcome	O
parameters	O
were	O
measured	O
at	O
baseline	O
and	O
4,	O
8	O
and	O
12	O
weeks	O
after	O
commencing	O
radiotherapy	O
using	O
valid	O
and	O
reliable	O
tools.	O

A	O
total	O
of	O
60	O
patients	O
(51	O
M	O
:	O
9	O
F;	O
mean	O
age	O
61.9+/-14.0	O
years)	O
were	O
randomised	O
to	O
receive	O
either	O
NI	O
(n=29)	O
or	O
usual	O
care	O
(UC)	O
(n=31).	O

The	B-Premise
NI	I-Premise
group	I-Premise
had	I-Premise
statistically	I-Premise
smaller	I-Premise
deteriorations	I-Premise
in	I-Premise
weight	I-Premise
(P<0.001),	I-Premise
nutritional	I-Premise
status	I-Premise
(P=0.020)	I-Premise
and	I-Premise
global	I-Premise
QoL	I-Premise
(P=0.009)	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
receiving	I-Premise
UC.	I-Premise

Clinically,	B-Premise
but	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
fat-free	I-Premise
mass	I-Premise
were	I-Premise
observed	I-Premise
between	I-Premise
the	I-Premise
groups	I-Premise
(P=0.195).	I-Premise

Early	B-Claim
and	I-Claim
intensive	I-Claim
NI	I-Claim
appears	I-Claim
beneficial	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
minimising	I-Claim
weight	I-Claim
loss,	I-Claim
deterioration	I-Claim
in	I-Claim
nutritional	I-Claim
status,	I-Claim
global	I-Claim
QoL	I-Claim
and	I-Claim
physical	I-Claim
function	I-Claim
in	I-Claim
oncology	I-Claim
outpatients	I-Claim
receiving	I-Claim
radiotherapy	I-Claim
to	I-Claim
the	I-Claim
GI	I-Claim
or	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
area.	I-Claim

Weight	B-Claim
maintenance	I-Claim
in	I-Claim
this	I-Claim
population	I-Claim
leads	I-Claim
to	I-Claim
beneficial	I-Claim
outcomes	I-Claim
and	I-Claim
suggests	I-Claim
that	I-Claim
this,	I-Claim
rather	I-Claim
than	I-Claim
weight	I-Claim
gain,	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
more	I-Claim
appropriate	I-Claim
aim	I-Claim
of	I-Claim
NI.	I-Claim

Bone	B-Claim
metastases	I-Claim
occur	I-Claim
in	I-Claim
most	I-Claim
women	I-Claim
with	I-Claim
advanced	I-Claim
breast	I-Claim
cancer	I-Claim
and	I-Claim
can	I-Claim
lead	I-Claim
to	I-Claim
considerable	I-Claim
morbidity	I-Claim
and	I-Claim
a	I-Claim
rapid	I-Claim
deterioration	I-Claim
in	I-Claim
the	I-Claim
patient's	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

It	O
was	O
the	O
aim	O
of	O
the	O
present	O
study	O
to	O
assess	O
changes	O
in	O
quality	O
of	O
life	O
and	O
bone	O
pain	O
due	O
to	O
intravenous	O
(i.v.)	O

ibandronate,	O
a	O
potent	O
third-generation	O
bisphosphonate.	O

In	O
a	O
phase	O
III	O
randomised,	O
double-blind,	O
placebo-controlled	O
trial	O
in	O
patients	O
with	O
bone	O
metastases	O
due	O
to	O
breast	O
cancer,	O
466	O
women	O
were	O
randomised	O
to	O
receive	O
placebo,	O
2	O
mg	O
ibandronate	O
or	O
6	O
mg	O
ibandronate	O
for	O
up	O
to	O
96	O
weeks.	O

Treatment	O
was	O
administered	O
i.v.	O

at	O
3-	O
or	O
4-weekly	O
intervals.	O

Clinical	O
endpoints	O
included	O
the	O
incidence	O
of	O
adverse	O
events,	O
quality	O
of	O
life	O
(assessed	O
using	O
the	O
European	O
Organisation	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Scale	O
-	O
Core	O
30	O
questionnaire	O
(QLQ-C30)),	O
and	O
bone	O
pain	O
(assessed	O
on	O
a	O
5-point	O
scale	O
from	O
0=none	O
to	O
4=intolerable).	O

Ibandronate	B-Premise
was	I-Premise
generally	I-Premise
well	I-Premise
tolerated.	I-Premise

Compared	B-Premise
with	I-Premise
baseline	I-Premise
measurements,	I-Premise
the	I-Premise
bone	I-Premise
pain	I-Premise
score	I-Premise
was	I-Premise
increased	I-Premise
at	I-Premise
the	I-Premise
last	I-Premise
assessment	I-Premise
in	I-Premise
both	I-Premise
the	I-Premise
placebo	I-Premise
and	I-Premise
2	I-Premise
mg	I-Premise
ibandronate	I-Premise
groups,	I-Premise
but	B-Premise
was	I-Premise
significantly	I-Premise
reduced	I-Premise
in	I-Premise
the	I-Premise
patients	I-Premise
receiving	I-Premise
6	I-Premise
mg	I-Premise
ibandronate	I-Premise
(-0.28+/-1.11,	I-Premise
P	I-Premise
<	I-Premise
0.001).	I-Premise

A	B-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
demonstrated	I-Premise
for	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
ibandronate	I-Premise
(P	I-Premise
<	I-Premise
0.05)	I-Premise
for	I-Premise
all	I-Premise
global	I-Premise
health	I-Premise
status.	I-Premise

Overall,	B-Premise
at	I-Premise
the	I-Premise
last	I-Premise
assessment,	I-Premise
the	I-Premise
6	I-Premise
mg	I-Premise
ibandronate	I-Premise
group	I-Premise
showed	I-Premise
significantly	I-Premise
better	I-Premise
functioning	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(P	I-Premise
=	I-Premise
0.004),	I-Premise
and	I-Premise
had	I-Premise
significantly	I-Premise
better	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
domains	I-Premise
of	I-Premise
physical,	I-Premise
emotional,	I-Premise
and	I-Premise
social	I-Premise
functioning,	I-Premise
and	I-Premise
in	I-Premise
global	I-Premise
health	I-Premise
status	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Significant	B-Premise
improvements	I-Premise
in	I-Premise
the	I-Premise
symptoms	I-Premise
of	I-Premise
fatigue	I-Premise
and	I-Premise
pain	I-Premise
were	I-Premise
also	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
6	I-Premise
mg	I-Premise
ibandronate	I-Premise
group.	I-Premise

I.v.	B-Claim
ibandronate	I-Claim
treatment	I-Claim
leads	I-Claim
to	I-Claim
significant	I-Claim
improvements	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
and	I-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
and	I-Claim
well-tolerated	I-Claim
palliative	I-Claim
treatment	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
bone	I-Claim
metastases	I-Claim
due	I-Claim
to	I-Claim
breast	I-Claim
cancer.	I-Claim

Advice	B-Claim
to	I-Claim
rest	I-Claim
and	I-Claim
take	I-Claim
things	I-Claim
easy	I-Claim
if	I-Claim
patients	I-Claim
become	I-Claim
fatigued	I-Claim
during	I-Claim
radiotherapy	I-Claim
may	I-Claim
be	I-Claim
detrimental.	I-Claim

Aerobic	B-Premise
walking	I-Premise
improves	I-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
has	I-Premise
been	I-Premise
an	I-Premise
intervention	I-Premise
for	I-Premise
chemotherapy-related	I-Premise
fatigue.	I-Premise

A	O
prospective,	O
randomized,	O
controlled	O
trial	O
was	O
performed	O
to	O
determine	O
whether	O
aerobic	O
exercise	O
would	O
reduce	O
the	O
incidence	O
of	O
fatigue	O
and	O
prevent	O
deterioration	O
in	O
physical	O
functioning	O
during	O
radiotherapy	O
for	O
localized	O
prostate	O
carcinoma.	O

Sixty-six	O
men	O
were	O
randomized	O
before	O
they	O
received	O
radical	O
radiotherapy	O
for	O
localized	O
prostate	O
carcinoma,	O
with	O
33	O
men	O
randomized	O
to	O
an	O
exercise	O
group	O
and	O
33	O
men	O
randomized	O
to	O
a	O
control	O
group.	O

Outcome	O
measures	O
were	O
fatigue	O
and	O
distance	O
walked	O
in	O
a	O
modified	O
shuttle	O
test	O
before	O
and	O
after	O
radiotherapy.	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
between	I-Premise
group	I-Premise
differences	I-Premise
noted	I-Premise
with	I-Premise
regard	I-Premise
to	I-Premise
fatigue	I-Premise
scores	I-Premise
at	I-Premise
baseline	I-Premise
(P	I-Premise
=	I-Premise
0.55)	I-Premise
or	I-Premise
after	I-Premise
4	I-Premise
weeks	I-Premise
of	I-Premise
radiotherapy	I-Premise
(P	I-Premise
=	I-Premise
0.18).	I-Premise

Men	B-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
had	I-Premise
significant	I-Premise
increases	I-Premise
in	I-Premise
fatigue	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
radiotherapy	I-Premise
(P	I-Premise
=	I-Premise
0.013),	I-Premise
with	I-Premise
no	I-Premise
significant	I-Premise
increases	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.203).	I-Premise

A	B-Premise
nonsignificant	I-Premise
reduction	I-Premise
(2.4%)	I-Premise
in	I-Premise
shuttle	I-Premise
test	I-Premise
distance	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
radiotherapy	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group;	I-Premise
however,	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group,	I-Premise
there	I-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
increase	I-Premise
(13.2%)	I-Premise
in	I-Premise
distance	I-Premise
walked	I-Premise
(P	I-Premise
=	I-Premise
0.0003).	I-Premise

Men	B-Premise
who	I-Premise
followed	I-Premise
advice	I-Premise
to	I-Premise
rest	I-Premise
and	I-Premise
take	I-Premise
things	I-Premise
easy	I-Premise
if	I-Premise
they	I-Premise
became	I-Premise
fatigued	I-Premise
demonstrated	I-Premise
a	I-Premise
slight	I-Premise
deterioration	I-Premise
in	I-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
a	I-Premise
significant	I-Premise
increase	I-Premise
in	I-Premise
fatigue	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
radiotherapy.	I-Premise

Home-based,	B-Claim
moderate-intensity	I-Claim
walking	I-Claim
produced	I-Claim
a	I-Claim
significant	I-Claim
improvement	I-Claim
in	I-Claim
physical	I-Claim
functioning	I-Claim
with	I-Claim
no	I-Claim
significant	I-Claim
increase	I-Claim
in	I-Claim
fatigue.	I-Claim

Improved	B-Claim
physical	I-Claim
functioning	I-Claim
may	I-Claim
be	I-Claim
necessary	I-Claim
to	I-Claim
combat	I-Claim
radiation	I-Claim
fatigue.	I-Claim

To	O
determine	O
whether	O
cisplatin	O
plus	O
paclitaxel	O
(C+P)	O
improved	O
response	O
rate,	O
progression-free	O
survival	O
(PFS),	O
or	O
survival	O
compared	O
with	O
cisplatin	O
alone	O
in	O
patients	O
with	O
stage	O
IVB,	O
recurrent,	O
or	O
persistent	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
cervix.	O

PATIENTS	O
AND	O
METHODS	O
Eligible:	O
patients	O
with	O
measurable	O
disease,	O
performance	O
status	O
(PS)	O
0	O
to	O
2,	O
and	O
adequate	O
hematologic,	O
hepatic,	O
and	O
renal	O
function	O
received	O
either	O
cisplatin	O
50	O
mg/m2	O
or	O
C+P	O
(cisplatin	O
50	O
mg/m2	O
plus	O
paclitaxel	O
135	O
mg/m2)	O
every	O
3	O
weeks	O
for	O
six	O
cycles.	O

Tumor	O
measurements	O
and	O
quality-of-life	O
(QOL)	O
assessments	O
were	O
obtained	O
before	O
each	O
treatment	O
cycle.	O

Of	O
280	O
patients	O
entered,	O
6%	O
were	O
ineligible.	O

Among	O
264	O
eligible	O
patients,	O
134	O
received	O
cisplatin	O
and	O
130	O
received	O
C+P.	O

Groups	O
were	O
well	O
matched	O
with	O
respect	O
to	O
age,	O
ethnicity,	O
PS,	O
tumor	O
grade,	O
disease	O
site,	O
and	O
number	O
of	O
cycles	O
received.	O

The	O
majority	O
of	O
all	O
patients	O
had	O
prior	O
radiation	O
therapy	O
(cisplatin,	O
92%;	O
C+P,	O
91%).	O

Objective	B-Premise
responses	I-Premise
occurred	I-Premise
in	I-Premise
19%	I-Premise
(6%	I-Premise
complete	I-Premise
plus	I-Premise
13%	I-Premise
partial)	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
cisplatin	I-Premise
versus	I-Premise
36%	I-Premise
(15%	I-Premise
complete	I-Premise
plus	I-Premise
21%	I-Premise
partial)	I-Premise
receiving	I-Premise
C+P	I-Premise
(P	I-Premise
=	I-Premise
.002).	I-Premise

The	B-Premise
median	I-Premise
PFS	I-Premise
was	I-Premise
2.8	I-Premise
and	I-Premise
4.8	I-Premise
months,	I-Premise
respectively,	I-Premise
for	I-Premise
cisplatin	I-Premise
versus	I-Premise
C+P	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
median	I-Premise
survival	I-Premise
(8.8	I-Premise
months	I-Premise
v	I-Premise
9.7	I-Premise
months).	I-Premise

Grade	B-Premise
3	I-Premise
to	I-Premise
4	I-Premise
anemia	I-Premise
and	I-Premise
neutropenia	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
combination	I-Premise
arm.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
QOL	I-Premise
scores,	I-Premise
although	B-Premise
a	I-Premise
disproportionate	I-Premise
number	I-Premise
of	I-Premise
patients	I-Premise
(cisplatin,	I-Premise
n	I-Premise
=	I-Premise
50;	I-Premise
C+P,	I-Premise
n	I-Premise
=	I-Premise
33)	I-Premise
dropped	I-Premise
out	I-Premise
of	I-Premise
the	I-Premise
QOL	I-Premise
component,	I-Premise
presumably	I-Premise
because	I-Premise
of	I-Premise
increasing	I-Premise
disease,	I-Premise
deteriorating	I-Premise
health	I-Premise
status,	I-Premise
or	I-Premise
early	I-Premise
death.	I-Premise

C+P	B-Claim
is	I-Claim
superior	I-Claim
to	I-Claim
cisplatin	I-Claim
alone	I-Claim
with	I-Claim
respect	I-Claim
to	I-Claim
response	I-Claim
rate	I-Claim
and	I-Claim
PFS	I-Claim
with	I-Claim
sustained	I-Claim
QOL.	I-Claim

Metal	O
stent	O
placement	O
and	O
single	O
dose	O
brachytherapy	O
are	O
commonly	O
used	O
treatment	O
modalities	O
for	O
the	O
palliation	O
of	O
inoperable	O
oesophageal	O
carcinoma.	O

We	O
investigated	O
generic	O
and	O
disease-specific	O
health-related	O
quality	O
of	O
life	O
(HRQoL)	O
after	O
these	O
palliative	O
treatments.	O

Patients	O
with	O
dysphagia	O
from	O
inoperable	O
oesophageal	O
carcinoma	O
were	O
randomised	O
to	O
placement	O
of	O
a	O
covered	O
Ultraflex	O
stent	O
(n	O
=	O
108)	O
or	O
single	O
dose	O
(12	O
Gy)	O
brachytherapy	O
(n	O
=	O
101).	O

We	O
obtained	O
longitudinal	O
data	O
on	O
disease-specific	O
(dysphagia	O
score,	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
OES-23,	O
visual	O
analogue	O
pain	O
scale)	O
and	O
generic	O
(EORTC	O
Quality	O
of	O
Life-Core	O
30	O
Questionnaire	O
(QLQ-C30),	O
Euroqol	O
(EQ)-5D)	O
HRQoL	O
at	O
monthly	O
home	O
visits	O
by	O
a	O
specially-trained	O
research	O
nurse.	O

We	O
compared	O
HRQoL	O
between	O
the	O
two	O
treatments	O
and	O
analysed	O
changes	O
in	O
HRQoL	O
during	O
follow-up.	O

Dysphagia	B-Premise
improved	I-Premise
more	I-Premise
rapidly	I-Premise
after	I-Premise
stent	I-Premise
placement	I-Premise
than	I-Premise
after	I-Premise
brachytherapy,	I-Premise
but	B-Premise
long-term	I-Premise
relief	I-Premise
of	I-Premise
dysphagia	I-Premise
was	I-Premise
better	I-Premise
after	I-Premise
brachytherapy.	I-Premise

For	B-Premise
generic	I-Premise
HRQoL,	I-Premise
there	I-Premise
was	I-Premise
an	I-Premise
overall	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
brachytherapy	I-Premise
on	I-Premise
four	I-Premise
out	I-Premise
of	I-Premise
five	I-Premise
functional	I-Premise
scales	I-Premise
of	I-Premise
the	I-Premise
EORTC	I-Premise
QLQ-C30	I-Premise
(role,	I-Premise
emotional,	I-Premise
cognitive	I-Premise
and	I-Premise
social)	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Generic	B-Premise
HRQoL	I-Premise
deteriorated	I-Premise
over	I-Premise
time	I-Premise
on	I-Premise
all	I-Premise
functional	I-Premise
scales	I-Premise
of	I-Premise
the	I-Premise
EORTC	I-Premise
QLQ	I-Premise
C-30	I-Premise
and	I-Premise
EQ-5D,	I-Premise
in	I-Premise
particular	I-Premise
physical	I-Premise
and	I-Premise
role	I-Premise
functioning	I-Premise
(on	I-Premise
average	I-Premise
-23	I-Premise
and	I-Premise
-24	I-Premise
on	I-Premise
a	I-Premise
100	I-Premise
points	I-Premise
scale	I-Premise
during	I-Premise
0.5	I-Premise
years	I-Premise
of	I-Premise
follow-up).	I-Premise

This	B-Premise
decline	I-Premise
was	I-Premise
more	I-Premise
pronounced	I-Premise
in	I-Premise
the	I-Premise
stent	I-Premise
group.	I-Premise

Major	B-Premise
improvements	I-Premise
were	I-Premise
seen	I-Premise
on	I-Premise
the	I-Premise
dysphagia	I-Premise
and	I-Premise
eating	I-Premise
scales	I-Premise
of	I-Premise
the	I-Premise
EORTC	I-Premise
OES-23,	I-Premise
in	I-Premise
contrast	I-Premise
to	I-Premise
other	I-Premise
scales	I-Premise
of	I-Premise
this	I-Premise
disease-specific	I-Premise
measure,	I-Premise
which	I-Premise
remained	I-Premise
almost	I-Premise
stable	I-Premise
during	I-Premise
follow-up.	I-Premise

Reported	B-Premise
levels	I-Premise
of	I-Premise
chest	I-Premise
or	I-Premise
abdominal	I-Premise
pain	I-Premise
remained	I-Premise
stable	I-Premise
during	I-Premise
follow-up	I-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
groups,	I-Premise
general	B-Premise
pain	I-Premise
levels	I-Premise
increased	I-Premise
to	I-Premise
a	I-Premise
minor	I-Premise
extent.	I-Premise

The	B-Claim
effects	I-Claim
of	I-Claim
single	I-Claim
dose	I-Claim
brachytherapy	I-Claim
on	I-Claim
HRQoL	I-Claim
compared	I-Claim
favourably	I-Claim
to	I-Claim
those	I-Claim
of	I-Claim
stent	I-Claim
placement	I-Claim
for	I-Claim
the	I-Claim
palliation	I-Claim
of	I-Claim
oesophageal	I-Claim
cancer.	I-Claim

Future	B-Claim
studies	I-Claim
on	I-Claim
palliative	I-Claim
care	I-Claim
for	I-Claim
oesophageal	I-Claim
cancer	I-Claim
should	I-Claim
at	I-Claim
least	I-Claim
include	I-Claim
generic	I-Claim
HRQoL	I-Claim
scales,	I-Claim
since	B-Premise
these	I-Premise
were	I-Premise
more	I-Premise
responsive	I-Premise
in	I-Premise
measuring	I-Premise
patients'	I-Premise
functioning	I-Premise
and	I-Premise
well-being	I-Premise
during	I-Premise
follow-up	I-Premise
than	I-Premise
disease-specific	I-Premise
HRQoL	I-Premise
scales.	I-Premise

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
quality	O
of	O
life	O
(QoL)	O
of	O
ovarian	O
cancer	O
patients	O
treated	O
with	O
paclitaxel/carboplatin	O
(TC)	O
versus	O
paclitaxel/cisplatin	O
(PT)	O
and	O
to	O
determine	O
the	O
impact	O
of	O
treatment	O
toxicity	O
on	O
the	O
various	O
QoL	O
domains.	O

In	O
this	O
phase	O
III	O
trial,	O
798	O
patients	O
with	O
ovarian	O
cancer	O
stages	O
IIB-IV	O
were	O
randomly	O
assigned	O
to	O
receive	O
TC	O
or	O
PT.	O

The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival;	O
secondary	O
end	O
points	O
included	O
toxicity,	O
QoL,	O
and	O
response	O
to	O
treatment.	O

Patients	O
completed	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
QLQ-C30	O
before	O
treatment,	O
within	O
3	O
days	O
before	O
the	O
second	O
and	O
the	O
fourth	O
chemotherapy	O
cycle,	O
and	O
3	O
weeks	O
after	O
completion	O
of	O
chemotherapy.	O

Previously	O
reported	O
data	O
showed	O
that	O
patients	O
undergoing	O
TC	O
or	O
PT	O
did	O
not	O
differ	O
in	O
progression-free	O
survival	O
and	O
overall	O
survival.	O

However,	O
the	O
TC	O
arm	O
was	O
superior,	O
indicating	O
a	O
better	O
overall	O
QoL	O
compared	O
with	O
the	O
PT	O
arm.	O

Controlling	O
for	O
toxicity	O
and	O
age,	O
a	O
significant	O
treatment	O
by	O
assessment	O
time	O
interaction	O
was	O
found	O
for	O
four	O
QoL	O
functioning	O
scales	O
and	O
three	O
symptoms	O
scales.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
showed	I-Premise
better	I-Premise
means	I-Premise
scores	I-Premise
after	I-Premise
treatment	I-Premise
on	I-Premise
overall	I-Premise
QoL	I-Premise
(P	I-Premise
=	I-Premise
.012),	I-Premise
physical	I-Premise
functioning	I-Premise
(P	I-Premise
=	I-Premise
.012),	I-Premise
role	I-Premise
functioning	I-Premise
(P	I-Premise
=	I-Premise
.005),	I-Premise
and	I-Premise
cognitive	I-Premise
functioning	I-Premise
(P	I-Premise
=	I-Premise
.024),	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
PT	I-Premise
arm.	I-Premise

Concerning	B-Premise
symptom	I-Premise
experience,	I-Premise
patients	I-Premise
undergoing	I-Premise
TC	I-Premise
showed	I-Premise
less	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
less	I-Premise
appetite	I-Premise
loss	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
less	I-Premise
fatigue	I-Premise
(P	I-Premise
=	I-Premise
.033)	I-Premise
after	I-Premise
completion	I-Premise
of	I-Premise
treatment	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
undergoing	I-Premise
PT.	I-Premise

The	B-Claim
TC	I-Claim
regimen	I-Claim
achieved	I-Claim
better	I-Claim
QoL	I-Claim
outcomes	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
PT	I-Claim
regimen.	I-Claim

Thus,	B-Claim
clinicians	I-Claim
may	I-Claim
consider	I-Claim
replacing	I-Claim
cisplatin	I-Claim
with	I-Claim
carboplatin	I-Claim
when	I-Claim
treating	I-Claim
ovarian	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
chemotherapy.	I-Claim

The	O
primary	O
goal	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
and	O
effectiveness	O
of	O
a	O
structured,	O
multidisciplinary	O
intervention	O
targeted	O
to	O
maintain	O
the	O
overall	O
quality	O
of	O
life	O
(QOL),	O
which	O
is	O
more	O
comprehensive	O
than	O
psychosocial	O
distress,	O
of	O
patients	O
undergoing	O
radiation	O
therapy	O
for	O
advanced-stage	O
cancer.	O

Radiation	O
therapy	O
patients	O
with	O
advanced	O
cancer	O
and	O
an	O
estimated	O
5-year	O
survival	O
rate	O
of	O
0%	O
to	O
50%	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
eight-session	O
structured	O
multidisciplinary	O
intervention	O
arm	O
or	O
a	O
standard	O
care	O
arm.	O

The	O
eight	O
90-minute	O
sessions	O
addressed	O
the	O
five	O
domains	O
of	O
QOL	O
including	O
cognitive,	O
physical,	O
emotional,	O
spiritual,	O
and	O
social	O
functioning.	O

The	O
primary	O
end	O
point	O
of	O
maintaining	O
overall	O
QOL	O
was	O
assessed	O
by	O
a	O
single-item	O
linear	O
analog	O
scale	O
(Linear	O
Analog	O
Scale	O
of	O
Assessment	O
or	O
modified	O
Spitzer	O
Uniscale).	O

QOL	O
was	O
assessed	O
at	O
baseline,	O
week	O
4	O
(end	O
of	O
multidisciplinary	O
intervention),	O
week	O
8,	O
and	O
week	O
27.	O

Of	B-Premise
the	I-Premise
103	I-Premise
participants,	I-Premise
overall	I-Premise
QOL	I-Premise
at	I-Premise
week	I-Premise
4	I-Premise
was	I-Premise
maintained	I-Premise
by	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
(n	I-Premise
=	I-Premise
49),	I-Premise
whereas	I-Premise
QOL	I-Premise
at	I-Premise
week	I-Premise
4	I-Premise
significantly	I-Premise
decreased	I-Premise
for	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(n	I-Premise
=	I-Premise
54).	I-Premise

This	B-Premise
change	I-Premise
reflected	I-Premise
a	I-Premise
3-point	I-Premise
increase	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
and	I-Premise
a	I-Premise
9-point	I-Premise
decrease	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
.009).	I-Premise

Intervention	B-Premise
participants	I-Premise
maintained	I-Premise
their	I-Premise
QOL,	I-Premise
and	I-Premise
controls	I-Premise
gradually	I-Premise
returned	I-Premise
to	I-Premise
baseline	I-Premise
by	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
6-month	I-Premise
follow-up	I-Premise
period.	I-Premise

Although	B-Claim
intervention	I-Claim
participants	I-Claim
maintained	I-Claim
and	I-Claim
actually	I-Claim
improved	I-Claim
their	I-Claim
QOL	I-Claim
during	I-Claim
radiation	I-Claim
therapy,	I-Claim
control	I-Claim
participants	I-Claim
experienced	I-Claim
a	I-Claim
significant	I-Claim
decrease	I-Claim
in	I-Claim
their	I-Claim
QOL.	I-Claim

Thus,	B-Claim
a	I-Claim
structured	I-Claim
multidisciplinary	I-Claim
intervention	I-Claim
can	I-Claim
help	I-Claim
maintain	I-Claim
or	I-Claim
even	I-Claim
improve	I-Claim
QOL	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
cancer	I-Claim
who	I-Claim
are	I-Claim
undergoing	I-Claim
cancer	I-Claim
treatment.	I-Claim

Fatigue	B-Claim
has	I-Claim
a	I-Claim
significant	I-Claim
impact	I-Claim
on	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL)	I-Claim
of	I-Claim
cancer	I-Claim
patients.	I-Claim

Recent	B-Claim
research	I-Claim
has	I-Claim
suggested	I-Claim
that	I-Claim
physical	I-Claim
activity	I-Claim
can	I-Claim
reduce	I-Claim
fatigue	I-Claim
in	I-Claim
patients	I-Claim
receiving	I-Claim
active	I-Claim
cancer	I-Claim
treatment.	I-Claim

In	O
this	O
project,	O
we	O
examined	O
the	O
impact	O
that	O
participation	O
in	O
a	O
randomized	O
controlled	O
trial	O
of	O
a	O
multidisciplinary	O
intervention	O
designed	O
to	O
impact	O
overall	O
QOL	O
had	O
on	O
fatigue	O
for	O
advanced	O
cancer	O
patients	O
actively	O
receiving	O
treatment.	O

Patients	O
with	O
newly	O
diagnosed	O
cancer	O
were	O
randomly	O
assigned	O
to	O
an	O
8-session	O
structured	O
multidisciplinary	O
intervention	O
or	O
a	O
standard-care	O
arm	O
at	O
the	O
beginning	O
of	O
their	O
course	O
of	O
radiotherapy	O
(RT)	O
designed	O
to	O
impact	O
QOL.	O

Ninety-minute	O
sessions	O
were	O
led	O
by	O
either	O
a	O
psychiatrist	O
or	O
psychologist,	O
collaborating	O
with	O
a	O
nurse,	O
physical	O
therapist,	O
chaplain,	O
or	O
social	O
worker,	O
depending	O
on	O
the	O
session's	O
theme.	O

The	O
fatigue	O
assessments	O
used	O
in	O
this	O
trial	O
included	O
the	O
Linear	O
Analogue	O
Self	O
Assessment	O
(LASA),	O
the	O
Profile	O
of	O
Mood	O
States	O
(POMS),	O
Spielberger's	O
State-Trait	O
Anxiety	O
Inventory	O
(STAI),	O
and	O
the	O
Symptom	O
Distress	O
Scale	O
(SDS).	O

There	O
were	O
115	O
participants	O
enrolled	O
and	O
the	O
2	O
randomization	O
arms	O
were	O
well	O
balanced	O
in	O
terms	O
of	O
baseline	O
characteristics	O
and	O
treatment	O
received	O
except	O
for	O
increased	O
commuting	O
distance	O
for	O
the	O
patients	O
in	O
the	O
intervention	O
arm	O
(P	O
=	O
0.042).	O

Most	B-Premise
of	I-Premise
scores	I-Premise
indicated	I-Premise
less	I-Premise
fatigue	I-Premise
(higher	I-Premise
score)	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
treatment	I-Premise
group,	I-Premise
but	B-Premise
there	I-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
found	I-Premise
at	I-Premise
baseline	I-Premise
and	I-Premise
weeks	I-Premise
4,	I-Premise
8,	I-Premise
and	I-Premise
27	I-Premise
except	I-Premise
for	I-Premise
SDS	I-Premise
at	I-Premise
week	I-Premise
8	I-Premise
(P	I-Premise
=	I-Premise
0.018)	I-Premise
with	I-Premise
less	I-Premise
patients	I-Premise
reporting	I-Premise
significant	I-Premise
fatigue	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
treatment	I-Premise
arm.	I-Premise

For	B-Premise
the	I-Premise
entire	I-Premise
participant	I-Premise
population,	I-Premise
fatigue	I-Premise
levels	I-Premise
initially	I-Premise
worsened	I-Premise
with	I-Premise
radiotherapy,	I-Premise
stabilized	I-Premise
at	I-Premise
week	I-Premise
8,	I-Premise
and	I-Premise
returned	I-Premise
to	I-Premise
baseline	I-Premise
by	I-Premise
week	I-Premise
27.	I-Premise

Disease	B-Premise
site,	I-Premise
chemotherapy	I-Premise
use,	I-Premise
and	I-Premise
radiotherapy	I-Premise
dose	I-Premise
did	I-Premise
not	I-Premise
have	I-Premise
a	I-Premise
significant	I-Premise
impact	I-Premise
on	I-Premise
fatigue	I-Premise
levels.	I-Premise

Radiotherapy	B-Premise
initially	I-Premise
caused	I-Premise
a	I-Premise
worsening	I-Premise
of	I-Premise
fatigue	I-Premise
but	I-Premise
with	I-Premise
time	I-Premise
fatigue	I-Premise
levels	I-Premise
returned	I-Premise
to	I-Premise
baseline.	I-Premise

Clinically,	B-Claim
this	I-Claim
structured	I-Claim
multidisciplinary	I-Claim
intervention	I-Claim
had	I-Claim
no	I-Claim
impact	I-Claim
on	I-Claim
fatigue,	I-Claim
and	O
there	B-Claim
was	I-Claim
the	I-Claim
suggestion	I-Claim
the	I-Claim
multiple	I-Claim
sessions	I-Claim
may	I-Claim
have	I-Claim
contributed	I-Claim
to	I-Claim
worse	I-Claim
fatigue	I-Claim
during	I-Claim
active	I-Claim
cancer	I-Claim
treatment.	I-Claim

To	O
assess	O
the	O
cost-effectiveness	O
of	O
Mohs	O
micrographic	O
surgery	O
(MMS)	O
compared	O
with	O
the	O
surgical	O
excision	O
for	O
both	O
primary	O
and	O
recurrent	O
basal	O
cell	O
carcinoma	O
(BCC).	O

A	O
cost-effectiveness	O
study	O
performed	O
alongside	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
in	O
which	O
MMS	O
was	O
compared	O
with	O
surgical	O
excision.	O

The	O
study	O
was	O
carried	O
out	O
from	O
1999	O
to	O
2002	O
at	O
the	O
dermatology	O
outpatient	O
clinic	O
of	O
the	O
University	O
Hospital	O
Maastricht,	O
Maastricht,	O
The	O
Netherlands.	O

A	O
total	O
of	O
408	O
primary	O
(374	O
patients)	O
and	O
204	O
recurrent	O
(191	O
patients)	O
cases	O
of	O
facial	O
BCC	O
were	O
included.	O

The	O
mean	O
total	O
treatment	O
costs	O
of	O
MMS	O
and	O
surgical	O
excision	O
for	O
both	O
primary	O
and	O
recurrent	O
BCC	O
and	O
the	O
incremental	O
cost-effectiveness	O
ratio,	O
calculated	O
as	O
the	O
difference	O
in	O
costs	O
between	O
MMS	O
and	O
surgical	O
excision	O
divided	O
by	O
their	O
difference	O
in	O
effectiveness.	O

The	O
resulting	O
ratio	O
is	O
defined	O
as	O
the	O
incremental	O
costs	O
of	O
MMS	O
compared	O
with	O
surgical	O
excision	O
to	O
prevent	O
1	O
additional	O
recurrence.	O

Compared	B-Premise
with	I-Premise
surgical	I-Premise
excision,	I-Premise
the	I-Premise
total	I-Premise
treatment	I-Premise
costs	I-Premise
of	I-Premise
MMS	I-Premise
are	I-Premise
significantly	I-Premise
higher	I-Premise
(cost	I-Premise
difference:	I-Premise
primary	I-Premise
BCC,	I-Premise
254	I-Premise
euros;	I-Premise
95%	I-Premise
confidence	I-Premise
interval,	I-Premise
181-324	I-Premise
euros;	I-Premise
recurrent	I-Premise
BCC,	I-Premise
249	I-Premise
euros;	I-Premise
95%	I-Premise
confidence	I-Premise
interval,	I-Premise
175-323	I-Premise
euros).	I-Premise

For	B-Premise
primary	I-Premise
BCC,	I-Premise
the	I-Premise
incremental	I-Premise
cost-effectiveness	I-Premise
ratio	I-Premise
was	I-Premise
29,231	I-Premise
euros,	I-Premise
while	I-Premise
the	I-Premise
ratio	I-Premise
for	I-Premise
recurrent	I-Premise
BCC	I-Premise
amounted	I-Premise
to	I-Premise
8094	I-Premise
euros.	I-Premise

The	B-Premise
acceptability	I-Premise
curves	I-Premise
showed	I-Premise
that	I-Premise
for	I-Premise
these	I-Premise
ratios,	I-Premise
the	I-Premise
probability	I-Premise
of	I-Premise
MMS	I-Premise
being	I-Premise
more	I-Premise
cost-effective	I-Premise
than	I-Premise
surgical	I-Premise
excision	I-Premise
never	I-Premise
reached	I-Premise
50%.	I-Premise

At	B-Claim
present,	I-Claim
it	I-Claim
does	I-Claim
not	I-Claim
seem	I-Claim
cost-effective	I-Claim
to	I-Claim
introduce	I-Claim
MMS	I-Claim
on	I-Claim
a	I-Claim
large	I-Claim
scale	I-Claim
for	I-Claim
both	I-Claim
primary	I-Claim
and	I-Claim
recurrent	I-Claim
BCC.	I-Claim

However,	O
because	B-Premise
a	I-Premise
5-year	I-Premise
period	I-Premise
is	I-Premise
normally	I-Premise
required	I-Premise
to	I-Premise
determine	I-Premise
definite	I-Premise
recurrence	I-Premise
rates,	I-Premise
it	B-Claim
is	I-Claim
possible	I-Claim
that	I-Claim
MMS	I-Claim
may	I-Claim
become	I-Claim
a	I-Claim
cost-effective	I-Claim
treatment	I-Claim
for	I-Claim
recurrent	I-Claim
BCC.	I-Claim

Hepatic	O
metastases	O
derive	O
most	O
of	O
their	O
blood	O
supply	O
from	O
the	O
hepatic	O
artery;	O
therefore,	O
for	B-Claim
patients	I-Claim
with	I-Claim
hepatic	I-Claim
metastases	I-Claim
from	I-Claim
colorectal	I-Claim
cancer,	I-Claim
hepatic	I-Claim
arterial	I-Claim
infusion	I-Claim
(HAI)	I-Claim
of	I-Claim
chemotherapy	I-Claim
may	I-Claim
improve	I-Claim
outcome.	I-Claim

In	O
a	O
multi-institutional	O
trial,	O
135	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
HAI	O
versus	O
systemic	O
bolus	O
fluorouracil	O
and	O
leucovorin.	O

The	O
primary	O
end	O
point	O
was	O
survival;	O
secondary	O
end	O
points	O
were	O
response,	O
recurrence,	O
toxicity,	O
quality	O
of	O
life,	O
cost,	O
and	O
the	O
influence	O
of	O
molecular	O
markers.	O

Overall	B-Premise
survival	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
for	I-Premise
HAI	I-Premise
versus	I-Premise
systemic	I-Premise
treatment	I-Premise
(median,	I-Premise
24.4	I-Premise
v	I-Premise
20	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.0034),	I-Premise
as	I-Premise
were	I-Premise
response	I-Premise
rates	I-Premise
(47%	I-Premise
and	I-Premise
24%;	I-Premise
P	I-Premise
=	I-Premise
.012)	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
hepatic	I-Premise
progression	I-Premise
(THP;	I-Premise
9.8	I-Premise
v	I-Premise
7.3	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.034).	I-Premise

Time	B-Premise
to	I-Premise
extrahepatic	I-Premise
progression	I-Premise
(7.7	I-Premise
v	I-Premise
14.8	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.029)	I-Premise
was	I-Premise
significantly	I-Premise
shorter	I-Premise
in	I-Premise
the	I-Premise
HAI	I-Premise
group.	I-Premise

Quality-of-life	B-Premise
measurements	I-Premise
showed	I-Premise
improved	I-Premise
physical	I-Premise
functioning	I-Premise
in	I-Premise
the	I-Premise
HAI	I-Premise
group	I-Premise
at	I-Premise
the	I-Premise
3-	I-Premise
and	I-Premise
6-month	I-Premise
follow-up	I-Premise
assessments.	I-Premise

Toxicity	B-Premise
included	I-Premise
grade	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
3	I-Premise
neutropenia	I-Premise
(2%	I-Premise
and	I-Premise
45%;	I-Premise
P	I-Premise
<	I-Premise
.01),	I-Premise
stomatitis	I-Premise
(0%	I-Premise
and	I-Premise
24%;	I-Premise
P	I-Premise
<	I-Premise
.01),	I-Premise
and	I-Premise
bilirubin	I-Premise
elevation	I-Premise
(18.6%	I-Premise
and	I-Premise
0;	I-Premise
P	I-Premise
<	I-Premise
.01)	I-Premise
in	I-Premise
the	I-Premise
HAI	I-Premise
and	I-Premise
systemic	I-Premise
treatment	I-Premise
groups,	I-Premise
respectively.	I-Premise

A	B-Premise
greater	I-Premise
proportion	I-Premise
of	I-Premise
men	I-Premise
versus	I-Premise
women	I-Premise
receiving	I-Premise
HAI	I-Premise
experienced	I-Premise
biliary	I-Premise
toxicity	I-Premise
(37%	I-Premise
and	I-Premise
15%,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.05).	I-Premise

For	B-Premise
HAI	I-Premise
patients	I-Premise
with	I-Premise
thymidylate	I-Premise
synthase	I-Premise
levels	I-Premise
in	I-Premise
tumor	I-Premise
less	I-Premise
than	I-Premise
or	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
4,	I-Premise
the	I-Premise
median	I-Premise
survival	I-Premise
was	I-Premise
24	I-Premise
and	I-Premise
14	I-Premise
months,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
.17).	I-Premise

HAI	B-Claim
therapy	I-Claim
increased	I-Claim
overall	I-Claim
survival,	I-Claim
response	I-Claim
rate,	I-Claim
THP,	I-Claim
and	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
better	I-Claim
physical	I-Claim
functioning	I-Claim
compared	I-Claim
with	I-Claim
systemic	I-Claim
therapy.	I-Claim

Additional	B-Claim
studies	I-Claim
need	I-Claim
to	I-Claim
address	I-Claim
the	I-Claim
overall	I-Claim
benefit	I-Claim
and	I-Claim
cost	I-Claim
of	I-Claim
new	I-Claim
chemotherapy	I-Claim
agents	I-Claim
versus	I-Claim
HAI	I-Claim
alone	I-Claim
or	I-Claim
the	I-Claim
combination	I-Claim
of	I-Claim
HAI	I-Claim
with	I-Claim
new	I-Claim
agents.	I-Claim

Morbidity	B-Claim
is	I-Claim
an	I-Claim
important	I-Claim
issue	I-Claim
in	I-Claim
cancer	I-Claim
research.	I-Claim

The	B-Claim
observer-based	I-Claim
toxicity	I-Claim
scoring	I-Claim
system	I-Claim
used	I-Claim
by	I-Claim
DAHANCA	I-Claim
(the	I-Claim
Danish	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer	I-Claim
study	I-Claim
group)	I-Claim
has	I-Claim
proved	I-Claim
itself	I-Claim
sensitive	I-Claim
to	I-Claim
differences	I-Claim
in	I-Claim
toxicity	I-Claim
in	I-Claim
a	I-Claim
large	I-Claim
randomised	I-Claim
study,	I-Claim
but	B-Claim
like	I-Claim
other	I-Claim
toxicity	I-Claim
scoring	I-Claim
systems	I-Claim
it	I-Claim
has	I-Claim
not	I-Claim
been	I-Claim
formally	I-Claim
validated.	I-Claim

Conversely,	O
the	O
EORTC	O
quality	O
of	O
life	O
questionnaire	O
(QLQ)	O
has	O
been	O
validated	O
as	O
a	O
tool	O
for	O
collecting	O
information	O
about	O
the	O
consequences	O
of	O
disease	O
and	O
treatment	O
on	O
the	O
well	O
being	O
of	O
cancer	O
patients.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
the	O
two	O
methods	O
of	O
side	O
effect	O
recording.	O

One	O
hundred	O
and	O
sixteen	O
recurrence	O
free	O
patients	O
with	O
laryngeal	O
(n=44),	O
pharyngeal	O
(n=34)	O
and	O
oral	O
cavity	O
(n=38)	O
cancer	O
attending	O
follow-up	O
after	O
radiotherapy	O
(n=83)	O
or	O
surgery	O
(n=33)	O
completed	O
EORTC	O
C30,	O
the	O
core	O
questionnaire	O
concerning	O
general	O
symptoms	O
and	O
function	O
and	O
EORTC	O
H&amp;N35	O
the	O
head	O
and	O
neck	O
specific	O
questionnaire.	O

The	O
attending	O
physicians	O
in	O
the	O
follow-up	O
clinic	O
evaluated	O
and	O
recorded	O
DAHANCA	O
toxicity	O
scores	O
on	O
the	O
same	O
patients.	O

The	B-Premise
DAHANCA	I-Premise
toxicity	I-Premise
scoring	I-Premise
system	I-Premise
and	I-Premise
the	I-Premise
EORTC	I-Premise
QLQ	I-Premise
correlated	I-Premise
with	I-Premise
several	I-Premise
clinical	I-Premise
endpoints.	I-Premise

The	B-Premise
conceptually	I-Premise
similar	I-Premise
endpoints	I-Premise
of	I-Premise
the	I-Premise
two	I-Premise
methods	I-Premise
correlated	I-Premise
significantly.	I-Premise

The	B-Premise
objective	I-Premise
endpoints	I-Premise
of	I-Premise
the	I-Premise
DAHANCA	I-Premise
scoring	I-Premise
system	I-Premise
were	I-Premise
only	I-Premise
correlated	I-Premise
with	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
endpoints	I-Premise
to	I-Premise
a	I-Premise
very	I-Premise
low	I-Premise
degree.	I-Premise

The	B-Premise
DAHANCA	I-Premise
toxicity	I-Premise
scores	I-Premise
had	I-Premise
a	I-Premise
low	I-Premise
sensitivity	I-Premise
(0.48-0.74)	I-Premise
in	I-Premise
detecting	I-Premise
equivalent	I-Premise
subjective	I-Premise
complaints	I-Premise
from	I-Premise
the	I-Premise
questionnaires	I-Premise
and	I-Premise
the	I-Premise
observer-based	I-Premise
scoring	I-Premise
system	I-Premise
severely	I-Premise
underestimated	I-Premise
patient	I-Premise
complaints.	I-Premise

A	B-Premise
specific	I-Premise
patient	I-Premise
group	I-Premise
where	I-Premise
the	I-Premise
DAHANCA	I-Premise
score	I-Premise
had	I-Premise
a	I-Premise
higher	I-Premise
tendency	I-Premise
to	I-Premise
fail	I-Premise
could	I-Premise
not	I-Premise
be	I-Premise
detected.	I-Premise

The	B-Claim
DAHANCA	I-Claim
toxicity	I-Claim
score	I-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
instrument	I-Claim
in	I-Claim
assessing	I-Claim
objective	I-Claim
treatment	I-Claim
induced	I-Claim
toxicity	I-Claim
in	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer	I-Claim
patients	I-Claim
but	I-Claim
insensitive	I-Claim
and	I-Claim
non-specific	I-Claim
with	I-Claim
regard	I-Claim
to	I-Claim
patient	I-Claim
assessed	I-Claim
subjective	I-Claim
endpoints.	I-Claim

This	B-Claim
weakness	I-Claim
seems	I-Claim
inherent	I-Claim
in	I-Claim
an	I-Claim
observer-based	I-Claim
scoring	I-Claim
system,	I-Claim
and	I-Claim
will	I-Claim
probably	I-Claim
also	I-Claim
apply	I-Claim
to	I-Claim
newer	I-Claim
ones	I-Claim
like	I-Claim
CTCAE	I-Claim
3.0.	I-Claim

Prospective	B-Claim
investigations	I-Claim
of	I-Claim
complete	I-Claim
decongestive	I-Claim
lymphatic	I-Claim
physiotherapy	I-Claim
(CDPT),	I-Claim
including	I-Claim
manual	I-Claim
lymphatic	I-Claim
drainage	I-Claim
(MLD),	I-Claim
have	I-Claim
validated	I-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
these	I-Claim
interventions	I-Claim
for	I-Claim
the	I-Claim
initial	I-Claim
reduction	I-Claim
of	I-Claim
edema	I-Claim
and	I-Claim
long-term	I-Claim
maintenance	I-Claim
of	I-Claim
limb	I-Claim
volume	I-Claim
in	I-Claim
lymphedema.	I-Claim

However,	O
CDPT	O
demands	O
substantial	O
time	O
and	O
effort	O
from	O
patients	O
to	O
maintain	O
these	O
benefits;	O
the	B-Claim
treatments	I-Claim
are	I-Claim
not	I-Claim
always	I-Claim
well-accepted,	I-Claim
and	O
patients	B-Claim
may	I-Claim
suffer	I-Claim
from	I-Claim
a	I-Claim
deterioration	I-Claim
in	I-Claim
quality-of-life	I-Claim
or	I-Claim
a	I-Claim
time-dependent	I-Claim
loss	I-Claim
of	I-Claim
initial	I-Claim
treatment	I-Claim
benefits.	I-Claim

A	O
new	O
device	O
designed	O
for	O
home	O
use	O
by	O
the	O
patient,	O
the	O
Flexitouch,	O
has	O
been	O
developed	O
to	O
mechanically	O
simulate	O
MLD.	O

We	O
have	O
undertaken	O
a	O
prospective,	O
randomized,	O
crossover	O
study	O
of	O
the	O
efficacy	O
of	O
the	O
Flexitouch,	O
when	O
compared	O
to	O
massage,	O
in	O
the	O
self-administered	O
maintenance	O
therapy	O
of	O
lymphedema.	O

A	O
prospective,	O
randomized,	O
crossover	O
study	O
of	O
maintenance	O
therapy	O
was	O
performed	O
in	O
10	O
patients	O
with	O
unilateral	O
breast	O
cancer-associated	O
lymphedema	O
of	O
the	O
arm.	O

Each	O
observation	O
phase	O
included	O
self-administered	O
treatment	O
with	O
the	O
Flexitouch	O
or	O
massage,	O
1	O
hour	O
daily	O
for	O
14	O
days,	O
respectively,	O
followed	O
by	O
crossover	O
to	O
the	O
alternate	O
treatment	O
phase.	O

Each	O
treatment	O
phase	O
was	O
preceded	O
by	O
a	O
1	O
week	O
treatment	O
washout,	O
with	O
use	O
of	O
garment	O
only.	O

The	O
sequence	O
of	O
treatment	O
was	O
randomly	O
assigned.	O

The	O
potential	O
impact	O
of	O
treatment	O
modality	O
on	O
quality	O
of	O
life	O
was	O
assessed	O
with	O
serial	O
administration	O
of	O
the	O
SF-36.	O

Statistical	O
analysis	O
disclosed	O
that	O
the	O
order	O
of	O
treatment	O
had	O
no	O
outcome	O
influence,	O
permitting	O
10	O
comparisons	O
within	O
each	O
treatment	O
group.	O

Post-treatment	B-Premise
arm	I-Premise
volume	I-Premise
reduced	I-Premise
significantly	I-Premise
after	I-Premise
the	I-Premise
Flexitouch,	I-Premise
but	I-Premise
not	I-Premise
after	I-Premise
self-administered	I-Premise
massage.	I-Premise

The	B-Premise
patients'	I-Premise
mean	I-Premise
weight	I-Premise
decreased	I-Premise
significantly	I-Premise
with	I-Premise
Flexitouch	I-Premise
use,	I-Premise
but	I-Premise
not	I-Premise
with	I-Premise
massage.	I-Premise

The	B-Premise
Flexitouch	I-Premise
device	I-Premise
was	I-Premise
apparently	I-Premise
well-tolerated	I-Premise
and	I-Premise
accepted	I-Premise
by	I-Premise
patients.	I-Premise

Serial	B-Premise
SF-36	I-Premise
administration	I-Premise
showed	I-Premise
no	I-Premise
deterioration	I-Premise
in	I-Premise
physical	I-Premise
or	I-Premise
psychosocial	I-Premise
scores	I-Premise
compared	I-Premise
to	I-Premise
baseline	I-Premise
measurements;	I-Premise
there	B-Premise
were	I-Premise
no	I-Premise
statistical	I-Premise
differences	I-Premise
in	I-Premise
scores	I-Premise
when	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
modalities	I-Premise
were	I-Premise
compared.	I-Premise

This	B-Claim
short-term	I-Claim
prospective	I-Claim
evaluation	I-Claim
of	I-Claim
the	I-Claim
Flexitouch	I-Claim
suggests	I-Claim
that	I-Claim
the	I-Claim
device	I-Claim
may	I-Claim
provide	I-Claim
better	I-Claim
maintenance	I-Claim
edema	I-Claim
control	I-Claim
than	I-Claim
self-adiminstered	I-Claim
massage	I-Claim
in	I-Claim
breast	I-Claim
cancer-associated	I-Claim
lymphedema.	I-Claim

The	B-Claim
apparent	I-Claim
ease	I-Claim
of	I-Claim
use	I-Claim
and	I-Claim
reliability	I-Claim
of	I-Claim
response	I-Claim
to	I-Claim
the	I-Claim
device	I-Claim
suggest	I-Claim
that	I-Claim
further	I-Claim
broad-scale	I-Claim
testing	I-Claim
is	I-Claim
warranted.	I-Claim

Tumor	B-Claim
necrosis	I-Claim
factor-alpha	I-Claim
(TNF-alpha)	I-Claim
is	I-Claim
a	I-Claim
putative	I-Claim
mediator	I-Claim
of	I-Claim
the	I-Claim
cancer	I-Claim
anorexia/weight	I-Claim
loss	I-Claim
syndrome.	I-Claim

The	O
current	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
etanercept	O
(a	O
dimeric	O
fusion	O
protein	O
consisting	O
of	O
the	O
extracellular	O
ligand-binding	O
portion	O
of	O
the	O
human	O
75-kilodalton	O
TNF	O
receptor	O
linked	O
to	O
the	O
Fc	O
portion	O
of	O
human	O
immunoglobulin	O
[Ig]	O
G1)	O
could	O
palliate	O
this	O
syndrome.	O

A	O
total	O
of	O
63	O
evaluable	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
etanercept	O
at	O
a	O
dose	O
of	O
25	O
mg	O
subcutaneously	O
twice	O
weekly	O
versus	O
a	O
comparably	O
administered	O
placebo.	O

All	O
patients	O
had	O
an	O
incurable	O
malignancy,	O
acknowledged	O
loss	O
of	O
weight	O
and/or	O
appetite	O
as	O
a	O
concern,	O
and	O
reported	O
a	O
weight	O
loss	O
of	O
>2.27	O
kg	O
over	O
2	O
months	O
and/or	O
a	O
daily	O
intake	O
of	O
<20	O
calories/kg	O
body	O
weight.	O

Over	B-Premise
time,	I-Premise
weight	I-Premise
gain	I-Premise
was	I-Premise
found	I-Premise
to	I-Premise
be	I-Premise
minimal	I-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
arms;	I-Premise
no	I-Premise
patient	I-Premise
gained	I-Premise
>or=10%	I-Premise
of	I-Premise
their	I-Premise
baseline	I-Premise
weight.	I-Premise

Previously	B-Premise
validated	I-Premise
appetite	I-Premise
questionnaires	I-Premise
revealed	I-Premise
negligible	I-Premise
improvements	I-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
arms.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
was	I-Premise
also	I-Premise
comparable	I-Premise
(175	I-Premise
days	I-Premise
vs	I-Premise
148	I-Premise
days	I-Premise
in	I-Premise
etanercept-treated	I-Premise
and	I-Premise
placebo-exposed	I-Premise
patients,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.82).	I-Premise

Finally,	O
preliminary	B-Premise
data	I-Premise
regarding	I-Premise
adverse	I-Premise
events	I-Premise
demonstrated	I-Premise
that	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
etanercept	I-Premise
had	I-Premise
higher	I-Premise
rates	I-Premise
of	I-Premise
neurotoxicity	I-Premise
(29%	I-Premise
vs	I-Premise
0%)	I-Premise
but	I-Premise
lower	I-Premise
rates	I-Premise
of	I-Premise
anemia	I-Premise
(0%	I-Premise
vs	I-Premise
19%)	I-Premise
and	I-Premise
thrombocytopenia	I-Premise
(0%	I-Premise
vs	I-Premise
14%).	I-Premise

Infection	B-Premise
rates	I-Premise
were	I-Premise
negligible	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Genotyping	B-Premise
for	I-Premise
TNF-alpha-238	I-Premise
and	I-Premise
TNF-alpha-308	I-Premise
polymorphisms	I-Premise
revealed	I-Premise
no	I-Premise
clinical	I-Premise
significance	I-Premise
for	I-Premise
these	I-Premise
genotypes,	I-Premise
except	I-Premise
for	I-Premise
a	I-Premise
preliminary	I-Premise
association	I-Premise
between	I-Premise
presence	I-Premise
of	I-Premise
the	I-Premise
-238	I-Premise
G/A	I-Premise
genotype	I-Premise
and	I-Premise
relatively	I-Premise
less	I-Premise
favorable	I-Premise
survival.	I-Premise

Etanercept,	B-Claim
as	I-Claim
prescribed	I-Claim
in	I-Claim
the	I-Claim
current	I-Claim
trial,	I-Claim
does	I-Claim
not	I-Claim
appear	I-Claim
to	I-Claim
palliate	I-Claim
the	I-Claim
cancer	I-Claim
anorexia/weight	I-Claim
loss	I-Claim
syndrome	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
disease.	I-Claim

To	O
evaluate	O
if	O
raising	O
baseline	O
and	O
maintaining	O
hemoglobin	O
(Hb)	O
levels	O
with	O
red	O
blood	O
cell	O
(RBC)	O
transfusion	O
could	O
improve	O
the	O
outcomes	O
of	O
chemotherapy	O
for	O
advanced	O
gastric	O
cancer	O
(AGC).	O

Patients	O
were	O
randomized	O
to	O
receive	O
RBC	O
transfusion	O
to	O
maintain	O
their	O
Hb	O
levels	O
>or=10	O
g/dl	O
(arm	O
1)	O
or	O
>or=12	O
(arm	O
2)	O
before	O
the	O
start	O
of	O
their	O
5-fluorouracil-based	O
first-line	O
chemotherapy.	O

Objective	O
response,	O
KPS	O
and	O
quality	O
of	O
life	O
(QOL)	O
data	O
were	O
measured.	O

For	O
87	O
patients	O
enrolled,	O
mean	O
baseline	O
Hb	O
was	O
10.1	O
g/dl,	O
and	O
54	O
patients	O
received	O
RBC	O
prior	O
to	O
chemotherapy	O
initiation.	O

Despite	O
transfusion,	O
we	O
failed	O
to	O
maintain	O
the	O
Hb	O
level	O
above	O
the	O
predefined	O
target	O
range.	O

Eighteen	B-Premise
patients	I-Premise
experienced	I-Premise
brief	I-Premise
and	I-Premise
reversible	I-Premise
adverse	I-Premise
events	I-Premise
during	I-Premise
transfusion,	I-Premise
including	I-Premise
two	I-Premise
patients	I-Premise
with	I-Premise
acute	I-Premise
pulmonary	I-Premise
edema.	I-Premise

KPS	B-Premise
was	I-Premise
improved	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
post-chemotherapy	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

QOL	B-Premise
data	I-Premise
showed	I-Premise
improvement	I-Premise
in	I-Premise
some	I-Premise
symptom	I-Premise
scores,	I-Premise
but	B-Premise
there	I-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
QOL	I-Premise
scores	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms	I-Premise
at	I-Premise
baseline	I-Premise
and	I-Premise
all	I-Premise
four	I-Premise
cycles	I-Premise
of	I-Premise
treatment.	I-Premise

Similar	B-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
(arm	I-Premise
1,	I-Premise
30%;	I-Premise
arm	I-Premise
2,	I-Premise
35%).	I-Premise

Both	B-Premise
arms	I-Premise
showed	I-Premise
similar	I-Premise
chemotherapy	I-Premise
duration	I-Premise
(3.8	I-Premise
and	I-Premise
4.1	I-Premise
months,	I-Premise
respectively),	I-Premise
progression-free	I-Premise
survival	I-Premise
(4.0	I-Premise
and	I-Premise
4.1	I-Premise
months)	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
(9.9	I-Premise
and	I-Premise
9.3	I-Premise
months).	I-Premise

Red	B-Claim
blood	I-Claim
cell	I-Claim
transfusion	I-Claim
achieving	I-Claim
Hb	I-Claim
level	I-Claim
above	I-Claim
10	I-Claim
g/dl	I-Claim
might	I-Claim
contribute	I-Claim
to	I-Claim
the	I-Claim
improvement	I-Claim
of	I-Claim
the	I-Claim
KPS	I-Claim
and	I-Claim
QOL	I-Claim
seen	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
AGC.	I-Claim

The	B-Claim
observation	I-Claim
of	I-Claim
equivalent	I-Claim
outcomes	I-Claim
at	I-Claim
the	I-Claim
two	I-Claim
target	I-Claim
Hb	I-Claim
levels	I-Claim
supports	I-Claim
the	I-Claim
feasibility	I-Claim
of	I-Claim
anemia	I-Claim
correction	I-Claim
to	I-Claim
Hb	I-Claim
10	I-Claim
g/dl,	I-Claim
which	I-Claim
merits	I-Claim
further	I-Claim
evaluation.	I-Claim

Colonic	O
pouches	O
have	O
been	O
used	O
for	O
20	O
years	O
to	O
provide	O
reservoir	O
function	O
after	O
reconstructive	O
proctectomy	O
for	O
rectal	O
cancer.	O

More	B-Claim
recently	I-Claim
coloplasty	I-Claim
has	I-Claim
been	I-Claim
advocated	I-Claim
as	I-Claim
an	I-Claim
alternative	I-Claim
to	I-Claim
a	I-Claim
colonic	I-Claim
pouch.	I-Claim

However	O
there	O
have	O
been	O
no	O
long-term	O
randomized,	O
controlled	O
trials	O
to	O
compare	O
functional	O
outcomes	O
of	O
coloplasty,	O
colonic	O
J-Pouch	O
(JP),	O
or	O
a	O
straight	O
anastomosis	O
(SA)	O
after	O
the	O
treatment	O
of	O
low	O
rectal	O
cancer.	O

:	O
To	O
compare	O
the	O
complications,	O
long-term	O
functional	O
outcome,	O
and	O
quality	O
of	O
life	O
(QOL)	O
of	O
patients	O
undergoing	O
a	O
coloplasty,	O
JP,	O
or	O
an	O
SA	O
in	O
reconstruction	O
of	O
the	O
lower	O
gastrointestinal	O
tract	O
after	O
proctectomy	O
for	O
low	O
rectal	O
cancer.	O

A	O
multicenter	O
study	O
enrolled	O
patients	O
with	O
low	O
rectal	O
cancer,	O
who	O
were	O
randomized	O
intraoperatively	O
to	O
coloplasty	O
(CP-1)	O
or	O
SA	O
if	O
JP	O
was	O
not	O
feasible,	O
or	O
JP	O
or	O
coloplasty	O
(CP-2)	O
if	O
a	O
JP	O
was	O
feasible.	O

Patients	O
were	O
followed	O
for	O
24	O
months	O
with	O
SF-36	O
surveys	O
to	O
evaluate	O
the	O
QOL.	O

Bowel	O
function	O
was	O
measured	O
quantitatively	O
and	O
using	O
Fecal	O
Incontinence	O
Severity	O
Index	O
(FISI).	O

Urinary	O
function	O
and	O
sexual	O
function	O
were	O
also	O
assessed.	O

Three	O
hundred	O
sixty-four	O
patients	O
were	O
randomized.	O

All	O
patients	O
were	O
evaluated	O
for	O
complications	O
and	O
recurrence.	O

Mean	O
age	O
was	O
60	O
+/-12	O
years,	O
71%	O
were	O
male.	O

Twenty-three	B-Premise
(7.4%)	I-Premise
died	I-Premise
within	I-Premise
24	I-Premise
months	I-Premise
of	I-Premise
surgery.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
complications	I-Premise
among	I-Premise
the	I-Premise
4	I-Premise
groups.	I-Premise

Two	O
hundred	O
ninety-seven	O
of	O
364	O
were	O
evaluated	O
for	O
functional	O
outcome	O
at	O
24	O
months.	O

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
bowel	I-Premise
function	I-Premise
between	I-Premise
the	I-Premise
CP-1	I-Premise
and	I-Premise
SA	I-Premise
groups.	I-Premise

JP	B-Premise
patients	I-Premise
had	I-Premise
fewer	I-Premise
bowel	I-Premise
movements,	I-Premise
less	I-Premise
clustering,	I-Premise
used	I-Premise
fewer	I-Premise
pads	I-Premise
and	I-Premise
had	I-Premise
a	I-Premise
lower	I-Premise
FISI	I-Premise
than	I-Premise
the	I-Premise
CP-2	I-Premise
group.	I-Premise

Other	B-Premise
parameters	I-Premise
were	I-Premise
not	I-Premise
statistically	I-Premise
different.	I-Premise

QOL	B-Premise
scores	I-Premise
at	I-Premise
24	I-Premise
months	I-Premise
were	I-Premise
similar	I-Premise
for	I-Premise
each	I-Premise
of	I-Premise
the	I-Premise
4	I-Premise
groups.	I-Premise

In	B-Claim
patients	I-Claim
undergoing	I-Claim
a	I-Claim
restorative	I-Claim
resection	I-Claim
for	I-Claim
low	I-Claim
rectal	I-Claim
cancer,	I-Claim
a	I-Claim
colonic	I-Claim
JP	I-Claim
offers	I-Claim
significant	I-Claim
advantages	I-Claim
in	I-Claim
function	I-Claim
over	I-Claim
an	I-Claim
SA	I-Claim
or	I-Claim
a	I-Claim
coloplasty.	I-Claim

In	B-Claim
patients	I-Claim
who	I-Claim
cannot	I-Claim
have	I-Claim
a	I-Claim
pouch,	I-Claim
coloplasty	I-Claim
seems	I-Claim
not	I-Claim
to	I-Claim
improve	I-Claim
the	I-Claim
bowel	I-Claim
function	I-Claim
of	I-Claim
patients	I-Claim
over	I-Claim
that	I-Claim
with	I-Claim
an	I-Claim
SA.	I-Claim

Cancer-related	B-Claim
fatigue	I-Claim
is	I-Claim
the	I-Claim
most	I-Claim
disabling	I-Claim
symptom	I-Claim
experienced	I-Claim
by	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
following	I-Claim
the	I-Claim
cancer	I-Claim
treatment.	I-Claim

The	B-Premise
positive	I-Premise
effects	I-Premise
of	I-Premise
physical	I-Premise
activity	I-Premise
in	I-Premise
the	I-Premise
rehabilitation	I-Premise
of	I-Premise
breast	I-Premise
cancer	I-Premise
patients	I-Premise
are	I-Premise
documented	I-Premise
in	I-Premise
several	I-Premise
studies.	I-Premise

In	O
a	O
randomized	O
controlled	O
study	O
the	O
effects	O
of	O
a	O
structured	O
physical	O
training	O
program	O
on	O
fatigue	O
and	O
health-related	O
quality	O
of	O
life	O
were	O
evaluated.	O

63	O
breast	O
cancer	O
patients	O
with	O
cancer-related	O
chronic	O
fatigue	O
were	O
randomized	O
at	O
the	O
beginning	O
of	O
the	O
inpatient	O
rehabilitation.	O

The	O
control	O
group	O
received	O
the	O
standard	O
complex	O
rehabilitation	O
program,	O
the	O
intervention	O
group	O
a	O
structured	O
physical	O
training	O
program	O
and	O
additional	O
muscle	O
strength	O
and	O
aerobic	O
exercises.	O

The	O
effects	O
of	O
the	O
treatment	O
were	O
evaluated	O
by	O
questionnaires	O
at	O
the	O
start	O
of	O
rehabilitation	O
(t1),	O
end	O
of	O
rehabilitation	O
(t2),	O
and	O
3	O
months	O
after	O
t2	O
(t3).	O

Isometric	O
muscle	O
strength	O
and	O
aerobic	O
capacity	O
were	O
evaluated	O
at	O
t1	O
and	O
t2.	O

There	B-Premise
was	I-Premise
an	I-Premise
improvement	I-Premise
of	I-Premise
muscle	I-Premise
strength	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
rehabilitation	I-Premise
for	I-Premise
both	I-Premise
groups.	I-Premise

The	B-Premise
increase	I-Premise
from	I-Premise
t1	I-Premise
to	I-Premise
t2	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
for	I-Premise
the	I-Premise
training	I-Premise
group.	I-Premise

The	B-Premise
scores	I-Premise
for	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
physical	I-Premise
well-being,	I-Premise
and	I-Premise
functionality	I-Premise
increased	I-Premise
from	I-Premise
t1	I-Premise
to	I-Premise
t2,	I-Premise
but	B-Premise
further	I-Premise
improvement	I-Premise
in	I-Premise
the	I-Premise
follow-up	I-Premise
(t3)	I-Premise
was	I-Premise
only	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
training	I-Premise
group.	I-Premise

The	B-Premise
cancer-related	I-Premise
fatigue	I-Premise
was	I-Premise
significantly	I-Premise
reduced	I-Premise
in	I-Premise
the	I-Premise
training	I-Premise
group	I-Premise
from	I-Premise
t1	I-Premise
to	I-Premise
t3,	I-Premise
however,	I-Premise
not	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Structured	B-Claim
physical	I-Claim
training	I-Claim
programs	I-Claim
initiated	I-Claim
during	I-Claim
inpatient	I-Claim
rehabilitation	I-Claim
and	I-Claim
continuously	I-Claim
practiced	I-Claim
in	I-Claim
the	I-Claim
time	I-Claim
thereafter	I-Claim
can	I-Claim
improve	I-Claim
symptoms	I-Claim
of	I-Claim
chronic	I-Claim
fatigue	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
patients.	I-Claim

Patients	B-Claim
receiving	I-Claim
chemotherapy	I-Claim
for	I-Claim
cancer	I-Claim
often	I-Claim
develop	I-Claim
anemia,	I-Claim
which	I-Claim
can	I-Claim
contribute	I-Claim
to	I-Claim
increased	I-Claim
morbidity	I-Claim
and	I-Claim
reduced	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL).	I-Claim

Chemotherapy-induced	B-Claim
anemia	I-Claim
can	I-Claim
be	I-Claim
successfully	I-Claim
treated	I-Claim
using	I-Claim
recombinant	I-Claim
human	I-Claim
erythropoietin	I-Claim
(rHuEPO).	I-Claim

To	O
demonstrate	O
the	O
effectiveness	O
of	O
once-weekly	O
(QW)	O
rHuEPO	O
dosing	O
to	O
effect	O
improved	O
hemoglobin	O
levels,	O
decreased	O
transfusion	O
use,	O
and	O
improved	O
functional	O
outcomes	O
and	O
QOL	O
in	O
pediatric	O
leukemic	O
patients	O
(ALL)	O
receiving	O
maintenance	O
chemotherapy.	O

This	O
was	O
a	O
prospective	O
randomized,	O
single-center,	O
open-label,	O
12-week	O
case-control	O
study	O
of	O
epoetin	O
alfa	O
in	O
pediatric	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
in	O
remission	O
receiving	O
maintenance	O
chemotherapy.	O

Sixty	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
epoetin	O
alfa	O
(rHuEPO	O
group	O
=	O
30	O
cases,	O
17	O
males	O
and	O
13	O
females,	O
age;	O
6.8	O
+/-	O
2.33	O
years),	O
or	O
no	O
epoetin	O
alfa	O
(control	O
group	O
=	O
30	O
cases,	O
16	O
males	O
and	O
14	O
females,	O
age;	O
6.76	O
+/-	O
2.28	O
years).	O

Both	O
groups	O
were	O
matched	O
as	O
regard	O
age,	O
sex,	O
baseline	O
Hb	O
concentration,	O
remission	O
state,	O
chemotherapy	O
regimen,	O
numbers	O
and	O
amount	O
of	O
blood	O
transfusion,	O
and	O
leukemia	O
state	O
(both	O
were	O
low	O
and	O
standard	O
risk).	O

Epoetin	O
alfa	O
was	O
administered	O
at	O
a	O
dose	O
of	O
450	O
IU/kg,	O
once	O
weekly,	O
subcutaneously	O
(s.c.)	O
for	O
12	O
consecutive	O
weeks.	O

Endpoints	O
were	O
changes	O
in	O
hematologic	O
and	O
QOL	O
parameters.	O

Among	B-Premise
the	I-Premise
30	I-Premise
patients	I-Premise
evaluable	I-Premise
for	I-Premise
hematologic	I-Premise
response,	I-Premise
the	I-Premise
mean	I-Premise
increase	I-Premise
in	I-Premise
Hb	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
time	I-Premise
of	I-Premise
final	I-Premise
evaluation	I-Premise
was	I-Premise
3.08	I-Premise
+/-	I-Premise
1.48	I-Premise
g/dl	I-Premise
(p	I-Premise
<	I-Premise
0.001).	I-Premise

An	B-Premise
increase	I-Premise
in	I-Premise
Hb	I-Premise
of	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
2	I-Premise
g/dl,	I-Premise
in	I-Premise
the	I-Premise
absence	I-Premise
of	I-Premise
blood	I-Premise
transfusion,	I-Premise
occurred	I-Premise
in	I-Premise
70%	I-Premise
of	I-Premise
patients	I-Premise
(21	I-Premise
of	I-Premise
30	I-Premise
patients)	I-Premise
who	I-Premise
were	I-Premise
on	I-Premise
the	I-Premise
study	I-Premise
for	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
30	I-Premise
days.	I-Premise

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
(Hb	I-Premise
increase	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
2	I-Premise
g/dl	I-Premise
or	I-Premise
Hb	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
12	I-Premise
g/dl	I-Premise
in	I-Premise
the	I-Premise
absence	I-Premise
of	I-Premise
blood	I-Premise
transfusion)	I-Premise
was	I-Premise
90%	I-Premise
(27	I-Premise
of	I-Premise
30	I-Premise
patients).	I-Premise

In	B-Premise
30	I-Premise
patients	I-Premise
who	I-Premise
were	I-Premise
evaluable	I-Premise
for	I-Premise
QOL	I-Premise
assessment,	I-Premise
epoetin-alpha	I-Premise
therapy	I-Premise
was	I-Premise
found	I-Premise
to	I-Premise
significantly	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
improve	I-Premise
mean	I-Premise
cancer	I-Premise
linear	I-Premise
analog	I-Premise
scale	I-Premise
(CLAS)	I-Premise
scores	I-Premise
for	I-Premise
energy	I-Premise
level,	I-Premise
ability	I-Premise
to	I-Premise
perform	I-Premise
daily	I-Premise
activity,	I-Premise
and	I-Premise
overall	I-Premise
QOL	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
final	I-Premise
evaluation.	I-Premise

QW	B-Premise
epoetin-alpha	I-Premise
was	I-Premise
found	I-Premise
to	I-Premise
be	I-Premise
well	I-Premise
tolerated.	I-Premise

Treatment	B-Claim
with	I-Claim
QW	I-Claim
epoetin-alpha	I-Claim
was	I-Claim
found	I-Claim
to	I-Claim
increase	I-Claim
Hb	I-Claim
levels,	I-Claim
decrease	I-Claim
transfusion	I-Claim
requirement,	I-Claim
and	I-Claim
improve	I-Claim
functional	I-Claim
status	I-Claim
and	I-Claim
QOL	I-Claim
in	I-Claim
anemic	I-Claim
patients	I-Claim
with	I-Claim
ALL	I-Claim
in	I-Claim
maintenance	I-Claim
receiving	I-Claim
chemotherapy.	I-Claim

The	B-Claim
once-weekly	I-Claim
schedule	I-Claim
is	I-Claim
convenient,	I-Claim
safe,	I-Claim
and	I-Claim
may	I-Claim
reduce	I-Claim
the	I-Claim
burden	I-Claim
on	I-Claim
patients,	I-Claim
parents,	I-Claim
and	I-Claim
their	I-Claim
caregivers	I-Claim
by	I-Claim
reducing	I-Claim
the	I-Claim
number	I-Claim
of	I-Claim
visits	I-Claim
to	I-Claim
the	I-Claim
clinic.	I-Claim

This	O
study	O
sought	O
to	O
continue	O
research	O
on	O
psychosocial	O
interventions	O
for	O
patients	O
being	O
treated	O
with	O
radiation	O
therapy	O
across	O
multiple	O
centers	O
and	O
to	O
replicate	O
positive	O
findings	O
of	O
a	O
single-center	O
study	O
of	O
patients	O
being	O
treated	O
with	O
chemotherapy.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
a	O
stress	O
management	O
intervention	O
was	O
effective	O
in	O
improving	O
quality	O
of	O
life	O
and	O
decreasing	O
psychological	O
distress	O
in	O
patients	O
undergoing	O
radiotherapy	O
for	O
cancer.	O

A	O
total	O
of	O
310	O
patients	O
about	O
to	O
begin	O
radiotherapy	O
treatment	O
were	O
randomly	O
assigned	O
to	O
receive	O
usual	O
care	O
only	O
or	O
self-administered	O
stress	O
management	O
training.	O

Quality-of-life	O
assessments	O
occurred	O
at	O
baseline	O
and	O
for	O
3	O
weeks	O
after	O
the	O
beginning	O
of	O
radiotherapy	O
treatment.	O

Overall,	B-Premise
patients	I-Premise
assigned	I-Premise
to	I-Premise
receive	I-Premise
stress	I-Premise
management	I-Premise
training	I-Premise
did	I-Premise
not	I-Premise
report	I-Premise
significantly	I-Premise
less	I-Premise
psychological	I-Premise
distress	I-Premise
on	I-Premise
the	I-Premise
Medical	I-Premise
Outcomes	I-Premise
Study	I-Premise
36-Item	I-Premise
Short	I-Premise
Form	I-Premise
(SF-36)	I-Premise
Mental	I-Premise
Component	I-Premise
Summary	I-Premise
Scale	I-Premise
than	I-Premise
did	I-Premise
those	I-Premise
assigned	I-Premise
to	I-Premise
usual	I-Premise
care.	I-Premise

When	O
divided	O
into	O
subgroups	O
based	O
on	O
the	O
SF-36	O
Mental	O
Component	O
Summary	O
Scale	O
scores	O
immediately	O
after	O
their	O
first	O
radiotherapy	O
treatment,	O
patients	B-Premise
with	I-Premise
above-average	I-Premise
levels	I-Premise
of	I-Premise
psychological	I-Premise
distress	I-Premise
(scores	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
50)	I-Premise
who	I-Premise
were	I-Premise
randomly	I-Premise
assigned	I-Premise
to	I-Premise
the	I-Premise
intervention	I-Premise
condition	I-Premise
reported	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
their	I-Premise
distress	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
assigned	I-Premise
to	I-Premise
usual	I-Premise
care	I-Premise
only	I-Premise
on	I-Premise
the	I-Premise
SF-36	I-Premise
Mental	I-Premise
Health	I-Premise
Subscale	I-Premise
and	I-Premise
the	I-Premise
Center	I-Premise
for	I-Premise
Epidemiologic	I-Premise
Studies	I-Premise
Depression	I-Premise
Scale.	I-Premise

This	B-Claim
study	I-Claim
found	I-Claim
that	I-Claim
self-administered	I-Claim
stress	I-Claim
management	I-Claim
training	I-Claim
is	I-Claim
effective	I-Claim
only	I-Claim
in	I-Claim
those	I-Claim
radiotherapy	I-Claim
patients	I-Claim
with	I-Claim
initially	I-Claim
higher	I-Claim
levels	I-Claim
of	I-Claim
psychological	I-Claim
distress.	I-Claim

Additional	B-Claim
research	I-Claim
should	I-Claim
examine	I-Claim
the	I-Claim
benefits	I-Claim
of	I-Claim
stress	I-Claim
management	I-Claim
training	I-Claim
targeted	I-Claim
specifically	I-Claim
to	I-Claim
patients	I-Claim
experiencing	I-Claim
heightened	I-Claim
distress.	I-Claim

To	O
evaluate	O
whether	O
3-month	O
administration	O
of	O
CDB-2914,	O
a	O
selective	O
progesterone	O
receptor	O
modulator,	O
reduces	O
leiomyoma	O
size	O
and	O
symptoms.	O

Premenopausal	O
women	O
with	O
symptomatic	O
uterine	O
leiomyomata	O
were	O
randomly	O
assigned	O
to	O
CDB-2914	O
at	O
10	O
mg	O
(T1)	O
or	O
20	O
mg	O
(T2)	O
daily	O
or	O
to	O
placebo	O
(PLC)	O
for	O
3	O
cycles	O
or	O
90-102	O
days	O
if	O
no	O
menses	O
occurred.	O

The	O
primary	O
outcome	O
was	O
leiomyoma	O
volume	O
change	O
determined	O
by	O
magnetic	O
resonance	O
imaging	O
at	O
study	O
entry	O
and	O
within	O
2	O
weeks	O
of	O
hysterectomy.	O

Secondary	O
outcomes	O
included	O
the	O
proportion	O
of	O
amenorrhea,	O
change	O
in	O
hemoglobin	O
and	O
hematocrit,	O
ovulation	O
inhibition,	O
and	O
quality-of-life	O
assessment.	O

Twenty-two	O
patients	O
were	O
allocated,	O
and	O
18	O
completed	O
the	O
trial.	O

Age	O
and	O
body	O
mass	O
index	O
were	O
similar	O
among	O
groups.	O

Leiomyoma	O
volume	O
was	O
significantly	O
reduced	O
with	O
CDB-2914	O
administration	O
(PLC	O
6%;	O
CDB-2914	O
-29%;	O
P=.01),	O
decreasing	O
36%	O
and	O
21%	O
in	O
the	O
T1	O
and	O
T2	O
groups,	O
respectively.	O

During	O
treatment,	O
hemoglobin	O
was	O
unchanged,	O
and	O
the	O
median	O
estradiol	O
was	O
greater	O
than	O
50	O
pg/mL	O
in	O
all	O
groups.	O

CDB-2914	O
eliminated	O
menstrual	O
bleeding	O
and	O
inhibited	O
ovulation	O
(%	O
ovulatory	O
cycles:	O
CDB-2914,	O
20%;	O
PLC,	O
83%;	O
P=.001).	O

CDB-2914	O
improved	O
the	O
concern	O
scores	O
of	O
the	O
uterine	O
leiomyoma	O
symptom	O
quality-of-life	O
subscale	O
(P=.04).	O

One	O
CDB-2914	O
woman	O
developed	O
endometrial	O
cystic	O
hyperplasia	O
without	O
evidence	O
of	O
atypia.	O

No	B-Premise
serious	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
reported.	I-Premise

Compared	B-Premise
with	I-Premise
PLC,	I-Premise
CDB-2914	I-Premise
significantly	I-Premise
reduced	I-Premise
leiomyoma	I-Premise
volume	I-Premise
after	I-Premise
three	I-Premise
cycles,	I-Premise
or	I-Premise
90-102	I-Premise
days.	I-Premise

CDB-2914	B-Premise
treatment	I-Premise
resulted	I-Premise
in	I-Premise
improvements	I-Premise
in	I-Premise
the	I-Premise
concern	I-Premise
subscale	I-Premise
of	I-Premise
the	I-Premise
Uterine	I-Premise
Fibroid	I-Premise
Symptom	I-Premise
Quality	I-Premise
of	I-Premise
Life	I-Premise
assessment.	I-Premise

In	B-Claim
this	I-Claim
small	I-Claim
study,	I-Claim
CDB-2914	I-Claim
was	I-Claim
well-tolerated	I-Claim
without	I-Claim
serious	I-Claim
adverse	I-Claim
events.	I-Claim

Thus,	B-Claim
there	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
role	I-Claim
for	I-Claim
CDB-2914	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
leiomyomata.	I-Claim

Shoulder	O
pain	O
and	O
disability	O
are	O
well	O
recognized	O
complications	O
associated	O
with	O
surgery	O
for	O
head	O
and	O
neck	O
cancer.	O

This	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effects	O
of	O
progressive	O
resistance	O
exercise	O
training	O
(PRET)	O
on	O
upper	O
extremity	O
pain	O
and	O
dysfunction	O
in	O
postsurgical	O
head	O
and	O
neck	O
cancer	O
survivors.	O

Fifty-two	O
head	O
and	O
neck	O
cancer	O
survivors	O
were	O
assigned	O
randomly	O
to	O
PRET	O
(n	O
=	O
27)	O
or	O
a	O
standardized	O
therapeutic	O
exercise	O
protocol	O
(TP)	O
(n	O
=	O
25)	O
for	O
12	O
weeks.	O

The	O
primary	O
endpoint	O
was	O
change	O
in	O
patient-rated	O
shoulder	O
pain	O
and	O
disability	O
from	O
baseline	O
to	O
postintervention.	O

Secondary	O
endpoints	O
were	O
upper	O
extremity	O
strength	O
and	O
endurance,	O
range	O
of	O
motion,	O
fatigue,	O
and	O
quality	O
of	O
life.	O

Follow-up	O
assessment	O
for	O
the	O
primary	O
outcome	O
was	O
92%,	O
and	O
adherence	O
to	O
the	O
supervised	O
PRET	O
and	O
TP	O
programs	O
were	O
95%	O
and	O
87%,	O
respectively.	O

On	B-Premise
the	I-Premise
basis	I-Premise
of	I-Premise
intention-to-treat	I-Premise
analyses,	I-Premise
PRET	I-Premise
was	I-Premise
superior	I-Premise
to	I-Premise
TP	I-Premise
for	I-Premise
improving	I-Premise
shoulder	I-Premise
pain	I-Premise
and	I-Premise
disability	I-Premise
(-9.6;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[95%	I-Premise
CI],	I-Premise
-16.4	I-Premise
to	I-Premise
-4.5;	I-Premise
P	I-Premise
=	I-Premise
.001),	I-Premise
upper	I-Premise
extremity	I-Premise
strength	I-Premise
(+10.8	I-Premise
kg;	I-Premise
95%	I-Premise
CI,	I-Premise
5.4-16.2	I-Premise
kg;	I-Premise
P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
upper	I-Premise
extremity	I-Premise
endurance	I-Premise
(+194	I-Premise
repetitions	I-Premise
x	I-Premise
kg;	I-Premise
95%	I-Premise
CI,	I-Premise
10-378	I-Premise
repetitions	I-Premise
x	I-Premise
kg;	I-Premise
P	I-Premise
=	I-Premise
.039).	I-Premise

Changes	B-Premise
in	I-Premise
neck	I-Premise
dissection	I-Premise
impairment,	I-Premise
fatigue,	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
favored	I-Premise
the	I-Premise
PRET	I-Premise
group	I-Premise
but	B-Premise
did	I-Premise
not	I-Premise
reach	I-Premise
statistical	I-Premise
significance.	I-Premise

The	B-Premise
PRET	I-Premise
program	I-Premise
significantly	I-Premise
reduced	I-Premise
shoulder	I-Premise
pain	I-Premise
and	I-Premise
disability	I-Premise
and	I-Premise
improved	I-Premise
upper	I-Premise
extremity	I-Premise
muscular	I-Premise
strength	I-Premise
and	I-Premise
endurance	I-Premise
in	I-Premise
head	I-Premise
and	I-Premise
neck	I-Premise
cancer	I-Premise
survivors	I-Premise
who	I-Premise
had	I-Premise
shoulder	I-Premise
dysfunction	I-Premise
because	I-Premise
of	I-Premise
spinal	I-Premise
accessory	I-Premise
nerve	I-Premise
damage.	I-Premise

Clinicians	B-Claim
should	I-Claim
consider	I-Claim
the	I-Claim
addition	I-Claim
of	I-Claim
PRET	I-Claim
in	I-Claim
the	I-Claim
rehabilitation	I-Claim
of	I-Claim
postsurgical	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer	I-Claim
survivors.	I-Claim

Debilitating	B-Claim
hot	I-Claim
flushes	I-Claim
and	I-Claim
sleep	I-Claim
dysfunction	I-Claim
often	I-Claim
affect	I-Claim
survivors	I-Claim
of	I-Claim
breast	I-Claim
cancer,	I-Claim
most	I-Claim
notably	I-Claim
in	I-Claim
those	I-Claim
taking	I-Claim
anti-oestrogen	I-Claim
medications.	I-Claim

Conventional	B-Claim
treatments	I-Claim
have	I-Claim
been	I-Claim
only	I-Claim
partially	I-Claim
effective	I-Claim
in	I-Claim
diminishing	I-Claim
these	I-Claim
issues,	I-Claim
and	I-Claim
some	I-Claim
have	I-Claim
serious	I-Claim
risks.	I-Claim

We	O
did	O
a	O
pilot	O
study	O
to	O
investigate	O
our	O
hypothesis	O
that	O
stellate-ganglion	O
block	O
can	O
be	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
hot	O
flushes	O
and	O
sleep	O
dysfunction	O
in	O
this	O
patient	O
population.	O

13	O
survivors	O
of	O
breast	O
cancer	O
(in	O
remission)	O
with	O
severe	O
hot	O
flushes	O
and	O
night	O
awakenings	O
were	O
treated	O
with	O
stellate-ganglion	O
block	O
at	O
the	O
anterolateral	O
aspect	O
of	O
the	O
C6	O
vertebra	O
on	O
the	O
right	O
side	O
under	O
fluoroscopy.	O

Patients	O
recorded	O
hot	O
flushes	O
in	O
a	O
daily	O
diary	O
by	O
use	O
of	O
the	O
Hot-Flash	O
Score,	O
devised	O
by	O
Sloan	O
and	O
colleagues,	O
and	O
night	O
awakenings	O
by	O
use	O
of	O
the	O
Pittsburgh	O
Sleep	O
Quality	O
Index.	O

Both	O
instruments	O
were	O
used	O
1	O
week	O
before	O
the	O
procedure	O
[A40]	O
and	O
then	O
weekly	O
after	O
the	O
procedure	O
for	O
12	O
weeks.	O

We	O
used	O
the	O
generalised-estimating-equations	O
method	O
to	O
analyse	O
the	O
longitudinal	O
measurements	O
of	O
the	O
number	O
of	O
hot	O
flushes	O
and	O
night	O
awakenings	O
over	O
time.	O

This	O
method	O
is	O
a	O
popular	O
approach	O
to	O
analysing	O
datasets	O
that	O
have	O
repeated	O
measures	O
from	O
the	O
same	O
person,	O
and	O
is	O
robust	O
because	O
it	O
does	O
not	O
need	O
the	O
complete	O
distribution	O
of	O
the	O
outcomes	O
to	O
be	O
specified.	O

This	O
trial	O
is	O
registered	O
on	O
the	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
Number	O
register	O
(ISRCTN14318565).	O

There	O
were	O
no	O
adverse	O
events	O
resulting	O
from	O
the	O
stellate-ganglion	O
block,	O
although	O
patients	O
had	O
temporary	O
Horner's	O
syndrome	O
indicating	O
the	O
effectiveness	O
of	O
the	O
block.	O

Five	O
patients	O
had	O
only	O
one	O
stellate-ganglion	O
block	O
and	O
eight	O
had	O
two	O
stellate-ganglion	O
blocks.	O

The	B-Premise
total	I-Premise
number	I-Premise
of	I-Premise
hot	I-Premise
flushes	I-Premise
decreased	I-Premise
from	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
79.4	I-Premise
(SD	I-Premise
37.4)	I-Premise
per	I-Premise
week	I-Premise
before	I-Premise
the	I-Premise
procedure	I-Premise
to	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
49.9	I-Premise
(SD	I-Premise
39.9)	I-Premise
per	I-Premise
week	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
2	I-Premise
weeks	I-Premise
after	I-Premise
the	I-Premise
procedure	I-Premise
(p=0.0002).	I-Premise

The	B-Premise
total	I-Premise
number	I-Premise
of	I-Premise
hot	I-Premise
flushes	I-Premise
continued	I-Premise
to	I-Premise
decrease	I-Premise
over	I-Premise
the	I-Premise
remaining	I-Premise
follow-up	I-Premise
period	I-Premise
(weeks	I-Premise
3-12),	I-Premise
and	I-Premise
stabilised	I-Premise
at	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
8.1	I-Premise
(SD	I-Premise
5.6)	I-Premise
per	I-Premise
week	I-Premise
(p<0.0001).	I-Premise

The	B-Premise
number	I-Premise
of	I-Premise
very	I-Premise
severe	I-Premise
hot	I-Premise
flushes	I-Premise
was	I-Premise
decreased	I-Premise
to	I-Premise
near	I-Premise
zero	I-Premise
by	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
follow-up	I-Premise
period	I-Premise
(week	I-Premise
12;	I-Premise
p<0.0001).	I-Premise

Night	B-Premise
awakenings	I-Premise
decreased	I-Premise
from	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
19.5	I-Premise
(SD	I-Premise
14.8)	I-Premise
per	I-Premise
week	I-Premise
before	I-Premise
the	I-Premise
procedure	I-Premise
to	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
7.3	I-Premise
(SD	I-Premise
7.1)	I-Premise
per	I-Premise
week	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
2	I-Premise
weeks	I-Premise
after	I-Premise
the	I-Premise
procedure	I-Premise
(p<0.0001).	I-Premise

The	B-Premise
total	I-Premise
number	I-Premise
of	I-Premise
night	I-Premise
awakenings	I-Premise
continued	I-Premise
to	I-Premise
decrease	I-Premise
over	I-Premise
the	I-Premise
remaining	I-Premise
follow-up	I-Premise
period	I-Premise
(weeks	I-Premise
3-12)	I-Premise
and	I-Premise
stabilised	I-Premise
at	I-Premise
a	I-Premise
mean	I-Premise
of	I-Premise
1.4	I-Premise
(SD	I-Premise
1.2)	I-Premise
per	I-Premise
week	I-Premise
(p<0.0001).	I-Premise

The	B-Claim
findings	I-Claim
of	I-Claim
this	I-Claim
study	I-Claim
suggest	I-Claim
that	I-Claim
stellate-ganglion	I-Claim
block	I-Claim
can	I-Claim
provide	I-Claim
survivors	I-Claim
of	I-Claim
breast	I-Claim
cancer	I-Claim
with	I-Claim
relief	I-Claim
from	I-Claim
hot	I-Claim
flushes	I-Claim
and	I-Claim
sleep	I-Claim
dysfunction	I-Claim
with	I-Claim
few	I-Claim
or	I-Claim
no	I-Claim
side-effects.	I-Claim

Long-term	B-Claim
relief	I-Claim
of	I-Claim
symptoms	I-Claim
has	I-Claim
the	I-Claim
potential	I-Claim
to	I-Claim
improve	I-Claim
overall	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
increase	I-Claim
compliance	I-Claim
with	I-Claim
anti-oestrogen	I-Claim
medications	I-Claim
for	I-Claim
breast	I-Claim
cancer.	I-Claim

Performance	O
status	O
(PS)	O
2	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
experience	O
more	O
toxicity,	O
lower	O
response	O
rates,	O
and	O
shorter	O
survival	O
times	O
than	O
healthier	O
patients	O
treated	O
with	O
standard	O
chemotherapy.	O

Paclitaxel	O
poliglumex	O
(PPX),	O
a	O
macromolecule	O
drug	O
conjugate	O
of	O
paclitaxel	O
and	O
polyglutamic	O
acid,	O
reduces	O
systemic	O
exposure	O
to	O
peak	O
concentrations	O
of	O
free	O
paclitaxel	O
and	O
may	O
lead	O
to	O
increased	O
concentrations	O
in	O
tumors	O
due	O
to	O
enhanced	O
vascular	O
permeability.	O

Chemotherapy-naive	O
PS	O
2	O
patients	O
with	O
advanced	O
NSCLC	O
were	O
randomized	O
to	O
receive	O
carboplatin	O
(area	O
under	O
the	O
curve	O
=	O
6)	O
and	O
either	O
PPX	O
(210	O
mg/m/10	O
min	O
without	O
routine	O
steroid	O
premedication)	O
or	O
paclitaxel	O
(225	O
mg/m/3	O
h	O
with	O
standard	O
premedication)	O
every	O
3	O
weeks.	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival.	O

A	O
total	O
of	O
400	O
patients	O
were	O
enrolled.	O

Alopecia,	B-Premise
arthralgias/myalgias,	I-Premise
and	I-Premise
cardiac	I-Premise
events	I-Premise
were	I-Premise
significantly	I-Premise
less	I-Premise
frequent	I-Premise
with	I-Premise
PPX/carboplatin,	I-Premise
whereas	I-Premise
grade	I-Premise
>	I-Premise
or	I-Premise
=3	I-Premise
neutropenia	I-Premise
and	I-Premise
grade	I-Premise
3	I-Premise
neuropathy	I-Premise
showed	I-Premise
a	I-Premise
trend	I-Premise
of	I-Premise
worsening.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
incidence	I-Premise
of	I-Premise
hypersensitivity	I-Premise
reactions	I-Premise
despite	I-Premise
the	I-Premise
absence	I-Premise
of	I-Premise
routine	I-Premise
premedication	I-Premise
in	I-Premise
the	I-Premise
PPX	I-Premise
arm.	I-Premise

Overall	B-Premise
survival	I-Premise
was	I-Premise
similar	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.97;	I-Premise
log	I-Premise
rank	I-Premise
p	I-Premise
=	I-Premise
0.769).	I-Premise

Median	B-Premise
and	I-Premise
1-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
7.9	I-Premise
months	I-Premise
and	I-Premise
31%,	I-Premise
for	I-Premise
PPX	I-Premise
versus	I-Premise
8	I-Premise
months	I-Premise
and	I-Premise
31%	I-Premise
for	I-Premise
paclitaxel.	I-Premise

Disease	O
control	O
rates	O
were	O
64%	O
and	O
69%	O
for	O
PPX	O
and	O
paclitaxel,	O
respectively.	O

Time	O
to	O
progression	O
was	O
similar:	O
3.9	O
months	O
for	O
PPX/carboplatin	O
versus	O
4.6	O
months	O
for	O
paclitaxel/carboplatin	O
(p	O
=	O
0.210).	O

PPX/carboplatin	B-Claim
failed	I-Claim
to	I-Claim
provide	I-Claim
superior	I-Claim
survival	I-Claim
compared	I-Claim
with	I-Claim
paclitaxel/carboplatin	I-Claim
in	I-Claim
the	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
PS	I-Claim
2	I-Claim
patients	I-Claim
with	I-Claim
NSCLC,	I-Claim
but	B-Claim
the	I-Claim
results	I-Claim
with	I-Claim
respect	I-Claim
to	I-Claim
progression-free	I-Claim
survival	I-Claim
and	I-Claim
overall	I-Claim
survival	I-Claim
were	I-Claim
comparable	I-Claim
and	I-Claim
the	I-Claim
PPX	I-Claim
regimen	I-Claim
was	I-Claim
more	I-Claim
convenient.	I-Claim

To	O
investigate	O
whether	O
uterine	O
artery	O
embolization	O
(UAE)	O
is	O
a	O
cost-effective	O
alternative	O
to	O
hysterectomy	O
for	O
patients	O
with	O
symptomatic	O
uterine	O
fibroids,	O
the	O
authors	O
performed	O
an	O
economic	O
evaluation	O
alongside	O
the	O
multicenter	O
randomized	O
EMMY	O
(EMbolization	O
versus	O
hysterectoMY)	O
trial.	O

Between	O
February	O
2002	O
and	O
February	O
2004,	O
177	O
patients	O
were	O
randomized	O
to	O
undergo	O
UAE	O
(n	O
=	O
88)	O
or	O
hysterectomy	O
(n	O
=	O
89)	O
and	O
followed	O
up	O
until	O
24	O
months	O
after	O
initial	O
treatment	O
allocation.	O

Conditional	O
on	O
the	O
equivalence	O
of	O
clinical	O
outcome,	O
a	O
cost	O
minimization	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
principle.	O

Costs	O
included	O
health	O
care	O
costs	O
inside	O
and	O
outside	O
the	O
hospital	O
as	O
well	O
as	O
costs	O
related	O
to	O
absence	O
from	O
work	O
(societal	O
perspective).	O

Cumulative	O
standardized	O
costs	O
were	O
estimated	O
as	O
volumes	O
multiplied	O
with	O
prices.	O

The	O
nonparametric	O
bootstrap	O
method	O
was	O
used	O
to	O
quantify	O
differences	O
in	O
mean	O
(95%	O
confidence	O
interval	O
[CI])	O
costs	O
between	O
the	O
strategies.	O

In	O
total,	O
81	O
patients	O
underwent	O
UAE	O
and	O
75	O
underwent	O
hysterectomy.	O

In	O
the	O
UAE	O
group,	O
19	O
patients	O
(23%)	O
underwent	O
secondary	O
hysterectomies.	O

The	B-Premise
mean	I-Premise
total	I-Premise
costs	I-Premise
per	I-Premise
patient	I-Premise
in	I-Premise
the	I-Premise
UAE	I-Premise
group	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
hysterectomy	I-Premise
group	I-Premise
($11,626	I-Premise
vs	I-Premise
$18,563;	I-Premise
mean	I-Premise
difference,	I-Premise
-$6,936	I-Premise
[-37%],	I-Premise
95%	I-Premise
CI:	I-Premise
-$9,548,	I-Premise
$4,281).	I-Premise

The	B-Premise
direct	I-Premise
medical	I-Premise
in-hospital	I-Premise
costs	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
UAE	I-Premise
group:	I-Premise
$6,688	I-Premise
vs	I-Premise
$8,313	I-Premise
(mean	I-Premise
difference,	I-Premise
-$1,624	I-Premise
[-20%],	I-Premise
95%	I-Premise
CI:	I-Premise
-$2,605,	I-Premise
-$586).	I-Premise

Direct	B-Premise
medical	I-Premise
out-of-hospital	I-Premise
and	I-Premise
direct	I-Premise
nonmedical	I-Premise
costs	I-Premise
were	I-Premise
low	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
(mean	I-Premise
cost	I-Premise
difference,	I-Premise
$156	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
hysterectomy).	I-Premise

The	B-Premise
costs	I-Premise
related	I-Premise
to	I-Premise
absence	I-Premise
from	I-Premise
work	I-Premise
differed	I-Premise
significantly	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
strategies	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
UAE	I-Premise
(mean	I-Premise
difference,	I-Premise
-$5,453;	I-Premise
95%	I-Premise
CI:	I-Premise
-$7,718,	I-Premise
-$3,107).	I-Premise

The	O
costs	O
of	O
absence	O
from	O
work	O
accounted	O
for	O
79%	O
of	O
the	O
difference	O
in	O
total	O
costs.	O

The	B-Premise
24-month	I-Premise
cumulative	I-Premise
cost	I-Premise
of	I-Premise
UAE	I-Premise
is	I-Premise
lower	I-Premise
than	I-Premise
that	I-Premise
of	I-Premise
hysterectomy.	I-Premise

From	B-Claim
a	I-Claim
societal	I-Claim
economic	I-Claim
perspective,	I-Claim
UAE	I-Claim
is	I-Claim
the	I-Claim
superior	I-Claim
treatment	I-Claim
strategy	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
symptomatic	I-Claim
uterine	I-Claim
fibroids.	I-Claim

Persistent	O
insomnia	O
is	O
a	O
common	O
complaint	O
in	O
cancer	O
survivors,	O
but	O
is	O
seldom	O
satisfactorily	O
addressed.	O

The	O
adaptation	O
to	O
cancer	O
care	O
of	O
a	O
validated,	O
cost-effective	O
intervention	O
may	O
offer	O
a	O
practicable	O
solution.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
clinical	O
effectiveness	O
of	O
protocol-driven	O
cognitive	O
behavior	O
therapy	O
(CBT)	O
for	O
insomnia,	O
delivered	O
by	O
oncology	O
nurses.	O

Randomized,	O
controlled,	O
pragmatic,	O
two-center	O
trial	O
of	O
CBT	O
versus	O
treatment	O
as	O
usual	O
(TAU)	O
in	O
150	O
patients	O
(103	O
females;	O
mean	O
age,	O
61	O
years.)	O

who	O
had	O
completed	O
active	O
therapy	O
for	O
breast,	O
prostate,	O
colorectal,	O
or	O
gynecological	O
cancer.	O

The	O
study	O
conformed	O
to	O
CONSORT	O
guidelines.	O

Primary	O
outcomes	O
were	O
sleep	O
diary	O
measures	O
at	O
baseline,	O
post-treatment,	O
and	O
6-month	O
follow-up.	O

Actigraphic	O
sleep,	O
health-related	O
quality	O
of	O
life	O
(QOL),	O
psychopathology,	O
and	O
fatigue	O
were	O
secondary	O
measures.	O

CBT	O
comprised	O
five,	O
small	O
group	O
sessions	O
across	O
consecutive	O
weeks,	O
after	O
a	O
manualized	O
protocol.	O

TAU	O
represented	O
normal	O
clinical	O
practice;	O
the	O
appropriate	O
control	O
for	O
a	O
clinical	O
effectiveness	O
study.	O

CBT	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
mean	I-Premise
reductions	I-Premise
in	I-Premise
wakefulness	I-Premise
of	I-Premise
55	I-Premise
minutes	I-Premise
per	I-Premise
night	I-Premise
compared	I-Premise
with	I-Premise
no	I-Premise
change	I-Premise
in	I-Premise
TAU.	I-Premise

These	O
outcomes	O
were	O
sustained	O
6	O
months	O
after	O
treatment.	O

Standardized	B-Premise
relative	I-Premise
effect	I-Premise
sizes	I-Premise
were	I-Premise
large	I-Premise
for	I-Premise
complaints	I-Premise
of	I-Premise
difficulty	I-Premise
initiating	I-Premise
sleep,	I-Premise
waking	I-Premise
from	I-Premise
sleep	I-Premise
during	I-Premise
the	I-Premise
night,	I-Premise
and	I-Premise
for	I-Premise
sleep	I-Premise
efficiency	I-Premise
(percentage	I-Premise
of	I-Premise
time	I-Premise
in	I-Premise
bed	I-Premise
spent	I-Premise
asleep).	I-Premise

CBT	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
moderate	I-Premise
to	I-Premise
large	I-Premise
effect	I-Premise
sizes	I-Premise
for	I-Premise
five	I-Premise
of	I-Premise
seven	I-Premise
QOL	I-Premise
outcomes,	I-Premise
including	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
daytime	I-Premise
fatigue.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
interaction	I-Premise
effect	I-Premise
between	I-Premise
any	I-Premise
of	I-Premise
these	I-Premise
outcomes	I-Premise
and	I-Premise
baseline	I-Premise
demographic,	I-Premise
clinical,	I-Premise
or	I-Premise
sleep	I-Premise
characteristics.	I-Premise

CBT	B-Claim
for	I-Claim
insomnia	I-Claim
may	I-Claim
be	I-Claim
both	I-Claim
clinically	I-Claim
effective	I-Claim
and	I-Claim
feasible	I-Claim
to	I-Claim
deliver	I-Claim
in	I-Claim
real	I-Claim
world	I-Claim
practice.	I-Claim

The	O
management	O
of	O
recurrent	O
ovarian	O
cancer	O
remains	O
controversial.	O

Single-agent	O
topotecan	O
is	O
an	O
established	O
treatment	O
option,	O
and	O
preliminary	O
evidence	O
suggests	O
improved	O
tumor	O
control	O
by	O
combining	O
topotecan	O
with	O
etoposide	O
or	O
gemcitabine.	O

Women	O
with	O
relapsed	O
ovarian	O
cancer	O
after	O
primary	O
surgery	O
and	O
platinum-based	O
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
topotecan	O
monotherapy	O
1.25	O
mg/m(2)/d,	O
topotecan	O
1.0	O
mg/m(2)	O
plus	O
oral	O
etoposide	O
50	O
mg/d,	O
or	O
topotecan	O
0.5	O
mg/m(2)/d	O
plus	O
gemcitabine	O
800	O
mg/m(2)	O
on	O
day	O
1	O
and	O
600	O
mg/m(2)	O
on	O
day	O
8	O
every	O
3	O
weeks.	O

Patients	O
were	O
stratified	O
for	O
platinum-refractory	O
and	O
platinum-sensitive	O
disease	O
according	O
to	O
a	O
recurrence-free	O
interval	O
of	O
less	O
or	O
more	O
than	O
12	O
months,	O
respectively.	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival.	O

Secondary	O
end	O
points	O
included	O
progression-free	O
survival,	O
objective	O
response	O
rates,	O
toxicity,	O
and	O
quality	O
of	O
life	O
(as	O
measured	O
by	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
[EORTC]	O
30-item	O
Quality-of-Life	O
Questionnaire).	O

The	O
trial	O
enrolled	O
502	O
patients	O
with	O
a	O
mean	O
age	O
of	O
60.5	O
years	O
(+/-	O
10.2	O
years),	O
208	O
of	O
whom	O
were	O
platinum	O
resistant.	O

Median	B-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
17.2	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
13.5	I-Premise
to	I-Premise
21.9	I-Premise
months)	I-Premise
with	I-Premise
topotecan,	I-Premise
17.8	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
13.7	I-Premise
to	I-Premise
20.0	I-Premise
months)	I-Premise
with	I-Premise
topotecan	I-Premise
plus	I-Premise
etoposide	I-Premise
(log-rank	I-Premise
P	I-Premise
=	I-Premise
.7647),	I-Premise
and	I-Premise
15.2	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
11.3	I-Premise
to	I-Premise
20.9	I-Premise
months)	I-Premise
with	I-Premise
topotecan	I-Premise
plus	I-Premise
gemcitabine	I-Premise
(log-rank	I-Premise
P	I-Premise
=	I-Premise
.2344).	I-Premise

Platinum-sensitive	B-Premise
patients	I-Premise
lived	I-Premise
significantly	I-Premise
longer	I-Premise
than	I-Premise
platinum-refractory	I-Premise
patients	I-Premise
(21.9	I-Premise
v	I-Premise
10.6	I-Premise
months).	I-Premise

The	O
median	O
progression-free	O
survival	O
was	O
7.0,	O
7.8,	O
and	O
6.3	O
months,	O
respectively.	O

Objective	O
response	O
rates	O
were	O
27.8%,	O
36.1%,	O
and	O
31.6%,	O
respectively.	O

Patients	B-Premise
under	I-Premise
combined	I-Premise
treatment	I-Premise
were	I-Premise
at	I-Premise
higher	I-Premise
risk	I-Premise
of	I-Premise
severe	I-Premise
thrombocytopenia.	I-Premise

Nonplatinum	B-Claim
topotecan	I-Claim
combinations	I-Claim
do	I-Claim
not	I-Claim
provide	I-Claim
a	I-Claim
survival	I-Claim
advantage	I-Claim
over	I-Claim
topotecan	I-Claim
alone	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
relapsed	I-Claim
ovarian	I-Claim
cancer.	I-Claim

In	O
an	O
international,	O
randomized	O
phase	O
III	O
trial,	O
sunitinib	O
demonstrated	O
statistically	O
significant	O
efficacy	O
over	O
interferon	O
alfa	O
(IFN-alpha)	O
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
(mRCC)	O
(progression-free	O
survival	O
time,	O
11	O
v	O
5	O
months,	O
respectively;	O
P	O
<	O
.001;	O
objective	O
response	O
rate,	O
31%	O
v	O
6%,	O
respectively;	O
P	O
<	O
.001).	O

We	O
report	O
health-related	O
quality-of-life	O
(QOL)	O
results	O
from	O
this	O
trial.	O

Seven	O
hundred	O
fifty	O
mRCC	O
patients	O
were	O
randomly	O
assigned	O
to	O
sunitinib	O
(6-week	O
cycles:	O
50	O
mg	O
orally	O
once	O
daily	O
for	O
4	O
weeks,	O
followed	O
by	O
2	O
weeks	O
off)	O
or	O
IFN-alpha	O
(9	O
million	O
units	O
subcutaneous	O
injections,	O
three	O
times	O
weekly).	O

QOL	O
measures	O
included	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-General	O
(FACT-G),	O
the	O
FACT-Kidney	O
Symptom	O
Index-15	O
item	O
(FKSI-15),	O
and	O
the	O
EuroQoL-5D's	O
utility	O
score	O
(EQ-5D	O
Index)	O
and	O
its	O
visual	O
analog	O
scale	O
(EQ-VAS).	O

The	O
primary	O
QOL	O
end	O
point	O
was	O
the	O
FKSI	O
Disease-Related	O
Symptoms	O
(FKSI-DRS)	O
subscale.	O

Higher	O
scores	O
indicated	O
better	O
outcomes	O
(better	O
QOL	O
or	O
fewer	O
symptoms).	O

Data	O
were	O
analyzed	O
for	O
the	O
intent-to-treat	O
population	O
using	O
mixed-effects	O
models,	O
supplemented	O
with	O
pattern-mixture	O
models.	O

Patients	B-Premise
receiving	I-Premise
sunitinib	I-Premise
reported	I-Premise
higher	I-Premise
FKSI-15	I-Premise
and	I-Premise
FKSI-DRS	I-Premise
scores	I-Premise
at	I-Premise
each	I-Premise
cycle	I-Premise
than	I-Premise
those	I-Premise
receiving	I-Premise
IFN-alpha,	I-Premise
with	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
overall	I-Premise
least	I-Premise
squares	I-Premise
means	I-Premise
(3.27	I-Premise
and	I-Premise
1.98,	I-Premise
respectively;	I-Premise
P	I-Premise
<	I-Premise
.0001).	I-Premise

Similarly,	O
differences	B-Premise
in	I-Premise
least	I-Premise
squares	I-Premise
means	I-Premise
for	I-Premise
FACT-G	I-Premise
(and	I-Premise
all	I-Premise
subscales),	I-Premise
EQ-5D	I-Premise
Index,	I-Premise
and	I-Premise
EQ-VAS	I-Premise
were	I-Premise
all	I-Premise
significantly	I-Premise
favorable	I-Premise
for	I-Premise
sunitinib	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

Per	O
pre-established	O
thresholds,	O
between-treatment	O
differences	O
in	O
the	O
mean	O
scores	O
were	O
clinically	O
meaningful	O
after	O
cycle	O
4	O
for	O
FKSI-DRS	O
and	O
at	O
all	O
assessments	O
for	O
FKSI-15,	O
FACT-G,	O
and	O
the	O
FACT-G	O
functional	O
well-being	O
subscale.	O

Sunitinib	B-Claim
provides	I-Claim
superior	I-Claim
QOL	I-Claim
compared	I-Claim
with	I-Claim
IFN-alpha	I-Claim
in	I-Claim
mRCC	I-Claim
patients.	I-Claim

The	O
Medical	O
Research	O
Council	O
CR07/National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
C016	O
(MRC	O
CR07/NCIC	O
CTG	O
C016)	O
trial	O
showed	O
that,	O
in	O
patients	O
with	O
operable	O
rectal	O
cancer,	O
short-course	O
preoperative	O
radiotherapy	O
(PRE)	O
reduced	O
the	O
rate	O
of	O
local	O
recurrence	O
compared	O
with	O
surgery	O
followed	O
by	O
selective	O
postoperative	O
chemoradiotherapy	O
for	O
patients	O
with	O
a	O
positive	O
circumferential	O
resection	O
margin.	O

However,	O
the	O
advantages	O
of	O
giving	O
PRE	O
to	O
all	O
patients	O
needs	O
to	O
be	O
balanced	O
against	O
any	O
negative	O
impact	O
on	O
patients'	O
quality	O
of	O
life.	O

All	O
1,350	O
patients	O
were	O
asked	O
to	O
complete	O
the	O
Medical	O
Outcomes	O
Study	O
Short-Form	O
36-item	O
(MOS	O
SF-36)	O
and	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
Colorectal	O
38-item	O
(EORTC	O
QLQ-CR38)	O
questionnaires.	O

A	O
priori	O
hypotheses	O
related	O
to	O
the	O
impact	O
of	O
treatment	O
on	O
sexual,	O
bowel,	O
and	O
physical	O
function	O
and	O
general	O
health.	O

Male	B-Premise
sexual	I-Premise
dysfunction	I-Premise
was	I-Premise
significantly	I-Premise
increased	I-Premise
following	I-Premise
surgery	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
although	B-Premise
there	I-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
between	I-Premise
treatment	I-Premise
arms.	I-Premise

However,	O
a	O
treatment	O
difference	O
had	O
emerged	O
at	O
6	O
months	O
(PRE	O
patients	O
reporting	O
significantly	O
greater	O
dysfunction;	O
P	O
=	O
.004),	O
which	O
persisted	O
out	O
to	O
at	O
least	O
2	O
years	O
(an	O
insufficient	O
number	O
of	O
female	O
patients	O
completed	O
the	O
sexual	O
dysfunction	O
questions	O
to	O
draw	O
firm	O
conclusions).	O

Both	B-Premise
treatment	I-Premise
groups	I-Premise
reported	I-Premise
similar	I-Premise
levels	I-Premise
of	I-Premise
decreased	I-Premise
physical	I-Premise
function	I-Premise
at	I-Premise
3	I-Premise
months,	I-Premise
but	B-Premise
thereafter	I-Premise
it	I-Premise
returned	I-Premise
to	I-Premise
baseline	I-Premise
levels.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
any	I-Premise
major	I-Premise
changes	I-Premise
between	I-Premise
treatments	I-Premise
or	I-Premise
time	I-Premise
points	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
general	I-Premise
health	I-Premise
or	I-Premise
bowel	I-Premise
function,	I-Premise
but	B-Premise
exploratory	I-Premise
analysis	I-Premise
indicated	I-Premise
a	I-Premise
significant	I-Premise
(P	I-Premise
=	I-Premise
.006	I-Premise
at	I-Premise
2	I-Premise
years)	I-Premise
increase	I-Premise
in	I-Premise
the	I-Premise
level	I-Premise
of	I-Premise
fecal	I-Premise
incontinence	I-Premise
with	I-Premise
PRE.	I-Premise

These	B-Claim
results	I-Claim
from	I-Claim
a	I-Claim
large	I-Claim
randomized	I-Claim
trial	I-Claim
using	I-Claim
validated	I-Claim
patient-completed	I-Claim
questionnaires	I-Claim
show	I-Claim
that,	I-Claim
for	I-Claim
males,	I-Claim
the	I-Claim
main	I-Claim
adverse	I-Claim
effect	I-Claim
was	I-Claim
sexual	I-Claim
dysfunction,	I-Claim
and	I-Claim
the	I-Claim
main	I-Claim
cause	I-Claim
of	I-Claim
this	I-Claim
was	I-Claim
surgery,	I-Claim
but	O
that	O
PRE	B-Claim
also	I-Claim
affected	I-Claim
sexual	I-Claim
and	I-Claim
some	I-Claim
aspects	I-Claim
of	I-Claim
bowel	I-Claim
functioning.	I-Claim

Patients	O
receiving	O
chemoradiation	O
for	O
cervical	O
cancer	O
are	O
at	O
risk	O
for	O
distress,	O
chemoradiation-related	O
side-effects,	O
and	O
immunosuppression.	O

This	O
prospective	O
randomized	O
clinical	O
trial	O
examined	O
effects	O
of	O
a	O
complementary	O
therapy,	O
Healing	O
Touch	O
(HT),	O
versus	O
relaxation	O
training	O
(RT)	O
and	O
usual	O
care	O
(UC)	O
for	O
(1)	O
supporting	O
cellular	O
immunity,	O
(2)	O
improving	O
mood	O
and	O
quality	O
of	O
life	O
(QOL),	O
and	O
(3)	O
reducing	O
treatment-associated	O
toxicities	O
and	O
treatment	O
delay	O
in	O
cervical	O
cancer	O
patients	O
receiving	O
chemoradiation.	O

Sixty	O
women	O
with	O
stages	O
IB1	O
to	O
IVA	O
cervical	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
UC	O
or	O
4	O
×/weekly	O
individual	O
sessions	O
of	O
either	O
HT	O
or	O
RT	O
immediately	O
following	O
radiation	O
during	O
their	O
6-week	O
chemoradiation	O
treatment.	O

Patients	O
completed	O
psychosocial	O
assessments	O
and	O
blood	O
sampling	O
before	O
chemoradiation	O
at	O
baseline,	O
weeks	O
4	O
and	O
6.	O

Multilevel	O
regression	O
analyses	O
using	O
orthogonal	O
contrasts	O
tested	O
for	O
differences	O
between	O
treatment	O
conditions	O
over	O
time.	O

HT	B-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
minimal	I-Premise
decrease	I-Premise
in	I-Premise
natural	I-Premise
killer	I-Premise
cell	I-Premise
cytotoxicity	I-Premise
(NKCC)	I-Premise
over	I-Premise
the	I-Premise
course	I-Premise
of	I-Premise
treatment	I-Premise
whereas	I-Premise
NKCC	I-Premise
of	I-Premise
RT	I-Premise
and	I-Premise
UC	I-Premise
patients	I-Premise
declined	I-Premise
sharply	I-Premise
during	I-Premise
chemoradiation	I-Premise
(group	I-Premise
by	I-Premise
time	I-Premise
interaction:	I-Premise
p	I-Premise
=	I-Premise
0.018).	I-Premise

HT	B-Premise
patients	I-Premise
showed	I-Premise
greater	I-Premise
decreases	I-Premise
in	I-Premise
two	I-Premise
different	I-Premise
indicators	I-Premise
of	I-Premise
depressed	I-Premise
mood	I-Premise
(CES-D	I-Premise
depressed	I-Premise
mood	I-Premise
subscale	I-Premise
and	I-Premise
POMS	I-Premise
depression	I-Premise
scale)	I-Premise
compared	I-Premise
to	I-Premise
RT	I-Premise
and	I-Premise
UC	I-Premise
(group	I-Premise
by	I-Premise
time	I-Premise
interactions:	I-Premise
p<0.05).	I-Premise

No	B-Premise
between	I-Premise
group	I-Premise
differences	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
QOL,	I-Premise
treatment	I-Premise
delay,	I-Premise
or	I-Premise
clinically-rated	I-Premise
toxicities.	I-Premise

HT	B-Claim
may	I-Claim
benefit	I-Claim
cervical	I-Claim
cancer	I-Claim
patients	I-Claim
by	I-Claim
moderating	I-Claim
effects	I-Claim
of	I-Claim
chemoradiation	I-Claim
on	I-Claim
depressed	I-Claim
mood	I-Claim
and	I-Claim
cellular	I-Claim
immunity.	I-Claim

Effects	B-Claim
of	I-Claim
HT	I-Claim
on	I-Claim
toxicities,	I-Claim
treatment	I-Claim
delay,	I-Claim
QOL,	I-Claim
and	I-Claim
fatigue	I-Claim
were	I-Claim
not	I-Claim
observed.	I-Claim

Long-term	O
clinical	O
implications	O
of	O
findings	O
are	O
not	O
known.	O

Fatigue	O
is	O
one	O
of	O
the	O
most	O
common	O
symptoms	O
experienced	O
by	O
patients	O
with	O
cancer.	O

This	O
trial	O
was	O
developed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
long-acting	O
methylphenidate	O
for	O
improving	O
cancer-related	O
fatigue	O
and	O
to	O
assess	O
its	O
toxicities.	O

Adults	O
with	O
cancer	O
were	O
randomly	O
assigned	O
in	O
a	O
double-blinded	O
manner	O
to	O
receive	O
methylphenidate	O
(target	O
dose,	O
54	O
mg/d)	O
or	O
placebo	O
for	O
4	O
weeks.	O

The	O
Brief	O
Fatigue	O
Inventory	O
was	O
the	O
primary	O
outcome	O
measure,	O
while	O
secondary	O
outcome	O
measures	O
included	O
a	O
Symptom	O
Experience	O
Diary	O
(SED),	O
the	O
Short	O
Form-36	O
(SF-36)	O
Vitality	O
Subscale,	O
a	O
linear	O
analog	O
self-assessment,	O
the	O
Pittsburgh	O
Sleep	O
Quality	O
Index,	O
and	O
the	O
Subject	O
Global	O
Impression	O
of	O
Change.	O

In	O
total,	O
148	O
patients	O
were	O
enrolled.	O

Using	B-Premise
an	I-Premise
area	I-Premise
under	I-Premise
the	I-Premise
serum	I-Premise
concentration-time	I-Premise
curve	I-Premise
analysis,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
that	I-Premise
methylphenidate,	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
placebo,	I-Premise
improved	I-Premise
the	I-Premise
primary	I-Premise
end	I-Premise
point	I-Premise
of	I-Premise
cancer-related	I-Premise
fatigue	I-Premise
in	I-Premise
this	I-Premise
patient	I-Premise
population	I-Premise
(P	I-Premise
=	I-Premise
.35).	I-Premise

Comparisons	B-Premise
of	I-Premise
secondary	I-Premise
end	I-Premise
points,	I-Premise
including	I-Premise
clinically	I-Premise
significant	I-Premise
changes	I-Premise
in	I-Premise
quality-of-life	I-Premise
variables	I-Premise
and	I-Premise
cancer-related	I-Premise
fatigue	I-Premise
change	I-Premise
from	I-Premise
baseline,	I-Premise
were	I-Premise
similarly	I-Premise
negative.	I-Premise

However,	B-Premise
a	I-Premise
subset	I-Premise
analysis	I-Premise
suggested	I-Premise
that	I-Premise
patients	I-Premise
with	I-Premise
more	I-Premise
severe	I-Premise
fatigue	I-Premise
and/or	I-Premise
with	I-Premise
more	I-Premise
advanced	I-Premise
disease	I-Premise
did	I-Premise
have	I-Premise
some	I-Premise
fatigue	I-Premise
improvement	I-Premise
with	I-Premise
methylphenidate	I-Premise
(eg,	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
stage	I-Premise
III	I-Premise
or	I-Premise
IV	I-Premise
disease,	I-Premise
the	I-Premise
mean	I-Premise
improvement	I-Premise
in	I-Premise
usual	I-Premise
fatigue	I-Premise
was	I-Premise
19.7	I-Premise
with	I-Premise
methylphenidate	I-Premise
v	I-Premise
2.1	I-Premise
with	I-Premise
placebo;	I-Premise
P	I-Premise
=	I-Premise
.02).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
self-reported	I-Premise
toxicities	I-Premise
(SED),	I-Premise
with	I-Premise
increased	I-Premise
levels	I-Premise
of	I-Premise
nervousness	I-Premise
and	I-Premise
appetite	I-Premise
loss	I-Premise
in	I-Premise
the	I-Premise
methylphenidate	I-Premise
arm.	I-Premise

This	B-Claim
clinical	I-Claim
trial	I-Claim
was	I-Claim
unable	I-Claim
to	I-Claim
support	I-Claim
the	I-Claim
primary	I-Claim
prestudy	I-Claim
hypothesis	I-Claim
that	I-Claim
the	I-Claim
chosen	I-Claim
long-acting	I-Claim
methylphenidate	I-Claim
product	I-Claim
would	I-Claim
decrease	I-Claim
cancer-related	I-Claim
fatigue.	I-Claim

The	O
Australian	O
and	O
New	O
Zealand	O
Germ	O
Cell	O
Trials	O
Group	O
conducted	O
a	O
multicenter	O
randomized	O
phase	O
III	O
trial	O
in	O
men	O
with	O
good-prognosis	O
germ	O
cell	O
tumors	O
of	O
two	O
standard	O
chemotherapy	O
regimens	O
that	O
contained	O
bleomycin,	O
etoposide,	O
and	O
cisplatin	O
but	O
differed	O
in	O
the	O
scheduling	O
and	O
total	O
dose	O
of	O
cisplatin,	O
the	O
total	O
dose	O
of	O
bleomycin,	O
and	O
the	O
scheduling	O
and	O
dose	O
intensity	O
of	O
etoposide.	O

The	O
trial	O
was	O
stopped	O
early	O
at	O
a	O
median	O
follow-up	O
of	O
33	O
months	O
after	O
a	O
planned	O
interim	O
analysis	O
found	O
a	O
survival	O
benefit	O
for	O
the	O
more	O
dose-intense	O
regimen.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
if	O
this	O
survival	O
benefit	O
was	O
maintained	O
with	O
long-term	O
follow-up.	O

Between	O
February	O
1994	O
and	O
April	O
2000,	O
166	O
men	O
with	O
good-prognosis	O
metastatic	O
germ	O
cell	O
tumors	O
defined	O
by	O
modified	O
Memorial	O
Sloan-Kettering	O
criteria	O
were	O
randomly	O
assigned	O
to	O
receive	O
3B(90)E(500)P	O
(three	O
cycles,	O
repeated	O
every	O
21	O
days,	O
of	O
30	O
kU	O
bleomycin	O
on	O
days	O
1,	O
8,	O
and	O
15;	O
100	O
mg/m(2)	O
etoposide	O
on	O
days	O
1-5;	O
and	O
20	O
mg/m(2)	O
cisplatin	O
on	O
days	O
1-5;	O
n	O
=	O
83)	O
or	O
4B(30)E(360)P	O
(four	O
cycles,	O
repeated	O
every	O
21	O
days,	O
of	O
30	O
kU	O
bleomycin	O
on	O
day	O
1,	O
120	O
mg/m(2)	O
etoposide	O
on	O
days	O
1-3,	O
and	O
100	O
mg/m(2)	O
cisplatin	O
on	O
day	O
1;	O
n	O
=	O
83).	O

Endpoints	O
included	O
overall	O
survival,	O
progression-free	O
survival,	O
and	O
quality	O
of	O
life	O
and	O
side	O
effects,	O
which	O
were	O
assessed	O
using	O
the	O
Spitzer	O
Quality	O
of	O
Life	O
Index	O
and	O
the	O
GLQ-8,	O
respectively,	O
before	O
random	O
assignment	O
and	O
during	O
and	O
after	O
treatment.	O

All	O
analyses	O
were	O
by	O
intention	O
to	O
treat.	O

All	O
P	O
values	O
are	O
two-sided.	O

The	O
median	O
follow-up	O
was	O
8.5	O
years.	O

All	O
but	O
five	O
survivors	O
(3%)	O
were	O
followed	O
up	O
for	O
at	O
least	O
5	O
years.	O

Overall	B-Premise
survival	I-Premise
remained	I-Premise
better	I-Premise
in	I-Premise
those	I-Premise
assigned	I-Premise
to	I-Premise
3B(90)E(500)P	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
assigned	I-Premise
to	I-Premise
4B(30)E(360)P	I-Premise
(8-year	I-Premise
survival:	I-Premise
92%	I-Premise
vs	I-Premise
83%;	I-Premise
hazard	I-Premise
ratio	I-Premise
of	I-Premise
death	I-Premise
=	I-Premise
0.38,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
=	I-Premise
0.15	I-Premise
to	I-Premise
0.97,	I-Premise
P	I-Premise
=	I-Premise
.037).	I-Premise

Progression-free	B-Premise
survival	I-Premise
favored	I-Premise
3B(90)E(500)P	I-Premise
but	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
(8-year	I-Premise
progression-free	I-Premise
survival,	I-Premise
3B(90)E(500)P	I-Premise
vs	I-Premise
4B(30)E(360)P:	I-Premise
86%	I-Premise
vs	I-Premise
79%;	I-Premise
hazard	I-Premise
ratio	I-Premise
of	I-Premise
progression	I-Premise
=	I-Premise
0.6,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
=	I-Premise
0.3	I-Premise
to	I-Premise
1.1,	I-Premise
P	I-Premise
=	I-Premise
.15).	I-Premise

At	B-Claim
the	I-Claim
end	I-Claim
of	I-Claim
treatment,	I-Claim
average	I-Claim
scores	I-Claim
for	I-Claim
most	I-Claim
side	I-Claim
effect	I-Claim
scales	I-Claim
favored	I-Claim
3B(90)E(500)P.	I-Claim
After	B-Premise
the	I-Premise
completion	I-Premise
of	I-Premise
treatment,	I-Premise
average	I-Premise
GLQ-8	I-Premise
scores	I-Premise
for	I-Premise
numbness	I-Premise
(P	I-Premise
=	I-Premise
.003)	I-Premise
and	I-Premise
hair	I-Premise
loss	I-Premise
(P	I-Premise
=	I-Premise
.04)	I-Premise
and	I-Premise
the	I-Premise
Spitzer	I-Premise
Quality	I-Premise
of	I-Premise
Life	I-Premise
Index	I-Premise
(P	I-Premise
=	I-Premise
.05)	I-Premise
favored	I-Premise
3B(90)E(500)P.	I-Premise
The	B-Claim
survival	I-Claim
benefit	I-Claim
of	I-Claim
3B(90)E(500)P	I-Claim
over	I-Claim
4B(30)E(360)P	I-Claim
was	I-Claim
maintained	I-Claim
with	I-Claim
long-term	I-Claim
follow-up.	I-Claim

Research	O
suggests	O
that	O
cancer	O
rehabilitation	O
reduces	O
fatigue	O
in	O
survivors	O
of	O
cancer.	O

To	O
date,	O
it	O
is	O
unclear	O
what	O
type	O
of	O
rehabilitation	O
is	O
most	O
beneficial.	O

This	O
randomized	O
controlled	O
trial	O
compared	O
the	O
effect	O
on	O
cancer-related	O
fatigue	O
of	O
physical	O
training	O
combined	O
with	O
cognitive	O
behavioral	O
therapy	O
with	O
physical	O
training	O
alone	O
and	O
with	O
no	O
intervention.	O

In	O
this	O
multicenter	O
randomized	O
controlled	O
trial,	O
147	O
survivors	O
of	O
cancer	O
were	O
randomly	O
assigned	O
to	O
a	O
group	O
that	O
received	O
physical	O
training	O
combined	O
with	O
cognitive-behavioral	O
therapy	O
(PT+CBT	O
group,	O
n=76)	O
or	O
to	O
a	O
group	O
that	O
received	O
physical	O
training	O
alone	O
(PT	O
group,	O
n=71).	O

In	O
addition,	O
a	O
nonintervention	O
control	O
group	O
(WLC	O
group)	O
consisting	O
of	O
62	O
survivors	O
of	O
cancer	O
who	O
were	O
on	O
the	O
waiting	O
lists	O
of	O
rehabilitation	O
centers	O
elsewhere	O
was	O
included.	O

The	O
study	O
was	O
conducted	O
at	O
4	O
rehabilitation	O
centers	O
in	O
the	O
Netherlands.	O

All	O
patients	O
were	O
survivors	O
of	O
cancer.	O

Physical	O
training	O
consisting	O
of	O
2	O
hours	O
of	O
individual	O
training	O
and	O
group	O
sports	O
took	O
place	O
twice	O
weekly,	O
and	O
cognitive-behavioral	O
therapy	O
took	O
place	O
once	O
weekly	O
for	O
2	O
hours.	O

Fatigue	O
was	O
assessed	O
with	O
the	O
Multidimensional	O
Fatigue	O
Inventory	O
before	O
and	O
immediately	O
after	O
intervention	O
(12	O
weeks	O
after	O
enrollment).	O

The	O
WLC	O
group	O
completed	O
questionnaires	O
at	O
the	O
same	O
time	O
points.	O

Baseline	O
fatigue	O
did	O
not	O
differ	O
significantly	O
among	O
the	O
3	O
groups.	O

Over	B-Premise
time,	I-Premise
levels	I-Premise
of	I-Premise
fatigue	I-Premise
significantly	I-Premise
decreased	I-Premise
in	I-Premise
all	I-Premise
domains	I-Premise
in	I-Premise
all	I-Premise
groups,	I-Premise
except	B-Premise
in	I-Premise
mental	I-Premise
fatigue	I-Premise
in	I-Premise
the	I-Premise
WLC	I-Premise
group.	I-Premise

Analyses	B-Premise
of	I-Premise
variance	I-Premise
of	I-Premise
postintervention	I-Premise
fatigue	I-Premise
showed	I-Premise
statistically	I-Premise
significant	I-Premise
group	I-Premise
effects	I-Premise
on	I-Premise
general	I-Premise
fatigue,	I-Premise
on	I-Premise
physical	I-Premise
and	I-Premise
mental	I-Premise
fatigue,	I-Premise
and	I-Premise
on	I-Premise
reduced	I-Premise
activation	I-Premise
but	I-Premise
not	I-Premise
on	I-Premise
reduced	I-Premise
motivation.	I-Premise

Compared	B-Premise
with	I-Premise
the	I-Premise
WLC	I-Premise
group,	I-Premise
the	I-Premise
PT	I-Premise
group	I-Premise
reported	I-Premise
significantly	I-Premise
greater	I-Premise
decline	I-Premise
in	I-Premise
4	I-Premise
domains	I-Premise
of	I-Premise
fatigue,	I-Premise
whereas	I-Premise
the	I-Premise
PT+CBT	I-Premise
group	I-Premise
reported	I-Premise
significantly	I-Premise
greater	I-Premise
decline	I-Premise
in	I-Premise
physical	I-Premise
fatigue	I-Premise
only.	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
decline	I-Premise
in	I-Premise
fatigue	I-Premise
were	I-Premise
found	I-Premise
between	I-Premise
the	I-Premise
PT+CBT	I-Premise
and	I-Premise
PT	I-Premise
groups.	I-Premise

Physical	B-Premise
training	I-Premise
combined	I-Premise
with	I-Premise
cognitive-behavioral	I-Premise
therapy	I-Premise
and	I-Premise
physical	I-Premise
training	I-Premise
alone	I-Premise
had	I-Premise
significant	I-Premise
and	I-Premise
beneficial	I-Premise
effects	I-Premise
on	I-Premise
fatigue	I-Premise
compared	I-Premise
with	I-Premise
no	I-Premise
intervention.	I-Premise

Physical	B-Claim
training	I-Claim
was	I-Claim
equally	I-Claim
effective	I-Claim
as	I-Claim
or	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
physical	I-Claim
training	I-Claim
combined	I-Claim
with	I-Claim
cognitive-behavioral	I-Claim
therapy	I-Claim
in	I-Claim
reducing	I-Claim
cancer-related	I-Claim
fatigue,	I-Claim
suggesting	O
that	O
cognitive-behavioral	B-Claim
therapy	I-Claim
did	I-Claim
not	I-Claim
have	I-Claim
additional	I-Claim
beneficial	I-Claim
effects	I-Claim
beyond	I-Claim
the	I-Claim
benefits	I-Claim
of	I-Claim
physical	I-Claim
training.	I-Claim

Sentinel	O
lymph	O
node	O
resection	O
(SNR)	O
may	O
reduce	O
morbidity	O
while	O
providing	O
the	O
same	O
clinical	O
utility	O
as	O
conventional	O
axillary	O
dissection	O
(AD).	O

National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
(NSABP)	O
B-32	O
is	O
a	O
randomized	O
phase	O
III	O
trial	O
comparing	O
SNR	O
immediately	O
followed	O
by	O
AD	O
(SNAD)	O
to	O
SNR	O
and	O
subsequent	O
AD	O
if	O
SN	O
is	O
positive.	O

We	O
report	O
the	O
definitive	O
patient-reported	O
outcomes	O
(PRO)	O
comparisons.	O

Eligible	O
patients	O
had	O
clinically	O
node-negative,	O
operable	O
invasive	O
breast	O
cancer.	O

The	O
PRO	O
substudy	O
included	O
all	O
SN-negative	O
participants	O
enrolled	O
May	O
2001	O
to	O
February	O
2004	O
at	O
community	O
institutions	O
in	O
the	O
United	O
States	O
(n	O
=	O
749;	O
78%	O
age	O
>	O
or	O
=	O
50;	O
87%	O
clinical	O
tumor	O
size	O
<	O
or	O
=	O
2.0	O
cm;	O
84%	O
lumpectomy;	O
87%	O
white).	O

They	O
completed	O
questionnaires	O
presurgery,	O
1	O
and	O
2	O
to	O
3	O
weeks	O
postoperatively,	O
and	O
every	O
6	O
months	O
through	O
year	O
3.	O

Arm	O
symptoms,	O
arm	O
use	O
avoidance,	O
activity	O
limitations,	O
and	O
quality	O
of	O
life	O
(QOL)	O
were	O
compared	O
with	O
intent-to-treat	O
two-sample	O
t-tests	O
and	O
repeated	O
measures	O
analyses.	O

Arm	B-Premise
symptoms	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
bothersome	I-Premise
for	I-Premise
SNAD	I-Premise
compared	I-Premise
with	I-Premise
SNR	I-Premise
patients	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
(mean,	I-Premise
4.8	I-Premise
v	I-Premise
3.0;	I-Premise
P	I-Premise
<	I-Premise
.001)	I-Premise
and	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
(3.6	I-Premise
v	I-Premise
2.5;	I-Premise
P	I-Premise
=	I-Premise
.006).	I-Premise

Longitudinally,	B-Premise
SNAD	I-Premise
patients	I-Premise
were	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
experience	I-Premise
ipsilateral	I-Premise
arm	I-Premise
and	I-Premise
breast	I-Premise
symptoms,	I-Premise
restricted	I-Premise
work	I-Premise
and	I-Premise
social	I-Premise
activity,	I-Premise
and	I-Premise
impaired	I-Premise
QOL	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.002	I-Premise
all	I-Premise
items).	I-Premise

From	B-Premise
12	I-Premise
to	I-Premise
36	I-Premise
months,	I-Premise
fewer	I-Premise
than	I-Premise
15%	I-Premise
of	I-Premise
either	I-Premise
SNAD	I-Premise
or	I-Premise
SNR	I-Premise
patients	I-Premise
reported	I-Premise
moderate	I-Premise
or	I-Premise
greater	I-Premise
severity	I-Premise
of	I-Premise
any	I-Premise
given	I-Premise
symptom	I-Premise
or	I-Premise
activity	I-Premise
limitation.	I-Premise

Arm	B-Claim
morbidity	I-Claim
was	I-Claim
greater	I-Claim
with	I-Claim
SNAD	I-Claim
than	I-Claim
with	I-Claim
SNR.	I-Claim

Despite	O
considerable	O
fears	O
about	O
complications	O
from	O
AD	O
for	O
breast	O
cancer,	O
this	B-Claim
study	I-Claim
demonstrates	I-Claim
that	I-Claim
initial	I-Claim
problems	I-Claim
with	I-Claim
either	I-Claim
surgery	I-Claim
resolve	I-Claim
over	I-Claim
time.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
on	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
of	O
two	O
treatment	O
regimens	O
in	O
the	O
TEX	O
trial	O
during	O
9	O
month	O
from	O
random	O
assignment,	O
with	O
emphasis	O
on	O
the	O
2-	O
and	O
9-months	O
assessments.	O

A	O
total	O
of	O
287	O
patients	O
were	O
randomized	O
to	O
treatment	O
in	O
3-week	O
cycles	O
with	O
either	O
epirubicin	O
plus	O
paclitaxel	O
(ET,	O
143	O
patients),	O
or	O
epirubicin,	O
paclitaxel	O
and	O
capecitabine	O
(TEX,	O
144	O
patients).	O

HRQOL	O
was	O
assessed	O
by	O
the	O
EORTC-QLQ	O
C30	O
and	O
EORTC	O
QLQ-BR23	O
questionnaires	O
at	O
five	O
points	O
during	O
9	O
months.	O

A	O
total	O
of	O
252	O
(88%)	O
completed	O
questionnaires	O
before	O
randomization.	O

Response	O
rate	O
for	O
the	O
following	O
assessments	O
was	O
>75%.	O

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
TEX	I-Premise
group	I-Premise
and	I-Premise
the	I-Premise
ET	I-Premise
group	I-Premise
on	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
subscales	I-Premise
2	I-Premise
months	I-Premise
after	I-Premise
randomization.	I-Premise

Small	B-Premise
clinical	I-Premise
differences	I-Premise
(5-10	I-Premise
points)	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
ET	I-Premise
group	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
role	I-Premise
functioning,	I-Premise
social	I-Premise
functioning,	I-Premise
and	I-Premise
insomnia.	I-Premise

At	B-Premise
the	I-Premise
9-months	I-Premise
assessment,	I-Premise
the	I-Premise
TEX	I-Premise
group	I-Premise
scored	I-Premise
statistically	I-Premise
significantly	I-Premise
higher	I-Premise
on	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
and	I-Premise
physical	I-Premise
functioning.	I-Premise

Small	B-Premise
clinically	I-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
physical	I-Premise
functioning,	I-Premise
role	I-Premise
functioning,	I-Premise
emotional	I-Premise
functioning,	I-Premise
dyspnoea,	I-Premise
and	I-Premise
insomnia,	I-Premise
all	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
TEX	I-Premise
group.	I-Premise

At	B-Claim
the	I-Claim
2-months	I-Claim
assessment,	I-Claim
when	I-Claim
side-effects	I-Claim
of	I-Claim
chemotherapy	I-Claim
were	I-Claim
present,	I-Claim
patients	I-Claim
in	I-Claim
the	I-Claim
TEX	I-Claim
group	I-Claim
appeared	I-Claim
to	I-Claim
fare	I-Claim
a	I-Claim
bit	I-Claim
worse	I-Claim
than	I-Claim
those	I-Claim
receiving	I-Claim
ET.	I-Claim

However,	O
after	B-Claim
9	I-Claim
months,	I-Claim
when	I-Claim
the	I-Claim
patients	I-Claim
had	I-Claim
adapted	I-Claim
to	I-Claim
treatment,	I-Claim
the	I-Claim
TEX	I-Claim
group	I-Claim
seemed	I-Claim
to	I-Claim
have	I-Claim
a	I-Claim
slightly	I-Claim
better	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

To	O
observe	O
the	O
clinical	O
effectiveness	O
of	O
a	O
topical	O
application	O
of	O
Xiaozheng	O
Zhitong:	O
Paste	O
(,	O
XZP)	O
in	O
alleviating	O
the	O
cancerous	O
pain	O
of	O
patients	O
with	O
middle/late	O
stage	O
cancer	O
By:	O
adopting	O
a	O
random	O
number	O
table,	O
124	O
patients	O
enrolled	O
were	O
randomized	O
into	O
the	O
treatment	O
group	O
(64	O
patients)	O
and	O
the	O
control	O
group	O
(60	O
patients).	O

In	O
addition	O
to	O
the	O
basic	O
therapy	O
[including	O
the	O
three-ladder	O
(3L)	O
analgesia]	O
used	O
in	O
both	O
groups,	O
topical	O
application	O
of	O
XZP	O
was	O
given	O
to	O
patients	O
in	O
the	O
treatment	O
group	O
for	O
pain	O
alleviation.	O

The	O
analgesic	O
efficacy	O
was	O
recorded	O
in	O
terms	O
of	O
pain	O
intensity,	O
analgesia	O
initiating	O
time	O
and	O
sustaining	O
time,	O
and	O
the	O
optimal	O
analgesic	O
effect	O
revealing	O
time.	O

Meanwhile,	O
the	O
quality	O
of	O
life	O
(QOL)	O
and	O
adverse	O
reactions	O
that	O
occurred	O
in	O
patients	O
were	O
recorded	O
as	O
well.	O

The	B-Premise
total	I-Premise
effective	I-Premise
rate	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
was:	I-Premise
84.38%	I-Premise
(54/64),	I-Premise
and	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
it	I-Premise
was	I-Premise
88.33%	I-Premise
(53/60),	I-Premise
showing	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
them	I-Premise
(P>0.05),	I-Premise
but	B-Premise
the	I-Premise
analgesia	I-Premise
initiating	I-Premise
time	I-Premise
and	I-Premise
the	I-Premise
optimal	I-Premise
analgesia	I-Premise
effect	I-Premise
revealing	I-Premise
time	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
were	I-Premise
significantly	I-Premise
shorter	I-Premise
(both	I-Premise
P<0.01).	I-Premise

Moreover,	O
XZP	B-Premise
was	I-Premise
better	I-Premise
in	I-Premise
improving	I-Premise
patients'	I-Premise
QOL,	I-Premise
showing	I-Premise
more	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
than	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
in	I-Premise
aspects	I-Premise
of	I-Premise
mental	I-Premise
condition,	I-Premise
walking	I-Premise
capacity,	I-Premise
working	I-Premise
capacity,	I-Premise
social	I-Premise
acceptability,	I-Premise
sleep	I-Premise
and	I-Premise
joy	I-Premise
of	I-Premise
living	I-Premise
(P<0.05	I-Premise
or	I-Premise
P<0.01).	I-Premise

Lower	B-Premise
incidence	I-Premise
of	I-Premise
adverse	I-Premise
reactions,	I-Premise
such	I-Premise
as	I-Premise
nausea,	I-Premise
vomiting,	I-Premise
mouth	I-Premise
dryness,	I-Premise
dizziness,	I-Premise
etc.,	I-Premise
especially	I-Premise
constipation,	I-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
(P<0.05	I-Premise
or	I-Premise
P<0.01).	I-Premise

Applying	B-Claim
an	I-Claim
external	I-Claim
compress:	I-Claim
of	I-Claim
XZP	I-Claim
showed	I-Claim
a	I-Claim
synergistic	I-Claim
action	I-Claim
with	I-Claim
3L	I-Claim
analgesia	I-Claim
for	I-Claim
shortening	I-Claim
the	I-Claim
initiating	I-Claim
time	I-Claim
and	I-Claim
the	I-Claim
optimal	I-Claim
effect	I-Claim
revealing	I-Claim
time,	I-Claim
and	I-Claim
could	I-Claim
evidently	I-Claim
enhance	I-Claim
patients'	I-Claim
QOL	I-Claim
with	I-Claim
fewer	I-Claim
adverse	I-Claim
reactions.	I-Claim

One	O
attempt	O
to	O
improve	O
long-term	O
survival	O
in	O
patients	O
with	O
advanced	O
ovarian	O
cancer	O
was	O
thought	O
to	O
be	O
the	O
addition	O
of	O
more	O
non-cross-resistant	O
drugs	O
to	O
platinum-paclitaxel	O
combination	O
regimens.	O

Gemcitabine	O
was	O
among	O
the	O
candidates	O
for	O
a	O
third	O
drug.	O

We	O
performed	O
a	O
prospective,	O
randomized,	O
phase	O
III,	O
intergroup	O
trial	O
to	O
compare	O
carboplatin	O
plus	O
paclitaxel	O
(TC;	O
area	O
under	O
the	O
curve	O
[AUC]	O
5	O
and	O
175	O
mg/m(2),	O
respectively)	O
with	O
the	O
same	O
combination	O
and	O
additional	O
gemcitabine	O
800	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8	O
(TCG)	O
in	O
previously	O
untreated	O
patients	O
with	O
advanced	O
epithelial	O
ovarian	O
cancer.	O

TC	O
was	O
administered	O
intravenously	O
(IV)	O
on	O
day	O
1	O
every	O
21	O
days	O
for	O
a	O
planned	O
minimum	O
of	O
six	O
courses.	O

Gemcitabine	O
was	O
administered	O
by	O
IV	O
on	O
days	O
1	O
and	O
8	O
of	O
each	O
cycle	O
in	O
the	O
TCG	O
arm.	O

Between	O
2002	O
and	O
2004,	O
1,742	O
patients	O
were	O
randomly	O
assigned;	O
882	O
and	O
860	O
patients	O
received	O
TC	O
and	O
TCG,	O
respectively.	O

Grades	B-Premise
3	I-Premise
to	I-Premise
4	I-Premise
hematologic	I-Premise
toxicity	I-Premise
and	I-Premise
fatigue	I-Premise
occurred	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
the	I-Premise
TCG	I-Premise
arm.	I-Premise

Accordingly,	O
quality-of-life	B-Claim
analysis	I-Claim
during	I-Claim
chemotherapy	I-Claim
showed	I-Claim
a	I-Claim
disadvantage	I-Claim
in	I-Claim
the	I-Claim
TCG	I-Claim
arm.	I-Claim

Although	B-Premise
objective	I-Premise
response	I-Premise
was	I-Premise
slightly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
TCG	I-Premise
arm,	I-Premise
this	B-Premise
did	I-Premise
not	I-Premise
translate	I-Premise
into	I-Premise
improved	I-Premise
progression-free	I-Premise
survival	I-Premise
(PFS)	I-Premise
or	I-Premise
overall	I-Premise
survival	I-Premise
(OS).	I-Premise

Median	B-Premise
PFS	I-Premise
was	I-Premise
17.8	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
TCG	I-Premise
arm	I-Premise
and	I-Premise
19.3	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
1.18;	I-Premise
95%	I-Premise
CI,	I-Premise
1.06	I-Premise
to	I-Premise
1.32;	I-Premise
P	I-Premise
=	I-Premise
.0044).	I-Premise

Median	B-Premise
OS	I-Premise
was	I-Premise
49.5	I-Premise
for	I-Premise
the	I-Premise
TCG	I-Premise
arm	I-Premise
and	I-Premise
51.5	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
(HR,	I-Premise
1.05;	I-Premise
95%	I-Premise
CI,	I-Premise
0.91	I-Premise
to	I-Premise
1.20;	I-Premise
P	I-Premise
=	I-Premise
.5106).	I-Premise

The	B-Claim
addition	I-Claim
of	I-Claim
gemcitabine	I-Claim
to	I-Claim
carboplatin	I-Claim
plus	I-Claim
paclitaxel	I-Claim
increased	I-Claim
treatment	I-Claim
burden,	I-Claim
reduced	I-Claim
PFS	I-Claim
time,	I-Claim
and	I-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
OS	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
epithelial	I-Claim
ovarian	I-Claim
cancer.	I-Claim

Therefore,	B-Claim
we	I-Claim
recommend	I-Claim
no	I-Claim
additional	I-Claim
clinical	I-Claim
use	I-Claim
of	I-Claim
TCG	I-Claim
in	I-Claim
this	I-Claim
population.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
economic	O
efficiency	O
of	O
a	O
multimedia,	O
multimodal	O
physical	O
activity	O
program	O
for	O
women	O
undergoing	O
adjuvant	O
therapy	O
following	O
surgery	O
for	O
breast	O
cancer.	O

We	O
conducted	O
a	O
randomized	O
trial	O
with	O
concurrent	O
incremental	O
cost-effectiveness	O
analysis	O
and	O
blinded	O
baseline,	O
3,	O
6	O
and	O
12-month	O
follow-up	O
assessments	O
amongst	O
women	O
undergoing	O
adjuvant	O
therapy	O
following	O
surgery	O
for	O
breast	O
cancer	O
(n	O
=	O
89).	O

The	O
intervention	O
was	O
a	O
multimedia,	O
multimodal	O
exercise	O
program	O
comprising	O
strength,	O
balance	O
and	O
endurance	O
training	O
elements.	O

The	O
control	O
was	O
sham	O
flexibility	O
and	O
relaxation	O
program	O
delivered	O
using	O
similar	O
materials.	O

The	O
primary	O
outcome	O
was	O
health-related	O
quality	O
of	O
life	O
(EQ-5D	O
&amp;	O
VAS,	O
EORTC	O
C30,	O
BR23).	O

Economic	O
outcomes	O
included	O
direct	O
health	O
care	O
costs	O
and	O
productivity	O
gains	O
and	O
losses.	O

Participants	B-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
demonstrated	I-Premise
greater	I-Premise
improvement	I-Premise
in	I-Premise
health-related	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
between	I-Premise
baseline	I-Premise
and	I-Premise
the	I-Premise
3-month	I-Premise
assessment	I-Premise
[mean	I-Premise
(sd)	I-Premise
EQ-5D	I-Premise
VAS	I-Premise
(0-100)	I-Premise
baseline:	I-Premise
72.6	I-Premise
(15.6),	I-Premise
3	I-Premise
month:	I-Premise
80.6	I-Premise
(11.6)]	I-Premise
when	I-Premise
compared	I-Premise
to	I-Premise
control	I-Premise
group	I-Premise
participants	I-Premise
[baseline:	I-Premise
77.5	I-Premise
(13.5),	I-Premise
3	I-Premise
month:	I-Premise
74.1	I-Premise
(20.6),	I-Premise
P	I-Premise
=	I-Premise
0.006]	I-Premise
and	I-Premise
also	I-Premise
improved	I-Premise
more	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
physical	I-Premise
function	I-Premise
[mean	I-Premise
(sd)	I-Premise
EORTC	I-Premise
C30	I-Premise
physical	I-Premise
function	I-Premise
scale	I-Premise
intervention	I-Premise
(0-100)	I-Premise
baseline:	I-Premise
84.9	I-Premise
(14.8),	I-Premise
3	I-Premise
month:	I-Premise
86.9	I-Premise
(10.7),	I-Premise
control	I-Premise
baseline:	I-Premise
91.3	I-Premise
(9.6),	I-Premise
3	I-Premise
month:	I-Premise
86.7	I-Premise
(14.9),	I-Premise
P	I-Premise
=	I-Premise
0.02].	I-Premise

These	O
improvements	O
were	O
not	O
sustained	O
beyond	O
this	O
point.	O

Upper	B-Premise
limb	I-Premise
volumes	I-Premise
were	I-Premise
also	I-Premise
lower	I-Premise
amongst	I-Premise
intervention	I-Premise
group	I-Premise
participants.	I-Premise

However,	O
there	B-Premise
was	I-Premise
low	I-Premise
probability	I-Premise
that	I-Premise
the	I-Premise
intervention	I-Premise
would	I-Premise
be	I-Premise
both	I-Premise
less	I-Premise
costly	I-Premise
and	I-Premise
more	I-Premise
effective	I-Premise
than	I-Premise
the	I-Premise
control	I-Premise
condition	I-Premise
(range	I-Premise
probability	I-Premise
=	I-Premise
0.05-50.02%	I-Premise
depending	I-Premise
on	I-Premise
approach).	I-Premise

Provision	B-Claim
of	I-Claim
multimodal	I-Claim
exercise	I-Claim
programs	I-Claim
will	I-Claim
improve	I-Claim
the	I-Claim
short-term	I-Claim
health	I-Claim
of	I-Claim
women	I-Claim
undergoing	I-Claim
adjuvant	I-Claim
therapy	I-Claim
for	I-Claim
breast	I-Claim
cancer	I-Claim
but	I-Claim
are	I-Claim
of	I-Claim
questionable	I-Claim
economic	I-Claim
efficiency.	I-Claim

Quality	O
of	O
life	O
is	O
an	O
important	O
outcome	O
measure	O
in	O
the	O
care	O
of	O
patients	O
with	O
cancer.	O

We	O
developed	O
a	O
new	O
scoring	O
system	O
specifically	O
for	O
the	O
evaluation	O
of	O
patients	O
with	O
upper	O
gastrointestinal	O
cancer	O
and	O
postoperative	O
gastrointestinal	O
dysfunction.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
scoring	O
system's	O
validity	O
in	O
comparing	O
outcomes	O
after	O
gastric	O
resection.	O

Patients	O
with	O
gastric	O
cancer,	O
3	O
months	O
to	O
3	O
years	O
postoperatively,	O
were	O
surveyed	O
using	O
the	O
survey	O
instrument.	O

Postoperative	O
dysfunction	O
scores	O
and	O
the	O
status	O
of	O
resuming	O
activities	O
of	O
daily	O
living	O
were	O
compared	O
with	O
the	O
surgical	O
procedure	O
performed	O
by	O
analysis	O
of	O
variance	O
and	O
multiple-comparison	O
techniques.	O

Of	O
211	O
patients	O
surveyed,	O
165	O
(119	O
men,	O
46	O
women;	O
mean	O
age,	O
65.1	O
±	O
10.5	O
years)	O
responded.	O

Procedures	O
included	O
distal	O
gastrectomy	O
in	O
100,	O
total	O
gastrectomy	O
in	O
57,	O
and	O
pylorus-preserving	O
gastrectomy	O
in	O
8.	O

The	O
overall	O
dysfunction	O
score	O
was	O
61.8	O
±	O
15.5.	O

The	B-Premise
dysfunction	I-Premise
score	I-Premise
was	I-Premise
58.9	I-Premise
±	I-Premise
15.0	I-Premise
after	I-Premise
distal	I-Premise
gastrectomy,	I-Premise
66.8	I-Premise
±	I-Premise
14.1	I-Premise
after	I-Premise
total	I-Premise
gastrectomy,	I-Premise
and	I-Premise
62.4	I-Premise
±	I-Premise
21.6	I-Premise
after	I-Premise
pylorus-preserving	I-Premise
gastrectomy.	I-Premise

These	B-Premise
values	I-Premise
differed	I-Premise
significantly	I-Premise
among	I-Premise
the	I-Premise
groups	I-Premise
(P	I-Premise
=	I-Premise
.007).	I-Premise

Dysfunction	B-Premise
scores	I-Premise
according	I-Premise
to	I-Premise
postoperative	I-Premise
activity	I-Premise
status	I-Premise
were	I-Premise
49.1	I-Premise
±	I-Premise
15.6	I-Premise
in	I-Premise
71	I-Premise
patients	I-Premise
who	I-Premise
resumed	I-Premise
their	I-Premise
activities,	I-Premise
56.9	I-Premise
±	I-Premise
15.7	I-Premise
in	I-Premise
39	I-Premise
patients	I-Premise
with	I-Premise
reduced	I-Premise
activities,	I-Premise
57.3	I-Premise
±	I-Premise
8.8	I-Premise
in	I-Premise
15	I-Premise
patients	I-Premise
with	I-Premise
minimal	I-Premise
activities,	I-Premise
and	I-Premise
63.3	I-Premise
±	I-Premise
11.8	I-Premise
(P	I-Premise
<	I-Premise
.05)	I-Premise
in	I-Premise
16	I-Premise
patients	I-Premise
who	I-Premise
did	I-Premise
not	I-Premise
resume	I-Premise
activities	I-Premise
because	I-Premise
of	I-Premise
poor	I-Premise
physical	I-Premise
condition.	I-Premise

This	B-Claim
scoring	I-Claim
system	I-Claim
for	I-Claim
postoperative	I-Claim
gastrointestinal	I-Claim
dysfunction	I-Claim
provides	I-Claim
an	I-Claim
objective	I-Claim
measure	I-Claim
of	I-Claim
dysfunction	I-Claim
related	I-Claim
to	I-Claim
specific	I-Claim
surgical	I-Claim
procedures	I-Claim
and	I-Claim
correlates	I-Claim
with	I-Claim
activities	I-Claim
of	I-Claim
daily	I-Claim
living	I-Claim
in	I-Claim
the	I-Claim
postoperative	I-Claim
period.	I-Claim

Previous	O
studies	O
have	O
demonstrated	O
that	O
both	O
anastrozole	O
and	O
letrozole	O
are	O
well	O
tolerated.	O

Letrozole	O
suppresses	O
estrogen	O
to	O
a	O
greater	O
degree	O
than	O
anastrozole	O
in	O
the	O
serum	O
and	O
breast	O
tumor.	O

Concerns	O
have	O
been	O
raised	O
that	O
greater	O
potency	O
may	O
adversely	O
affect	O
patients'	O
quality	O
of	O
life	O
(QOL).	O

One	O
hundred	O
eighty-one	O
postmenopausal	O
women	O
with	O
invasive	O
estrogen	O
receptor-positive	O
breast	O
cancers	O
were	O
randomized	O
to	O
receive	O
either	O
12	O
weeks	O
of	O
letrozole	O
followed	O
by	O
12	O
weeks	O
of	O
anastrozole	O
or	O
the	O
reverse	O
sequence.	O

One	O
hundred	O
and	O
six	O
received	O
immediate	O
adjuvant	O
aromatase	O
inhibitors	O
(AIs)	O
following	O
surgery,	O
and	O
75	O
received	O
extended	O
adjuvant	O
therapy.	O

The	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
Endocrine	O
Subscale	O
(FACT-B-ES)	O
QOL	O
questionnaires	O
were	O
completed	O
to	O
assess	O
QOL	O
on	O
each	O
drug.	O

Additional	O
side-effect	O
profiles	O
were	O
collected.	O

Each	O
patient	O
completed	O
a	O
patient	O
preference	O
form.	O

Twenty-one	O
patients	O
withdrew	O
before	O
study	O
end,	O
10/179	O
(5.6%)	O
while	O
taking	O
letrozole	O
and	O
4/173	O
(2.3%)	O
while	O
taking	O
anastrozole	O
(P	O
=	O
0.12).	O

Tamoxifen-naïve	B-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
higher	I-Premise
mean	I-Premise
ES	I-Premise
(endocrine	I-Premise
symptoms	I-Premise
subscale)	I-Premise
score	I-Premise
at	I-Premise
entry	I-Premise
versus	I-Premise
those	I-Premise
having	I-Premise
extended	I-Premise
therapy	I-Premise
(66.0	I-Premise
vs.	I-Premise
61.9;	I-Premise
P	I-Premise
=	I-Premise
0.001).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
change	I-Premise
in	I-Premise
FACT-B-ES	I-Premise
(overall)	I-Premise
scores	I-Premise
or	I-Premise
ES	I-Premise
scores	I-Premise
while	I-Premise
patients	I-Premise
were	I-Premise
taking	I-Premise
anastrozole	I-Premise
or	I-Premise
letrozole	I-Premise
and	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
drugs.	I-Premise

Nearly	B-Premise
80%	I-Premise
of	I-Premise
patients	I-Premise
reported	I-Premise
one	I-Premise
or	I-Premise
more	I-Premise
side	I-Premise
effects	I-Premise
with	I-Premise
either	I-Premise
agent.	I-Premise

No	B-Premise
differences	I-Premise
in	I-Premise
frequency,	I-Premise
grade,	I-Premise
or	I-Premise
range	I-Premise
of	I-Premise
side	I-Premise
effects	I-Premise
were	I-Premise
seen	I-Premise
between	I-Premise
drugs.	I-Premise

Of	O
160	O
patients,	O
49	O
(30.6%)	O
preferred	O
letrozole,	O
57	O
(35.6%)	O
preferred	O
anastrozole,	O
and	O
54	O
(33.8%)	O
had	O
no	O
preference	O
(P	O
=	O
0.26,	O
Pearson's	O
Chi-squared	O
test).	O

In	O
conclusion,	O
both	B-Claim
AIs	I-Claim
are	I-Claim
equally	I-Claim
well	I-Claim
tolerated.	I-Claim

There	B-Claim
were	I-Claim
no	I-Claim
significant	I-Claim
differences	I-Claim
in	I-Claim
QOL	I-Claim
scores	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
drugs.	I-Claim

There	O
are	O
patients	O
with	O
stage	O
I-III	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
who	O
are	O
not	O
suitable	O
for	O
curative	O
radical	O
chemoradiation	O
therapy.	O

There	O
are	O
patients	O
with	O
an	O
isolated	O
solitary	O
extracranial	O
metastasis	O
who	O
have	O
improved	O
outcomes	O
compared	O
with	O
those	O
with	O
cranial	O
or	O
multiple	O
metastases.	O

Patients	O
of	O
good	O
performance	O
status	O
receiving	O
moderate	O
dose	O
radiation	O
therapy	O
have	O
improved	O
survival.	O

Two	O
regimens	O
of	O
moderate	O
dose	O
chemoradiation	O
therapy	O
for	O
such	O
patients	O
were	O
compared	O
in	O
a	O
randomized	O
phase	O
II	O
trial.	O

Patients	O
were	O
eligible	O
if	O
they	O
had	O
stage	O
I-IIIB	O
NSCLC,	O
unsuitable	O
for	O
curative	O
therapy,	O
or	O
stage	O
IV	O
with	O
a	O
PET-detected	O
extracranial	O
solitary	O
metastasis.	O

Patients	O
were	O
randomized	O
to	O
the	O
following	O
groups-arm	O
A:	O
40	O
Gy/20	O
fractions/4	O
weeks	O
with	O
concurrent	O
weekly	O
vinorelbine	O
25	O
mg/m	O
+	O
cisplatin	O
20	O
mg/m	O
or	O
arm	O
B:	O
30	O
Gy/15	O
fractions/3	O
weeks	O
with	O
concurrent	O
weekly	O
gemcitabine	O
200	O
mg.	O
Primary	O
end	O
points	O
were	O
feasibility,	O
response	O
rates,	O
and	O
toxicity.	O

Secondary	O
end	O
points	O
were	O
progression-free	O
survival,	O
overall	O
survival,	O
and	O
quality	O
of	O
life.	O

Eighty-four	O
patients	O
were	O
randomized.	O

Compliance	O
was	O
above	O
90%	O
for	O
both	O
arms.	O

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
51%	I-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
and	I-Premise
38%	I-Premise
in	I-Premise
arm	I-Premise
B	I-Premise
(p	I-Premise
=	I-Premise
0.147).	I-Premise

Grade	B-Premise
3/4	I-Premise
toxicity	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
was	I-Premise
acceptable.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms	I-Premise
(5.5	I-Premise
versus	I-Premise
5.0	I-Premise
months,	I-Premise
p	I-Premise
=	I-Premise
0.19).	I-Premise

Patients	B-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
had	I-Premise
longer	I-Premise
median	I-Premise
survival	I-Premise
but	B-Premise
this	I-Premise
did	I-Premise
not	I-Premise
reach	I-Premise
statistical	I-Premise
significance	I-Premise
(13.1	I-Premise
versus	I-Premise
8.3	I-Premise
months,	I-Premise
p	I-Premise
=	I-Premise
0.25).	I-Premise

No	B-Claim
difference	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
was	I-Claim
observed.	I-Claim

Arm	O
A	O
was	O
chosen	O
for	O
a	O
future	O
phase	O
II	O
comparison	O
with	O
radiation	B-Claim
therapy	I-Claim
alone	I-Claim
as	I-Claim
it	I-Claim
demonstrated	I-Claim
a	I-Claim
response	I-Claim
rate	I-Claim
greater	I-Claim
than	I-Claim
50%,	I-Claim
and	I-Claim
data	I-Claim
suggested	I-Claim
that	I-Claim
arm	I-Claim
A	I-Claim
had	I-Claim
superior	I-Claim
survival	I-Claim
to	I-Claim
arm	I-Claim
B.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
determine	O
the	O
effectiveness	O
of	O
a	O
mindfulness-based	O
stress-reduction	O
(MBSR)	O
program	O
on	O
quality	O
of	O
life	O
(QOL)	O
and	O
psychosocial	O
outcomes	O
in	O
women	O
with	O
early-stage	O
breast	O
cancer,	O
using	O
a	O
three-arm	O
randomized	O
controlled	O
clinical	O
trial	O
(RCT).	O

This	O
RCT	O
consisting	O
of	O
172	O
women,	O
aged	O
20-65	O
with	O
stage	O
I	O
or	O
II	O
breast	O
cancer	O
consisted	O
of	O
the	O
8-week	O
MBSR,	O
which	O
was	O
compared	O
to	O
a	O
nutrition	O
education	O
program	O
(NEP)	O
and	O
usual	O
supportive	O
care	O
(UC).	O

Follow-up	O
was	O
performed	O
at	O
three	O
post-intervention	O
points:	O
4	O
months,	O
1,	O
and	O
2	O
years.	O

Standardized,	O
validated	O
self-administered	O
questionnaires	O
were	O
adopted	O
to	O
assess	O
psychosocial	O
variables.	O

Statistical	O
analysis	O
included	O
descriptive	O
and	O
regression	O
analyses	O
incorporating	O
both	O
intention-to-treat	O
and	O
post	O
hoc	O
multivariable	O
approaches	O
of	O
the	O
163	O
women	O
with	O
complete	O
data	O
at	O
baseline,	O
those	O
who	O
were	O
randomized	O
to	O
MBSR	O
experienced	O
a	O
significant	O
improvement	O
in	O
the	O
primary	O
measures	O
of	O
QOL	O
and	O
coping	O
outcomes	O
compared	O
to	O
the	O
NEP,	O
UC,	O
or	O
both,	O
including	O
the	O
spirituality	O
subscale	O
of	O
the	O
FACT-B	O
as	O
well	O
as	O
dealing	O
with	O
illness	O
scale	O
increases	O
in	O
active	O
behavioral	O
coping	O
and	O
active	O
cognitive	O
coping.	O

Secondary	B-Premise
outcome	I-Premise
improvements	I-Premise
resulting	I-Premise
in	I-Premise
significant	I-Premise
between-group	I-Premise
contrasts	I-Premise
favoring	I-Premise
the	I-Premise
MBSR	I-Premise
group	I-Premise
at	I-Premise
4	I-Premise
months	I-Premise
included	I-Premise
meaningfulness,	I-Premise
depression,	I-Premise
paranoid	I-Premise
ideation,	I-Premise
hostility,	I-Premise
anxiety,	I-Premise
unhappiness,	I-Premise
and	I-Premise
emotional	I-Premise
control.	I-Premise

Results	B-Premise
tended	I-Premise
to	I-Premise
decline	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
and	I-Premise
even	I-Premise
more	I-Premise
at	I-Premise
24	I-Premise
months,	I-Premise
though	I-Premise
at	I-Premise
all	I-Premise
times,	I-Premise
they	I-Premise
were	I-Premise
as	I-Premise
robust	I-Premise
in	I-Premise
women	I-Premise
with	I-Premise
lower	I-Premise
expectation	I-Premise
of	I-Premise
effect	I-Premise
as	I-Premise
in	I-Premise
those	I-Premise
with	I-Premise
higher	I-Premise
expectation.	I-Premise

The	B-Claim
MBSR	I-Claim
intervention	I-Claim
appears	I-Claim
to	I-Claim
benefit	I-Claim
psychosocial	I-Claim
adjustment	I-Claim
in	I-Claim
cancer	I-Claim
patients,	I-Claim
over	I-Claim
and	I-Claim
above	I-Claim
the	I-Claim
effects	I-Claim
of	I-Claim
usual	I-Claim
care	I-Claim
or	I-Claim
a	I-Claim
credible	I-Claim
control	I-Claim
condition.	I-Claim

The	B-Claim
universality	I-Claim
of	I-Claim
effects	I-Claim
across	I-Claim
levels	I-Claim
of	I-Claim
expectation	I-Claim
indicates	I-Claim
a	I-Claim
potential	I-Claim
to	I-Claim
utilize	I-Claim
this	I-Claim
stress	I-Claim
reduction	I-Claim
approach	I-Claim
as	I-Claim
complementary	I-Claim
therapy	I-Claim
in	I-Claim
oncologic	I-Claim
practice.	I-Claim

The	O
efficacy	O
of	O
a	O
home-based	O
physical	O
activity	O
(PA)	O
intervention	O
for	O
colorectal	O
cancer	O
patients	O
versus	O
contact	O
control	O
was	O
evaluated	O
in	O
a	O
randomized	O
controlled	O
trial.	O

Forty-six	O
patients	O
(mean	O
age	O
=	O
57.3	O
years	O
[SD	O
=	O
9.7],	O
57%	O
female,	O
mean	O
=	O
2.99	O
years	O
post-diagnosis	O
[SD	O
=	O
1.64])	O
who	O
had	O
completed	O
treatment	O
for	O
stages	O
1-3	O
colorectal	O
cancer	O
were	O
randomized	O
to	O
telephone	O
counseling	O
to	O
support	O
PA	O
(PA	O
group,	O
n	O
=	O
20)	O
or	O
contact	O
control	O
(control	O
group,	O
n	O
=	O
26).	O

PA	O
group	O
participants	O
received	O
3	O
months	O
of	O
PA	O
counseling	O
(based	O
on	O
the	O
transtheoretical	O
model	O
and	O
the	O
social	O
cognitive	O
theory)	O
delivered	O
via	O
telephone,	O
as	O
well	O
as	O
weekly	O
PA	O
tip	O
sheets.	O

Assessments	O
of	O
PA	O
(Seven-day	O
Physical	O
Activity	O
Recall	O
[7-day	O
PAR]	O
and	O
Community	O
Healthy	O
Activities	O
Model	O
Program	O
for	O
Seniors	O
[CHAMPS]),	O
submaximal	O
aerobic	O
fitness	O
(Treadwalk	O
test),	O
motivational	O
readiness	O
for	O
PA,	O
and	O
psychosocial	O
outcomes	O
were	O
conducted	O
at	O
baseline,	O
3,	O
6,	O
and	O
12	O
months	O
post-baseline.	O

Objective	O
accelerometer	O
data	O
were	O
collected	O
at	O
the	O
same	O
time	O
points.	O

The	B-Premise
PA	I-Premise
group	I-Premise
reported	I-Premise
significant	I-Premise
increases	I-Premise
in	I-Premise
minutes	I-Premise
of	I-Premise
PA	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
(7-day	I-Premise
PAR)	I-Premise
and	I-Premise
caloric	I-Premise
expenditure	I-Premise
(CHAMPS)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
but	B-Premise
the	I-Premise
group	I-Premise
differences	I-Premise
were	I-Premise
attenuated	I-Premise
over	I-Premise
time.	I-Premise

The	B-Premise
PA	I-Premise
group	I-Premise
showed	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
fitness	I-Premise
at	I-Premise
3,	I-Premise
6,	I-Premise
and	I-Premise
12	I-Premise
months	I-Premise
versus	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Improvements	B-Premise
in	I-Premise
motivational	I-Premise
readiness	I-Premise
for	I-Premise
PA	I-Premise
were	I-Premise
reported	I-Premise
in	I-Premise
the	I-Premise
PA	I-Premise
group	I-Premise
only	I-Premise
at	I-Premise
3	I-Premise
months.	I-Premise

No	B-Premise
significant	I-Premise
group	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
fatigue,	I-Premise
self-reported	I-Premise
physical	I-Premise
functioning,	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
at	I-Premise
3,	I-Premise
6,	I-Premise
and	I-Premise
12	I-Premise
months.	I-Premise

A	B-Claim
home-based	I-Claim
intervention	I-Claim
improved	I-Claim
survivors'	I-Claim
PA	I-Claim
and	I-Claim
motivational	I-Claim
readiness	I-Claim
at	I-Claim
3	I-Claim
months	I-Claim
and	I-Claim
increased	I-Claim
submaximal	I-Claim
aerobic	I-Claim
fitness	I-Claim
at	I-Claim
3,	I-Claim
6,	I-Claim
and	I-Claim
12	I-Claim
months.	I-Claim

Somatostatin	O
analogs	O
act	O
directly	O
on	O
breast	O
cancer	O
cells	O
and	O
indirectly	O
on	O
insulin	O
and	O
insulin-like	O
growth	O
factor	O
1	O
(IGF-1)	O
levels.	O

This	O
trial	O
was	O
undertaken	O
to	O
assess	O
whether	O
octreotide	B-Claim
would	I-Claim
lower	I-Claim
insulin	I-Claim
and	I-Claim
IGF-1	I-Claim
levels	I-Claim
and	I-Claim
reduce	I-Claim
risk	I-Claim
of	I-Claim
breast	I-Claim
cancer	I-Claim
recurrence.	I-Claim

The	O
NCIC	O
CTG	O
MA.14	O
(NCIC	O
Clinical	O
Trials	O
Group	O
MA.14)	O
trial	O
randomly	O
assigned	O
postmenopausal	O
women	O
to	O
5	O
years	O
of	O
tamoxifen	O
20	O
mg	O
daily	O
(TAM)	O
or	O
TAM	O
plus	O
2	O
years	O
of	O
octreotide	O
90	O
mg	O
depot	O
intramuscular	O
injections	O
monthly	O
(TAM-OCT)	O
as	O
adjuvant	O
therapy.	O

The	O
primary	O
end	O
point	O
was	O
event-free	O
survival	O
(EFS).	O

Secondary	O
end	O
points	O
were	O
relapse-free	O
survival	O
(RFS),	O
overall	O
survival	O
(OS),	O
toxicity,	O
and	O
effects	O
of	O
treatment	O
on	O
IGF	O
physiology.	O

Among	O
667	O
women	O
with	O
a	O
median	O
follow-up	O
of	O
7.9	O
years,	O
220	O
events	O
occurred-108	O
with	O
TAM-OCT	O
and	O
112	O
with	O
TAM.	O

Adjusted	B-Premise
hazard	I-Premise
ratios	I-Premise
(HRs;	I-Premise
TAM-OCT	I-Premise
to	I-Premise
TAM)	I-Premise
were	I-Premise
0.93	I-Premise
for	I-Premise
EFS	I-Premise
(95%	I-Premise
CI,	I-Premise
0.71	I-Premise
to	I-Premise
1.22;	I-Premise
P	I-Premise
=	I-Premise
.62),	I-Premise
0.84	I-Premise
for	I-Premise
RFS	I-Premise
(95%	I-Premise
CI,	I-Premise
0.59	I-Premise
to	I-Premise
1.18;	I-Premise
P	I-Premise
=	I-Premise
.31),	I-Premise
and	I-Premise
0.97	I-Premise
for	I-Premise
OS	I-Premise
(95%	I-Premise
CI,	I-Premise
0.69	I-Premise
to	I-Premise
1.37;	I-Premise
P	I-Premise
=	I-Premise
.86).	I-Premise

Among	B-Premise
patients	I-Premise
with	I-Premise
normal	I-Premise
baseline	I-Premise
gallbladder	I-Premise
imaging,	I-Premise
cholecystectomy	I-Premise
was	I-Premise
required	I-Premise
in	I-Premise
23.0%	I-Premise
of	I-Premise
those	I-Premise
receiving	I-Premise
TAM-OCT	I-Premise
but	I-Premise
in	I-Premise
only	I-Premise
1.4%	I-Premise
of	I-Premise
those	I-Premise
receiving	I-Premise
TAM	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

At	B-Premise
4	I-Premise
months,	I-Premise
TAM-OCT	I-Premise
had	I-Premise
significantly	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
lowered	I-Premise
IGF-1,	I-Premise
IGF	I-Premise
binding	I-Premise
protein	I-Premise
3,	I-Premise
and	I-Premise
C-peptide	I-Premise
levels.	I-Premise

Older	B-Premise
age	I-Premise
(P	I-Premise
=	I-Premise
.02),	I-Premise
tumor	I-Premise
size	I-Premise
(P	I-Premise
=	I-Premise
.001),	I-Premise
nodal	I-Premise
status	I-Premise
(P	I-Premise
=	I-Premise
.01),	I-Premise
high	I-Premise
C-peptide	I-Premise
levels	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
higher	I-Premise
body	I-Premise
mass	I-Premise
index	I-Premise
(BMI)	I-Premise
in	I-Premise
models	I-Premise
excluding	I-Premise
C-peptide	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
poorer	I-Premise
EFS	I-Premise
in	I-Premise
multivariate	I-Premise
analysis.	I-Premise

Octreotide-related	O
changes	O
in	O
circulating	O
IGF-1	O
and	O
C-peptide	O
levels	O
were	O
statistically	O
significant.	O

Octreotide	B-Claim
did	I-Claim
not	I-Claim
add	I-Claim
significant	I-Claim
clinical	I-Claim
benefit.	I-Claim

High	B-Claim
C-peptide	I-Claim
levels	I-Claim
(surrogate	I-Claim
for	I-Claim
insulin	I-Claim
secretion	I-Claim
rate)	I-Claim
and	I-Claim
high	I-Claim
BMI	I-Claim
were	I-Claim
associated	I-Claim
with	I-Claim
poor	I-Claim
outcome.	I-Claim

Both	O
Billroth	O
I	O
(B-I)	O
and	O
Roux-en-Y	O
(R-Y)	O
reconstructions	O
are	O
commonly	O
performed	O
as	O
standard	O
procedures,	O
but	O
it	O
has	O
yet	O
to	O
be	O
determined	O
which	O
reconstruction	O
is	O
better	O
for	O
patients.	O

A	O
randomized	O
prospective	O
phase	O
II	O
trial	O
with	O
body	O
weight	O
loss	O
at	O
1	O
year	O
after	O
surgery	O
as	O
a	O
primary	O
endpoint	O
was	O
performed	O
to	O
address	O
this	O
issue.	O

The	O
current	O
report	O
delivers	O
data	O
on	O
the	O
quality	O
of	O
life	O
and	O
degree	O
of	O
postoperative	O
dysfunction,	O
which	O
were	O
the	O
secondary	O
endpoints	O
of	O
this	O
study.	O

Gastric	O
cancer	O
patients	O
who	O
underwent	O
distal	O
gastrectomy	O
were	O
intraoperatively	O
randomized	O
to	O
B-I	O
or	O
R-Y.	O

Postsurgical	O
QOL	O
was	O
evaluated	O
using	O
the	O
EORTC	O
QLQ-C30	O
and	O
DAUGS	O
20.	O

Between	O
August	O
2005	O
and	O
December	O
2008,	O
332	O
patients	O
were	O
enrolled	O
in	O
a	O
randomized	O
trial	O
comparing	O
B-I	O
versus	O
R-Y.	O

A	O
mail	O
survey	O
questionnaire	O
sent	O
to	O
327	O
patients	O
was	O
completed	O
by	O
268	O
(86.2%)	O
of	O
them.	O

EORTC	O
QLQ-C30	O
scores	O
were	O
as	O
follows:	O
global	O
health	O
status	O
was	O
similar	O
in	O
each	O
group	O
(B-I	O
73.5	O
±	O
18.8,	O
R-Y	O
73.2	O
±	O
20.2,	O
p	O
=	O
0.87).	O

Scores	O
of	O
five	O
functional	O
scales	O
were	O
also	O
similar.	O

Only	B-Premise
the	I-Premise
dyspnea	I-Premise
symptom	I-Premise
scale	I-Premise
showed	I-Premise
superior	I-Premise
results	I-Premise
for	I-Premise
R-Y	I-Premise
than	I-Premise
for	I-Premise
B-I	I-Premise
(B-I	I-Premise
13.6	I-Premise
±	I-Premise
17.9,	I-Premise
R-Y	I-Premise
8.6	I-Premise
±	I-Premise
16.3,	I-Premise
p	I-Premise
=	I-Premise
0.02).	I-Premise

With	B-Premise
respect	I-Premise
to	I-Premise
DAUGS	I-Premise
20,	I-Premise
the	I-Premise
total	I-Premise
score	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
between	I-Premise
the	I-Premise
R-Y	I-Premise
and	I-Premise
B-I	I-Premise
groups	I-Premise
(24.8	I-Premise
vs.	I-Premise
23.6,	I-Premise
p	I-Premise
=	I-Premise
0.41).	I-Premise

Only	B-Premise
reflux	I-Premise
symptoms	I-Premise
were	I-Premise
significantly	I-Premise
worse	I-Premise
for	I-Premise
B-I	I-Premise
than	I-Premise
for	I-Premise
R-Y	I-Premise
(0.7	I-Premise
±	I-Premise
0.6	I-Premise
vs.	I-Premise
0.5	I-Premise
±	I-Premise
0.6,	I-Premise
p	I-Premise
=	I-Premise
0.01).	I-Premise

The	B-Claim
B-I	I-Claim
and	I-Claim
R-Y	I-Claim
techniques	I-Claim
were	I-Claim
generally	I-Claim
equivalent	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
postoperative	I-Claim
QOL	I-Claim
and	I-Claim
dysfunction.	I-Claim

Both	B-Claim
procedures	I-Claim
seem	I-Claim
acceptable	I-Claim
as	I-Claim
standard	I-Claim
reconstructions	I-Claim
after	I-Claim
distal	I-Claim
gastrectomy	I-Claim
with	I-Claim
regard	I-Claim
to	I-Claim
postoperative	I-Claim
QOL	I-Claim
and	I-Claim
dysfunction.	I-Claim

In	O
a	O
phase	O
3	O
trial	O
comparing	O
the	O
efficacy	O
and	O
safety	O
of	O
axitinib	O
versus	O
sorafenib	O
as	O
second-line	O
treatment	O
for	O
metastatic	O
renal	O
cell	O
carcinoma,	O
patients	O
given	O
axitinib	O
had	O
a	O
longer	O
progression-free	O
survival	O
(PFS).	O

Here,	O
we	O
report	O
overall	O
survival	O
and	O
updated	O
efficacy,	O
quality	O
of	O
life,	O
and	O
safety	O
results.	O

Eligible	O
patients	O
had	O
clear	O
cell	O
metastatic	O
renal	O
cell	O
carcinoma,	O
progressive	O
disease	O
after	O
one	O
approved	O
systemic	O
treatment,	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
(ECOG	O
PS)	O
of	O
0-1.	O

723	O
patients	O
were	O
stratified	O
by	O
ECOG	O
PS	O
and	O
previous	O
treatment	O
and	O
randomly	O
allocated	O
(1:1)	O
to	O
receive	O
axitinib	O
(5	O
mg	O
twice	O
daily;	O
n=361)	O
or	O
sorafenib	O
(400	O
mg	O
twice	O
daily;	O
n=362).	O

The	O
primary	O
endpoint	O
was	O
PFS	O
assessed	O
by	O
a	O
masked,	O
independent	O
radiology	O
review	O
committee.	O

We	O
assessed	O
patient-reported	O
outcomes	O
using	O
validated	O
questionnaires.	O

Baseline	O
characteristics	O
and	O
development	O
of	O
hypertension	O
on	O
treatment	O
were	O
studied	O
as	O
prognostic	O
factors.	O

Efficacy	O
was	O
assessed	O
in	O
the	O
intention-to-treat	O
population,	O
and	O
safety	O
was	O
assessed	O
in	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
the	O
study	O
drug.	O

Median	B-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
20.1	I-Premise
months	I-Premise
(95%	I-Premise
CI	I-Premise
16.7-23.4)	I-Premise
with	I-Premise
axitinib	I-Premise
and	I-Premise
19.2	I-Premise
months	I-Premise
(17.5-22.3)	I-Premise
with	I-Premise
sorafenib	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
0.969,	I-Premise
95%	I-Premise
CI	I-Premise
0.800-1.174;	I-Premise
one-sided	I-Premise
p=0.3744).	I-Premise

Median	B-Premise
investigator-assessed	I-Premise
PFS	I-Premise
was	I-Premise
8.3	I-Premise
months	I-Premise
(95%	I-Premise
CI	I-Premise
6.7-9.2)	I-Premise
with	I-Premise
axitinib	I-Premise
and	I-Premise
5·7	I-Premise
months	I-Premise
(4.7-6.5)	I-Premise
with	I-Premise
sorafenib	I-Premise
(HR	I-Premise
0.656,	I-Premise
95%	I-Premise
CI	I-Premise
0.552-0.779;	I-Premise
one-sided	I-Premise
p<0.0001).	I-Premise

Patient-reported	B-Premise
outcomes	I-Premise
scores	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
at	I-Premise
baseline,	I-Premise
were	I-Premise
maintained	I-Premise
during	I-Premise
treatment,	I-Premise
but	B-Premise
decreased	I-Premise
at	I-Premise
end-of-treatment.	I-Premise

Common	B-Premise
grade	I-Premise
3	I-Premise
or	I-Premise
higher	I-Premise
treatment-related	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
hypertension	I-Premise
(60	I-Premise
[17%]),	I-Premise
diarrhoea	I-Premise
(40	I-Premise
[11%]),	I-Premise
and	I-Premise
fatigue	I-Premise
(37	I-Premise
[10%])	I-Premise
in	I-Premise
359	I-Premise
axitinib-treated	I-Premise
patients	I-Premise
and	I-Premise
hand-foot	I-Premise
syndrome	I-Premise
(61	I-Premise
[17%]),	I-Premise
hypertension	I-Premise
(43	I-Premise
[12%]),	I-Premise
and	I-Premise
diarrhoea	I-Premise
(27	I-Premise
[8%])	I-Premise
in	I-Premise
355	I-Premise
sorafenib-treated	I-Premise
patients.	I-Premise

In	B-Premise
a	I-Premise
post-hoc	I-Premise
12-week	I-Premise
landmark	I-Premise
analysis,	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
longer	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
a	I-Premise
diastolic	I-Premise
blood	I-Premise
pressure	I-Premise
of	I-Premise
90	I-Premise
mm	I-Premise
Hg	I-Premise
or	I-Premise
greater	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
with	I-Premise
a	I-Premise
diastolic	I-Premise
blood	I-Premise
pressure	I-Premise
of	I-Premise
less	I-Premise
than	I-Premise
90	I-Premise
mm	I-Premise
Hg:	I-Premise
20.7	I-Premise
months	I-Premise
(95%	I-Premise
CI	I-Premise
18.4-24.6)	I-Premise
versus	I-Premise
12.9	I-Premise
months	I-Premise
(10.1-20.4)	I-Premise
in	I-Premise
the	I-Premise
axitinib	I-Premise
group	I-Premise
(p=0.0116),	I-Premise
and	I-Premise
20.2	I-Premise
months	I-Premise
(17.1-32.0)	I-Premise
versus	I-Premise
14.8	I-Premise
months	I-Premise
(12.0-17.7)	I-Premise
in	I-Premise
the	I-Premise
sorafenib	I-Premise
group	I-Premise
(one-sided	I-Premise
p=0.0020).	I-Premise

Although	O
overall	B-Claim
survival,	I-Claim
a	I-Claim
secondary	I-Claim
endpoint	I-Claim
for	I-Claim
the	I-Claim
study,	I-Claim
did	I-Claim
not	I-Claim
differ	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
groups,	I-Claim
investigator-assessed	B-Claim
PFS	I-Claim
remained	I-Claim
longer	I-Claim
in	I-Claim
the	I-Claim
axitinib	I-Claim
group	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
sorafenib	I-Claim
group.	I-Claim

These	B-Claim
results	I-Claim
establish	I-Claim
axitinib	I-Claim
as	I-Claim
a	I-Claim
second-line	I-Claim
treatment	I-Claim
option	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
renal	I-Claim
cell	I-Claim
carcinoma.	I-Claim

Cancer	O
treatment	O
can	O
profoundly	O
impact	O
the	O
patient's	O
quality	O
of	O
life	O
(QOL).	O

It	O
has	O
been	O
well	O
documented	O
that	O
there	O
are	O
gender	O
differences	O
in	O
the	O
symptoms	O
associated	O
with	O
cancer	O
treatment.	O

This	O
study	O
explores	O
the	O
impact	O
of	O
gender	O
on	O
QOL	O
for	O
patients	O
with	O
newly	O
diagnosed	O
advanced	O
cancer.	O

A	O
randomized,	O
controlled	O
clinical	O
trial	O
in	O
patients	O
receiving	O
radiotherapy	O
for	O
advanced	O
cancer	O
demonstrated	O
maintenance	O
of	O
QOL	O
with	O
a	O
six	O
session	O
multidisciplinary	O
structured	O
intervention	O
compared	O
to	O
controls.	O

This	O
current	O
study	O
reports	O
the	O
gender	O
differences	O
in	O
that	O
trial.	O

Outcome	O
measures	O
included	O
the	O
functional	O
assessment	O
of	O
cancer	O
therapy-general	O
(FACT-G),	O
linear	O
analog	O
self-assessment	O
(LASA),	O
and	O
profile	O
of	O
mood	O
states	O
(POMS)	O
at	O
baseline	O
and	O
weeks	O
4,	O
27,	O
and	O
52.	O

Kruskal-Wallis	O
was	O
used	O
to	O
compare	O
QOL	O
scores.	O

One	O
hundred	O
thirty-one	O
patients	O
(45	O
women	O
and	O
86	O
men,	O
mean	O
age	O
58.7)	O
participated	O
in	O
the	O
clinical	O
trial.	O

At	B-Premise
week	I-Premise
4	I-Premise
postintervention,	I-Premise
women	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
had	I-Premise
statistically	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
their	I-Premise
FACT-G	I-Premise
score,	I-Premise
FACT-G	I-Premise
physical	I-Premise
well-being	I-Premise
subscale,	I-Premise
LASA	I-Premise
fatigue,	I-Premise
POMS	I-Premise
total	I-Premise
score,	I-Premise
POMS	I-Premise
fatigue-inertia	I-Premise
subscale,	I-Premise
and	I-Premise
POMS	I-Premise
confusion-bewilderment	I-Premise
subscale	I-Premise
(p	I-Premise
<	I-Premise
0.05).	I-Premise

Men	B-Premise
receiving	I-Premise
the	I-Premise
intervention	I-Premise
had	I-Premise
a	I-Premise
smaller	I-Premise
decrease	I-Premise
in	I-Premise
FACT-G	I-Premise
score	I-Premise
compared	I-Premise
to	I-Premise
controls	I-Premise
(p	I-Premise
=	I-Premise
0.048)	I-Premise
and	I-Premise
also	I-Premise
worsened	I-Premise
on	I-Premise
the	I-Premise
LASA	I-Premise
financial	I-Premise
(p	I-Premise
=	I-Premise
0.02).	I-Premise

At	B-Premise
week	I-Premise
27,	I-Premise
the	I-Premise
only	I-Premise
gender	I-Premise
difference	I-Premise
was	I-Premise
that	I-Premise
intervention	I-Premise
group	I-Premise
men	I-Premise
had	I-Premise
more	I-Premise
POMS	I-Premise
anger-hostility	I-Premise
(p	I-Premise
=	I-Premise
0.009).	I-Premise

By	B-Premise
week	I-Premise
52,	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
gender	I-Premise
differences	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
QOL	I-Premise
measures.	I-Premise

Gender-based	B-Claim
differences	I-Claim
appear	I-Claim
to	I-Claim
play	I-Claim
a	I-Claim
role	I-Claim
in	I-Claim
the	I-Claim
early,	I-Claim
but	I-Claim
not	I-Claim
late,	I-Claim
response	I-Claim
to	I-Claim
a	I-Claim
multidisciplinary	I-Claim
intervention	I-Claim
to	I-Claim
improve	I-Claim
QOL	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
cancer,	I-Claim
suggesting	O
that	O
early	B-Claim
interventions	I-Claim
can	I-Claim
be	I-Claim
tailored	I-Claim
for	I-Claim
each	I-Claim
gender.	I-Claim

There	O
are	O
few	O
reports	O
about	O
the	O
course	O
of	O
vestibular	O
schwannoma	O
(VS)	O
patients	O
following	O
gamma	O
knife	O
radiosurgery	O
(GKRS)	O
compared	O
with	O
the	O
course	O
following	O
conservative	O
management	O
(CM).	O

In	O
this	O
study,	O
we	O
present	O
prospectively	O
collected	O
data	O
of	O
237	O
patients	O
with	O
unilateral	O
VS	O
extending	O
outside	O
the	O
internal	O
acoustic	O
canal	O
who	O
received	O
either	O
GKRS	O
(113)	O
or	O
CM	O
(124).	O

The	O
aim	O
was	O
to	O
measure	O
the	O
effect	O
of	O
GKRS	O
compared	O
with	O
the	O
natural	O
course	O
on	O
tumor	O
growth	O
rate	O
and	O
hearing	O
loss.	O

Secondary	O
end	O
points	O
were	O
postinclusion	O
additional	O
treatment,	O
quality	O
of	O
life	O
(QoL),	O
and	O
symptom	O
development.	O

The	O
patients	O
underwent	O
magnetic	O
resonance	O
imaging	O
scans,	O
clinical	O
examination,	O
and	O
QoL	O
assessment	O
by	O
SF-36	O
questionnaire.	O

Statistics	O
were	O
performed	O
by	O
using	O
Spearman	O
correlation	O
coefficient,	O
Kaplan-Meier	O
plot,	O
Poisson	O
regression	O
model,	O
mixed	O
linear	O
regression	O
models,	O
and	O
mixed	O
logistic	O
regression	O
models.	O

Mean	O
follow-up	O
time	O
was	O
55.0	O
months	O
(26.1	O
standard	O
deviation,	O
range	O
10-132).	O

Thirteen	O
patients	O
were	O
lost	O
to	O
follow-up.	O

Serviceable	B-Premise
hearing	I-Premise
was	I-Premise
lost	I-Premise
in	I-Premise
54	I-Premise
of	I-Premise
71	I-Premise
(76%)	I-Premise
(CM)	I-Premise
and	I-Premise
34	I-Premise
of	I-Premise
53	I-Premise
(64%)	I-Premise
(GKRS)	I-Premise
patients	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
period	I-Premise
(not	I-Premise
significant,	I-Premise
log-rank	I-Premise
test).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
tumor	I-Premise
volume	I-Premise
over	I-Premise
time	I-Premise
in	I-Premise
the	I-Premise
GKRS	I-Premise
group.	I-Premise

The	B-Premise
need	I-Premise
for	I-Premise
treatment	I-Premise
following	I-Premise
initial	I-Premise
GKRS	I-Premise
or	I-Premise
CM	I-Premise
differed	I-Premise
at	I-Premise
highly	I-Premise
significant	I-Premise
levels	I-Premise
(log-rank	I-Premise
test,	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

Symptom	B-Premise
and	I-Premise
QoL	I-Premise
development	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
between	I-Premise
the	I-Premise
groups.	I-Premise

In	B-Claim
VS	I-Claim
patients,	I-Claim
GKRS	I-Claim
reduces	I-Claim
the	I-Claim
tumor	I-Claim
growth	I-Claim
rate	I-Claim
and	I-Claim
thereby	I-Claim
the	I-Claim
incidence	I-Claim
rate	I-Claim
of	I-Claim
new	I-Claim
treatment	I-Claim
about	I-Claim
tenfold.	I-Claim

Hearing	B-Claim
is	I-Claim
lost	I-Claim
at	I-Claim
similar	I-Claim
rates	I-Claim
in	I-Claim
both	I-Claim
groups.	I-Claim

Symptoms	B-Claim
and	I-Claim
QoL	I-Claim
seem	I-Claim
not	I-Claim
to	I-Claim
be	I-Claim
significantly	I-Claim
affected	I-Claim
by	I-Claim
GKRS.	I-Claim

Patients	O
undergoing	O
gastrectomy	O
because	O
of	O
stomach	O
cancer	O
often	O
face	O
weight	O
loss	O
in	O
the	O
perioperational	O
period,	O
which	O
can	O
lead	O
to	O
malnutrition	O
and	O
negative	O
treatment	O
outcomes.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
patient	O
participation-based	O
dietary	O
intervention	O
(PPDI)	O
and	O
evaluate	O
its	O
effects	O
on	O
patient	O
outcomes.	O

This	O
was	O
a	O
prospective,	O
randomized	O
controlled	O
trial	O
in	O
which	O
the	O
patients	O
were	O
recruited	O
in	O
a	O
cancer	O
center	O
in	O
South	O
Korea.	O

The	O
participants	O
(N	O
=	O
56),	O
who	O
underwent	O
gastrectomy	O
with	O
stomach	O
cancer	O
stage	O
I	O
to	O
III,	O
were	O
randomly	O
assigned	O
into	O
either	O
the	O
experimental	O
or	O
the	O
control	O
group.	O

The	O
PPDI,	O
which	O
was	O
given	O
on	O
the	O
day	O
before	O
the	O
hospital	O
discharge,	O
comprised	O
2	O
face-to-face	O
and	O
2	O
telephone	O
interventions.	O

The	O
outcome	O
variables	O
included	O
body	O
weight,	O
body	O
mass	O
index,	O
muscle	O
mass,	O
the	O
Patient-Generated	O
Subjective	O
Global	O
Assessment,	O
Dietary	O
Symptom	O
Scale,	O
Functional	O
Assessment	O
Cancer	O
Therapy-General,	O
Karnofsky	O
Performance	O
Status,	O
Adherence	O
to	O
Dietary	O
Guidelines	O
Scale,	O
Scale	O
of	O
Dietary	O
Knowledge,	O
Patient	O
Satisfaction	O
Scale,	O
and	O
a	O
3-day	O
food	O
diary.	O

Participants	B-Premise
in	I-Premise
the	I-Premise
PPDI	I-Premise
intervention	I-Premise
demonstrated	I-Premise
significant	I-Premise
(P	I-Premise
<	I-Premise
.05)	I-Premise
reductions	I-Premise
in	I-Premise
adverse	I-Premise
dietary	I-Premise
symptoms	I-Premise
and	I-Premise
significant	I-Premise
improvements	I-Premise
(P	I-Premise
<	I-Premise
.05)	I-Premise
in	I-Premise
functional	I-Premise
status,	I-Premise
performance	I-Premise
status,	I-Premise
dietary	I-Premise
intake,	I-Premise
adherence	I-Premise
to	I-Premise
dietary	I-Premise
guidelines,	I-Premise
dietary	I-Premise
knowledge,	I-Premise
and	I-Premise
satisfaction	I-Premise
with	I-Premise
the	I-Premise
intervention	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
over	I-Premise
time.	I-Premise

The	B-Claim
PPDI	I-Claim
was	I-Claim
an	I-Claim
effective	I-Claim
dietary	I-Claim
intervention	I-Claim
for	I-Claim
patients	I-Claim
undergoing	I-Claim
a	I-Claim
gastrectomy	I-Claim
for	I-Claim
gastric	I-Claim
cancer	I-Claim
and	I-Claim
deserves	I-Claim
additional	I-Claim
study	I-Claim
in	I-Claim
other	I-Claim
populations	I-Claim
of	I-Claim
patients.	I-Claim

Incorporating	B-Claim
patients'	I-Claim
perspectives	I-Claim
into	I-Claim
a	I-Claim
dietary	I-Claim
intervention	I-Claim
after	I-Claim
gastrectomy	I-Claim
for	I-Claim
gastric	I-Claim
cancer	I-Claim
may	I-Claim
contribute	I-Claim
to	I-Claim
improved	I-Claim
patient	I-Claim
outcomes	I-Claim
and	I-Claim
quality	I-Claim
care.	I-Claim

There	O
will	O
be	O
a	O
detectable	O
increase	O
in	O
overall	O
survival	O
(OS)	O
using	O
preoperative	O
(PRE)	O
as	O
opposed	O
to	O
perioperative	O
(PERI)	O
chemotherapy	O
in	O
resectable	O
StageI-II	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

This	O
multicenter,	O
open-label,	O
randomised	O
trial	O
with	O
a	O
2×2	O
factorial	O
design	O
first	O
compared	O
two	O
chemotherapy	O
strategies	O
(PRE	O
versus	O
PERI),	O
then	O
two	O
chemotherapy	O
regimens	O
(gemcitabine-cisplatin	O
[GP]	O
versus	O
paclitaxel-carboplatin	O
[TC]).	O

The	O
PRE	O
group	O
received	O
two	O
preoperative	O
cycles	O
followed	O
by	O
two	O
additional	O
preoperative	O
cycles,	O
while	O
the	O
PERI	O
group	O
underwent	O
two	O
preoperative	O
cycles	O
followed	O
by	O
two	O
postoperative	O
cycles,	O
the	O
3rd	O
and	O
4th	O
cycles	O
being	O
given	O
only	O
to	O
responders	O
in	O
both	O
cases.	O

A	O
total	O
of	O
528	O
patients	O
were	O
randomised,	O
267	O
of	O
which	O
were	O
assigned	O
to	O
the	O
PRE	O
group	O
and	O
261	O
to	O
the	O
PERI	O
group.	O

Three-year	O
OS	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
(67.4%	O
and	O
67.7%,	O
respectively;	O
hazard	O
ratio	O
(HR)=1.01	O
[0.79-1.30],	O
p=0.92),	O
nor	O
did	O
3-year	O
disease-free	O
survival,	O
response	O
rates,	O
toxicity,	O
or	O
postoperative	O
mortality.	O

Pathological	B-Premise
complete	I-Premise
response	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
22	I-Premise
(8.2%)	I-Premise
and	I-Premise
16	I-Premise
patients	I-Premise
(6.1%),	I-Premise
respectively.	I-Premise

Although	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly,	I-Premise
chemotherapy	B-Premise
compliance	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
PRE	I-Premise
group.	I-Premise

The	B-Premise
proportion	I-Premise
of	I-Premise
responders	I-Premise
who	I-Premise
received	I-Premise
Cycles	I-Premise
3	I-Premise
and	I-Premise
4	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
PRE	I-Premise
group	I-Premise
(90.4%	I-Premise
versus	I-Premise
75.2%,	I-Premise
p=0.001).	I-Premise

In	B-Premise
responders,	I-Premise
the	I-Premise
dose	I-Premise
intensity	I-Premise
of	I-Premise
Cycles	I-Premise
3	I-Premise
and	I-Premise
4	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
PRE	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
PERI	I-Premise
group	I-Premise
(mean	I-Premise
relative	I-Premise
dose	I-Premise
intensity	I-Premise
of	I-Premise
90.4%	I-Premise
versus	I-Premise
82.6%,	I-Premise
respectively;	I-Premise
p=0.0007).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
between	I-Premise
GP	I-Premise
and	I-Premise
TC	I-Premise
in	I-Premise
3-year	I-Premise
OS	I-Premise
(HR=0.97	I-Premise
[95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI):	I-Premise
0.76-1.25],	I-Premise
p=0.80)	I-Premise
or	I-Premise
response	I-Premise
rates.	I-Premise

However,	O
the	B-Premise
regimens'	I-Premise
toxicity	I-Premise
profiles	I-Premise
differed.	I-Premise

This	B-Claim
study	I-Claim
failed	I-Claim
to	I-Claim
demonstrate	I-Claim
any	I-Claim
difference	I-Claim
in	I-Claim
survival	I-Claim
between	I-Claim
patients	I-Claim
receiving	I-Claim
preoperative	I-Claim
and	I-Claim
perioperative	I-Claim
chemotherapy	I-Claim
in	I-Claim
early-stage	I-Claim
NSCLC.	I-Claim

The	B-Claim
increase	I-Claim
from	I-Claim
two	I-Claim
to	I-Claim
four	I-Claim
preoperative	I-Claim
chemotherapy	I-Claim
cycles	I-Claim
did	I-Claim
not	I-Claim
increase	I-Claim
the	I-Claim
pathological	I-Claim
response	I-Claim
rate.	I-Claim

This	O
study	O
aims	O
to	O
evaluate	O
the	O
feasibility	O
and	O
efficacy	O
of	O
an	O
8-week	O
supervised	O
exercise	O
program	O
in	O
de-conditioned	O
cancer	O
survivors	O
within	O
2-6	O
months	O
of	O
chemotherapy	O
completion.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
an	O
8-week,	O
twice-weekly,	O
supervised	O
aerobic	O
exercise	O
training	O
regime	O
(n	O
=	O
23)	O
or	O
a	O
usual	O
care	O
group	O
(n	O
=	O
20).	O

Feasibility	O
was	O
assessed	O
by	O
recruitment	O
rate,	O
program	O
adherence	O
and	O
participant	O
feedback.	O

The	O
primary	O
outcome	O
was	O
aerobic	O
fitness	O
assessed	O
by	O
the	O
Modified	O
Bruce	O
fitness	O
test	O
at	O
baseline	O
(0	O
weeks),	O
post-intervention	O
(8	O
weeks)	O
and	O
at	O
3-month	O
follow-up.	O

Secondary	O
outcomes	O
included	O
physical	O
activity,	O
waist	O
circumference,	O
fatigue	O
and	O
quality	O
of	O
life.	O

The	O
recruitment	O
rate	O
was	O
81	O
%	O
and	O
adherence	O
to	O
the	O
supervised	O
exercise	O
was	O
78.3	O
%.	O

Meaningful	B-Premise
differences	I-Premise
in	I-Premise
aerobic	I-Premise
fitness	I-Premise
between	I-Premise
the	I-Premise
exercise	I-Premise
and	I-Premise
usual	I-Premise
care	I-Premise
groups	I-Premise
at	I-Premise
both	I-Premise
the	I-Premise
8-week	I-Premise
[mean	I-Premise
3.0	I-Premise
mL	I-Premise
kg(-1)	I-Premise
min(-1)	I-Premise
(95	I-Premise
%	I-Premise
CI	I-Premise
-1.1-7.0)]	I-Premise
and	I-Premise
3-month	I-Premise
follow-up	I-Premise
[2.1	I-Premise
mL	I-Premise
kg(-1)	I-Premise
min(-1)	I-Premise
(-2.3-6.6)]	I-Premise
were	I-Premise
found,	I-Premise
although	B-Premise
these	I-Premise
differences	I-Premise
did	I-Premise
not	I-Premise
achieve	I-Premise
statistical	I-Premise
significance	I-Premise
(p	I-Premise
values	I-Premise
>0.14).	I-Premise

Self-reported	B-Premise
physical	I-Premise
activity	I-Premise
increased	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group	I-Premise
(EG)	I-Premise
compared	I-Premise
to	I-Premise
the	I-Premise
usual	I-Premise
care	I-Premise
group	I-Premise
at	I-Premise
both	I-Premise
8-week	I-Premise
(p	I-Premise
=	I-Premise
0.01)	I-Premise
and	I-Premise
3-month	I-Premise
follow-up	I-Premise
(p	I-Premise
=	I-Premise
0.03)	I-Premise
and	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
EG	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
physical	I-Premise
well-being	I-Premise
at	I-Premise
both	I-Premise
the	I-Premise
8-week	I-Premise
(p	I-Premise
=	I-Premise
0.03)	I-Premise
and	I-Premise
3-month	I-Premise
follow-up	I-Premise
(p	I-Premise
=	I-Premise
0.04).	I-Premise

Improvements	B-Premise
in	I-Premise
fatigue	I-Premise
(p	I-Premise
=	I-Premise
0.01),	I-Premise
total	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
plus	I-Premise
fatigue	I-Premise
(p	I-Premise
=	I-Premise
0.04),	I-Premise
and	I-Premise
a	I-Premise
composite	I-Premise
physical	I-Premise
functioning	I-Premise
score	I-Premise
(p	I-Premise
=	I-Premise
0.01)	I-Premise
at	I-Premise
the	I-Premise
3-month	I-Premise
follow-up	I-Premise
were	I-Premise
also	I-Premise
found.	I-Premise

The	B-Claim
PEACH	I-Claim
trial	I-Claim
suggests	I-Claim
that	I-Claim
8	I-Claim
weeks	I-Claim
of	I-Claim
supervised	I-Claim
aerobic	I-Claim
exercise	I-Claim
training	I-Claim
was	I-Claim
feasible	I-Claim
and	I-Claim
may	I-Claim
improve	I-Claim
aerobic	I-Claim
fitness,	I-Claim
fatigue	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
de-conditioned	I-Claim
cancer	I-Claim
survivors	I-Claim
during	I-Claim
the	I-Claim
early	I-Claim
survivorship	I-Claim
phase.	I-Claim

Exercise	B-Claim
interventions	I-Claim
commenced	I-Claim
in	I-Claim
the	I-Claim
early	I-Claim
survivorship	I-Claim
phase	I-Claim
appear	I-Claim
safe,	I-Claim
feasible	I-Claim
and	I-Claim
may	I-Claim
lead	I-Claim
to	I-Claim
improvements	I-Claim
in	I-Claim
QOL	I-Claim
and	I-Claim
fatigue.	I-Claim

There	O
is	O
a	O
paucity	O
of	O
methodologically	O
robust	O
vocational	O
rehabilitation	O
(VR)	O
intervention	O
trials.	O

This	O
study	O
assessed	O
the	O
feasibility	O
and	O
acceptability	O
of	O
a	O
VR	O
trial	O
of	O
women	O
with	O
breast	O
cancer	O
to	O
inform	O
the	O
development	O
of	O
a	O
larger	O
interventional	O
study.	O

Women	O
were	O
recruited	O
in	O
Scotland	O
and	O
randomised	O
to	O
either	O
a	O
case	O
management	O
VR	O
service	O
or	O
to	O
usual	O
care.	O

Data	O
were	O
collected	O
on	O
eligibility,	O
recruitment	O
and	O
attrition	O
rates	O
to	O
assess	O
trial	O
feasibility,	O
and	O
interviews	O
conducted	O
to	O
determine	O
trial	O
acceptability.	O

Sick	O
leave	O
days	O
(primary	O
outcome)	O
were	O
self-reported	O
via	O
postal	O
questionnaire	O
every	O
4	O
weeks	O
during	O
the	O
first	O
6	O
months	O
post-surgery	O
and	O
at	O
12	O
months.	O

Secondary	O
outcome	O
measures	O
were	O
change	O
in	O
employment	O
pattern,	O
quality	O
of	O
life	O
and	O
fatigue.	O

Of	O
the	O
1,114	O
women	O
assessed	O
for	O
eligibility,	O
163	O
(15%)	O
were	O
eligible.	O

The	O
main	O
reason	O
for	O
ineligibility	O
was	O
age	O
(>65	O
years,	O
n	O
=	O
637,	O
67%).	O

Of	O
those	O
eligible,	O
111	O
(68%)	O
received	O
study	O
information,	O
of	O
which	O
23	O
(21%)	O
consented	O
to	O
participate	O
in	O
the	O
study.	O

Data	O
for	O
18	O
(78%)	O
women	O
were	O
analysed	O
(intervention:	O
n	O
=	O
7;	O
control:	O
n	O
=	O
11).	O

Participants	B-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
reported,	I-Premise
on	I-Premise
average,	I-Premise
53	I-Premise
fewer	I-Premise
days	I-Premise
of	I-Premise
sick	I-Premise
leave	I-Premise
over	I-Premise
the	I-Premise
first	I-Premise
6	I-Premise
months	I-Premise
post-surgery	I-Premise
than	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group;	I-Premise
however,	B-Premise
this	I-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(p	I-Premise
=	I-Premise
0.122;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
-15.8,	I-Premise
122.0).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
secondary	I-Premise
outcomes.	I-Premise

Interviews	B-Premise
with	I-Premise
trial	I-Premise
participants	I-Premise
indicated	I-Premise
that	I-Premise
trial	I-Premise
procedures,	I-Premise
including	I-Premise
recruitment,	I-Premise
randomisation	I-Premise
and	I-Premise
research	I-Premise
instruments,	I-Premise
were	I-Premise
acceptable.	I-Premise

Conducting	B-Claim
a	I-Claim
pragmatic	I-Claim
trial	I-Claim
of	I-Claim
effectiveness	I-Claim
of	I-Claim
a	I-Claim
VR	I-Claim
intervention	I-Claim
among	I-Claim
cancer	I-Claim
survivors	I-Claim
is	I-Claim
both	I-Claim
feasible	I-Claim
and	I-Claim
acceptable,	I-Claim
but	B-Claim
more	I-Claim
research	I-Claim
about	I-Claim
the	I-Claim
exact	I-Claim
components	I-Claim
of	I-Claim
a	I-Claim
VR	I-Claim
intervention	I-Claim
and	I-Claim
choice	I-Claim
of	I-Claim
outcomes	I-Claim
to	I-Claim
measure	I-Claim
effectiveness	I-Claim
is	I-Claim
required.	I-Claim

VR	B-Claim
to	I-Claim
assist	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
in	I-Claim
the	I-Claim
return	I-Claim
to	I-Claim
work	I-Claim
process	I-Claim
is	I-Claim
an	I-Claim
important	I-Claim
component	I-Claim
of	I-Claim
cancer	I-Claim
survivorship	I-Claim
plans.	I-Claim

Capecitabine/taxane	O
combinations	O
are	O
highly	O
active	O
in	O
metastatic	O
breast	O
cancer	O
(MBC).	O

We	O
conducted	O
a	O
randomized,	O
phase	O
III,	O
noninferiority	O
trial	O
comparing	O
capecitabine	O
plus	O
paclitaxel	O
(XP)	O
with	O
epirubicin	O
plus	O
paclitaxel	O
(EP)	O
as	O
first-line	O
therapy	O
for	O
MBC,	O
regarding	O
progression-free	O
survival	O
(PFS)	O
as	O
primary	O
efficacy	O
endpoint.	O

Females	O
who	O
had	O
received	O
no	O
prior	O
chemotherapy	O
for	O
MBC	O
were	O
randomized	O
to	O
six	O
3-weekly	O
cycles	O
of	O
XP	O
(capecitabine	O
1000	O
mg/m(2)	O
b.i.d.,	O
days	O
1-14;	O
paclitaxel	O
175	O
mg/m(2)	O
3-h	O
infusion,	O
day	O
1)	O
or	O
EP	O
(epirubicin	O
60	O
mg/m(2)	O
1-h	O
infusion,	O
day	O
1;	O
paclitaxel	O
as	O
above).	O

Secondary	O
endpoints	O
included	O
response	O
rate,	O
overall	O
survival,	O
tolerability,	O
and	O
quality	O
of	O
life	O
(QoL).	O

Each	O
arm	O
included	O
170	O
patients,	O
most	O
of	O
whom	O
received	O
all	O
six	O
cycles	O
as	O
planned.	O

The	O
difference	O
in	O
means	O
of	O
(logarithmic)	O
PFS	O
times	O
(-0.205)	O
did	O
not	O
meet	O
the	O
pre-defined	O
level	O
for	O
noninferiority	O
(-0.186).	O

However,	O
PFS	B-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
arms	I-Premise
[HR:	I-Premise
XP	I-Premise
vs.	I-Premise
EP:	I-Premise
1.012	I-Premise
(95	I-Premise
%	I-Premise
CI	I-Premise
0.785-1.304);	I-Premise
median	I-Premise
10.4	I-Premise
months	I-Premise
XP	I-Premise
vs.	I-Premise
9.2	I-Premise
months	I-Premise
EP].	I-Premise

Overall	B-Premise
survival	I-Premise
was	I-Premise
also	I-Premise
similar	I-Premise
[HR	I-Premise
1.027	I-Premise
(95	I-Premise
%	I-Premise
CI	I-Premise
0.740-1.424);	I-Premise
median	I-Premise
22.0	I-Premise
vs.	I-Premise
26.1	I-Premise
months],	I-Premise
and	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
47	I-Premise
%	I-Premise
versus	I-Premise
42	I-Premise
%.	I-Premise

Both	B-Premise
regimens	I-Premise
were	I-Premise
tolerable:	I-Premise
there	I-Premise
were	I-Premise
more	I-Premise
grade	I-Premise
3/4	I-Premise
diarrhea	I-Premise
and	I-Premise
grade	I-Premise
3	I-Premise
hand-foot	I-Premise
syndromes	I-Premise
with	I-Premise
XP	I-Premise
and	I-Premise
more	I-Premise
grade	I-Premise
3/4	I-Premise
hematologic	I-Premise
toxicities	I-Premise
with	I-Premise
EP.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
major	I-Premise
differences	I-Premise
in	I-Premise
QoL.	I-Premise

Although,	B-Claim
noninferiority	I-Claim
of	I-Claim
XP	I-Claim
to	I-Claim
EP	I-Claim
was	I-Claim
formally	I-Claim
not	I-Claim
proven,	I-Claim
first-line	B-Claim
XP	I-Claim
was	I-Claim
active	I-Claim
and	I-Claim
feasible.	I-Claim

XP	B-Claim
is	I-Claim
a	I-Claim
valid	I-Claim
first-line	I-Claim
alternative	I-Claim
to	I-Claim
anthracycline/taxane	I-Claim
regimens,	I-Claim
especially	I-Claim
in	I-Claim
patients	I-Claim
previously	I-Claim
treated	I-Claim
with	I-Claim
adjuvant	I-Claim
anthracyclines.	I-Claim

Major	O
depressive	O
disorder	O
develops	O
in	O
up	O
to	O
half	O
the	O
patients	O
undergoing	O
treatment	O
for	O
head	O
and	O
neck	O
cancer,	O
resulting	O
in	O
significant	O
morbidity;	O
therefore,	O
preventing	O
depression	O
during	O
cancer	O
treatment	O
may	O
be	O
of	O
great	O
benefit.	O

To	O
determine	O
whether	O
prophylactic	O
use	O
of	O
the	O
antidepressant	O
escitalopram	O
oxalate	O
would	O
decrease	O
the	O
incidence	O
of	O
depression	O
in	O
patients	O
receiving	O
primary	O
therapy	O
for	O
head	O
and	O
neck	O
cancer.	O

A	O
randomized,	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
escitalopram	O
vs	O
placebo	O
was	O
conducted	O
in	O
a	O
group	O
of	O
nondepressed	O
patients	O
diagnosed	O
as	O
having	O
head	O
and	O
neck	O
cancer	O
who	O
were	O
about	O
to	O
enter	O
cancer	O
treatment.	O

Patients	O
were	O
stratified	O
by	O
sex,	O
site,	O
stage	O
(early	O
vs	O
advanced),	O
and	O
primary	O
modality	O
of	O
treatment	O
(radiation	O
vs	O
surgery).	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
participants	O
who	O
developed	O
moderate	O
or	O
greater	O
depression	O
(scores	O
on	O
the	O
Quick	O
Inventory	O
of	O
Depressive	O
Symptomology-Self	O
Rated	O
of	O
≥11).	O

From	O
January	O
6,	O
2008,	O
to	O
December	O
28,	O
2011,	O
148	O
patients	O
were	O
randomized.	O

Significantly	B-Premise
fewer	I-Premise
patients	I-Premise
receiving	I-Premise
escitalopram	I-Premise
developed	I-Premise
depression	I-Premise
(24.6%	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
vs	I-Premise
10.0%	I-Premise
in	I-Premise
the	I-Premise
escitalopram	I-Premise
group;	I-Premise
stratified	I-Premise
log-rank	I-Premise
test,	I-Premise
P	I-Premise
=	I-Premise
.04).	I-Premise

A	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
compared	O
the	O
2	O
treatment	O
groups	O
after	O
controlling	O
for	O
age,	O
baseline	O
smoking	O
status,	O
and	O
stratification	O
variables.	O

The	B-Premise
hazard	I-Premise
ratio	I-Premise
of	I-Premise
0.37	I-Premise
(95%	I-Premise
CI,	I-Premise
0.14-0.96)	I-Premise
demonstrated	I-Premise
an	I-Premise
advantage	I-Premise
of	I-Premise
escitalopram	I-Premise
(P	I-Premise
=	I-Premise
.04).	I-Premise

Patients	B-Premise
undergoing	I-Premise
radiotherapy	I-Premise
as	I-Premise
the	I-Premise
initial	I-Premise
modality	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
develop	I-Premise
depression	I-Premise
than	I-Premise
those	I-Premise
undergoing	I-Premise
surgery	I-Premise
(radiotherapy	I-Premise
compared	I-Premise
with	I-Premise
surgery	I-Premise
group;	I-Premise
hazard	I-Premise
ratio,	I-Premise
3.6;	I-Premise
95%	I-Premise
CI,	I-Premise
1.38-9.40;	I-Premise
P	I-Premise
=	I-Premise
.009).	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
escitalopram	I-Premise
group	I-Premise
who	I-Premise
completed	I-Premise
the	I-Premise
study	I-Premise
and	I-Premise
were	I-Premise
not	I-Premise
depressed	I-Premise
rated	I-Premise
their	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
as	I-Premise
significantly	I-Premise
better	I-Premise
for	I-Premise
3	I-Premise
consecutive	I-Premise
months	I-Premise
after	I-Premise
cessation	I-Premise
of	I-Premise
drug	I-Premise
use.	I-Premise

In	B-Claim
nondepressed	I-Claim
patients	I-Claim
undergoing	I-Claim
treatment	I-Claim
for	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer,	I-Claim
prophylactic	I-Claim
escitalopram	I-Claim
reduced	I-Claim
the	I-Claim
risk	I-Claim
of	I-Claim
developing	I-Claim
depression	I-Claim
by	I-Claim
more	I-Claim
than	I-Claim
50%.	I-Claim

In	B-Claim
nondepressed	I-Claim
patients	I-Claim
who	I-Claim
completed	I-Claim
the	I-Claim
trial,	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
was	I-Claim
also	I-Claim
significantly	I-Claim
better	I-Claim
for	I-Claim
3	I-Claim
consecutive	I-Claim
months	I-Claim
after	I-Claim
cessation	I-Claim
of	I-Claim
drug	I-Claim
use	I-Claim
in	I-Claim
the	I-Claim
escitalopram	I-Claim
group.	I-Claim

These	B-Claim
findings	I-Claim
have	I-Claim
important	I-Claim
implications	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer.	I-Claim

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
laparoscopy-assisted	O
distal	O
gastrectomy	O
(LADG)	O
compared	O
to	O
open	O
distal	O
gastrectomy	O
(ODG)	O
in	O
the	O
treatment	O
of	O
early	O
gastric	O
cancer	O
with	O
respect	O
to	O
survival,	O
surgical	O
outcomes,	O
complications,	O
and	O
quality	O
of	O
life	O
(QOL).	O

One	O
hundred	O
sixty-four	O
patients	O
with	O
cT1N0M0	O
and	O
cT1N1M0	O
distal	O
gastric	O
cancer	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
LADG	O
group	O
or	O
the	O
ODG	O
group.	O

The	O
primary	O
end	O
point	O
was	O
the	O
5-year	O
disease-free	O
survival	O
(DFS)	O
rate.	O

Complications	O
were	O
classified	O
using	O
the	O
accordion	O
severity	O
classification	O
of	O
postoperative	O
complications	O
scheme.	O

QOL	O
was	O
measured	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
QLQ-C30	O
and	O
QLQ-STO22	O
preoperatively	O
and	O
postoperatively	O
during	O
regular	O
follow-up	O
visits.	O

This	O
trial	O
is	O
registered	O
at	O
ClinicalTrials.gov.	O

The	O
median	O
(range)	O
follow-up	O
period	O
was	O
74.3	O
(24.8-90.8)	O
months.	O

The	B-Premise
LADG	I-Premise
and	I-Premise
ODG	I-Premise
groups	I-Premise
showed	I-Premise
similar	I-Premise
survival	I-Premise
[5-year	I-Premise
DFS	I-Premise
rate:	I-Premise
98.8	I-Premise
%	I-Premise
vs.	I-Premise
97.6	I-Premise
%,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.514),	I-Premise
5-year	I-Premise
overall	I-Premise
survival	I-Premise
(OS)	I-Premise
rate:	I-Premise
97.6	I-Premise
vs.	I-Premise
96.3	I-Premise
%,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
0.721)]	I-Premise
or	I-Premise
overall	I-Premise
complication	I-Premise
rate	I-Premise
(29.3	I-Premise
vs.	I-Premise
42.7	I-Premise
%,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
0.073).	I-Premise

Mild	B-Premise
complications	I-Premise
were	I-Premise
significantly	I-Premise
less	I-Premise
frequent	I-Premise
in	I-Premise
the	I-Premise
LADG	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
ODG	I-Premise
group	I-Premise
(23.2	I-Premise
vs.	I-Premise
41.5	I-Premise
%;	I-Premise
P	I-Premise
=	I-Premise
0.012).	I-Premise

The	B-Premise
rates	I-Premise
of	I-Premise
moderate,	I-Premise
severe,	I-Premise
and	I-Premise
long-term	I-Premise
complications	I-Premise
(i.e.,	I-Premise
31	I-Premise
days	I-Premise
to	I-Premise
5	I-Premise
years	I-Premise
after	I-Premise
surgery)	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
between	I-Premise
groups.	I-Premise

No	B-Premise
clinically	I-Premise
meaningful	I-Premise
differences	I-Premise
were	I-Premise
detected	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
in	I-Premise
long-term	I-Premise
QOL.	I-Premise

LADG	B-Claim
showed	I-Claim
similar	I-Claim
DFS	I-Claim
and	I-Claim
OS	I-Claim
compared	I-Claim
to	I-Claim
ODG	I-Claim
in	I-Claim
treating	I-Claim
early	I-Claim
gastric	I-Claim
cancer.	I-Claim

Marginal	B-Claim
benefits	I-Claim
in	I-Claim
mild	I-Claim
complications	I-Claim
were	I-Claim
observed	I-Claim
with	I-Claim
LADG.	I-Claim

LADG	B-Claim
did	I-Claim
not	I-Claim
show	I-Claim
advantages	I-Claim
over	I-Claim
ODG	I-Claim
regarding	I-Claim
other	I-Claim
complications	I-Claim
and	I-Claim
long-term	I-Claim
QOL.	I-Claim

To	O
examine	O
the	O
impact	O
of	O
advanced	O
practice	O
nurse	O
(APN)-administered	O
low-level	O
laser	O
therapy	O
(LLLT)	O
as	O
both	O
a	O
stand-alone	O
and	O
complementary	O
treatment	O
for	O
arm	O
volume,	O
symptoms,	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
women	O
with	O
breast	O
cancer-related	O
lymphedema.	O

A	O
three-group,	O
pilot,	O
randomized	O
clinical	O
trial.	O

A	O
private	O
rehabilitation	O
practice	O
in	O
the	O
southeastern	O
United	O
States.	O

46	O
breast	O
cancer	O
survivors	O
with	O
treatment-related	O
lymphedema.	O

Patients	O
were	O
screened	O
for	O
eligibility	O
and	O
then	O
randomized	O
to	O
either	O
manual	O
lymphatic	O
drainage	O
(MLD)	O
for	O
40	O
minutes,	O
LLLT	O
for	O
20	O
minutes,	O
or	O
20	O
minutes	O
of	O
MLD	O
followed	O
by	O
20	O
minutes	O
of	O
LLLT.	O

Compression	O
bandaging	O
was	O
applied	O
after	O
each	O
treatment.	O

Data	O
were	O
collected	O
pretreatment,	O
daily,	O
weekly,	O
and	O
at	O
the	O
end	O
of	O
treatment.	O

Independent	O
variables	O
consisted	O
of	O
three	O
types	O
of	O
APN-administered	O
lymphedema	O
treatment.	O

Outcome	O
variables	O
included	O
limb	O
volume,	O
extracellular	O
fluid,	O
psychological	O
and	O
physical	O
symptoms,	O
and	O
QOL.	O

No	B-Premise
statistically	I-Premise
significant	I-Premise
between-group	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
volume	I-Premise
reduction;	I-Premise
however,	B-Premise
all	I-Premise
groups	I-Premise
had	I-Premise
clinically	I-Premise
and	I-Premise
statistically	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
volume.	I-Premise

No	B-Premise
group	I-Premise
differences	I-Premise
were	I-Premise
noted	I-Premise
in	I-Premise
psychological	I-Premise
and	I-Premise
physical	I-Premise
symptoms	I-Premise
or	I-Premise
QOL;	I-Premise
however,	B-Premise
treatment-related	I-Premise
improvements	I-Premise
were	I-Premise
noted	I-Premise
in	I-Premise
symptom	I-Premise
burden	I-Premise
within	I-Premise
all	I-Premise
groups.	I-Premise

Skin	B-Premise
improvement	I-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
each	I-Premise
group	I-Premise
that	I-Premise
received	I-Premise
LLLT.	I-Premise

LLLT	B-Claim
with	I-Claim
bandaging	I-Claim
may	I-Claim
offer	I-Claim
a	I-Claim
time-saving	I-Claim
therapeutic	I-Claim
option	I-Claim
to	I-Claim
conventional	I-Claim
MLD.	I-Claim

Alternatively,	O
compression	B-Claim
bandaging	I-Claim
alone	I-Claim
could	I-Claim
account	I-Claim
for	I-Claim
the	I-Claim
demonstrated	I-Claim
volume	I-Claim
reduction.	I-Claim

APNs	B-Claim
can	I-Claim
effectively	I-Claim
treat	I-Claim
lymphedema.	I-Claim

APNs	O
in	O
private	O
healthcare	O
practices	O
can	O
serve	O
as	O
valuable	O
research	O
collaborators.	O

Lasers	B-Claim
may	I-Claim
provide	I-Claim
effective,	I-Claim
less	I-Claim
burdensome	I-Claim
treatment	I-Claim
for	I-Claim
lymphedema.	I-Claim

APNs	B-Claim
with	I-Claim
lymphedema	I-Claim
certification	I-Claim
can	I-Claim
effectively	I-Claim
treat	I-Claim
this	I-Claim
patient	I-Claim
population	I-Claim
with	I-Claim
the	I-Claim
use	I-Claim
of	I-Claim
LLLT.	I-Claim

In	O
addition,	O
bioelectrical	B-Claim
impedance	I-Claim
and	I-Claim
tape	I-Claim
measurements	I-Claim
can	I-Claim
be	I-Claim
used	I-Claim
to	I-Claim
assess	I-Claim
lymphedema.	I-Claim

This	O
study	O
aims	O
to	O
describe	O
and	O
compare	O
health-related	O
quality	O
of	O
life	O
(HRQL)	O
in	O
patients	O
with	O
node-positive	O
and	O
high-risk	O
node-negative	O
HER2-positive	O
early	O
breast	O
cancer	O
receiving	O
adjuvant	O
docetaxel	O
and	O
trastuzumab-based	O
or	O
docetaxel-based	O
regimens	O
alone.	O

Eligible	O
patients	O
(n	O
=	O
3,222)	O
were	O
randomly	O
assigned	O
to	O
either	O
four	O
cycles	O
of	O
adjuvant	O
doxorubicin	O
and	O
cyclophosphamide	O
followed	O
by	O
four	O
cycles	O
of	O
docetaxel	O
(AC→T)	O
or	O
one	O
of	O
two	O
trastuzumab-containing	O
regimens:	O
adjuvant	O
doxorubicin	O
and	O
cyclophosphamide	O
followed	O
by	O
docetaxel	O
plus	O
trastuzumab	O
administered	O
for	O
1	O
year	O
(AC→TH)	O
or	O
six	O
cycles	O
of	O
docetaxel	O
plus	O
carboplatin	O
combined	O
with	O
trastuzumab	O
administered	O
for	O
1	O
year	O
(TCH).	O

The	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
and	O
BR-23	O
were	O
administered	O
at	O
baseline,	O
the	O
start	O
of	O
cycle	O
4	O
(mid),	O
and	O
the	O
end	O
of	O
chemotherapy	O
(EOC),	O
as	O
well	O
as	O
at	O
6,	O
12,	O
and	O
24	O
months	O
after	O
chemotherapy.	O

Compliance	B-Premise
rates	I-Premise
for	I-Premise
the	I-Premise
EORTC	I-Premise
questionnaires	I-Premise
were	I-Premise
acceptable	I-Premise
at	I-Premise
72%-93%	I-Premise
of	I-Premise
eligible	I-Premise
patients	I-Premise
out	I-Premise
to	I-Premise
the	I-Premise
12-month	I-Premise
assessment.	I-Premise

Systemic	B-Premise
side	I-Premise
effect	I-Premise
(SE)	I-Premise
change	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
improved	I-Premise
for	I-Premise
TCH-treated	I-Premise
patients	I-Premise
compared	I-Premise
with	I-Premise
AC→TH	I-Premise
and	I-Premise
AC→T	I-Premise
at	I-Premise
EOC,	I-Premise
suggesting	I-Premise
improved	I-Premise
tolerability.	I-Premise

Physical	B-Premise
functioning	I-Premise
(PF)	I-Premise
was	I-Premise
only	I-Premise
slightly	I-Premise
worse	I-Premise
at	I-Premise
midpoint	I-Premise
for	I-Premise
those	I-Premise
receiving	I-Premise
TCH,	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
who	I-Premise
were	I-Premise
just	I-Premise
starting	I-Premise
on	I-Premise
taxane	I-Premise
in	I-Premise
an	I-Premise
AC→TH	I-Premise
regimen,	I-Premise
but	I-Premise
was	I-Premise
otherwise	I-Premise
similar	I-Premise
between	I-Premise
arms.	I-Premise

All	B-Claim
treatment	I-Claim
arms	I-Claim
recovered	I-Claim
from	I-Claim
the	I-Claim
deterioration	I-Claim
in	I-Claim
SE,	I-Claim
PF,	I-Claim
and	I-Claim
Global	I-Claim
Health	I-Claim
Scale	I-Claim
scores	I-Claim
by	I-Claim
1	I-Claim
year	I-Claim
and	I-Claim
median	I-Claim
future	I-Claim
perspective	I-Claim
change	I-Claim
scores	I-Claim
continued	I-Claim
to	I-Claim
improve	I-Claim
throughout	I-Claim
treatment	I-Claim
and	I-Claim
follow-up.	I-Claim

HRQL	B-Claim
outcomes	I-Claim
for	I-Claim
adjuvant	I-Claim
docetaxel	I-Claim
and	I-Claim
trastuzumab-based	I-Claim
regimens	I-Claim
are	I-Claim
favorable	I-Claim
and	I-Claim
support	I-Claim
TCH	I-Claim
as	I-Claim
a	I-Claim
more	I-Claim
tolerable	I-Claim
treatment	I-Claim
option.	I-Claim

Patient-reported	O
symptoms	O
and	O
health-related	O
quality	O
of	O
life	O
(QoL)	O
benefits	O
were	O
investigated	O
in	O
a	O
randomized,	O
phase	O
III	O
trial	O
of	O
afatinib	O
or	O
cisplatin/pemetrexed.	O

Three	O
hundred	O
forty-five	O
patients	O
with	O
advanced	O
epidermal	O
growth	O
factor	O
receptor	O
(EGFR)	O
mutation-positive	O
lung	O
adenocarcinoma	O
were	O
randomly	O
assigned	O
2:1	O
to	O
afatinib	O
40	O
mg	O
per	O
day	O
or	O
up	O
to	O
six	O
cycles	O
of	O
cisplatin/pemetrexed.	O

Lung	O
cancer	O
symptoms	O
and	O
health-related	O
QoL	O
were	O
assessed	O
every	O
21	O
days	O
until	O
progression	O
using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
and	O
Lung	O
Cancer-13	O
questionnaires.	O

Analyses	O
of	O
cough,	O
dyspnea,	O
and	O
pain	O
were	O
preplanned,	O
including	O
percentage	O
of	O
patients	O
who	O
improved	O
on	O
therapy,	O
time	O
to	O
deterioration	O
of	O
symptoms,	O
and	O
change	O
in	O
symptoms	O
over	O
time.	O

Questionnaire	O
compliance	O
was	O
high.	O

Compared	B-Premise
with	I-Premise
chemotherapy,	I-Premise
afatinib	I-Premise
significantly	I-Premise
delayed	I-Premise
the	I-Premise
time	I-Premise
to	I-Premise
deterioration	I-Premise
for	I-Premise
cough	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.60;	I-Premise
95%	I-Premise
CI,	I-Premise
0.41	I-Premise
to	I-Premise
0.87;	I-Premise
P	I-Premise
=	I-Premise
.007)	I-Premise
and	I-Premise
dyspnea	I-Premise
(HR,	I-Premise
0.68;	I-Premise
95%	I-Premise
CI,	I-Premise
0.50	I-Premise
to	I-Premise
0.93;	I-Premise
P	I-Premise
=	I-Premise
.015),	I-Premise
but	I-Premise
not	I-Premise
pain	I-Premise
(HR,	I-Premise
0.83;	I-Premise
95%	I-Premise
CI,	I-Premise
0.62	I-Premise
to	I-Premise
1.10;	I-Premise
P	I-Premise
=	I-Premise
.19).	I-Premise

More	B-Premise
patients	I-Premise
on	I-Premise
afatinib	I-Premise
(64%)	I-Premise
versus	I-Premise
chemotherapy	I-Premise
(50%)	I-Premise
experienced	I-Premise
improvements	I-Premise
in	I-Premise
dyspnea	I-Premise
scores	I-Premise
(P	I-Premise
=	I-Premise
.010).	I-Premise

Differences	B-Premise
in	I-Premise
mean	I-Premise
scores	I-Premise
over	I-Premise
time	I-Premise
significantly	I-Premise
favored	I-Premise
afatinib	I-Premise
over	I-Premise
chemotherapy	I-Premise
for	I-Premise
cough	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
and	I-Premise
dyspnea	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

Afatinib	B-Premise
showed	I-Premise
significantly	I-Premise
better	I-Premise
mean	I-Premise
scores	I-Premise
over	I-Premise
time	I-Premise
in	I-Premise
global	I-Premise
health	I-Premise
status/QoL	I-Premise
(P	I-Premise
=	I-Premise
.015)	I-Premise
and	I-Premise
physical	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
role	I-Premise
(P	I-Premise
=	I-Premise
.004),	I-Premise
and	I-Premise
cognitive	I-Premise
(P	I-Premise
=	I-Premise
.007)	I-Premise
functioning	I-Premise
compared	I-Premise
with	I-Premise
chemotherapy.	I-Premise

Fatigue	B-Premise
and	I-Premise
nausea	I-Premise
were	I-Premise
worse	I-Premise
with	I-Premise
chemotherapy,	I-Premise
whereas	I-Premise
diarrhea,	I-Premise
dysphagia,	I-Premise
and	I-Premise
sore	I-Premise
mouth	I-Premise
were	I-Premise
worse	I-Premise
with	I-Premise
afatinib	I-Premise
(all	I-Premise
P	I-Premise
<	I-Premise
.01).	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
lung	I-Claim
adenocarcinoma	I-Claim
with	I-Claim
EGFR	I-Claim
mutations,	I-Claim
first-line	I-Claim
afatinib	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
better	I-Claim
control	I-Claim
of	I-Claim
cough	I-Claim
and	I-Claim
dyspnea	I-Claim
compared	I-Claim
with	I-Claim
chemotherapy,	I-Claim
although	I-Claim
diarrhea,	I-Claim
dysphagia,	I-Claim
and	I-Claim
sore	I-Claim
mouth	I-Claim
were	I-Claim
worse.	I-Claim

Global	B-Claim
health	I-Claim
status/QoL	I-Claim
was	I-Claim
also	I-Claim
improved	I-Claim
over	I-Claim
time	I-Claim
with	I-Claim
afatinib	I-Claim
compared	I-Claim
with	I-Claim
chemotherapy.	I-Claim

To	O
compare	O
the	O
health-related	O
quality	O
of	O
life	O
in	O
patients	O
with	O
narrow	O
gastric	O
tube	O
and	O
whole	O
stomach	O
reconstructions	O
after	O
oncologic	O
esophagectomy.	O

In	O
a	O
prospective	O
randomized	O
single-center	O
study	O
from	O
2007	O
to	O
2008,	O
104	O
patients	O
underwent	O
esophagectomy	O
for	O
cancer.	O

To	O
assess	O
health-related	O
quality	O
of	O
life,	O
the	O
questionnaire	O
(European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
Core	O
30	O
and	O
the	O
Oesophagus-Specific	O
Quality	O
of	O
Life	O
Questionnaire	O
18)	O
was	O
administered	O
at	O
3	O
weeks,	O
6	O
months,	O
1	O
year,	O
and	O
2	O
years	O
after	O
surgery.	O

The	B-Premise
perioperative	I-Premise
complication	I-Premise
rate	I-Premise
was	I-Premise
26.9%	I-Premise
in	I-Premise
narrow	I-Premise
gastric	I-Premise
tube	I-Premise
group	I-Premise
and	I-Premise
48.1%	I-Premise
in	I-Premise
whole	I-Premise
stomach	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.31).	I-Premise

At	B-Premise
the	I-Premise
time	I-Premise
of	I-Premise
3	I-Premise
weeks	I-Premise
after	I-Premise
surgery,	I-Premise
the	I-Premise
reflux	I-Premise
and	I-Premise
dyspnea	I-Premise
scores	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
whole	I-Premise
stomach	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
narrow	I-Premise
gastric	I-Premise
tube	I-Premise
group,	I-Premise
which	I-Premise
meant	I-Premise
that	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
whole	I-Premise
stomach	I-Premise
group	I-Premise
suffered	I-Premise
more	I-Premise
severe	I-Premise
problem.	I-Premise

At	B-Premise
the	I-Premise
time	I-Premise
of	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
1	I-Premise
year	I-Premise
after	I-Premise
surgery,	I-Premise
the	I-Premise
reflux	I-Premise
scores	I-Premise
were	I-Premise
lower	I-Premise
in	I-Premise
narrow	I-Premise
gastric	I-Premise
tube	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
whole	I-Premise
stomach	I-Premise
group,	I-Premise
which	I-Premise
revealed	I-Premise
that	I-Premise
there	I-Premise
were	I-Premise
less	I-Premise
problems	I-Premise
of	I-Premise
reflux	I-Premise
in	I-Premise
the	I-Premise
patients	I-Premise
of	I-Premise
narrow	I-Premise
gastric	I-Premise
tube	I-Premise
group;	I-Premise
meanwhile,	O
the	B-Premise
score	I-Premise
of	I-Premise
physical	I-Premise
function	I-Premise
scale	I-Premise
in	I-Premise
narrow	I-Premise
gastric	I-Premise
tube	I-Premise
group	I-Premise
was	I-Premise
higher	I-Premise
conversely,	I-Premise
which	I-Premise
suggested	I-Premise
that	I-Premise
the	I-Premise
patients	I-Premise
gain	I-Premise
a	I-Premise
better	I-Premise
status	I-Premise
in	I-Premise
physical	I-Premise
function.	I-Premise

Nausea	B-Premise
and	I-Premise
vomiting	I-Premise
is	I-Premise
the	I-Premise
only	I-Premise
notable	I-Premise
symptom	I-Premise
that	I-Premise
was	I-Premise
worse	I-Premise
in	I-Premise
whole	I-Premise
stomach	I-Premise
group	I-Premise
at	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
2	I-Premise
years	I-Premise
after	I-Premise
surgery,	I-Premise
which	O
suggested	O
that	O
patients	B-Claim
in	I-Claim
whole	I-Claim
stomach	I-Claim
group	I-Claim
suffered	I-Claim
more	I-Claim
severe	I-Claim
nausea	I-Claim
and	I-Claim
vomiting.	I-Claim

Narrow	B-Claim
gastric	I-Claim
tube	I-Claim
reconstruction	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
good	I-Claim
alternative	I-Claim
choice	I-Claim
for	I-Claim
patients	I-Claim
undergoing	I-Claim
oncologic	I-Claim
esophagectomy	I-Claim
in	I-Claim
view	I-Claim
of	I-Claim
better	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
after	I-Claim
the	I-Claim
surgery.	I-Claim

Delirium	B-Claim
is	I-Claim
a	I-Claim
serious	I-Claim
and	I-Claim
common	I-Claim
postoperative	I-Claim
complication,	I-Claim
especially	O
in	O
frail	O
elderly	O
patients.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
geriatric	O
liaison	O
intervention	O
in	O
comparison	O
with	O
standard	O
care	O
on	O
the	O
incidence	O
of	O
postoperative	O
delirium	O
in	O
frail	O
elderly	O
cancer	O
patients	O
treated	O
with	O
an	O
elective	O
surgical	O
procedure	O
for	O
a	O
solid	O
tumour.	O

Patients	O
over	O
65	O
years	O
of	O
age	O
who	O
were	O
undergoing	O
elective	O
surgery	O
for	O
a	O
solid	O
tumour	O
were	O
recruited	O
to	O
a	O
multicentre,	O
prospective,	O
randomized,	O
controlled	O
trial.	O

The	O
patients	O
were	O
randomized	O
to	O
standard	O
treatment	O
versus	O
a	O
geriatric	O
liaison	O
intervention.	O

The	O
intervention	O
consisted	O
of	O
a	O
preoperative	O
geriatric	O
consultation,	O
an	O
individual	O
treatment	O
plan	O
targeted	O
at	O
risk	O
factors	O
for	O
delirium,	O
daily	O
visits	O
by	O
a	O
geriatric	O
nurse	O
during	O
the	O
hospital	O
stay	O
and	O
advice	O
on	O
managing	O
any	O
problems	O
encountered.	O

The	O
primary	O
outcome	O
was	O
the	O
incidence	O
of	O
postoperative	O
delirium.	O

The	O
secondary	O
outcome	O
measures	O
were	O
the	O
severity	O
of	O
delirium,	O
length	O
of	O
hospital	O
stay,	O
complications,	O
mortality,	O
care	O
dependency,	O
quality	O
of	O
life,	O
return	O
to	O
an	O
independent	O
preoperative	O
living	O
situation	O
and	O
additional	O
care	O
at	O
home.	O

In	O
total,	O
the	O
data	O
of	O
260	O
patients	O
were	O
analysed.	O

Delirium	B-Premise
occurred	I-Premise
in	I-Premise
31	I-Premise
patients	I-Premise
(11.9%),	I-Premise
and	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
incidence	I-Premise
of	I-Premise
delirium	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
and	I-Premise
the	I-Premise
usual-care	I-Premise
group	I-Premise
(9.4%	I-Premise
vs.	I-Premise
14.3%,	I-Premise
OR:	I-Premise
0.63,	I-Premise
95%	I-Premise
CI:	I-Premise
0.29-1.35).	I-Premise

Within	B-Claim
this	I-Claim
study,	I-Claim
a	I-Claim
geriatric	I-Claim
liaison	I-Claim
intervention	I-Claim
based	I-Claim
on	I-Claim
frailty	I-Claim
for	I-Claim
the	I-Claim
prevention	I-Claim
of	I-Claim
postoperative	I-Claim
delirium	I-Claim
in	I-Claim
frail	I-Claim
elderly	I-Claim
cancer	I-Claim
patients	I-Claim
undergoing	I-Claim
elective	I-Claim
surgery	I-Claim
for	I-Claim
a	I-Claim
solid	I-Claim
tumour	I-Claim
has	I-Claim
not	I-Claim
proven	I-Claim
to	I-Claim
be	I-Claim
effective.	I-Claim

The	O
AGO-ETC	O
trial	O
compared	O
5-year	O
relapse-free	O
survival	O
of	O
intense	O
dose-dense	O
(IDD)	O
sequential	O
chemotherapy	O
with	O
epirubicin	O
(E),	O
paclitaxel	O
(T),	O
and	O
cyclophosphamide	O
(C)	O
(IDD-ETC)	O
every	O
2	O
weeks	O
vs	O
conventional	O
scheduled	O
epirubicin/cyclophosphamide	O
followed	O
by	O
paclitaxel	O
(EC→T)	O
(every	O
3	O
weeks)	O
as	O
adjuvant	O
treatment	O
in	O
high-risk	O
breast	O
cancer	O
patients.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
epoetin	O
alfa	O
in	O
a	O
second	O
randomization	O
of	O
the	O
intense	O
dose-dense	O
arm.	O

One	O
thousand	O
two	O
hundred	O
eighty-four	O
patients	O
were	O
enrolled;	O
658	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
IDD-ETC	O
treatment	O
group.	O

Within	O
the	O
IDD-ETC	O
group,	O
324	O
patients	O
were	O
further	O
randomly	O
assigned	O
to	O
the	O
epoetin	O
alfa	O
group,	O
and	O
319	O
were	O
randomly	O
assigned	O
to	O
the	O
non-erythropoiesis-stimulating	O
agent	O
(ESA)	O
control	O
group.	O

Primary	O
efficacy	O
endpoints	O
included	O
change	O
in	O
hemoglobin	O
level	O
from	O
baseline	O
to	O
Cycle	O
9	O
and	O
the	O
percentage	O
of	O
subjects	O
requiring	O
red	O
blood	O
cell	O
transfusion.	O

Relapse-free	O
survival,	O
overall	O
survival,	O
and	O
intramammary	O
relapse	O
were	O
secondary	O
endpoints	O
estimated	O
with	O
Kaplan-Meier	O
and	O
Cox	O
regression	O
methods.	O

Except	O
for	O
the	O
primary	O
hypothesis,	O
all	O
statistical	O
tests	O
were	O
two-sided.	O

Epoetin	B-Premise
alfa	I-Premise
avoided	I-Premise
the	I-Premise
decrease	I-Premise
in	I-Premise
hemoglobin	I-Premise
level	I-Premise
(no	I-Premise
decrease	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
group	I-Premise
vs	I-Premise
-2.20g/dL	I-Premise
change	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group;	I-Premise
P	I-Premise
<	I-Premise
.001)	I-Premise
and	I-Premise
statistically	I-Premise
significantly	I-Premise
reduced	I-Premise
the	I-Premise
percentage	I-Premise
of	I-Premise
subjects	I-Premise
requiring	I-Premise
red	I-Premise
blood	I-Premise
cell	I-Premise
transfusion	I-Premise
(12.8%	I-Premise
vs	I-Premise
28.1%;	I-Premise
P	I-Premise
<	I-Premise
.0001).	I-Premise

The	B-Premise
incidence	I-Premise
of	I-Premise
thrombotic	I-Premise
events	I-Premise
was	I-Premise
7%	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
arm	I-Premise
vs	I-Premise
3%	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
arm.	I-Premise

After	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
62	I-Premise
months,	I-Premise
epoetin	I-Premise
alfa	I-Premise
treatment	I-Premise
did	I-Premise
not	I-Premise
affect	I-Premise
overall	I-Premise
survival,	I-Premise
relapse-free	I-Premise
survival,	I-Premise
or	I-Premise
intramammary	I-Premise
relapse.	I-Premise

Epoetin	B-Claim
alfa	I-Claim
resulted	I-Claim
in	I-Claim
improved	I-Claim
hemoglobin	I-Claim
levels	I-Claim
and	I-Claim
decreased	I-Claim
transfusions	I-Claim
without	I-Claim
an	I-Claim
impact	I-Claim
on	I-Claim
relapse-free	I-Claim
or	I-Claim
overall	I-Claim
survival.	I-Claim

However,	B-Claim
epoetin	I-Claim
alfa	I-Claim
had	I-Claim
an	I-Claim
adverse	I-Claim
effect,	I-Claim
resulting	I-Claim
in	I-Claim
increased	I-Claim
thrombosis.	I-Claim

Analgesia	B-Claim
and	I-Claim
early	I-Claim
quality	I-Claim
of	I-Claim
recovery	I-Claim
may	I-Claim
be	I-Claim
improved	I-Claim
by	I-Claim
epidural	I-Claim
analgesia.	I-Claim

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
receiving	O
epidural	O
analgesia	O
on	O
surgical	O
adverse	O
events	O
and	O
quality	O
of	O
life	O
after	O
laparotomy	O
for	O
endometrial	O
cancer.	O

Patients	O
were	O
enrolled	O
in	O
an	O
international,	O
multicentre,	O
prospective	O
randomised	O
trial	O
of	O
outcomes	O
for	O
laparoscopic	O
versus	O
open	O
surgical	O
treatment	O
for	O
the	O
management	O
of	O
apparent	O
stage	O
I	O
endometrial	O
cancer	O
(LACE	O
trial).	O

The	O
current	O
analysis	O
focussed	O
on	O
patients	O
who	O
received	O
an	O
open	O
abdominal	O
hysterectomy	O
via	O
vertical	O
midline	O
incision	O
only	O
(n=257),	O
examining	O
outcomes	O
in	O
patients	O
who	O
did	O
(n=108)	O
and	O
did	O
not	O
(n=149)	O
receive	O
epidural	O
analgesia.	O

Baseline	O
characteristics	O
were	O
comparable	O
between	O
patients	O
with	O
or	O
without	O
epidural	O
analgesia.	O

More	B-Premise
patients	I-Premise
without	I-Premise
epidural	I-Premise
(34%)	I-Premise
ceased	I-Premise
opioid	I-Premise
analgesia	I-Premise
3-5	I-Premise
days	I-Premise
after	I-Premise
surgery	I-Premise
compared	I-Premise
to	I-Premise
patients	I-Premise
who	I-Premise
had	I-Premise
an	I-Premise
epidural	I-Premise
(7%;	I-Premise
p<0.01).	I-Premise

Postoperative	B-Premise
complications	I-Premise
(any	I-Premise
grade)	I-Premise
occurred	I-Premise
in	I-Premise
86%	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
and	I-Premise
in	I-Premise
66%	I-Premise
of	I-Premise
patients	I-Premise
without	I-Premise
an	I-Premise
epidural	I-Premise
(p<0.01)	I-Premise
but	O
there	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
serious	I-Premise
adverse	I-Premise
events	I-Premise
(p=0.19).	I-Premise

Epidural	B-Premise
analgesia	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
increased	I-Premise
length	I-Premise
of	I-Premise
stay	I-Premise
(up	I-Premise
to	I-Premise
48	I-Premise
days	I-Premise
compared	I-Premise
to	I-Premise
up	I-Premise
to	I-Premise
34	I-Premise
days	I-Premise
in	I-Premise
the	I-Premise
non-epidural	I-Premise
group).	I-Premise

There	B-Claim
was	I-Claim
no	I-Claim
difference	I-Claim
in	I-Claim
postoperative	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
up	I-Claim
to	I-Claim
six	I-Claim
months	I-Claim
after	I-Claim
surgery.	I-Claim

Epidural	B-Claim
analgesia	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
an	I-Claim
increase	I-Claim
in	I-Claim
any,	I-Claim
but	I-Claim
not	I-Claim
serious,	I-Claim
postoperative	I-Claim
complications	I-Claim
and	I-Claim
length	I-Claim
of	I-Claim
stay	I-Claim
after	I-Claim
abdominal	I-Claim
hysterectomy.	I-Claim

Randomised	B-Claim
controlled	I-Claim
trials	I-Claim
are	I-Claim
needed	I-Claim
to	I-Claim
examine	I-Claim
the	I-Claim
effect	I-Claim
of	I-Claim
epidural	I-Claim
analgesia	I-Claim
on	I-Claim
surgical	I-Claim
adverse	I-Claim
events,	I-Claim
especially	O
as	O
the	B-Claim
present	I-Claim
data	I-Claim
do	I-Claim
not	I-Claim
support	I-Claim
a	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
benefit	I-Claim
with	I-Claim
epidural	I-Claim
analgesia.	I-Claim

Tivozanib	B-Claim
is	I-Claim
a	I-Claim
potent	I-Claim
and	I-Claim
selective	I-Claim
tyrosine	I-Claim
kinase	I-Claim
inhibitor	I-Claim
of	I-Claim
vascular	I-Claim
endothelial	I-Claim
growth	I-Claim
factor	I-Claim
receptor	I-Claim
1	I-Claim
(VEGFR1),	I-Claim
-2,	I-Claim
and	I-Claim
-3.	I-Claim

This	O
phase	O
III	O
trial	O
compared	O
tivozanib	O
with	O
sorafenib	O
as	O
initial	O
targeted	O
therapy	O
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
(RCC).	O

Patients	O
with	O
metastatic	O
RCC,	O
with	O
a	O
clear	O
cell	O
component,	O
prior	O
nephrectomy,	O
measurable	O
disease,	O
and	O
0	O
or	O
1	O
prior	O
therapies	O
for	O
metastatic	O
RCC	O
were	O
randomly	O
assigned	O
to	O
tivozanib	O
or	O
sorafenib.	O

Prior	O
VEGF-targeted	O
therapy	O
and	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
were	O
not	O
permitted.	O

The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(PFS)	O
by	O
independent	O
review.	O

A	O
total	O
of	O
517	O
patients	O
were	O
randomly	O
assigned	O
to	O
tivozanib	O
(n	O
=	O
260)	O
or	O
sorafenib	O
(n	O
=	O
257).	O

PFS	B-Premise
was	I-Premise
longer	I-Premise
with	I-Premise
tivozanib	I-Premise
than	I-Premise
with	I-Premise
sorafenib	I-Premise
in	I-Premise
the	I-Premise
overall	I-Premise
population	I-Premise
(median,	I-Premise
11.9	I-Premise
v	I-Premise
9.1	I-Premise
months;	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.797;	I-Premise
95%	I-Premise
CI,	I-Premise
0.639	I-Premise
to	I-Premise
0.993;	I-Premise
P	I-Premise
=	I-Premise
.042).	I-Premise

One	O
hundred	O
fifty-six	O
patients	O
(61%)	O
who	O
progressed	O
on	O
sorafenib	O
crossed	O
over	O
to	O
receive	O
tivozanib.	O

The	B-Premise
final	I-Premise
overall	I-Premise
survival	I-Premise
(OS)	I-Premise
analysis	I-Premise
showed	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
longer	I-Premise
survival	I-Premise
on	I-Premise
the	I-Premise
sorafenib	I-Premise
arm	I-Premise
than	I-Premise
on	I-Premise
the	I-Premise
tivozanib	I-Premise
arm	I-Premise
(median,	I-Premise
29.3	I-Premise
v	I-Premise
28.8	I-Premise
months;	I-Premise
HR,	I-Premise
1.245;	I-Premise
95%	I-Premise
CI,	I-Premise
0.954	I-Premise
to	I-Premise
1.624;	I-Premise
P	I-Premise
=	I-Premise
.105).	I-Premise

Adverse	B-Premise
events	I-Premise
(AEs)	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
tivozanib	I-Premise
than	I-Premise
with	I-Premise
sorafenib	I-Premise
were	I-Premise
hypertension	I-Premise
(44%	I-Premise
v	I-Premise
34%)	I-Premise
and	I-Premise
dysphonia	I-Premise
(21%	I-Premise
v	I-Premise
5%).	I-Premise

AEs	B-Premise
more	I-Premise
common	I-Premise
with	I-Premise
sorafenib	I-Premise
than	I-Premise
with	I-Premise
tivozanib	I-Premise
were	I-Premise
hand-foot	I-Premise
skin	I-Premise
reaction	I-Premise
(54%	I-Premise
v	I-Premise
14%)	I-Premise
and	I-Premise
diarrhea	I-Premise
(33%	I-Premise
v	I-Premise
23%).	I-Premise

Tivozanib	B-Claim
demonstrated	I-Claim
improved	I-Claim
PFS,	I-Claim
but	I-Claim
not	I-Claim
OS,	I-Claim
and	I-Claim
a	I-Claim
differentiated	I-Claim
safety	I-Claim
profile,	I-Claim
compared	I-Claim
with	I-Claim
sorafenib,	I-Claim
as	I-Claim
initial	I-Claim
targeted	I-Claim
therapy	I-Claim
for	I-Claim
metastatic	I-Claim
RCC.	I-Claim

Non-randomised	O
studies	O
have	O
suggested	O
that	O
the	B-Claim
postoperative	I-Claim
complications	I-Claim
of	I-Claim
(Campos	I-Claim
LS,	I-Claim
Limberger	I-Claim
LF,	I-Claim
Stein	I-Claim
AT,	I-Claim
Kalil	I-Claim
AN)	I-Claim
laparoscopic	I-Claim
radical	I-Claim
hysterectomy	I-Claim
are	I-Claim
similar	I-Claim
to	I-Claim
those	I-Claim
in	I-Claim
abdominal	I-Claim
radical	I-Claim
hysterectomy.	I-Claim

However,	O
no	O
study	O
evaluating	O
postoperative	O
pain	O
comparing	O
both	O
techniques	O
has	O
been	O
published	O
thus	O
far.	O

Our	O
objective	O
was	O
to	O
compare	O
pain	O
intensity	O
and	O
other	O
perioperative	O
outcomes	O
between	O
laparoscopic	O
radical	O
hysterectomy	O
(LRH)	O
and	O
abdominal	O
radical	O
hysterectomy	O
(ARH)	O
in	O
early	O
cervical	O
cancer.	O

This	O
single	O
centre,	O
randomised,	O
controlled	O
trial	O
enrolled	O
30	O
cervical	O
cancer	O
patients	O
who	O
were	O
clinically	O
staged	O
IA2	O
with	O
lymph	O
vascular	O
invasion	O
and	O
IB	O
according	O
to	O
the	O
FIGO	O
(International	O
Federation	O
of	O
Gynaecology	O
and	O
Obstetrics)	O
classification,	O
and	O
underwent	O
LRH	O
or	O
ARH	O
between	O
late	O
1999	O
and	O
early	O
2004.	O

Postoperative	O
pain,	O
as	O
measured	O
by	O
a	O
10-point	O
numerical	O
rate	O
scale,	O
was	O
considered	O
the	O
primary	O
endpoint.	O

Postoperative	O
pain	O
was	O
assessed	O
every	O
six	O
hours	O
during	O
a	O
patient's	O
usual	O
postoperative	O
care.	O

Perioperative	O
outcomes	O
were	O
also	O
registered.	O

Both	O
surgical	O
techniques	O
were	O
executed	O
by	O
the	O
same	O
surgical	O
team.	O

Secondary	O
outcomes	O
included	O
intraoperative	O
and	O
other	O
postoperative	O
surgicopathological	O
factors	O
and	O
5-year	O
survival	O
rates.	O

IA2	O
patients	O
with	O
lymphatic	O
vascular	O
space	O
invasion	O
and	O
IB	O
cervical	O
cancer	O
patients	O
were	O
randomised	O
to	O
either	O
the	O
LRH	O
group	O
(16	O
patients)	O
or	O
the	O
ARH	O
group	O
(14	O
patients).	O

Four	B-Premise
patients	I-Premise
(25%)	I-Premise
in	I-Premise
the	I-Premise
LRH	I-Premise
group	I-Premise
and	I-Premise
5	I-Premise
patients	I-Premise
(36%)	I-Premise
in	I-Premise
the	I-Premise
ARH	I-Premise
group	I-Premise
presented	I-Premise
with	I-Premise
transoperative	I-Premise
or	I-Premise
serious	I-Premise
postoperative	I-Premise
complications.	I-Premise

All	B-Premise
of	I-Premise
the	I-Premise
transoperative	I-Premise
complications	I-Premise
occurred	I-Premise
in	I-Premise
the	I-Premise
LRH	I-Premise
group.	I-Premise

The	B-Premise
relative	I-Premise
risk	I-Premise
of	I-Premise
presenting	I-Premise
with	I-Premise
complications	I-Premise
was	I-Premise
0.70;	I-Premise
CI	I-Premise
95%	I-Premise
(0.23-2.11);	I-Premise
P	I-Premise
=	I-Premise
0.694.	I-Premise

LRH	B-Premise
group	I-Premise
mean	I-Premise
pain	I-Premise
score	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
ARH	I-Premise
after	I-Premise
36	I-Premise
h	I-Premise
of	I-Premise
observation	I-Premise
(P	I-Premise
=	I-Premise
0.044;	I-Premise
mean	I-Premise
difference	I-Premise
score:	I-Premise
1.42;	I-Premise
95%	I-Premise
CI:	I-Premise
0.04-2.80).	I-Premise

The	O
survival	O
results	O
will	O
be	O
published	O
elsewhere.	O

LRH	B-Claim
provided	I-Claim
lower	I-Claim
pain	I-Claim
scores	I-Claim
after	I-Claim
36	I-Claim
h	I-Claim
of	I-Claim
observation	I-Claim
in	I-Claim
this	I-Claim
series.	I-Claim

The	B-Claim
perioperative	I-Claim
and	I-Claim
serious	I-Claim
postoperative	I-Claim
complications	I-Claim
ratios	I-Claim
were	I-Claim
comparable	I-Claim
between	I-Claim
the	I-Claim
groups.	I-Claim

We	O
analyzed	O
the	O
long-term	O
survival	O
of	O
children	O
under	O
6	O
years	O
of	O
age	O
(<6	O
years)	O
enrolled	O
upon	O
the	O
Children's	O
Cancer	O
Group	O
(CCG)-945	O
high-grade	O
glioma	O
(HGG)	O
study	O
to	O
determine	O
the	O
impact	O
of	O
intrinsic	O
biological	O
characteristics	O
as	O
well	O
as	O
treatment	O
upon	O
both	O
survival	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
this	O
younger	O
age	O
population.	O

Analyses	O
were	O
undertaken	O
on	O
patients	O
<6	O
years	O
with	O
institutionally	O
diagnosed	O
HGG	O
enrolled	O
on	O
the	O
CCG-945	O
trial.	O

Comparisons	O
of	O
survival	O
were	O
performed	O
for	O
patients	O
<3	O
years	O
of	O
age	O
(<3	O
years)	O
(treated	O
with	O
intent	O
to	O
avoid	O
irradiation)	O
versus	O
those	O
between	O
3	O
and	O
6	O
years	O
of	O
age	O
(3-6	O
years)	O
(treated	O
with	O
irradiation	O
and	O
chemotherapy)	O
at	O
diagnosis.	O

Discordance	O
between	O
the	O
institutional	O
diagnoses	O
of	O
HGG	O
and	O
consensus-reviewed	O
diagnoses	O
led	O
us	O
to	O
perform	O
further	O
survival	O
analyses	O
for	O
both	O
groups.	O

We	O
compared	O
the	O
two	O
groups	O
of	O
patients	O
for	O
biological	O
markers,	O
and	O
evaluated	O
the	O
neuropsychological	O
and	O
QOL	O
outcomes	O
of	O
long-term	O
survivors.	O

Patients	B-Premise
<3	I-Premise
years	I-Premise
(n	I-Premise
=	I-Premise
49,	I-Premise
19.5%	I-Premise
of	I-Premise
all	I-Premise
enrolled	I-Premise
patients)	I-Premise
at	I-Premise
diagnosis	I-Premise
had	I-Premise
a	I-Premise
10-year	I-Premise
EFS	I-Premise
and	I-Premise
OS	I-Premise
of	I-Premise
29	I-Premise
±	I-Premise
6.5%	I-Premise
and	I-Premise
37.5	I-Premise
±	I-Premise
7%,	I-Premise
respectively,	I-Premise
while	I-Premise
for	I-Premise
patients	I-Premise
3-6	I-Premise
years	I-Premise
(n	I-Premise
=	I-Premise
34,	I-Premise
13.5%	I-Premise
of	I-Premise
all	I-Premise
enrolled	I-Premise
patients)	I-Premise
10-year	I-Premise
EFS	I-Premise
and	I-Premise
OS	I-Premise
were	I-Premise
35	I-Premise
±	I-Premise
8%	I-Premise
and	I-Premise
36	I-Premise
±	I-Premise
8%,	I-Premise
respectively.	I-Premise

Molecular	B-Premise
marker	I-Premise
analysis	I-Premise
showed	I-Premise
that	I-Premise
a	I-Premise
smaller	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
<3	I-Premise
years	I-Premise
harbored	I-Premise
TP53	I-Premise
mutations	I-Premise
(P	I-Premise
=	I-Premise
0.05).	I-Premise

Analysis	B-Premise
of	I-Premise
QOL	I-Premise
outcomes	I-Premise
with	I-Premise
a	I-Premise
median	I-Premise
length	I-Premise
of	I-Premise
follow-up	I-Premise
of	I-Premise
15.1	I-Premise
years	I-Premise
(9.5-19.2)	I-Premise
showed	I-Premise
comparable	I-Premise
results.	I-Premise

QOL	B-Claim
and	I-Claim
survival	I-Claim
data	I-Claim
were	I-Claim
similar	I-Claim
for	I-Claim
the	I-Claim
two	I-Claim
groups.	I-Claim

A	B-Claim
larger	I-Claim
prospective	I-Claim
study	I-Claim
is	I-Claim
justified	I-Claim
to	I-Claim
study	I-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
chemotherapy	I-Claim
only	I-Claim
regimens	I-Claim
in	I-Claim
younger	I-Claim
children.	I-Claim

Postcancer	B-Claim
fatigue	I-Claim
is	I-Claim
a	I-Claim
frequently	I-Claim
occurring	I-Claim
problem,	I-Claim
impairing	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Until	O
now,	O
little	O
is	O
known	O
about	O
(neuro)	O
physiological	O
factors	O
determining	O
postcancer	O
fatigue.	O

For	O
non-cancer	O
patients	O
with	O
chronic	O
fatigue	O
syndrome,	O
certain	O
characteristics	O
of	O
brain	O
morphology	O
and	O
metabolism	O
have	O
been	O
identified	O
in	O
previous	O
studies.	O

We	O
investigated	O
whether	O
these	O
volumetric	O
and	O
metabolic	O
traits	O
are	O
a	O
reflection	O
of	O
fatigue	O
in	O
general	O
and	O
thus	O
also	O
of	O
importance	O
for	O
postcancer	O
fatigue.	O

Fatigued	O
patients	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
intervention	O
condition	O
(cognitive	O
behavior	O
therapy)	O
or	O
the	O
waiting	O
list	O
condition.	O

Twenty-five	O
patients	O
in	O
the	O
intervention	O
condition	O
and	O
fourteen	O
patients	O
in	O
the	O
waiting	O
list	O
condition	O
were	O
assessed	O
twice,	O
at	O
baseline	O
and	O
six	O
months	O
later.	O

Baseline	O
measurements	O
of	O
20	O
fatigued	O
patients	O
were	O
compared	O
with	O
20	O
matched	O
non-fatigued	O
controls.	O

All	O
participants	O
had	O
completed	O
treatment	O
of	O
a	O
malignant,	O
solid	O
tumor	O
minimal	O
one	O
year	O
earlier.	O

Global	O
brain	O
volumes,	O
subcortical	O
brain	O
volumes,	O
metabolite	O
tissue	O
concentrations,	O
and	O
metabolite	O
ratios	O
were	O
primary	O
outcome	O
measures.	O

Volumetric	O
and	O
metabolic	O
parameters	O
were	O
not	O
significantly	O
different	O
between	O
fatigued	O
and	O
non-fatigued	O
patients.	O

Change	B-Premise
scores	I-Premise
of	I-Premise
volumetric	I-Premise
and	I-Premise
metabolic	I-Premise
parameters	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
follow-up	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
therapy	I-Premise
and	I-Premise
the	I-Premise
waiting	I-Premise
list	I-Premise
group.	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
therapy	I-Premise
group	I-Premise
reported	I-Premise
a	I-Premise
significant	I-Premise
larger	I-Premise
decrease	I-Premise
in	I-Premise
fatigue	I-Premise
scores	I-Premise
than	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
waiting	I-Premise
list	I-Premise
group.	I-Premise

No	B-Premise
relation	I-Premise
was	I-Premise
found	I-Premise
between	I-Premise
postcancer	I-Premise
fatigue	I-Premise
and	I-Premise
the	I-Premise
studied	I-Premise
volumetric	I-Premise
and	I-Premise
metabolic	I-Premise
markers.	I-Premise

This	B-Claim
may	I-Claim
suggest	I-Claim
that,	I-Claim
although	I-Claim
postcancer	I-Claim
fatigue	I-Claim
and	I-Claim
chronic	I-Claim
fatigue	I-Claim
syndrome	I-Claim
show	I-Claim
strong	I-Claim
resemblances	I-Claim
as	I-Claim
a	I-Claim
clinical	I-Claim
syndrome,	I-Claim
the	I-Claim
underlying	I-Claim
physiology	I-Claim
is	I-Claim
different.	I-Claim

The	O
CO.20	O
trial	O
randomized	O
patients	O
with	O
K-RAS	O
wild-type,	O
chemotherapy-refractory,	O
metastatic	O
colorectal	O
cancer	O
to	O
receive	O
cetuximab	O
(CET)	O
plus	O
brivanib	O
alaninate	O
(BRIV)	O
or	O
CET	O
plus	O
placebo	O
(CET/placebo).	O

Quality	O
of	O
life	O
(QoL)	O
was	O
assessed	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
at	O
baseline	O
and	O
at	O
2,	O
4,	O
6,	O
8,	O
12,	O
16,	O
and	O
24	O
weeks	O
until	O
disease	O
progression.	O

Predefined	O
coprimary	O
QoL	O
endpoints	O
were	O
time	O
to	O
deterioration	O
(first	O
worsening	O
from	O
baseline	O
of	O
≥	O
10	O
points)	O
on	O
the	O
Physical	O
Function	O
(PF)	O
and	O
Global	O
(GHS)	O
scales.	O

Of	O
750	O
randomized	O
patients,	O
721	O
(358	O
of	O
whom	O
received	O
CET/BRIV)	O
were	O
assessable	O
for	O
QoL.	O

QoL	O
compliance	O
and	O
baseline	O
PF	O
and	O
GHS	O
scores	O
did	O
not	O
differ	O
by	O
treatment	O
arm.	O

The	B-Premise
median	I-Premise
time	I-Premise
to	I-Premise
deterioration	I-Premise
was	I-Premise
1.6	I-Premise
months	I-Premise
versus	I-Premise
1.1	I-Premise
months	I-Premise
for	I-Premise
GHS	I-Premise
(P	I-Premise
=.02)	I-Premise
and	I-Premise
5.6	I-Premise
months	I-Premise
versus	I-Premise
1.7	I-Premise
months	I-Premise
for	I-Premise
PF	I-Premise
(P	I-Premise
<.0001)	I-Premise
favoring	I-Premise
CET/placebo.	I-Premise

Secondary	B-Premise
analysis	I-Premise
favored	I-Premise
CET/placebo	I-Premise
for	I-Premise
QOL	I-Premise
response	I-Premise
on	I-Premise
the	I-Premise
PF,	I-Premise
Cognitive	I-Premise
Function,	I-Premise
Fatigue,	I-Premise
Nausea,	I-Premise
Appetite,	I-Premise
and	I-Premise
Diarrhea	I-Premise
scales.	I-Premise

A	B-Premise
greater	I-Premise
percentage	I-Premise
of	I-Premise
patients	I-Premise
on	I-Premise
the	I-Premise
CET/BRIV	I-Premise
arm	I-Premise
had	I-Premise
PF	I-Premise
worsening	I-Premise
at	I-Premise
6	I-Premise
weeks	I-Premise
(31%	I-Premise
vs	I-Premise
17%).	I-Premise

Clinical	B-Premise
adverse	I-Premise
events	I-Premise
of	I-Premise
≥	I-Premise
grade	I-Premise
3	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
CET/BRIV	I-Premise
than	I-Premise
with	I-Premise
CET/placebo,	I-Premise
including	I-Premise
fatigue	I-Premise
(25%	I-Premise
vs	I-Premise
11%),	I-Premise
hypertension,	I-Premise
rash,	I-Premise
diarrhea,	I-Premise
abdominal	I-Premise
pain,	I-Premise
dehydration,	I-Premise
and	I-Premise
anorexia.	I-Premise

Compared	B-Claim
with	I-Claim
CET/placebo,	I-Claim
the	I-Claim
combination	I-Claim
of	I-Claim
CET/BRIV	I-Claim
worsened	I-Claim
time	I-Claim
to	I-Claim
QoL	I-Claim
deterioration	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
K-RAS	I-Claim
wild-type,	I-Claim
chemotherapy-refractory,	I-Claim
metastatic	I-Claim
colorectal	I-Claim
cancer	I-Claim
on	I-Claim
the	I-Claim
PF	I-Claim
and	I-Claim
GHS	I-Claim
scales	I-Claim
of	I-Claim
European	I-Claim
Organization	I-Claim
for	I-Claim
Research	I-Claim
and	I-Claim
Treatment	I-Claim
of	I-Claim
Cancer	I-Claim
Quality	I-Claim
of	I-Claim
Life	I-Claim
Questionnaire	I-Claim
C30.	I-Claim

This	B-Claim
result	I-Claim
may	I-Claim
be	I-Claim
due	I-Claim
to	I-Claim
higher	I-Claim
rates	I-Claim
of	I-Claim
fatigue	I-Claim
and	I-Claim
gastrointestinal	I-Claim
adverse	I-Claim
events.	I-Claim

Exercise	O
improves	O
physical	O
functioning	O
and	O
symptom	O
management	O
during	O
breast	O
cancer	O
chemotherapy,	O
but	O
the	O
effects	O
of	O
different	O
doses	O
and	O
types	O
of	O
exercise	O
are	O
unknown.	O

A	O
multicenter	O
trial	O
in	O
Canada	O
randomized	O
301	O
breast	O
cancer	O
patients	O
to	O
thrice-weekly	O
supervised	O
exercise	O
during	O
chemotherapy	O
consisting	O
of	O
either	O
a	O
standard	O
dose	O
of	O
25	O
to	O
30	O
minutes	O
of	O
aerobic	O
exercise	O
(STAN;	O
n	O
=	O
96),	O
a	O
higher	O
dose	O
of	O
50	O
to	O
60	O
minutes	O
of	O
aerobic	O
exercise	O
(HIGH;	O
n	O
=	O
101),	O
or	O
a	O
combined	O
dose	O
of	O
50	O
to	O
60	O
minutes	O
of	O
aerobic	O
and	O
resistance	O
exercise	O
(COMB;	O
n	O
=	O
104).	O

The	O
primary	O
endpoint	O
was	O
physical	O
functioning	O
assessed	O
by	O
the	O
Medical	O
Outcomes	O
Survey-Short	O
Form	O
(SF)-36.	O

Secondary	O
endpoints	O
were	O
other	O
physical	O
functioning	O
scales,	O
symptoms,	O
fitness,	O
and	O
chemotherapy	O
completion.	O

All	O
statistical	O
tests	O
were	O
linear	O
mixed	O
model	O
analyses,	O
and	O
the	O
P	O
values	O
were	O
two-sided.	O

Follow-up	O
assessment	O
of	O
patient-reported	O
outcomes	O
was	O
99.0%.	O

Adjusted	B-Premise
linear	I-Premise
mixed-model	I-Premise
analyses	I-Premise
showed	I-Premise
that	I-Premise
neither	I-Premise
HIGH	I-Premise
(+0.8;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
-0.8	I-Premise
to	I-Premise
2.4;	I-Premise
P	I-Premise
=	I-Premise
.30)	I-Premise
nor	I-Premise
COMB	I-Premise
(+0.5;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-1.1	I-Premise
to	I-Premise
2.1;	I-Premise
P	I-Premise
=	I-Premise
.52]	I-Premise
were	I-Premise
superior	I-Premise
to	I-Premise
STAN	I-Premise
for	I-Premise
the	I-Premise
primary	I-Premise
outcome.	I-Premise

In	B-Premise
secondary	I-Premise
analyses	I-Premise
not	I-Premise
adjusted	I-Premise
for	I-Premise
multiple	I-Premise
comparisons,	I-Premise
HIGH	I-Premise
was	I-Premise
superior	I-Premise
to	I-Premise
STAN	I-Premise
for	I-Premise
the	I-Premise
SF-36	I-Premise
physical	I-Premise
component	I-Premise
summary	I-Premise
(P	I-Premise
=	I-Premise
.04),	I-Premise
SF-36	I-Premise
bodily	I-Premise
pain	I-Premise
(P	I-Premise
=	I-Premise
.02),	I-Premise
and	I-Premise
endocrine	I-Premise
symptoms	I-Premise
(P	I-Premise
=	I-Premise
.02).	I-Premise

COMB	B-Premise
was	I-Premise
superior	I-Premise
to	I-Premise
STAN	I-Premise
for	I-Premise
endocrine	I-Premise
symptoms	I-Premise
(P	I-Premise
=	I-Premise
.009)	I-Premise
and	I-Premise
superior	I-Premise
to	I-Premise
STAN	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
and	I-Premise
HIGH	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
for	I-Premise
muscular	I-Premise
strength.	I-Premise

HIGH	B-Premise
was	I-Premise
superior	I-Premise
to	I-Premise
COMB	I-Premise
for	I-Premise
the	I-Premise
SF-36	I-Premise
bodily	I-Premise
pain	I-Premise
(P	I-Premise
=	I-Premise
.04)	I-Premise
and	I-Premise
aerobic	I-Premise
fitness	I-Premise
(P	I-Premise
=	I-Premise
.03).	I-Premise

No	B-Premise
differences	I-Premise
emerged	I-Premise
for	I-Premise
body	I-Premise
composition	I-Premise
or	I-Premise
chemotherapy	I-Premise
completion.	I-Premise

A	B-Claim
higher	I-Claim
volume	I-Claim
of	I-Claim
aerobic	I-Claim
or	I-Claim
combined	I-Claim
exercise	I-Claim
is	I-Claim
achievable	I-Claim
and	I-Claim
safe	I-Claim
during	I-Claim
breast	I-Claim
cancer	I-Claim
chemotherapy	I-Claim
and	I-Claim
may	I-Claim
manage	I-Claim
declines	I-Claim
in	I-Claim
physical	I-Claim
functioning	I-Claim
and	I-Claim
worsening	I-Claim
symptoms	I-Claim
better	I-Claim
than	I-Claim
standard	I-Claim
volumes.	I-Claim

Intravenous	O
(IV)	O
granulocyte	O
colony	O
stimulating	O
factor	O
(G-CSF)	O
might	O
be	O
safer	O
and	O
more	O
convenient	O
than	O
subcutaneous	O
(SC)	O
administration	O
to	O
hospitalized	O
hemato-oncological	O
patients	O
receiving	O
chemotherapy.	O

To	O
compare	O
IV	O
vs.	O
SC	O
G-CSF	O
administration,	O
we	O
conducted	O
a	O
randomized,	O
open-label	O
trial.	O

We	O
included	O
inpatients	O
receiving	O
chemotherapy	O
for	O
acute	O
myeloid	O
leukemia,	O
acute	O
lymphoblastic	O
leukemia,	O
lymphoma	O
or	O
multiple	O
myeloma,	O
and	O
allogeneic	O
or	O
autologous	O
hematopoietic	O
cell	O
transplantation	O
(HCT).	O

Patients	O
were	O
randomized	O
to	O
5	O
mcg/kg	O
single	O
daily	O
dose	O
of	O
IV	O
bolus	O
versus	O
SC	O
filgrastim	O
given	O
for	O
its	O
clinical	O
indications.	O

Patients	O
were	O
crossed-over	O
to	O
the	O
alternate	O
study	O
arm	O
on	O
the	O
subsequent	O
chemotherapy	O
course.	O

The	O
primary	O
outcomes	O
were	O
time	O
from	O
initiation	O
of	O
filgrastim	O
to	O
recovery	O
of	O
stable	O
neutrophil	O
count	O
of	O
>500	O
cells/µL	O
and	O
a	O
composite	O
clinical	O
outcome	O
of	O
infection	O
or	O
death	O
assessed	O
for	O
the	O
first	O
course	O
post-randomization.	O

The	O
study	O
was	O
stopped	O
on	O
the	O
second	O
interim	O
analysis.	O

Of	O
120	O
patients	O
randomized,	O
118	O
were	O
evaluated	O
in	O
the	O
first	O
treatment	O
course.	O

The	B-Premise
mean	I-Premise
time	I-Premise
to	I-Premise
neutropenia	I-Premise
resolution	I-Premise
was	I-Premise
longer	I-Premise
with	I-Premise
IV	I-Premise
G-CSF	I-Premise
[7.9	I-Premise
days,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
6.6-9.1]	I-Premise
compared	I-Premise
with	I-Premise
SC	I-Premise
G-CSF	I-Premise
(5.4	I-Premise
days,	I-Premise
95%	I-Premise
CI	I-Premise
4.6-6.2),	I-Premise
log-rank	I-Premise
P	I-Premise
=	I-Premise
0.001.	I-Premise

Longer	B-Premise
neutropenia	I-Premise
duration	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
all	I-Premise
patient	I-Premise
subgroups,	I-Premise
except	B-Premise
for	I-Premise
patients	I-Premise
undergoing	I-Premise
autologous	I-Premise
HCT.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
groups	I-Premise
in	I-Premise
the	I-Premise
occurrence	I-Premise
of	I-Premise
infection	I-Premise
or	I-Premise
death,	I-Premise
but	B-Premise
more	I-Premise
deaths	I-Premise
were	I-Premise
observed	I-Premise
with	I-Premise
IV	I-Premise
(4/57,	I-Premise
7%)	I-Premise
versus	I-Premise
SC	I-Premise
(1/61,	I-Premise
1.6%)	I-Premise
G-CSF	I-Premise
administration,	I-Premise
P	I-Premise
=	I-Premise
0.196.	I-Premise

Similar	O
results	O
were	O
observed	O
when	O
all	O
158	O
courses	O
following	O
cross-over	O
were	O
analyzed.	O

Patients	B-Claim
reported	I-Claim
similar	I-Claim
pain	I-Claim
and	I-Claim
satisfaction	I-Claim
scores	I-Claim
in	I-Claim
both	I-Claim
groups.	I-Claim

Bolus	B-Claim
IV	I-Claim
administration	I-Claim
of	I-Claim
G-CSF	I-Claim
results	I-Claim
in	I-Claim
longer	I-Claim
neutropenia	I-Claim
duration	I-Claim
than	I-Claim
SC	I-Claim
administration,	I-Claim
with	I-Claim
no	I-Claim
difference	I-Claim
in	I-Claim
clinical	I-Claim
or	I-Claim
quality-of-life	I-Claim
measures.	I-Claim

Surgical	O
resection	O
enhances	O
long-term	O
survival	O
after	O
lung	O
cancer,	O
but	O
survivors	O
face	O
functional	O
deficits	O
and	O
report	O
on	O
poor	O
quality	O
of	O
life	O
long	O
time	O
after	O
surgery.	O

This	O
study	O
evaluated	O
short	O
and	O
long-term	O
effects	O
of	O
supervised	O
group	O
exercise	O
training	O
on	O
health-related	O
quality	O
of	O
life	O
and	O
physical	O
performance	O
in	O
patients,	O
who	O
were	O
radically	O
operated	O
for	O
lung	O
cancer.	O

A	O
randomized,	O
assessor-blinded,	O
controlled	O
trial	O
was	O
performed	O
on	O
78	O
patients	O
undergoing	O
lung	O
cancer	O
surgery.	O

The	O
intervention	O
group	O
(IG,	O
n=41)	O
participated	O
in	O
supervised	O
out-patient	O
exercise	O
training	O
sessions,	O
one	O
hour	O
once	O
a	O
week	O
for	O
ten	O
weeks.	O

The	O
sessions	O
were	O
based	O
on	O
aerobic	O
exercises	O
with	O
target	O
intensity	O
of	O
60-80%	O
of	O
work	O
capacity,	O
resistance	O
training	O
and	O
dyspnoea	O
management.	O

The	O
control	O
group	O
(CG,	O
n=37)	O
received	O
one	O
individual	O
instruction	O
in	O
exercise	O
training.	O

Measurements	O
consisted	O
of:	O
health-related	O
quality	O
of	O
life	O
(SF36),	O
six	O
minute	O
walk	O
test	O
(6MWT)	O
and	O
lung	O
function	O
(spirometry),	O
assessed	O
three	O
weeks	O
after	O
surgery	O
and	O
after	O
four	O
and	O
twelve	O
months.	O

Both	O
groups	O
were	O
comparable	O
at	O
baseline	O
on	O
demographic	O
characteristic	O
and	O
outcome	O
values.	O

We	B-Premise
found	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
effect	I-Premise
after	I-Premise
four	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
bodily	I-Premise
pain	I-Premise
domain	I-Premise
of	I-Premise
SF36,	I-Premise
with	I-Premise
an	I-Premise
estimated	I-Premise
mean	I-Premise
difference	I-Premise
(EMD)	I-Premise
of	I-Premise
15.3	I-Premise
(95%	I-Premise
CI:4	I-Premise
to	I-Premise
26.6,	I-Premise
p=0.01)	I-Premise
and	I-Premise
a	I-Premise
trend	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
intervention	I-Premise
for	I-Premise
role	I-Premise
physical	I-Premise
functioning	I-Premise
(EMD	I-Premise
12.04,	I-Premise
95%	I-Premise
CI:	I-Premise
-1	I-Premise
to	I-Premise
25.1,	I-Premise
p=0.07)	I-Premise
and	I-Premise
physical	I-Premise
component	I-Premise
summary	I-Premise
(EMD	I-Premise
3.76,	I-Premise
95%	I-Premise
CI:-0.1	I-Premise
to	I-Premise
7.6,	I-Premise
p=0.06).	I-Premise

At	B-Premise
12	I-Premise
months,	I-Premise
the	I-Premise
tendency	I-Premise
was	I-Premise
reversed,	I-Premise
with	I-Premise
the	I-Premise
CG	I-Premise
presenting	I-Premise
overall	I-Premise
slightly	I-Premise
better	I-Premise
measures.	I-Premise

We	B-Claim
found	I-Claim
no	I-Claim
effect	I-Claim
of	I-Claim
the	I-Claim
intervention	I-Claim
on	I-Claim
6MWT	I-Claim
or	I-Claim
lung	I-Claim
volumes	I-Claim
at	I-Claim
any	I-Claim
time-point.	I-Claim

Supervised	B-Claim
compared	I-Claim
to	I-Claim
unsupervised	I-Claim
exercise	I-Claim
training	I-Claim
resulted	I-Claim
in	I-Claim
no	I-Claim
improvement	I-Claim
in	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
except	B-Claim
for	I-Claim
the	I-Claim
bodily	I-Claim
pain	I-Claim
domain,	I-Claim
four	I-Claim
months	I-Claim
after	I-Claim
lung	I-Claim
cancer	I-Claim
surgery.	I-Claim

No	B-Claim
effects	I-Claim
of	I-Claim
the	I-Claim
intervention	I-Claim
were	I-Claim
found	I-Claim
for	I-Claim
any	I-Claim
outcome	I-Claim
after	I-Claim
one	I-Claim
year.	I-Claim

To	O
investigate	O
the	O
effects	O
of	O
medroxyprogesterone	O
acetate	O
(MPA)	O
on	O
appetite,	O
weight,	O
and	O
quality	O
of	O
life	O
(QL)	O
in	O
patients	O
with	O
advanced-stage,	O
incurable,	O
non-hormone-sensitive	O
cancer.	O

Two	O
hundred	O
six	O
eligible	O
patients	O
were	O
randomized	O
between	O
double-blind	O
MPA	O
500	O
mg	O
twice	O
daily	O
or	O
placebo.	O

Appetite	O
(0	O
to	O
10	O
numerical	O
rating	O
scale),	O
weight,	O
and	O
QL	O
(European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
[EORTC-QLQ-C30])	O
were	O
assessed	O
before	O
the	O
start	O
of	O
treatment	O
(t	O
=	O
0),	O
and	O
6	O
weeks	O
(t	O
=	O
6)	O
and	O
12	O
weeks	O
(t	O
=	O
12)	O
thereafter.	O

One	O
hundred	O
thirty-four	O
patients	O
(68	O
MPA	O
and	O
66	O
placebo)	O
were	O
assessable	O
at	O
t	O
=	O
6	O
and	O
99	O
patients	O
(53	O
MPA	O
and	O
46	O
placebo)	O
at	O
t	O
=	O
12.	O

A	B-Premise
beneficial	I-Premise
effect	I-Premise
of	I-Premise
MPA	I-Premise
on	I-Premise
appetite	I-Premise
was	I-Premise
observed	I-Premise
after	I-Premise
both	I-Premise
6	I-Premise
weeks	I-Premise
(P	I-Premise
=	I-Premise
.008)	I-Premise
and	I-Premise
12	I-Premise
weeks	I-Premise
(P	I-Premise
=	I-Premise
.01)	I-Premise
of	I-Premise
treatment.	I-Premise

After	B-Premise
12	I-Premise
weeks,	I-Premise
a	I-Premise
mean	I-Premise
weight	I-Premise
gain	I-Premise
of	I-Premise
0.6	I-Premise
+/-	I-Premise
4.4	I-Premise
kg	I-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
the	I-Premise
MPA,	I-Premise
versus	I-Premise
an	I-Premise
ongoing	I-Premise
mean	I-Premise
weight	I-Premise
loss	I-Premise
of	I-Premise
1.4	I-Premise
+/-	I-Premise
4.6	I-Premise
kg	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

This	B-Premise
difference	I-Premise
of	I-Premise
2.0	I-Premise
kg	I-Premise
was	I-Premise
statistically	I-Premise
significant	I-Premise
(P	I-Premise
=	I-Premise
.04).	I-Premise

During	B-Premise
the	I-Premise
study,	I-Premise
several	I-Premise
areas	I-Premise
of	I-Premise
QL	I-Premise
deteriorated	I-Premise
in	I-Premise
the	I-Premise
total	I-Premise
group	I-Premise
of	I-Premise
patients.	I-Premise

With	B-Claim
the	I-Claim
exception	I-Claim
of	I-Claim
an	I-Claim
improvement	I-Claim
in	I-Claim
appetite	I-Claim
and	I-Claim
possible	I-Claim
also	I-Claim
a	I-Claim
reduction	I-Claim
in	I-Claim
nausea	I-Claim
and	I-Claim
vomiting,	I-Claim
no	I-Claim
measurable	I-Claim
beneficial	I-Claim
effects	I-Claim
of	I-Claim
MPA	I-Claim
on	I-Claim
QL	I-Claim
could	I-Claim
be	I-Claim
demonstrated.	I-Claim

The	B-Premise
side	I-Premise
effects	I-Premise
profile	I-Premise
of	I-Premise
MPA	I-Premise
was	I-Premise
favorable:	I-Premise
only	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
(usually	I-Premise
mild)	I-Premise
peripheral	I-Premise
edema	I-Premise
was	I-Premise
observed.	I-Premise

In	B-Claim
weight-losing,	I-Claim
advanced-stage	I-Claim
non-hormone-sensitive	I-Claim
cancer	I-Claim
patients,	I-Claim
MPA	I-Claim
exhibits	I-Claim
a	I-Claim
mild	I-Claim
side	I-Claim
effects	I-Claim
profile,	I-Claim
has	I-Claim
a	I-Claim
beneficial	I-Claim
effect	I-Claim
on	I-Claim
appetite,	I-Claim
and	I-Claim
may	I-Claim
prevent	I-Claim
further	I-Claim
weight	I-Claim
loss.	I-Claim

However,	B-Claim
general	I-Claim
QL	I-Claim
in	I-Claim
the	I-Claim
present	I-Claim
study	I-Claim
was	I-Claim
not	I-Claim
measurably	I-Claim
influenced	I-Claim
by	I-Claim
MPA	I-Claim
treatment.	I-Claim

Combined	B-Claim
radiation	I-Claim
therapy	I-Claim
and	I-Claim
chemotherapy	I-Claim
after	I-Claim
surgery,	I-Claim
compared	I-Claim
with	I-Claim
postsurgical	I-Claim
radiation	I-Claim
therapy	I-Claim
alone,	I-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
improve	I-Claim
disease-free	I-Claim
survival	I-Claim
and	I-Claim
overall	I-Claim
survival	I-Claim
significantly	I-Claim
among	I-Claim
patients	I-Claim
with	I-Claim
poor-prognosis	I-Claim
(i.e.,	I-Claim
advanced	I-Claim
stage	I-Claim
disease	I-Claim
or	I-Claim
metastasis	I-Claim
to	I-Claim
regional	I-Claim
lymph	I-Claim
nodes)	I-Claim
resectable	I-Claim
rectal	I-Claim
cancer.	I-Claim

However,	B-Claim
the	I-Claim
combined	I-Claim
therapy	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
more	I-Claim
toxic	I-Claim
effects,	I-Claim
raising	I-Claim
the	I-Claim
question	I-Claim
of	I-Claim
whether	I-Claim
the	I-Claim
benefits	I-Claim
of	I-Claim
the	I-Claim
treatment	I-Claim
justify	I-Claim
its	I-Claim
quality-of-life	I-Claim
costs	I-Claim
for	I-Claim
the	I-Claim
individual	I-Claim
patient.	I-Claim

To	O
assess	O
the	O
trade-offs	O
between	O
improved	O
survival	O
and	O
increased	O
treatment	O
toxicity,	O
we	O
reanalyzed	O
data	O
from	O
a	O
randomized	O
clinical	O
trial	O
that	O
compared	O
the	O
efficacy	O
of	O
combined	O
adjuvant	O
chemotherapy	O
and	O
radiation	O
therapy	O
with	O
adjuvant	O
radiation	O
therapy	O
alone	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
poor-prognosis	O
resectable	O
rectal	O
cancer.	O

The	O
data	O
were	O
from	O
a	O
North	O
Central	O
Cancer	O
Treatment	O
Group	O
trial	O
in	O
which	O
204	O
patients	O
with	O
poor-prognosis	O
rectal	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
postoperative	O
radiation	O
therapy	O
alone	O
or	O
radiation	O
therapy	O
plus	O
fluorouracil-based	O
chemotherapy.	O

A	O
quality-adjusted	O
time	O
without	O
symptoms	O
or	O
toxicity	O
(Q-TWiST)	O
analysis	O
was	O
used	O
to	O
account	O
for	O
freedom	O
from	O
symptomatic	O
disease	O
and	O
from	O
early	O
and	O
late	O
side	O
effects	O
of	O
treatment.	O

All	O
reported	O
P	O
values	O
are	O
two-sided.	O

As	B-Premise
reported	I-Premise
previously,	I-Premise
the	I-Premise
combined	I-Premise
therapy	I-Premise
reduced	I-Premise
the	I-Premise
risk	I-Premise
of	I-Premise
relapse	I-Premise
by	I-Premise
34%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
12%-50%;	I-Premise
P	I-Premise
=	I-Premise
.0016)	I-Premise
and	I-Premise
reduced	I-Premise
the	I-Premise
overall	I-Premise
death	I-Premise
rate	I-Premise
by	I-Premise
29%	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
7%-45%;	I-Premise
P	I-Premise
=	I-Premise
.025)	I-Premise
in	I-Premise
comparison	I-Premise
with	I-Premise
adjuvant	I-Premise
radiation	I-Premise
therapy	I-Premise
alone.	I-Premise

In	B-Premise
the	I-Premise
5	I-Premise
years	I-Premise
following	I-Premise
assignment	I-Premise
to	I-Premise
treatment,	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
the	I-Premise
combined	I-Premise
therapy	I-Premise
had	I-Premise
more	I-Premise
time	I-Premise
with	I-Premise
toxicity	I-Premise
(3.1	I-Premise
months;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
2.0-4.1	I-Premise
months),	I-Premise
shorter	I-Premise
survival	I-Premise
after	I-Premise
relapse	I-Premise
(3.6	I-Premise
months	I-Premise
less;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.9-6.3	I-Premise
months	I-Premise
less),	I-Premise
and	I-Premise
more	I-Premise
TWiST	I-Premise
(6.1	I-Premise
months;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.2-12.0	I-Premise
months)	I-Premise
than	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
adjuvant	I-Premise
radiation	I-Premise
therapy	I-Premise
alone.	I-Premise

Despite	B-Claim
an	I-Claim
increase	I-Claim
in	I-Claim
the	I-Claim
amount	I-Claim
of	I-Claim
time	I-Claim
that	I-Claim
individuals	I-Claim
spent	I-Claim
with	I-Claim
early	I-Claim
and	I-Claim
late	I-Claim
toxic	I-Claim
effects,	I-Claim
the	I-Claim
Q-TWiST	I-Claim
analysis	I-Claim
indicated	I-Claim
that	I-Claim
the	I-Claim
combined	I-Claim
therapy	I-Claim
conferred	I-Claim
significantly	I-Claim
greater	I-Claim
benefit	I-Claim
for	I-Claim
a	I-Claim
wide	I-Claim
range	I-Claim
of	I-Claim
patient	I-Claim
preferences	I-Claim
about	I-Claim
living	I-Claim
with	I-Claim
the	I-Claim
toxicity	I-Claim
of	I-Claim
treatment	I-Claim
or	I-Claim
the	I-Claim
symptoms	I-Claim
of	I-Claim
overt	I-Claim
disease.	I-Claim

Use	B-Claim
of	I-Claim
combined	I-Claim
chemotherapy	I-Claim
and	I-Claim
radiation	I-Claim
therapy	I-Claim
as	I-Claim
an	I-Claim
adjuvant	I-Claim
to	I-Claim
surgery	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
poor-prognosis	I-Claim
resectable	I-Claim
rectal	I-Claim
cancer	I-Claim
is	I-Claim
justified,	I-Claim
since	B-Premise
the	I-Premise
improved	I-Premise
outcome	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
delayed	I-Premise
recurrence	I-Premise
and	I-Premise
increased	I-Premise
survival	I-Premise
balances	I-Premise
the	I-Premise
time	I-Premise
spent	I-Premise
with	I-Premise
early	I-Premise
and	I-Premise
late	I-Premise
toxic	I-Premise
effects.	I-Premise

The	B-Claim
Q-TWiST	I-Claim
method	I-Claim
is	I-Claim
an	I-Claim
excellent	I-Claim
way	I-Claim
to	I-Claim
compare	I-Claim
treatment	I-Claim
outcomes	I-Claim
that	I-Claim
include	I-Claim
quality-of-life	I-Claim
considerations.	I-Claim

Cerebral	B-Claim
metastasis	I-Claim
is	I-Claim
a	I-Claim
common	I-Claim
oncologic	I-Claim
problem	I-Claim
that	I-Claim
occurs	I-Claim
in	I-Claim
15-30%	I-Claim
of	I-Claim
cancer	I-Claim
patients;	I-Claim
approximately	O
half	O
such	O
metastases	O
are	O
single.	O

Previous	O
retrospective	O
studies	O
and	O
two	O
randomized	O
trials	O
reported	O
that	O
the	O
addition	O
of	O
surgical	O
extirpation	O
prior	O
to	O
radiation	O
therapy	O
increased	O
survival,	O
neurologic	O
function,	O
and	O
quality	O
of	O
life	O
compared	O
with	O
radiation	O
alone	O
in	O
patients	O
with	O
a	O
single	O
brain	O
metastasis.	O

A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
which	O
patients	O
with	O
a	O
single	O
brain	O
metastasis	O
were	O
allocated	O
to	O
undergo	O
radiation	O
alone	O
or	O
surgery	O
plus	O
radiation.	O

Radiation	O
consisted	O
of	O
3000	O
centigray	O
to	O
the	O
whole	O
brain	O
in	O
10	O
fractions.	O

Forty-three	O
patients	O
received	O
radiation	O
alone	O
and	O
41	O
patients	O
surgery	O
plus	O
radiation.	O

All	O
but	O
two	O
of	O
the	O
study	O
patients	O
died.	O

No	B-Premise
difference	I-Premise
in	I-Premise
survival	I-Premise
was	I-Premise
detected	I-Premise
between	I-Premise
the	I-Premise
groups;	I-Premise
the	B-Premise
median	I-Premise
survival	I-Premise
for	I-Premise
the	I-Premise
radiation	I-Premise
group	I-Premise
was	I-Premise
6.3	I-Premise
months	I-Premise
(95%	I-Premise
confidence	I-Premise
interval,	I-Premise
3-11.4)	I-Premise
compared	I-Premise
with	I-Premise
5.6	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
surgery	I-Premise
plus	I-Premise
radiation	I-Premise
group	I-Premise
(95%	I-Premise
confidence	I-Premise
interval,	I-Premise
3.9-7.2)	I-Premise
(P	I-Premise
=	I-Premise
0.24).	I-Premise

Most	B-Premise
patients	I-Premise
died	I-Premise
within	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
(69.8%	I-Premise
in	I-Premise
the	I-Premise
radiation	I-Premise
arm	I-Premise
vs.	I-Premise
87.8%	I-Premise
in	I-Premise
the	I-Premise
surgery	I-Premise
plus	I-Premise
radiation	I-Premise
arm).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
30-day	I-Premise
mortality,	I-Premise
morbidity,	I-Premise
or	I-Premise
causes	I-Premise
of	I-Premise
death.	I-Premise

Extracranial	B-Premise
metastases	I-Premise
was	I-Premise
an	I-Premise
important	I-Premise
predictor	I-Premise
of	I-Premise
mortality	I-Premise
(relative	I-Premise
risk,	I-Premise
2.3).	I-Premise

The	B-Premise
mean	I-Premise
proportion	I-Premise
of	I-Premise
days	I-Premise
that	I-Premise
the	I-Premise
Karnofsky	I-Premise
performance	I-Premise
status	I-Premise
was	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
70%	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
groups.	I-Premise

This	B-Claim
trial	I-Claim
failed	I-Claim
to	I-Claim
demonstrate	I-Claim
that	I-Claim
the	I-Claim
addition	I-Claim
of	I-Claim
surgery	I-Claim
to	I-Claim
radiation	I-Claim
therapy	I-Claim
improved	I-Claim
outcome	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
a	I-Claim
single	I-Claim
brain	I-Claim
metastasis.	I-Claim

Thus,	B-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
surgery	I-Claim
plus	I-Claim
radiation	I-Claim
compared	I-Claim
with	I-Claim
radiation	I-Claim
alone	I-Claim
needs	I-Claim
to	I-Claim
be	I-Claim
addressed	I-Claim
by	I-Claim
further	I-Claim
clinical	I-Claim
trials	I-Claim
and/or	I-Claim
a	I-Claim
meta-analysis.	I-Claim

To	O
compare	O
two	O
cisplatin	O
based	O
chemotherapy	O
schedules	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

A	O
total	O
of	O
332	O
patients	O
with	O
advanced	O
NSCLC	O
were	O
randomized	O
to	O
receive	O
cisplatin	O
80	O
mg/m2	O
on	O
day	O
1	O
either	O
in	O
combination	O
with	O
teniposide	O
100	O
mg/m2	O
on	O
days	O
1,	O
3,	O
and	O
5	O
(arm	O
A)	O
or	O
paclitaxel	O
175	O
mg/m2	O
by	O
3-hour	O
infusion	O
on	O
day	O
1	O
(arm	O
B);	O
cycles	O
were	O
repeated	O
every	O
3	O
weeks.	O

Fifteen	O
patients	O
were	O
ineligible;	O
patient	O
characteristics	O
were	O
well	O
balanced	O
between	O
the	O
two	O
arms:	O
71%	O
were	O
male,	O
71%	O
had	O
less	O
than	O
5%	O
weight	O
loss,	O
89%	O
had	O
a	O
World	O
Health	O
Organization	O
(WHO)	O
performance	O
status	O
of	O
0	O
to	O
1,	O
51%	O
had	O
adenocarcinoma,	O
and	O
61%	O
had	O
stage	O
IV	O
disease.	O

Hematologic	B-Premise
toxicity	I-Premise
was	I-Premise
significantly	I-Premise
more	I-Premise
severe	I-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
(leukopenia,	I-Premise
neutropenia,	I-Premise
and	I-Premise
thrombocytopenia	I-Premise
grade	I-Premise
3	I-Premise
or	I-Premise
4:	I-Premise
66%	I-Premise
v	I-Premise
19%,	I-Premise
83%	I-Premise
v	I-Premise
55%,	I-Premise
36%	I-Premise
v	I-Premise
2%	I-Premise
in	I-Premise
arms	I-Premise
A	I-Premise
and	I-Premise
B,	I-Premise
respectively),	I-Premise
which	I-Premise
resulted	I-Premise
in	I-Premise
more	I-Premise
febrile	I-Premise
neutropenia	I-Premise
(27%	I-Premise
v	I-Premise
3%	I-Premise
in	I-Premise
arms	I-Premise
A	I-Premise
and	I-Premise
B,	I-Premise
respectively),	I-Premise
dose	I-Premise
reductions,	I-Premise
and	I-Premise
treatment	I-Premise
delays.	I-Premise

There	B-Premise
were	I-Premise
a	I-Premise
total	I-Premise
of	I-Premise
nine	I-Premise
toxic	I-Premise
deaths,	I-Premise
six	I-Premise
due	I-Premise
to	I-Premise
neutropenic	I-Premise
sepsis:	I-Premise
five	I-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
and	I-Premise
one	I-Premise
in	I-Premise
arm	I-Premise
B.	I-Premise

In	B-Premise
contrast,	I-Premise
arthralgia/myalgia	I-Premise
(grade	I-Premise
2	I-Premise
or	I-Premise
3,	I-Premise
4%	I-Premise
v	I-Premise
17%),	I-Premise
peripheral	I-Premise
neurotoxicity	I-Premise
(grade	I-Premise
2	I-Premise
or	I-Premise
3,	I-Premise
6%	I-Premise
v	I-Premise
29%),	I-Premise
and	I-Premise
hypersensitivity	I-Premise
reactions	I-Premise
(1%	I-Premise
v	I-Premise
7%,	I-Premise
all	I-Premise
grades)	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
arm	I-Premise
B.	I-Premise

The	B-Claim
frequency	I-Claim
and	I-Claim
severity	I-Claim
of	I-Claim
other	I-Claim
toxicities	I-Claim
were	I-Claim
comparable	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
arms.	I-Claim

Responses	B-Premise
were	I-Premise
one	I-Premise
complete	I-Premise
and	I-Premise
44	I-Premise
partial	I-Premise
on	I-Premise
arm	I-Premise
A	I-Premise
(28%)	I-Premise
and	I-Premise
two	I-Premise
complete	I-Premise
and	I-Premise
61	I-Premise
partial	I-Premise
(41%)	I-Premise
on	I-Premise
arm	I-Premise
B	I-Premise
(P	I-Premise
=	I-Premise
.018).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
survival,	I-Premise
with	I-Premise
median	I-Premise
and	I-Premise
1-year	I-Premise
survivals	I-Premise
9.9	I-Premise
versus	I-Premise
9.7	I-Premise
months	I-Premise
and	I-Premise
41%	I-Premise
versus	I-Premise
43%,	I-Premise
respectively	I-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
and	I-Premise
B.	I-Premise
Progression-free	B-Premise
survival	I-Premise
was	I-Premise
4.9	I-Premise
and	I-Premise
5.4	I-Premise
months	I-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
and	I-Premise
B,	I-Premise
respectively.	I-Premise

Selected	O
centers	O
participated	O
in	O
a	O
quality-of-life	O
(QoL)	O
assessment,	O
which	O
was	O
performed	O
by	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
QLQ-C30	O
and	O
LC-13	O
administered	O
at	O
baseline	O
and	O
every	O
6	O
weeks	O
thereafter.	O

Arm	B-Premise
B	I-Premise
achieved	I-Premise
a	I-Premise
better	I-Premise
score	I-Premise
at	I-Premise
week	I-Premise
6	I-Premise
for	I-Premise
emotional,	I-Premise
cognitive	I-Premise
and	I-Premise
social	I-Premise
functioning,	I-Premise
global	I-Premise
health	I-Premise
status,	I-Premise
fatigue,	I-Premise
and	I-Premise
appetite	I-Premise
loss,	I-Premise
which	I-Premise
was	I-Premise
lost	I-Premise
at	I-Premise
12	I-Premise
weeks.	I-Premise

In	B-Claim
conclusion,	I-Claim
arm	I-Claim
B	I-Claim
appears	I-Claim
superior	I-Claim
to	I-Claim
arm	I-Claim
A	I-Claim
with	I-Claim
regard	I-Claim
to	I-Claim
response	I-Claim
rate,	I-Claim
side	I-Claim
effects,	I-Claim
and	I-Claim
QoL.	I-Claim

Although	B-Claim
survival	I-Claim
was	I-Claim
not	I-Claim
improved,	I-Claim
arm	B-Claim
B	I-Claim
offers	I-Claim
a	I-Claim
better	I-Claim
palliation	I-Claim
for	I-Claim
advanced	I-Claim
NSCLC	I-Claim
patients	I-Claim
than	I-Claim
arm	I-Claim
A.	I-Claim

In	O
1980	O
the	O
EORTC-BCCG	O
initiated	O
a	O
multicentre	O
randomised	O
clinical	O
trial	O
comparing	O
modified	O
radical	O
mastectomy	O
(MRM)	O
with	O
breast-conserving	O
therapy	O
(BCT)	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer.	O

The	O
main	O
endpoint	O
of	O
the	O
trial	O
was	O
survival.	O

A	O
brief	O
quality	O
of	O
life	O
(QoL)	O
questionnaire	O
consisting	O
of	O
two	O
multi-item	O
scales	O
(body	O
image	O
and	O
fear	O
of	O
recurrence)	O
and	O
two	O
single	O
items	O
(satisfaction	O
with	O
treatment	O
and	O
cosmetic	O
result)	O
was	O
included	O
in	O
the	O
trial.	O

A	O
cosmetic	O
evaluation	O
of	O
the	O
breast	O
after	O
conservative	O
surgery	O
was	O
also	O
performed.	O

This	O
report	O
concentrates	O
on	O
the	O
results	O
of	O
the	O
QoL	O
study	O
and	O
the	O
cosmetic	O
evaluation.	O

Multitrait	O
scaling	O
analysis	O
was	O
employed	O
to	O
verify	O
the	O
hypothesised	O
scale	O
structure	O
of	O
the	O
questionnaire.	O

Treatment	O
comparison	O
of	O
the	O
QoL	O
scores	O
at	O
2	O
years	O
post-treatment	O
was	O
performed	O
using	O
a	O
stratified	O
Wilcoxon	O
rank	O
sum	O
test.	O

Both	O
patients'	O
and	O
doctors'	O
ratings	O
of	O
the	O
cosmetic	O
result	O
were	O
documented	O
on	O
the	O
clinical	O
follow-up	O
form.	O

A	O
multivariate	O
analysis	O
was	O
performed	O
to	O
identify	O
which	O
factors	O
influenced	O
the	O
cosmetic	O
outcome.	O

In	O
total,	O
127	O
patients	O
in	O
the	O
MRM	O
arm	O
and	O
151	O
in	O
the	O
BCT	O
arm	O
completed	O
a	O
QoL	O
questionnaire	O
at	O
approximately	O
2	O
years	O
after	O
randomisation	O
(months	O
25-36).	O

The	B-Premise
Cronbach's	I-Premise
alpha	I-Premise
coefficients	I-Premise
were	I-Premise
0.79	I-Premise
and	I-Premise
0.73	I-Premise
for	I-Premise
the	I-Premise
body	I-Premise
image	I-Premise
and	I-Premise
fear	I-Premise
of	I-Premise
recurrence	I-Premise
scales,	I-Premise
respectively.	I-Premise

Significant	B-Premise
benefit	I-Premise
in	I-Premise
body	I-Premise
image	I-Premise
and	I-Premise
satisfaction	I-Premise
with	I-Premise
treatment	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
BCT	I-Premise
patients.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
fear	I-Premise
of	I-Premise
recurrence	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

Ratings	B-Premise
of	I-Premise
cosmetic	I-Premise
results	I-Premise
decreased	I-Premise
with	I-Premise
time,	I-Premise
in	I-Premise
line	I-Premise
with	I-Premise
clinical	I-Premise
observations	I-Premise
of	I-Premise
long-term	I-Premise
side-effects	I-Premise
of	I-Premise
radiotherapy.	I-Premise

Wide	B-Claim
excision	I-Claim
appeared	I-Claim
to	I-Claim
be	I-Claim
the	I-Claim
most	I-Claim
important	I-Claim
predictive	I-Claim
factor	I-Claim
for	I-Claim
poor	I-Claim
cosmetic	I-Claim
result.	I-Claim

In	B-Claim
this	I-Claim
multicentre	I-Claim
randomised	I-Claim
study,	I-Claim
BCT	I-Claim
helped	I-Claim
to	I-Claim
maintain	I-Claim
the	I-Claim
patients'	I-Claim
body	I-Claim
image,	I-Claim
resulted	I-Claim
in	I-Claim
higher	I-Claim
satisfaction	I-Claim
with	I-Claim
treatment	I-Claim
and	I-Claim
yielded	I-Claim
no	I-Claim
significant	I-Claim
difference	I-Claim
from	I-Claim
MRM	I-Claim
with	I-Claim
respect	I-Claim
to	I-Claim
fear	I-Claim
of	I-Claim
recurrence.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
'Casodex'	O
monotherapy	O
(150	O
mg	O
daily)	O
for	O
metastatic	O
and	O
locally	O
advanced	O
prostate	O
cancer.	O

A	O
total	O
of	O
1,453	O
patients	O
with	O
either	O
confirmed	O
metastatic	O
disease	O
(M1),	O
or	O
T3/T4	O
non-metastatic	O
disease	O
with	O
elevated	O
prostate-specific	O
antigen	O
(M0)	O
were	O
recruited	O
into	O
one	O
of	O
two	O
identical,	O
multicentre,	O
randomised	O
studies	O
to	O
compare	O
'Casodex'	O
150	O
mg/day	O
with	O
castration.	O

The	O
protocols	O
allowed	O
for	O
combined	O
analysis.	O

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
period	I-Premise
of	I-Premise
approximately	I-Premise
100	I-Premise
weeks	I-Premise
for	I-Premise
both	I-Premise
studies,	I-Premise
'Casodex'	I-Premise
150	I-Premise
mg	I-Premise
was	I-Premise
found	I-Premise
to	I-Premise
be	I-Premise
less	I-Premise
effective	I-Premise
than	I-Premise
castration	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
metastatic	I-Premise
disease	I-Premise
(M1)	I-Premise
at	I-Premise
entry	I-Premise
(hazard	I-Premise
ratio	I-Premise
of	I-Premise
1.30	I-Premise
for	I-Premise
time	I-Premise
to	I-Premise
death)	I-Premise
with	I-Premise
a	I-Premise
difference	I-Premise
in	I-Premise
median	I-Premise
survival	I-Premise
of	I-Premise
6	I-Premise
weeks.	I-Premise

In	B-Premise
symptomatic	I-Premise
M1	I-Premise
patients,	I-Premise
'Casodex'	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
subjective	I-Premise
response	I-Premise
(70%)	I-Premise
compared	I-Premise
with	I-Premise
castration	I-Premise
(58%).	I-Premise

Analysis	B-Premise
of	I-Premise
a	I-Premise
validated	I-Premise
quality-of-life	I-Premise
questionnaire	I-Premise
proved	I-Premise
an	I-Premise
advantage	I-Premise
for	I-Premise
'Casodex'	I-Premise
in	I-Premise
sexual	I-Premise
interest	I-Premise
and	I-Premise
physical	I-Premise
capacity.	I-Premise

'Casodex'	B-Premise
had	I-Premise
a	I-Premise
substantially	I-Premise
lower	I-Premise
incidence	I-Premise
of	I-Premise
hot	I-Premise
flushes	I-Premise
compared	I-Premise
to	I-Premise
castration	I-Premise
(6-13%	I-Premise
compared	I-Premise
with	I-Premise
39-44%)	I-Premise
and	I-Premise
the	I-Premise
most	I-Premise
commonly	I-Premise
reported	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
those	I-Premise
expected	I-Premise
for	I-Premise
a	I-Premise
potent	I-Premise
antiandrogen.	I-Premise

However,	O
in	B-Claim
patients	I-Claim
with	I-Claim
M0	I-Claim
disease	I-Claim
at	I-Claim
entry,	I-Claim
the	I-Claim
data	I-Claim
are	I-Claim
still	I-Claim
immature	I-Claim
with	I-Claim
only	I-Claim
13%	I-Claim
of	I-Claim
M0	I-Claim
patients	I-Claim
having	I-Claim
died.	I-Claim

An	B-Claim
initial	I-Claim
analysis	I-Claim
of	I-Claim
this	I-Claim
immature	I-Claim
data	I-Claim
has	I-Claim
suggested	I-Claim
that	I-Claim
the	I-Claim
results	I-Claim
in	I-Claim
these	I-Claim
patients	I-Claim
may	I-Claim
be	I-Claim
different	I-Claim
to	I-Claim
those	I-Claim
obtained	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
M1	I-Claim
disease.	I-Claim

A	O
further	O
survival	O
analysis	O
in	O
patients	O
with	O
M0	O
disease	O
is	O
therefore	O
planned	O
when	O
the	O
data	O
are	O
more	O
mature.	O

'Casodex'	B-Claim
150	I-Claim
mg	I-Claim
is	I-Claim
less	I-Claim
effective	I-Claim
than	I-Claim
castration	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
M1	I-Claim
disease.	I-Claim

However,	O
'Casodex'	B-Claim
has	I-Claim
shown	I-Claim
a	I-Claim
benefit	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
subjective	I-Claim
response	I-Claim
when	I-Claim
compared	I-Claim
to	I-Claim
castration	I-Claim
and	I-Claim
has	I-Claim
an	I-Claim
acceptable	I-Claim
tolerability	I-Claim
profile.	I-Claim

Thus	B-Claim
'Casodex'	I-Claim
150	I-Claim
mg	I-Claim
monotherapy	I-Claim
is	I-Claim
an	I-Claim
option	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
M1	I-Claim
prostate	I-Claim
cancer	I-Claim
for	I-Claim
whom	I-Claim
surgical	I-Claim
or	I-Claim
medical	I-Claim
castration	I-Claim
is	I-Claim
not	I-Claim
indicated	I-Claim
or	I-Claim
is	I-Claim
not	I-Claim
acceptable.	I-Claim

